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Abstract
A systematic review and economic evaluation of
bisphosphonates for the prevention of fragility fractures
Sarah Davis,1* Marrissa Martyn-St James,1 Jean Sanderson,1
John Stevens,1 Edward Goka,1 Andrew Rawdin,1 Susi Sadler,1
Ruth Wong,1 Fiona Campbell,1 Matt Stevenson,1 Mark Strong,1
Peter Selby2 and Neil Gittoes3
1Health Economics and Decision Science, School of Health and Related Research, University of
Sheffield, Sheffield, UK
2Department of Medicine, University of Manchester, Manchester Royal Infirmary, Manchester, UK
3Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners,
University Hospitals Birmingham, Birmingham, UK
*Corresponding author s.davis@sheffield.ac.uk
Background: Fragility fractures are fractures that result from mechanical forces that would not ordinarily
result in fracture.
Objectives: To evaluate the clinical effectiveness and safety of bisphosphonates [alendronic acid
(Fosamax® and Fosamax® Once Weekly, Merck Sharp & Dohme Ltd), risedronic acid (Actonel® and Actonel
Once a Week®, Warner Chilcott UK Ltd), ibandronic acid (Bonviva®, Roche Products Ltd) and zoledronic
acid (Aclasta®, Novartis Pharmaceuticals UK Ltd)] for the prevention of fragility fracture and to assess their
cost-effectiveness at varying levels of fracture risk.
Data sources: For the clinical effectiveness review, six electronic databases and two trial registries
were searched: MEDLINE, EMBASE, The Cochrane Library, Cumulative Index to Nursing and Allied Health
Literature, Web of Science and BIOSIS Previews, Clinicaltrials.gov and World Health Organization
International Clinical Trials Registry Platform. Searches were limited by date from 2008 until
September 2014.
Review methods: A systematic review and network meta-analysis (NMA) of effectiveness studies were
conducted. A review of published economic analyses was undertaken and a de novo health economic
model was constructed. Discrete event simulation was used to estimate lifetime costs and quality-adjusted
life-years (QALYs) for each bisphosphonate treatment strategy and a strategy of no treatment for a
simulated cohort of patients with heterogeneous characteristics. The model was populated with
effectiveness evidence from the systematic review and NMA. All other parameters were estimated from
published sources. A NHS and Personal Social Services perspective was taken, and costs and benefits were
discounted at 3.5% per annum. Fracture risk was estimated from patient characteristics using the
QFracture® (QFracture-2012 open source revision 38, Clinrisk Ltd, Leeds, UK) and FRAX® (web version 3.9,
University of Sheffield, Sheffield, UK) tools. The relationship between fracture risk and incremental net
benefit (INB) was estimated using non-parametric regression. Probabilistic sensitivity analysis (PSA) and
scenario analyses were used to assess uncertainty.
Results: Forty-six randomised controlled trials (RCTs) were included in the clinical effectiveness systematic
review, with 27 RCTs providing data for the fracture NMA and 35 RCTs providing data for the femoral
neck bone mineral density (BMD) NMA. All treatments had beneficial effects on fractures versus placebo,
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with hazard ratios varying from 0.41 to 0.92 depending on treatment and fracture type. The effects on
vertebral fractures and percentage change in BMD were statistically significant for all treatments. There
was no evidence of a difference in effect on fractures between bisphosphonates. A statistically significant
difference in the incidence of influenza-like symptoms was identified from the RCTs for zoledronic acid
compared with placebo. Reviews of observational studies suggest that upper gastrointestinal symptoms
are frequently reported in the first month of oral bisphosphonate treatment, but pooled analyses of
placebo-controlled trials found no statistically significant difference. A strategy of no treatment was
estimated to have the maximum INB for patients with a 10-year QFracture risk under 1.5%, whereas oral
bisphosphonates provided maximum INB at higher levels of risk. However, the PSA suggested that there is
considerable uncertainty regarding whether or not no treatment is the optimal strategy until the QFracture
score is around 5.5%. In the model using FRAX, the mean INBs were positive for all oral bisphosphonate
treatments across all risk categories. Intravenous bisphosphonates were estimated to have lower INBs than
oral bisphosphonates across all levels of fracture risk when estimated using either QFracture or FRAX.
Limitations: We assumed that all treatment strategies are viable alternatives across the whole population.
Conclusions: Bisphosphonates are effective in preventing fragility fractures. However, the benefit-to-risk
ratio in the lowest-risk patients may be debatable given the low absolute QALY gains and the potential for
adverse events. We plan to extend the analysis to include non-bisphosphonate therapies.
Study registration: This study is registered as PROSPERO CRD42013006883.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Background
Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in
fracture, known as low-level (or ‘low-energy’) trauma. Some patients are at a particularly high risk of
fragility fractures.
Aims
We aimed to determine how effective bisphosphonates [alendronic acid (Fosamax® and Fosamax®
Once Weekly, Merck Sharp & Dohme Ltd), risedronic acid (Actonel® and Actonel Once a Week®, Warner
Chilcott UK Ltd), ibandronic acid (Bonviva®, Roche Products Ltd) and zoledronic acid (Aclasta®, Novartis
Pharmaceuticals UK Ltd)] are at preventing fractures, whether or not treatment has any risks for patients
and whether or not the clinical benefits are achieved at a reasonable cost.
Methods
We have systematically identified and examined trials that assessed the clinical effects of bisphosphonates.
For each clinical outcome, we have combined data from multiple trials to estimate the clinical effectiveness
of each bisphosphonate treatment.
We combined data from published sources in an economic model to estimate lifetime costs and clinical
benefits for each bisphosphonate and compared these to the estimated costs and clinical outcomes for
untreated patients.
Results
All bisphosphonates reduced the risk of vertebral fractures compared with no treatment. For fractures
at other sites (e.g. hip and wrist), all of the bisphosphonates reduced the average number of fractures,
but for some bisphosphonates we could not exclude the possibility that this was a chance finding.
No bisphosphonate was found to be superior to any other at preventing fractures.
Patients taking oral bisphosphonates may experience side effects affecting the stomach and gullet.
Patients treated with zoledronic acid may experience flu-like symptoms.
Bisphosphonates taken orally provide greater value for money than those delivered through intravenous
infusion. The benefits of bisphosphonate treatment may not outweigh the costs in those with the lowest
risk of fracture.
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Scientific summary
Background
Osteoporosis is a disease characterised by low bone mass and structural deterioration of bone tissue, with
a consequent increase in susceptibility to fragility fracture. Fragility fractures are fractures that result from
mechanical forces that would not ordinarily result in fracture, known as low-level (or ‘low-energy’) trauma.
The World Health Organization (WHO) has quantified this as forces equivalent to a fall from a standing
height or less. Although osteoporosis is an important predictor of the risk of fragility fracture, 70% of
fragility fractures in postmenopausal women occur in those who do not meet the criteria for osteoporosis.
Every year 300,000 people in the UK suffer a fragility fracture, of which over 70,000 are hip fractures.
Objectives
To evaluate the clinical effectiveness, safety and cost-effectiveness of bisphosphonates for the prevention
of fragility fractures.
Methods
A systematic review of the literature including network meta-analyses (NMA) was conducted in order to
evaluate the clinical effectiveness and safety of oral [alendronic acid (Fosamax® and Fosamax® Once
Weekly, Merck Sharp & Dohme Ltd), ibandronic acid (Bonviva®, Roche Products Ltd) and risedronic acid
(Actonel® and Actonel Once a Week®, Warner Chilcott UK Ltd)] and intravenous (i.v.) [ibandronic acid and
zoledronic acid (Aclasta®, Novartis Pharmaceuticals UK Ltd)] bisphosphonates in the prevention of fragility
fractures. For the clinical effectiveness review, six electronic databases and two trial registries were
searched: MEDLINE, EMBASE, The Cochrane Library, Cumulative Index to Nursing and Allied Health
Literature (CINAHL), Web of Science and BIOSIS Previews, Clinicaltrials.gov and WHO International Clinical
Trials Registry Platform. Searches were limited by date from 2008 until September 2014. A review of the
existing cost-effectiveness literature was undertaken. In the cost-effectiveness review (economic evaluation
and quality-of-life studies), seven electronic databases were searched from 2006 until September 2014:
MEDLINE, EMBASE, The Cochrane Library, CINAHL, EconLit, Web of Science and BIOSIS Previews.
Additional searches were carried out in October 2014–January 2015 in MEDLINE and EMBASE for adverse
events, compliance and EuroQol five dimensions questionnaire to inform the model parameters. A de novo
health economic model was constructed using discrete event simulation in order to evaluate the cost-
effectiveness of the interventions under assessment.
Results
Number and quality of studies
A total of 46 randomised controlled trials (RCTs) were identified for the clinical effectiveness systematic
review. Alendronic acid was evaluated against placebo in 17 RCTs. Daily oral ibandronic acid (unlicensed
dose) was evaluated against placebo in three RCTs and against i.v. administration in one RCT. Daily
administration of oral ibandronic acid was evaluated against monthly oral administration in one RCT.
Risedronic acid was evaluated against placebo in 12 RCTs and zoledronic acid was evaluated against
placebo in four RCTs. One RCT evaluated alendronic acid compared with monthly oral ibandronic acid,
five RCTs compared alendronic acid with risedronic acid, one RCT compared zoledronic acid with alendronic
acid and one RCT compared zoledronic acid with risedronic acid.
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The risk of bias associated with the included RCTs was assessed using the Cochrane risk-of-bias
instrument. Attrition ≥ 10% across treatment groups was evident for 29 (63%) of the included RCTs.
Five trials were reported as either open label or single blind and were considered at high risk of
performance bias. Blinded outcome assessment was reported by only 13 (28%) trials.
Summary of benefits and risks
The outcome measures prespecified in the final National Institute for Health and Care Excellence scope
were addressed by the included trial evidence to varying degrees. Femoral neck bone mineral density
(BMD) was the most widely reported outcome; fracture was the second most widely reported outcome.
Adverse events (AEs) were reported by the majority of included trials. Across the included trials there was
limited reporting on the outcomes of compliance (adherence and persistence), hospitalisation and service
use, and quality of life.
A total of 27 RCTs provided suitable fracture data for inclusion in the NMA and a total of 35 RCTs
provided suitable femoral neck BMD data for inclusion in the BMD NMA. Based on the NMA, all
treatments were associated with beneficial effects relative to placebo, with hazard ratios varying from 0.41
to 0.92 depending on treatment and fracture site. For vertebral fractures and percentage change in BMD,
the treatment effects were also statistically significant at a conventional 5% significance level for all
treatments. Pairwise comparisons between bisphosphonates indicated that no bisphosphonate was
statistically significantly more effective than any other bisphosphonate for fracture outcomes. For vertebral
fractures and BMD, the greatest effect was for zoledronic acid, although, in general, the ranking of
treatments varied for the different outcomes, with the treatments providing broadly similar effects.
Assessment of vertebral fractures within the trials was based on both clinical and morphometric fractures.
Ideally, the effect of assessment method would have been assessed using metaregression, but there were
insufficient data to facilitate this. Consideration of the trials reporting clinical fractures did not provide any
evidence to suggest significantly different treatment effects according to assessment method.
Pooled RCT data for each bisphosphonate indicated no statistically significant differences in the incidence
of upper gastrointestinal (GI) events, no evidence of significant differences in mortality and no significant
differences in participants withdrawing because of AEs. Evidence from single RCTs indicated that the risk
of upper GI events was significantly higher in men receiving risedronic acid than in those receiving placebo,
that men and women receiving placebo were significantly more likely to die following hip fracture than
those receiving zoledronic acid, and that the proportion of men withdrawing because of AEs was
significantly higher among those receiving alendronic acid than among those receiving placebo.
Pooled RCT data indicated evidence of influenza-like symptoms associated with zoledronic acid. Single RCT
evidence indicated no statistically significant difference in the incidence of atrial fibrillation, bone pain or
stroke. Single RCT evidence indicated a statistically significant risk of eye inflammation in the first 3 days
following administration of zoledronic acid. All RCTs evaluating zoledronic acid reported no cases of
spontaneous osteonecrosis of the jaw.
Adverse events of hypocalcaemia and atypical femoral fracture were not reported outcomes in any RCT of
any bisphosphonate.
Summary of cost-effectiveness evidence
The de novo economic model estimates that a strategy of no treatment is predicted to have the greatest
net benefit for patients, with an absolute risk < 1.5% when using QFracture® (QFracture-2012 open source
revision 38, Clinrisk Ltd, Leeds, UK) to estimate absolute risk and valuing a quality-adjusted life-year (QALY)
at £20,000. Alendronic acid is predicted to have the maximum incremental net benefit (INB) from 1.5% to
7.2% and risedronic acid is predicted to have the maximum INB from 7.2% upwards. However, the
absolute costs and QALY gains are small in patients with low absolute risk and the probabilistic sensitivity
analysis (PSA) suggested that there is considerable uncertainty regarding whether or not no treatment is
the optimal strategy until the QFracture score is around 5.5% (the mean absolute risk for the eighth risk
category for QFracture).
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The mean INBs for oral bisphosphonate treatment (alendronic acid, risedronic acid and ibandronic acid)
compared with no treatment were positive across all FRAX® (web version 3.9; University of Sheffield,
Sheffield, UK) risk categories. An exact threshold for the absolute risk at which the INB became positive
was therefore not available but the minimum FRAX score in the modelled population was 1.2% and the
lowest risk category (containing one-tenth of the modelled population) had a mean absolute risk of 3.1%.
Oral ibandronic acid is predicted to have the highest INB compared with no treatment up to 8.6%, with
alendronic acid having the highest INB from 8.6% to 38.5% and risedronic acid having the maximum INB
above 38.5%. The PSA suggested that there was a low probability of the no-treatment strategy being
optimal across all FRAX risk categories when valuing a QALY at £20,000. However, the PSA also
demonstrated that there is considerable uncertainty regarding the optimal bisphosphonate treatment, with
all of the oral bisphosphonates having reasonably similar probabilities of having maximum INB across most
of the FRAX risk categories.
Intravenous bisphosphonates (ibandronic acid and zoledronic acid) were predicted to have lower INBs than
oral bisphosphonates across all levels of absolute risk when estimated using either QFracture or FRAX.
In the highest risk categories the incremental cost-effectiveness ratios for i.v. ibandronic acid and i.v.
zoledronic acid compared with oral bisphosphonates were consistently > £50,000 per QALY, even though
the base-case analysis assumed that patients treated with i.v. bisphosphonates persisted with treatment
for longer than patients treated with oral bisphosphonates. Although the mean INB compared with no
treatment for i.v. ibandronic acid did become positive at very high levels of absolute risk when using
QFracture, the results when using FRAX went in the opposite direction. This may be as a result of the small
number of patients and parameter samples informing the estimates at high levels of absolute risk, which
makes these estimates more uncertain.
The results appeared to be broadly similar across the majority of the structural sensitivity analyses that
examined the application of alternative data or assumptions. The results were more favourable to treatment
when assuming that participants persisted with treatment for the full intended treatment duration (3 years
for zoledronic acid and 5 years for all other bisphosphonates) or when assuming no AEs. The sensitivity
analysis examining an AE rate of 30% in the month following initiation of oral bisphosphonate therapy
showed that the cost-effectiveness of oral bisphosphonates is very sensitive to the rate of AEs experienced,
with the INBs for oral bisphosphonates versus no treatment falling below zero (when valuing a QALY at
£20,000) for all 10 QFracture risk categories and for all but the highest FRAX risk category.
Two structural sensitivity analyses that varied the way in which the fracture risk was estimated showed
results that were broadly similar for QFracture but slightly less favourable for FRAX. In these sensitivity
analyses, the cost-effectiveness estimates from the QFracture and FRAX model were closer together for
patients with similar mean absolute risk than in the base case.
Discussion
Strengths, limitations of the analyses and uncertainties
The clinical effectiveness systematic review was based on rigorous methods, with comprehensive searches
for evidence (up to September 2014), a good level of consistency between reviewers in study selection and
double-checking of data extraction. A formal assessment of methodological quality of included trials was
undertaken. Attrition ≥ 10% across treatment groups was evident for 63% of the included RCTs.
Not all of the included studies provided data suitable for inclusion in the NMA. For fracture there was
variability across the included trials in the skeletal fracture site evaluated, the most frequently evaluated
being vertebral fracture. Femoral neck BMD summary statistics were not provided by all trials but were
extracted from graphical representations where possible. NMAs were performed to permit a coherent
comparison of the efficacy of interventions in terms of fracture and femoral neck BMD.
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Adverse event data were widely reported in the included RCTs and supplemented by review evidence of
observational data. Evidence for compliance and persistence was mainly limited to review evidence of
observational data.
The Assessment Group’s economic analysis has a number of strengths.
l The patient-level simulation approach used in the economic model allowed for the distribution of
patient characteristics to differ across the risk categories providing estimates of cost-effectiveness that
have taken into account the differing consequences of fracture in patients with different characteristics.
l The economic modelling approach used allowed intervention thresholds to be linked to absolute risk
measured using the two risk assessment tools recommended in clinical guideline 146 (CG146)
(National Institute for Health and Care Excellence. Osteoporosis: Assessing the Risk of Fragility Fracture.
Manchester: National Institute for Health and Care Excellence; 2014) as specified in the scope.
l Non-parametric regression was used to estimate the relationship between INB and absolute risk when
averaging over both parameter uncertainty and the stochastic uncertainty associated with patient-
level simulations.
l The economic model was underpinned by a NMA across all drug options, which provided a consistent
framework for synthesising relevant efficacy data within a single network of evidence.
The Assessment Group’s economic model is also subject to a number of limitations.
l In order to provide a single intervention threshold for each treatment that could be applied across the
whole population, we had to assume that all of the bisphosphonate treatment strategies were viable
treatment options in all patients eligible for risk assessment within CG146. This would not be true if
the licensed indications for each intervention were to be strictly applied. Furthermore, the studies
included in the NMA that informed the economic evaluation are not strictly exchangeable because not
all interventions are licensed in all patient populations.
l The cost-effectiveness of treatment in the lowest-risk categories was particularly sensitive to the
assumptions regarding the adverse effects of treatment because of the low absolute QALY gains and
cost savings attributable to prevented fractures.
l The results of structural sensitivity analyses suggest that the model using FRAX to estimate absolute risk
may have overestimated the INB of treatment because of the assumption that the proportion of
fractures occurring at the hip is similar for QFracture and FRAX.
Key uncertainties in this assessment include:
l There was no evidence of differential treatment effects with respect to sex and age. However, there
was some heterogeneity in treatment effects between studies, suggesting differential treatment effects
according to study characteristics and the effect of treatment on femoral neck BMD depended on the
baseline response.
l It is uncertain whether or not the cost-effectiveness of bisphosphonate treatment at a particular level of
absolute fracture risk would be similar for patients who have been assessed using the FRAX algorithm
for patients with known BMD.
l The incidence of upper GI AEs following initiation of oral bisphosphonate treatment is uncertain as the
findings differ between the RCT evidence and the observational evidence from prescription event
monitoring studies.
Conclusions
All treatments were associated with beneficial effects relative to placebo. Pairwise comparisons between
treatments indicated that no active treatment was significantly more effective than other active treatments
in reducing fracture outcomes. Bisphosphonates are generally well tolerated in patients enrolled in clinical
SCIENTIFIC SUMMARY
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trials but may be less well tolerated in clinical practice. Influenza-like symptoms are associated with
treatment with zoledronic acid, although clinical advice was that these symptoms are generally limited to
the first dose and usually last only a few days.
The de novo economic model estimates that, when using QFracture to estimate absolute risk, a strategy of
no treatment is predicted to have the greatest net benefit, when valuing a QALY at £20,000, in the
lowest-risk patients (QFracture absolute risk < 1.5%), with oral bisphosphonates having the greatest INB at
higher levels of absolute risk. However, the absolute costs and QALY gains are small in patients with low
absolute risk and the PSA suggested that there is considerable uncertainty regarding whether or not no
treatment is the optimal strategy until the QFracture score is around 5.5% (the mean absolute risk for the
eighth risk category for QFracture). Therefore, it is possible that patients and clinicians may not consider
treatment worthwhile in the lowest-risk patients even though it may be cost-effective.
The mean INBs compared with no treatment (when valuing a QALY at £20,000) were positive for all oral
bisphosphonate treatments across all FRAX risk categories. However, the results of two structural sensitivity
analyses suggest that the base-case analysis may have overestimated the INBs of treatment in the model
based on FRAX, owing to the assumption that the proportion of major osteoporotic fractures occurring at
the hip is the same for FRAX and QFracture. Given this possible bias, and our belief that the results should
be broadly similar across the two risk scores, it would be reasonable to assume that the absolute risk
thresholds estimated in the QFracture model could be applied to patients whose score had been calculated
using either QFracture or FRAX.
The de novo economic model suggests that the cost-effectiveness of i.v. bisphosphonates is less favourable
than for oral bisphosphonates.
Further work is planned to extend the analysis to include non-bisphosphonate therapies.
Study registration
This study is registered as PROSPERO CRD42013006883.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of health problem
Osteoporosis is a disease characterised by low bone mass and structural deterioration of bone tissue, with
a consequent increase in susceptibility to fragility fracture (a broken bone resulting from a fall at standing
height or less). An internationally accepted definition provided by the World Health Organization (WHO)
(in 1994) defines the condition as bone mineral density (BMD) 2.5 standard deviations (SDs) below peak
bone mass (20-year-old healthy female average) as measured by DXA (dual-energy X-ray absorptiometry).1
The term ‘established osteoporosis’ includes the presence of a fragility fracture.1 Primary osteoporosis can
occur in both men and women, but is most common in women after menopause, when it is termed
postmenopausal osteoporosis. In contrast, secondary osteoporosis may occur in anyone as a result of
medications, specifically glucocorticoids, or in the presence of particular hormonal disorders or other
chronic diseases.2
Osteoporosis was not classified as a disease until relatively recently.3 Previously, it was considered an
inevitable accompaniment of ageing. During human growth, bone formation exceeds resorption.4 Peak
bone mass is achieved by men and women in the third decade of life.5 There then follows a period during
which there is a constant turnover of bone formation when the amount of bone formed by osteoblasts
approximately equals the amount resorbed by osteoclasts.5 Both men and women lose bone after midlife,
when bone resorption starts to exceed formation, and in women there is also a significant rapid loss due
to menopausal hypogonadism.6,7
In 2010, the number of postmenopausal women living with osteoporosis in the UK, based on the
definition of a BMD at least 2.5 SDs lower than that of a young healthy woman (T-score of ≤ –2.5 SDs),
was predicted to increase from 1.8 million in 2010 to 2.1 million in 2020 (+16.5%).8 The prevalence of
osteoporosis in the general population of women aged ≥ 50 years was assumed to remain stable over
time, at approximately 15.5%. In 2014, the reported prevalence of osteoporosis in women ranged from
9% (UK) to 15% (France and Germany) based on total hip BMD and from 16% (USA) to 38% (Japan)
when spine BMD data were included.9 Among males, prevalence ranged from 1% (UK) to 4% (Japan)
based on total hip BMD and from 3% (Canada) to 8% (France, Germany, Italy, and Spain) when spine
BMD data were included.9
Fragility fractures are fractures that result from mechanical forces that would not ordinarily result in
fracture, known as low-level (or ‘low-energy’) trauma. The WHO has quantified this as forces
equivalent to a fall from a standing height or lower. Although osteoporosis is an important predictor
of the risk of fragility fracture, 70% of fragility fractures in postmenopausal women occur in those
who do not meet the criteria for osteoporosis.10 The UK has one of the highest rates of fracture in
Europe: every year 300,000 people in the UK suffer a fragility fracture, of which over 70,000 are hip
fractures.11
Impact of health problem
Significance for patients
Fractures cause significant pain, disability and loss of independence, and can be fatal.1 Osteoporosis
affects over 3 million people in the UK.12 In the UK, 1150 people die every month following a hip
fracture.13
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Significance for the NHS
In 2002, the cost to the NHS per annum was estimated to be £1.7B, with the potential to increase to
£2.1B by 2020, as estimated in 2005.14
Measurement of disease
Quantitative diagnosis in the UK relies on the assessment of BMD, usually by central DXA; BMD at the
femoral neck provides the reference site. It is defined as a value for BMD of ≥ 2.5 SDs below the young
female adult mean (T-score of ≤ –2.5 SDs). Severe osteoporosis (established osteoporosis) describes
osteoporosis in the presence of one or more fragility fractures.15
The National Institute for Health and Care Excellence (NICE) clinical guideline (CG) 146 (CG146)
recommends the use of absolute risk of fragility fracture and recommends the use of one of two
assessment tools:16 FRAX® (web version 3.9; University of Sheffield, Sheffield, UK)17 and QFracture®
(QFracture-2012 open source revision 38; Clinrisk Ltd, Leeds, UK).18,19 Both of these tools provide
estimation of absolute fracture risk over a 10-year period. FRAX is intended for use in individuals aged
40–90 years and QFracture for those aged 30–99 years. The guideline recommends that assessment is
indicated for all women aged > 65 years and all men aged > 75 years.20 Above the age limit of the
tools, people should be considered to be at high risk. Women aged between 50 and 65 years and men
aged between 50 and 75 years should be assessed if they have additional risk factors of previous fragility
fracture, current or frequent recent use of oral or systemic glucocorticoids, a known secondary cause of
osteoporosis, a history of falls, a family history of hip fracture, low body mass index (BMI), smoking or
weekly alcohol intake of > 14 units in women or > 21 units in men. Routine assessment of risk is not
recommended for people under 50 years unless they have major risk factors. The guideline suggests that
risk tools are likely to provide an underestimate of risk if the individual has previously suffered a vertebral
fracture, has a very high alcohol intake, has secondary causes of osteoporosis or is receiving high-dose
oral or high-dose systemic glucocorticoids. The guideline recommends that fracture risk in people under
40 years should be assessed using BMD and only in those with major risk factors such as history of
multiple fragility fractures, major osteoporotic fracture or current/recent use of high-dose oral or
high-dose systemic glucocorticoid therapy.
Current service provision
Clinical guidelines
Currently, related NICE guidance includes a clinical guideline for identifying women and men at risk of
fracture and three technology appraisals of treatments for postmenopausal women only.
Current National Institute for Health and Care Excellence technology
appraisal guidance
The NICE technology appraisal (TA) 160 (TA160; Alendronic acid, etidronic acid, Risedronic acid,
Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in
Postmenopausal Women) guidance21 recommends alendronic acid (Fosamax® and Fosamax® Once Weekly,
Merck Sharp & Dohme Ltd) as first-line treatment for the primary prevention of fragility fractures in
postmenopausal women with osteoporosis who have an increased fracture risk defined by age, T-score
and number of independent clinical risk factors for fracture, or indicators of low BMD. For women who
cannot take alendronic acid, NICE TA16021 and TA20422 recommend risedronic acid (Actonel® and
Actonel Once a Week®, Actavis), etidronic acid (no longer marketed), strontium ranelate (Protelos®, Servier
Laboratories Ltd), teriparatide (Forsteo®, Eli Lilly and Company) or denosumab (Prolia®, AMGen), at
specified fracture risks, defined by age, T-score and number of independent clinical risk factors for
fracture.23
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The NICE TA16124 guidance recommends alendronic acid for secondary prevention of fragility fractures in
postmenopausal women with confirmed osteoporosis. For women who cannot take alendronic acid, the
NICE TA16124 guidance recommends risedronic acid, etidronic acid, raloxifene (Evista®, Daiichi Sankyo),
strontium ranelate and teriparatide at specified fracture risks, defined by age, T-score and number of
independent clinical risk factors for fracture.23
The NICE TA20422 guidance recommends denosumab as a treatment option for the secondary prevention
of osteoporotic fragility fractures only in postmenopausal women at increased risk of fractures who are
unable to comply with the special instructions for administering alendronic acid and either risedronic acid
or etidronic acid, or have an intolerance of, or a contraindication to, those treatments.23
Current service cost
Hernlund et al.25 reviewed the literature on fracture incidence and costs of fractures in the then 27 European
Union (EU) countries and incorporated data into a model estimating the clinical and economic burden of
osteoporotic fractures in 2010. The cost of osteoporosis, including pharmacological intervention, in the
EU in 2010 was estimated at €37B. Treatment of incident fractures accounted for 66% of this cost,
pharmacological prevention for 5% and long-term fracture care for 29%. Excluding the cost of
pharmacological prevention, hip fractures accounted for 54% of the costs, vertebral and forearm fractures
for 5% and 1%, respectively, and ‘other fractures’ for 39%. The estimated number of life-years lost in the
EU because of incident fractures was approximately 26,300 in 2010. The total health burden, measured in
terms of lost quality-adjusted life-years (QALYs), was estimated at 1,180,000 QALYs for the EU.
The cost of osteoporosis in 2010 in the UK (excluding the value of QALYs lost) was estimated by Hernlund
et al.25 at €103M (£88.3M in 2014 prices) for pharmacological fracture prevention, €3977M (£3410M in
2014 prices) for cost of fractures and €1328M (£1139M in 2014 prices) for long-term disability. The 2010
cost of UK osteoporosis fracture in relation to population and health-care spending was €5408M (£4637M
in 2014 prices). It should be noted that the prices reported by Hernlund et al.25 in euros have been
converted to pounds sterling (2006 prices). The conversion ratio used by Hernlund et al.25 was estimated
(at 1.4065) by comparing the unit cost for nursing home stay against the cited UK-specific source data
from 2006. The costs were then uplifted to 2014 prices using the hospital and community health services
inflation indices from the Personal Social Services Research Unit (PSSRU)26 (290.5 for 2013/14 vs. 240.9
for 2005/6).
Variation in services and uncertainty about best practice
Existing NICE technology appraisals (TA16020 and TA16121) do not provide guidance on either ibandronic
acid (Bonviva®, Roche Products Ltd) or zoledronic acid (Aclasta®, Novartis Pharmaceuticals UK Ltd). At
present there is also no NICE guidance on the use of any bisphosphonate for the treatment of primary or
secondary prevention in either men or people with steroid-induced osteoporosis.
Current treatment pathway
The NICE 2014 osteoporosis overview pathway27 is presented in Figure 1. This pathway covers NICE
guidance on osteoporosis in adults (≥ 18 years), including assessing the risk of fragility fracture and drug
treatment for the primary and secondary prevention of osteoporotic fragility fractures.27
Current CGs recommend that fracture risk be assessed by estimating the absolute risk of fracture, whereas
TAs use a defined set of risk factors to delineate people at risk. The modelling approach used in this
assessment report allows intervention thresholds to be linked to absolute risk measured using the two risk
assessment tools recommended in CG146,16 as specified in the scope.23
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The NICE 2014 fragility fracture risk assessment pathway28 is presented in Figure 2. This pathway covers
NICE guidance on osteoporosis in adults (≥ 18 years), including assessing the risk of fragility fracture and
drug treatment for the primary and secondary prevention of osteoporotic fragility fractures.21
Description of technology under assessment
Interventions considered in the scope of this report
Five interventions will be considered within this assessment: oral alendronic acid, oral ibandronic acid,
intravenous (i.v.) ibandronic acid, oral risedronic acid and i.v. zoledronic acid. These are all nitrogen-
containing bisphosphonates.
Mode of action
Bisphosphonates are adsorbed onto hydroxyapatite crystals in bone. Aminobisphosphonate inhibits
prenylation of proteins and leads to osteoclast apoptosis, reducing the rate of bone turnover.29
Marketing licence and administration method
The dosages and administration routes for each treatment are summarised below (see Table 1).
Alendronic acid
Alendronic acid has a UK marketing authorisation for treating postmenopausal osteoporosis, orally once
daily or weekly. The 10-mg daily dose has also has a UK marketing authorisation for treating osteoporosis
in men and for preventing and treating glucocorticoid-induced osteoporosis in postmenopausal women
not receiving hormone replacement therapy (HRT), orally once daily.23
Non-proprietary alendronic acid (AAH, Accord, Actavis, Alliance Healthcare, Almus, APOTEX UK, Fannin UK,
Focus, Generics (UK), Kent, Mylan UK, Phoenix Healthcare Distribution, PLIVA, Ranbaxy Laboratories,
Rosemont, Somex, Sun Pharmaceuticals Industries Ltd, Teva UK, Waymade, Wockhardt UK and Zentiva N.V.)
also has a UK marketing authorisation for the same indications.23
People presenting in any
health-care setting
Fragility fracture risk
assessment
Primary prevention of
osteoporotic fragility
fractures in postmenopausal
women
Secondary prevention of
osteoporotic fragility
fractures in postmenopausal
women
Treatment of vertebral
compression fractures
NICE pathway on patient
experience in adult 
NHS services
1
43
5
2
6
FIGURE 1 Osteoporosis overview pathway. Reproduced from NICE. Osteoporosis Overview – NICE Pathway. London:
NICE; 2014.27
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Alendronic acid in the treatment of postmenopausal osteoporosis is administered orally: 10 mg daily or
70 mg once weekly. Treatment of osteoporosis in men is administered as 10 mg daily. Prevention and
treatment of glucocorticoid-induced osteoporosis in postmenopausal women not receiving HRT is
administered as 10 mg daily. Treatment is administered while sitting or standing and patients should remain
seated or have stood for at least 30 minutes.30
Ibandronic acid
Ibandronic acid has a UK marketing authorisation for treating postmenopausal osteoporosis, orally once
monthly or every 3 months by i.v. injection. Non-proprietary ibandronic acid (produced by Actavis UK,
Consilient Health, Mylan UK, Sun Pharmaceuticals Industries Ltd and Teva UK) also has a UK marketing
authorisation for the same indications.23
Ibandronic acid in the treatment of postmenopausal osteoporosis is administered either by mouth,
150 mg once a month, or by i.v. injection over 15–30 seconds, 3 mg every 3 months. Oral treatment is
administered while sitting or standing and patients should remain seated or stand for at least 1 hour.30
Oral and i.v. ibandronic acid are treated as separate interventions within our analysis.
Risedronic acid
Risedronic acid has a UK marketing authorisation for treating postmenopausal osteoporosis to reduce the
risk of vertebral or hip fractures, orally once daily or weekly. It has a marketing authorisation for preventing
osteoporosis (including glucocorticoid-induced osteoporosis) in postmenopausal women, orally once daily,
and for treating osteoporosis in men at high risk of fractures, orally once weekly. Non-proprietary
risedronic acid (produced by AAH, Actavis, Alliance Healthcare, Aspire, Aurobindo Pharma, Bluefish
Pharmaceuticals AB, Dr Reddy’s Laboratories, Mylan UK, Phoenix Healthcare Distribution, Ranbaxy
Laboratories, Sandoz, Sovereign Medical, Teva UK and Zentiva N.V.) also has a UK marketing authorisation
for the same indications.23
Risedronic acid in the treatment of postmenopausal osteoporosis to reduce the risk of vertebral or hip
fractures is administered as 5 mg daily or 35 mg once weekly. For the prevention of osteoporosis (including
glucocorticoid-induced osteoporosis) in postmenopausal women, treatment is administered as 5 mg daily.
Treatment of osteoporosis in men at high risk of fractures is administered as 35 mg once weekly. Patients
should remain seated or stand for at least 1 hour after administration.30
Zoledronic acid
Zoledronic acid (Aclasta®, Novartis Pharmaceuticals) has a UK marketing authorisation for treating
postmenopausal osteoporosis and osteoporosis in men (including glucocorticoid-induced osteoporosis in
postmenopausal women and men) by i.v. infusion once a year.
Zoledronic acid in the treatment of postmenopausal osteoporosis and osteoporosis in men (including
glucocorticoid-induced osteoporosis in men and postmenopausal women) is administered by i.v. infusion,
5 mg over at least 15 minutes once a year. In patients with a recent low-trauma hip fracture, the dose
should be given ≥ 2 weeks following hip fracture repair.30 Non-proprietary zoledronic acid (produced by
Sun Pharmaceuticals Industries Ltd, Dr Reddy’s Laboratories and Teva UK) also has a UK marketing
authorisation for the same indications.31
Contraindications, special warnings and precautions
The summary of product characteristics (SmPC) for each intervention describes the contraindications and
special warnings for bisphosphonates.31–37
Alendronic acid
The alendronic acid 10-mg daily tablet and 70-mg weekly tablet are contraindicated in patients with
abnormalities of the oesophagus or other factors that delay oesophageal emptying, such as stricture or
BACKGROUND
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achalasia, inability to stand or sit upright for at least 30 minutes, hypersensitivity to alendronic acid or to
any of the excipients, or hypocalcaemia. Additional contraindications for the 70-mg oral solution are
patients who have difficulty swallowing liquids and patients at risk of aspiration.32,33
Special warnings and precautions for use include patients with active upper gastrointestinal (GI) problems and
patients with known Barrett’s oesophagus. Patients with signs or symptoms signalling a possible oesophageal
reaction should be instructed to discontinue treatment. While on treatment, patients with concomitant risk
factors for osteonecrosis of the jaw (e.g. cancer, chemotherapy, radiotherapy, glucocorticoids, poor oral
hygiene, periodontal disease) should avoid invasive dental procedures if possible.32,33
Ibandronic acid
The ibandronic acid 150-mg tablet is contraindicated in patients with hypersensitivity to ibandronic acid or
to any of the excipients, hypocalcaemia, abnormalities of the oesophagus that delay oesophageal
emptying, such as stricture or achalasia, or inability to stand or sit upright for at least 60 minutes. The
3 mg/3 ml solution for injection every 3 months is contraindicated in patients with hypersensitivity to
ibandronic acid or to any of the excipients and in patients with hypocalcaemia.34,35
Special warnings and precautions for use include patients with existing hypocalcaemia and patients with
active upper GI problems (e.g. known Barrett’s oesophagus, dysphagia, other oesophageal diseases, gastritis,
duodenitis or ulcers) (oral administration). Intravenous administration may cause a transient decrease in serum
calcium values. Adequate intake of calcium and vitamin D is important in all patients. Patients should be
instructed to discontinue ibandronic acid and seek medical attention if they develop dysphagia, odynophagia,
retrosternal pain or new or worsening heartburn. While on treatment, patients with concomitant risk factors
for osteonecrosis of the jaw (e.g. cancer, chemotherapy, radiotherapy, glucocorticoids, poor oral hygiene,
periodontal disease) should avoid invasive dental procedures if possible.34,35
Risedronic acid
The risedronic acid 5-mg daily tablet and 35-mg weekly tablet are contraindicated in patients with
hypersensitivity to the active substance or to any of the excipients, hypocalcaemia, or severe renal
impairment (a creatinine clearance of < 30 ml/minute) and during pregnancy and lactation.36,37
Special warnings and precautions for use include patients who have a history of oesophageal disorders that
delay oesophageal transit or emptying (e.g. stricture or achalasia, patients who are unable to stay in the
upright position for at least 30 minutes after taking the tablet and patients with active or recent oesophageal
or upper GI problems, including known Barrett’s oesophagus). Patients should be instructed to seek timely
medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing,
retrosternal pain or new or worsened heartburn. While on treatment, patients with concomitant risk factors
for osteonecrosis of the jaw (e.g. cancer, chemotherapy, radiotherapy, glucocorticoids, poor oral hygiene,
periodontal disease) should avoid invasive dental procedures if possible.36,37
Zoledronic acid
A 5-mg annual infusion of zoledronic acid is contraindicated in patients with hypersensitivity to the active
substance, to any bisphosphonates or to any of the excipients, patients with hypocalcaemia, patients
with severe renal impairment with a creatinine clearance of < 35 ml/minute, and during pregnancy
and breastfeeding.31
Special warnings and precautions for use are required in patients with severe renal impairment (creatinine
clearance < 35 ml/minute) and in those with pre-existing renal dysfunction or other risk factors, including
advanced age, concomitant nephrotoxic medicinal products, concomitant diuretic therapy or dehydration
occurring after administration, or with pre-existing hypocalcaemia. Adequate calcium and vitamin D
intake are recommended. The incidence of post-dose symptoms occurring within the first 3 days after
administration can be reduced with the administration of paracetamol (Panadol®, GlaxoSmithKline
Consumer Healthcare) or ibuprofen [Nurofen, Reckitt Benckiser Healthcare (UK) Ltd].31
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The SmPCs for each intervention also state that atypical subtrochanteric and diaphyseal femoral have been
reported with bisphosphonate therapy; during bisphosphonate treatment patients should be advised to
report any thigh, hip or groin pain and any patient presenting with such symptoms should be evaluated for
an incomplete femur fracture.31–37
Place in treatment pathway
Alendronic acid is recommended as first-line treatment for the primary prevention of fragility fractures in
postmenopausal women with osteoporosis who have an increased fracture risk. Risedronic acid, raloxifene,
strontium ranelate and teriparatide are recommended for women at specific risk of fracture who cannot
take alendronic acid.
In addition to first-line treatment for the primary prevention of fragility fractures in postmenopausal
women, alendronic acid is also recommended as a treatment option for the secondary prevention of
osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis.
Risedronic acid, raloxifene, strontium ranelate and teriparatide are recommended for women at specific
risk of fracture who cannot take alendronic acid.24
Ibandronic acid and zoledronic acid do not have recommendations from NICE for the prevention of
fragility fractures.
Denosumab is recommended as a treatment option for the primary prevention of osteoporotic fragility
fractures only in postmenopausal women at increased risk of fracture who are unable to comply with the
special instructions for administering alendronic acid and either risedronic acid or etidronic acid, or who
have an intolerance of, or a contraindication to, those treatments.22
Identification of important subgroups
The final NICE scope specified subgroups based on patient characteristics that increase the risk of fracture
(those specified in NICE CG146)16 or that affect the impact of fracture on lifetime costs and outcomes.23
Current usage in the NHS
Data from the Prescription Cost Analysis: England 201338 were analysed to determine the level of
bisphosphonate usage within primary care across England in 2013. It can be seen from the data
summarised in Table 1 that generic weekly alendronic acid was the most commonly prescribed preparation
in primary care. Furthermore, generic prescriptions were more common than branded prescriptions across
all treatments, where generic prescriptions were reported. Unlike primary care, there is no central NHS
collation of information on medicines issued and used in NHS hospitals. However, a report on hospital
prescribing in 201242 provides data on treatments recommended by NICE. From table 4 of the report42 it
can be seen that the vast majority of prescribing for alendronic acid and risedronic acid occurred in primary
care, with only 5% of the costs attributable to alendronic acid and risedronic acid prescribing occurring
within secondary care. As data from Prescription Cost Analysis: England 201338 cover those medicines
dispensed only in the community, and i.v. bisphosphonates are usually prescribed in secondary care, it
should be noted that the figures in Table 1 will underestimate the prescribing of i.v. ibandronic acid and
zoledronic acid. Data on i.v. bisphosphonates are not included in hospital prescribing data, as data were
provided for individual drugs only if they had already been recommended by NICE.
Anticipated costs associated with interventions
Table 1 summarises the 2014 net costs associated with the interventions based on their list prices.23
A list price was not available for generic zoledronic acid so the price reported in the manufacturer’s
product catalogue has been included in Table 1.
BACKGROUND
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TABLE 1 Summary of dosages, preparations, list prices and primary care prescribing for bisphosphonates treatments
Interventions
Dosing
schedule
Generic or
branded Description of preparations List price per unit
Prescriptions
in thousandsa
Alendronic acid
(oral)
Daily, 10 mg Branded Fosamax tablets, alendronic acid
(as sodium alendronate), 10 mg
28-tablet
pack = £23.12b
0.749
Generic Tablets, alendronic acid
(as sodium alendronate), 10 mg
28-tablet
pack = £2.17b
46.605
Weekly,
70 mg
Branded Fosamax tablets, alendronic acid
(as sodium alendronate), 70 mg
Four-tablet
pack = £22.80b
25.655
Generic Tablets, alendronic acid
(as sodium alendronate), 70 mg
Four-tablet
pack = £1.01b
7273.660
Oral solution, sugar-free,
alendronic acid (as sodium
alendronate), 70 mg/100ml
Four × 100ml=
£22.80b
10.442
Risedronic acid
(oral)
Daily, 5 mg Branded Actonel tablets, risedronate
sodium, 5 mg (yellow)
28-tablet
pack = £17.99b
1.023
Generic Tablets, risedronate sodium,
5 mg
28-tablet
pack = £13.24b
25.777
Weekly,
35 mg
Branded Actonel Once a Week tablets,
orange, risedronate sodium,
35 mg
Four-tablet
pack = £19.12b
19.961
Generic Tablets, risedronate sodium,
35 mg
Four-tablet
pack = £1.18b
679.026
Ibandronic acid
(oral)
Monthly,
150 mg
Branded Bonviva tablet, 150 mg One-tablet
pack = £18.40b
22.670
Three-tablet
pack = £55.21b
Generic Ibandronic acid tablet, 150 mg 150-mg tablet,
one-tablet
pack = £1.61c
204.006
Ibandronic acid tablet, 50 mg 50-mg tablet,
28-tablet
pack = £10.78b
Ibandronic acid
(i.v.)
Quarterly,
3 mg
Branded Bonviva injection, 3 mg/3 ml 3-ml prefilled
syringe = £68.64b
0.181
Generic Ibandronic acid injection,
3-mg/3-ml prefilled syringe
3-ml prefilled
syringe = £65.20c
0.324
Zoledronic acid
(i.v.)
Annually,
5 mg
Branded Aclasta i.v. infusion,
5-mg/100-ml bottle
100-ml
bottle = £253.38b
0.070
Generic i.v. infusion, zoledronic acid,
5 mg/100 ml
100-ml
bottle = £217.68d
Not reported
MIMS, Monthly Index of Medical Specialities.
a Prices based on British National Formulary.39
b Prescription items dispensed in the community in 201338 (prescriptions for i.v. bisphosphonates dispensed in secondary
care are not captured in these figures).
c Prices based on MIMS.40
d Price based on Hospira Product Catalogue.41
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Chapter 2 Definition of the decision problem
Decision problem
The aim of this assessment is to assess the clinical effectiveness and cost-effectiveness of alendronic acid,
risedronic acid, oral ibandronic acid, i.v. ibandronic acid and zoledronic acid in the prevention of fragility
fractures compared either with each other or with a non-active treatment.
Interventions
Five interventions will be considered within this assessment: alendronic acid, risedronic acid, oral ibandronic
acid, i.v. ibandronic acid and zoledronic acid. These interventions are described in detail in Chapter 1,
Description of technology under assessment.
Populations (including subgroups)
The assessment considers the following populations:
1. all women aged ≥ 65 years and men aged ≥ 75 years
2. women aged ≤ 64 years and men aged ≤ 74 years in the presence of risk factors, for example previous
fragility fracture; current use or frequent recent use of oral or systemic glucocorticoids; history of falls;
family history of hip fracture; other causes of secondary osteoporosis; low BMI (< 18.5 kg/m2); smoking;
alcohol intake of > 14 units per week in women or > 21 units per week in men
3. women aged 64 years and men aged ≤ 74 years with low BMD (a T-score of –1 SD or more below the
young adult mean).
An evaluation of the interventions in the following populations is outside the appraisal scope and will not
be considered in this assessment:
l women aged ≤ 64 years without a risk factor [see Populations (including subgroups)]
l men aged ≤ 74 years without a risk factor [see Populations (including subgroups)].
Relevant comparators
Bisphosphonates (alendronic acid, risedronic acid, oral ibandronic acid, i.v. ibandronic acid and zoledronic
acid) may be compared with each other or with a non-active agent, for example placebo.
Other bisphosphonates (e.g. etidronic acid) and other active agents (e.g. raloxifene, strontium ranelate and
teriparatide) will not be considered as comparators in this assessment.
Etidronic acid is not included as a comparator as it has been discontinued by the manufacturer in the UK.
Non-bisphosphonates licensed for the prevention of fragility fractures in women and men will be
considered in a separate multiple technology appraisal (MTA).
Outcomes
The outcome measures to be considered included:
l fragility fracture (fractures that result from mechanical forces that would not ordinarily result in fracture)
¢ hip fracture
¢ vertebral fracture (where data allow, clinical/symptomatic fractures will be reported separately from
morphometric/radiographic fractures, with the latter being defined as those resulting in a ≥ 20%
reduction in vertebral height)
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¢ all non-vertebral fracture
¢ wrist fracture
¢ proximal humerus fracture
¢ fragility fracture at other sites
l BMD at the femoral neck assessed by DXA
l mortality
¢ all cause
¢ mortality following hip fracture
¢ mortality following vertebral fracture
¢ mortality following fracture at site other than hip or vertebral
l adverse effects of treatment including but not limited to
¢ upper GI symptoms
¢ osteonecrosis of the jaw
¢ hypocalcaemia
¢ bone pain (not associated with influenza-type symptoms)
¢ atypical femoral fractures
¢ influenza-like symptoms including bone pain, myalgia, arthralgia, fever and rigors
¢ conjunctivitis
¢ atrial fibrillation
¢ stroke
l continuance (or persistence; proportion of people still on treatment at the end of a given period)
and concordance (or compliance; proportion of prescribed doses taken during a given period)
l health-related quality of life (HRQoL)
l health-care resource use, for example hospitalisation, entry into long-term residential care.
Key issues
An evaluation of the interventions in the following populations is outside the appraisal scope and will not
be considered in this assessment:
l women aged ≤ 64 years without a risk factor [see Populations (including subgroups)]
l men aged ≤ 74 years without a risk factor [see Populations (including subgroups)].
Overall aims and objectives of assessment
This assessment addresses the question ‘what is the clinical effectiveness and cost-effectiveness of
alendronic acid, risedronic acid, oral ibandronic acid, i.v. ibandronic acid and zoledronic acid in the
prevention of fragility fractures as compared against each other or a non-active treatment?’.
More specifically, the objectives of the assessment are to:
l evaluate the clinical effectiveness of each intervention
l evaluate the adverse effect profile of each intervention
l evaluate the incremental cost-effectiveness of each intervention compared with (1) each other and
(2) no active treatment
l estimate the overall NHS budget impact in England.
DEFINITION OF THE DECISION PROBLEM
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Chapter 3 Assessment of clinical effectiveness
A systematic review of the literature with evidence synthesis including a network meta-analysis (NMA)was conducted in order to evaluate the clinical effectiveness and safety of alendronic acid, risedronic
acid, oral ibandronic acid, i.v. ibandronic acid and zoledronic acid in the prevention of fragility fractures.
The systematic review of clinical effectiveness was undertaken in accordance with the general principles
recommended in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement.43
Methods for reviewing effectiveness
The protocol for this review is registered with PROSPERO (CRD42013006883).44
Identification of studies
A comprehensive search was undertaken to systematically identify clinical effectiveness literature relating to
alendronic acid, risedronic acid, oral ibandronic acid, i.v. ibandronic acid, and zoledronic acid within their
licensed indications for the prevention of fragility fractures. The search strategy comprised the following
main elements:
l searching of electronic databases
l contact with experts in the field
l scrutiny of bibliographies of retrieved papers.
The following databases were searched:
l MEDLINE In-Process & Other Non-Indexed Citations and MEDLINE (via Ovid) from 2008 to
23 September 2014
l EMBASE (via Ovid) from 2008 to 23 September 2014
l Cochrane Database of Systematic Reviews (via Wiley Online Library) from 2008 to 23 September 2014
l Database of Abstracts of Reviews of Effects (via Wiley Online Library) from 2008 to 23 September 2014
l Cochrane Central Register of Controlled Trials (via Wiley Online Library) from 2008 to
23 September 2014
l Health Technology Assessment Database (via Wiley Online Library) from 2008 to 23 September 2014
l Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost) from 2008 to
23 September 2014
l Science Citation Index Expanded (via Web of Science) from 2008 to 23 September 2014
l Conference Proceedings Citation Index – Science (via Web of Science) from 2008 to
23 September 2014
l Bioscience Information Service (via Web of Science) from 2008 to 23 September 2014.
Existing evidence reviews20 commissioned by NICE, which included literature published up to June 2008,
were assumed to have identified all papers relevant to this review published prior to 2008. Therefore,
searches were limited by date from 2008 until 26 September 2014. Searches were not restricted by
language or publication type. Subject headings and keywords for ‘osteoporosis’ were combined with each
of the named drug interventions. The MEDLINE search strategy is presented in Appendix 1. The search was
adapted for the other databases. Highly sensitive study design filters were used to retrieve clinical trials and
systematic reviews on MEDLINE and other databases, where appropriate. Consultee submissions and
relevant systematic reviews were also hand-searched in order to identify any further relevant clinical trials.
Two clinical trials research registers (ClinicalTrials.gov and the WHO’s International Clinical Trials Registry
Platform) were also searched for ongoing and recently completed research projects. Citation searches of
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key included studies were also undertaken using the Web of Science database. All potentially relevant
citations were downloaded to Reference Manager bibliographic software (version 12.0; Thomson Reuters,
Philadelphia, PA, USA) and deduplication of citation records was undertaken.
Inclusion and exclusion criteria
Inclusion criteria have been defined in line with the final scope provided by NICE23 and are outlined below.
Study selection process
The selection of eligible articles was undertaken by two reviewers (MMSJ and EG). Both reviewers sifted all
downloaded citations (4117). Citations not meeting the exclusion criteria based on the title and/or abstract
were excluded at the sifting stage. All potentially relevant citations were marked to be obtained at full text
for further scrutiny. A check for consistency was undertaken using a Cohen’s kappa coefficient of inter-
rater agreement. A high level of agreement between reviewers (0.951) was observed. Any uncertainty
regarding the eligibility of potentially relevant full-text articles was resolved through discussion. Articles that
were obtained as full text for screening that were subsequently excluded were recorded together with the
reason for exclusion. A table of excluded studies at full text with reason is presented in Appendix 2,
Table 41.
Inclusion criteria
Studies were included in the review if they met the inclusion criteria outlined below.
Interventions
Any of the following interventions were included:
l alendronic acid (oral)
l risedronic acid (oral)
l ibandronic acid (oral)
l ibandronic acid (i.v.)
l zoledronic acid (i.v.).
Studies in which the interventions were assessed in line with licensed indications were included in the
systematic review. Studies that titrated doses upwards from unlicensed to licensed doses within treatment
groups during the trial period were eligible for inclusion. Studies that evaluated both licensed and unlicensed
dose study groups were included where outcome data only for the licensed group could be extracted. Data
reported for licensed and unlicensed doses combined (pooled study groups) were not eligible for inclusion.
With respect to ibandronic acid, the licence authorisation was supported by trials assessing the antifracture
efficacy of 2.5 mg per day orally and 20 mg every other day orally (dose not licensed) compared with
placebo [iBandronate Osteoporosis vertebral fracture trial in North America and Europe (BONE)45,46] and
assessing non-inferiority of oral daily dosing (2.5 mg) compared with oral monthly dosing (100 mg or
150 mg) on BMD [the Monthly Oral iBandronate In LadiEs (MOBILE) trial].47,48 A bridging study then
demonstrated superiority for the current licensed i.v. dose of 3 mg every 3 months compared with the
2.5 mg once daily oral dose in terms of BMD [the Dosing IntraVenous Administration (DIVA) trial].49,50 As
such, these pivotal trials along with other trials comparing ibandronic acid 2.5 mg with placebo were
eligible for inclusion in addition to those assessing current licensed doses.
Populations
Studies were included that evaluated women aged ≥ 65 years or men aged ≥ 75 years. Studies were
included if they evaluated women aged ≤ 64 years and men aged ≤ 74 years in the presence of risk
factors, for example previous fragility fracture, current use or frequent recent use of oral or systemic
glucocorticoids, a history of falls, a family history of hip fracture, other causes of secondary osteoporosis,
low BMI (< 18.5 kg/m2), smoking or an alcohol intake of > 14 units per week in women or > 21 units per
week in men. Studies were also included if they evaluated women aged ≤ 64 years and men aged
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≤ 74 years with low BMD (a T-score of –1 SD or more below the young adult mean). Studies that recruited
mixed populations of men and women were also included, as were studies that recruited samples with
mixed population characteristics, for example if they recruited a sample of women aged ≤ 65 years with
and without risk fractures.
In studies evaluating participants with risk factors for or the presence of secondary osteoporosis [e.g.
treatment with aromatase inhibitors or androgen deprivation therapy (ADT)] that did not evaluate a treatment
of interest within its licensed indication, advice was sought from the clinical advisor (PS) regarding inclusion.
Comparators
Relevant comparators included interventions compared with each other. Interventions could be compared
with placebo or other non-active treatments (i.e. treatment without the potential to augment bone).
Studies that administered calcium and/or vitamin D to patients in both the intervention and comparator
arms were included (e.g. bisphosphonate plus calcium vs. placebo plus calcium).
Outcomes
Eligible outcomes for consideration included fragility fractures, BMD at the femoral neck, mortality, adverse
effects, compliance, HRQoL and health-care resource use. These are described in full in Chapter 2,
Decision problem.
Study design
Randomised controlled trials (RCTs) were eligible for inclusion in the clinical effectiveness systematic review.
If no RCTs were identified for an intervention, non-randomised studies were considered for inclusion.
Non-randomised studies were also considered for inclusion, where necessary, as a source of additional
evidence [e.g. relating to adverse events (AEs), long-term incidence of fragility fracture, treatment persistence,
etc.] associated with the interventions. This evidence was considered important for demonstrating rare,
catastrophic and delayed AEs of treatments along with information regarding long-term treatment continuance
and concordance that are not captured by RCTs. Observational studies can provide information about how
technologies function in real-world settings. For this assessment report, this evidence was summarised from
existing systematic reviews.
Studies published as abstracts or conference presentations were eligible for inclusion only if sufficient
details were presented to allow an assessment of the trial methodology and results to be undertaken.
Exclusion criteria
The following types of studies were excluded from the review:
l studies in patients with normal or unspecified BMD who were not selected based on the presence of
risk factors
l studies in patients with other indications for bisphosphonate treatment, for example Paget’s disease,
hypercalcaemia of malignancy, metastatic breast cancer
l studies in which administration of interventions was not in accordance with the licensed indications
l studies in which interventions were co-administered with any other therapy with the potential to
augment bone, unless concomitant treatments are specified in the SmPC
l systematic reviews and clinical guidelines (these were used as sources of references)
l studies that were considered methodologically unsound in terms of study design or the method used
to assess outcomes
l studies that were published only in languages other than English
l studies based on animal models
l preclinical and biological studies
l narrative reviews, editorials, opinions
l reports published as abstracts or conference presentations only, where insufficient details were
reported to allow an assessment of study quality or results.
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Data abstraction strategy
Data relevant to the decision problem were extracted by two reviewers (MMSJ or EG). Data were extracted
without blinding to authors or journal. A data extraction form was developed and piloted on two included
trials before use on all included trials. Data relating to study arms in which the intervention treatments
were administered in line with their licensed indications were extracted; data relating to the unlicensed
use of the interventions were not extracted. MMSJ and EG checked at least 10% of each other’s data
extraction forms. All extracted outcome data to be used in the analyses were double-checked by a third
reviewer (FC). The safety data extracted were informed by the SmPCs for each product (available from
www.medicines.org.uk/emc/).31–37 The key safety issues included such items as the number of patients
experiencing AEs, the number of patients withdrawing because of AEs, the number of patients experiencing
upper GI tract symptoms, the number of patients with osteonecrosis of the jaw, hypocalcaemia, bone pain,
atypical femoral fractures, atrial fibrillation or stroke, and the number of patients experiencing flu-like
symptoms. Outcome data that were presented only in graphical format were digitised and estimated using
xyExtract software (version 5.1; Wilton and Cleide Pereira da Silva, Paraiba, Brazil). Where multiple publications
of the same study were identified, data extraction was undertaken on all relevant associated publications
and findings were presented together with reference to their published source.
Critical appraisal strategy
The methodological quality of each included study was assessed by one reviewer (MMSJ or EG). The
quality of included studies was assessed using the Cochrane Risk of Bias Tool.51 This tool addresses specific
domains, namely sequence generation, allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data and selective outcome reporting. RCTs were
classified as being at ‘high risk’ of attrition bias if dropout in any treatment arm was ≥ 10%.52 In order to
inform the selective reporting domain of the Cochrane Risk of Bias Tool, a judgement was made that
peer-reviewed articles which reported approval of a trial protocol or a trial registration number could be
considered as being at ‘low risk’ of bias for this domain. All quality assessment findings were double
checked by a second reviewer (MMSJ or EG).
Methods of data synthesis
The extracted data were presented for each study both in structured tables and as a narrative description.
Methods for the estimation of efficacy using network meta-analysis
Network meta-analysis methods are described in full alongside results in Methods for the network
meta-analyses, with further details provided in Appendix 3.
Supplementary meta-analyses
Where considered appropriate, secondary outcomes of interest were analysed using classical meta-analysis
methods. Meta-analysis was undertaken using Cochrane Review Manager software (version 5.2, The
Cochrane Collaboration, Copenhagen, Denmark). Outcomes reported as continuous data were
summarised using a mean difference with 95% confidence intervals (CIs). Dichotomous outcomes were
summarised as risk ratios (RRs) with associated 95% CIs. Where RCTs reported AEs in sufficient detail,
these were analysed as dichotomous data. Clinical heterogeneity across RCTs (the degree to which RCTs
appear different in terms of participants, intervention type, and duration and outcome type) was
considered prior to data pooling. Random-effects models were applied. Effect estimates, estimated in
Review Manager as z-scores, were considered statistically significant at a p-value < 0.05.
Results
Quantity and quality of the available research
The searches described in Identification of studies identified 4117 potentially relevant citations from searches
of electronic databases after removal of duplicates. A further 83 citations were identified from an existing
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evidence review commissioned by NICE.20 Of these records, 4056 were excluded at the title or abstract
stage. Full texts of 144 citations were obtained for scrutiny. Of these, 85 citations were excluded (excluded
studies with reason for exclusion is presented in Appendix 2, Table 41). A total of 46 RCTs,45,47,49,53–95
reported across 59 citations, were included in the review.
The search process is summarised in the form of a PRISMA flow diagram96 in Figure 3.
The summary of the included RCTs is presented in Table 2 and the characteristics of the included RCTs are
presented in Table 3.
Study and population characteristics of included trials
A summary of the number of RCTs and citations by treatment along with the author, trial name (where
reported) and population is presented in Table 2. The trial design of the included studies including country,
inclusion/exclusion criteria, treatment doses and numbers randomised, outcome assessment methods and
final follow-up are presented in Table 3. Characteristics of included participants including sex, age and
baseline femoral neck BMD and fractures are presented in Table 4.
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59 citations relating to 46 RCTs
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FIGURE 3 Flow diagram of study selection process (adapted from PRISMA): clinical effectiveness review.
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TABLE 2 Summary of RCTs by treatment
Treatment, number of RCTs
(number of citations) Trial (trial acronym) Population
Alendronic acid vs. placebo, 17 RCTs
(19 citations)
Adami et al., 199553 Women with PMO
Black et al., 199655 Women with PMO
Cummings et al., 199864 Women with PMO
Bone et al., 200057 Women with PMO
Carfora et al., 199860 Women with PMO
Chesnut et al., 199561 Women with PMO
Dursun et al., 200165 Women with PMO
Greenspan et al., 200267 Women with PMO
Greenspan et al., 200368 Women aged ≥ 65 years
Ho and Kung, 200571 Women with PMO
Klotz et al., 201373 (CORAL) Men with androgen deprivation bone
loss in non-metastatic prostate cancer
Liberman et al., 199576 Women with PMO
Seeman 199997 Women with PMO
Orwoll et al., 200083 Men with OP
Pols et al., 199984 (FOSIT) Women with PMO
Saag et al., 1998;91 extension of
Adachi et al., 200198
Men and women with glucocorticoid-
induced OP
Shilbayeh et al., 200493 Women with PMO
Smith et al., 200494 Men and women with asthma and/or
chronic obstructive airways disease
Ibandronic acid (unlicensed daily oral
dose) vs. placebo, one RCT (two citations)
Chesnut et al., 200445;
Chesnut et al., 200546 (BONE)
Women with PMO
Ibandronic acid (monthly oral dose) vs.
placebo, two RCTs (two citations)
Lester et al., 200874 (ARIBON) Postmenopausal women with breast
cancer
McClung et al., 200980 Women with PMO
Ibandronic acid dose-ranging trials
(quarterly i.v. dose vs. unlicensed daily oral
dose), one RCT (two citations)
Delmas et al., 2006;49 Eisman et al.,
200850 (DIVA)
Women with PMO
Ibandronic acid dose-ranging trials
(monthly oral dose vs. unlicensed daily
oral dose), one RCT (two citations)
Miller et al., 2005;47
Reginster et al., 200648 (MOBILE)
Women with PMO
Risedronic acid vs. placebo, 12 RCTs
(15 citations)
Boonen et al., 200958 Men with OP
Choo et al., 201162 Men with androgen deprivation bone
loss in non-metastatic prostate cancer
Cohen et al., 199963 Men and women (≥ 1 year PM) aged
18–85 years on glucocorticoids
Fogelman et al., 200066 (BMD-MN) Women with PMO
Hooper et al., 200572 Early PM women with OP
Harris et al., 199970 (VERT-NA);
extension of Ste-Marie et al.,
200499
Women with PMO
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TABLE 2 Summary of RCTs by treatment (continued )
Treatment, number of RCTs
(number of citations) Trial (trial acronym) Population
Reginster et al., 200085 (VERT-MN);
extension of Sorensen et al.,
2003100
Women with PMO
Leung et al., 200575 Women with PMO
McClung et al., 200178 Women with PMO
Reid et al., 200086 Men and women taking
glucocorticoids for ≥ 6 months
Ringe et al., 2006;89 extension of
Ringe et al., 2009101
Men with OP
Taxel et al., 201095 Men aged > 55 years and within
1 month of receiving an initial
injection of ADT for prostate cancer
Zoledronic acid vs. placebo, four RCTs
(six citations)
Black et al., 200756 (HORIZON-PFT);
AEs following administration,
Reid et al. 2010102
Women with PMO
Lyles et al., 200777 (HORIZON-RFT);
HRQoL, Adachi et al., 2011103
Men and women ≥ 50 years of age
within 90 days after surgical repair of
a hip fracture
Boonen et al., 201259 Men with OP
McClung et al., 200979 Women with PMO
Alendronic acid vs. ibandronic acid
(monthly oral dose), one RCT
(one citation)
Miller et al., 200881 (MOTION) Women with PMO
Alendronic acid vs. risedronic acid,
five RCTs (seven citations)
Atmaca and Gedik 200654 Women with PMO
Muscoso et al., 200482 Women with PMO
Sarioglu et al., 200692 Women with PMO
Rosen et al., 200590 (FACT);
extension of Bonnick et al., 2006104
Women with PMO
Reid et al., 200687 (FACTS);
extension of Reid et al., 2008105
Women with PMO
Zoledronic acid vs. alendronic acid,
one RCT (two citations)
Hadji et al., 2010;106 Hadji et al.,
201269 (ROSE)
Women with PMO
Zoledronic acid vs. risedronic acid,
one RCT (one citation)
Reid et al., 200988 (HORIZON) Men and women taking
glucocorticoids for ≥ 3 months and for
< 3 months
ARIBON, reversal of anastrozole (ARImidex) induced bone loss with oral monthly ibandronate (BONdronat) treatment during
adjuvant therapy for breast cancer trial; CORAL, Cancer and Osteoporosis Research with Alendronate and Leuprolide trial;
FACT, Fosamax Actonel Comparison Trial; FACTS, Fosamax Actonel Comparison Trial International Study; FOSIT, FOSamax
International Trial; HORIZON, Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly trial; HORIZON-
PFT; Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly – Pivotal Fracture Trial; HORIZON-RFT,
Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly – Recurrent Fracture Trial; MOTION, Monthly
Oral Therapy with Ibandronate for Osteoporosis iNtervention trial; OP, osteoporosis; PM, postmenopausal; PMO,
postmenopausal osteoporosis; ROSE, Rapid Onset and Sustained Efficacy trial; VERT-NA, Vertebral efficacy with Risedronate
Therapy – North American trial; VERT-MN, Vertebral Efficacy with Risedronate Therapy – MultiNational trial.
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TABLE 3 Characteristics of included studies: clinical effectiveness review
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
ALN vs. PBO
Adami et al., 1995;53
Italy
Multicentre RCT,
11 centres
Sponsor NR
Inclusion: women at least 2 years
past natural menopause; the
majority were aged < 65 years.
Each had LS BMD which was
> 2 SDs below the mean for young
women. Evidence of previous
vertebral fracture was not an entry
criterion, and only 5% of subjects
had prevalent fractures
Exclusion: evidence of any
secondary cause of OP, other
metabolic bone disease, hyper- or
hypothyroidism. Medications
affecting bone metabolism
PBO, n= 71; ALN
10mg/day, n = 78
Adjuvant: both groups,
calcium 500mg/day
24 months
BMD assessed at
24 months
Primary: change in the LS
BMD (L1–L4)
Secondary: change in the FN
and trochanter spine BMD
Fractures: not an outcome
BMD: DXA (Hologic, Waltham,
MA, USA; Lunar, Madison, WI,
USA; Norland, WI, USA; and
Sophos, Paris, France)
Black et al., 199755
(FIT I); USA
Multicentre RCT, 11
centres
Merck Research
Laboratories
Inclusion: women aged between 55
and 81 years, postmenopausal for
at least 2 years, had at least one
vertebral fracture and FN BMD of
≤ 0.68 g/cm2 (≤ 2 SDs below
normal young adult)
Exclusion: peptic ulcer disease,
dyspepsia requiring treatment,
abnormal renal function, major
medical problems that would
preclude participation, severe
malabsorption syndrome,
hypertension, myocardial infarction,
unstable angina, disturbed thyroid
or parathyroid function, use of
oestrogen, calcitonin,
bisphosphonates or sodium fluoride
PBO, n= 1005; ALN
10mg/day, n = 1022
Adjuvant: both groups,
women with low calcium
intake 500 mg/day of
calcium supplements and
250 IU/day of vitamin D
36 months
Lateral radiographs were
obtained at baseline,
24 months and
36 months
Primary: new vertebral
fractures at 3 years – a new
vertebral fracture if any of
the ratios of vertebral
heights was more than
3 reports below the mean
population norm for that
vertebral level
Secondary: non-vertebral
fractures (hip, wrist, and
others); FN, LS and TH BMD
AEs
Fractures: vertebrae were
judged to be fractured by
morphometric assessment
using a translucent digitiser.
Clinical fractures (non-spine
clinical fractures, hip fractures,
wrist fractures and clinical
vertebral fractures, and other
clinical fractures) were
reported by participants and
confirmed by a required
written report of a radiological
procedure
BMD: DXA – QDR-2000
Hologic (Waltham, MA, USA)
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Cummings et al. 199864
(FIT II); USA
Multicentre RCT,
11 centres
Merck Research
Laboratories
Inclusion: women aged 55–80 years;
postmenopausal for at least 2 years;
FN BMD of ≤ 0.68 g/cm2 (≤ 2 SDs
below normal young adult)
Exclusion: peptic ulcer disease,
dyspepsia requiring treatment,
abnormal renal function, major
medical problems that would
preclude participation, severe
malabsorption syndrome,
hypertension, myocardial infarction,
unstable angina, disturbed thyroid
or parathyroid function, use of
oestrogen, calcitonin,
bisphosphonates or sodium fluoride
PBO: n= 2218; ALN
10mg/day, n = 2214
Adjuvant: both groups,
women with low calcium
intake 500 mg/day of
calcium supplements and
250 IU/day of vitamin D
48 months
Lateral radiographs were
obtained at baseline and
and 48 months
Primary: clinical fractures
(vertebral and non-vertebral)
confirmed by radiographs at
4.2 years
Secondary: change in BMD
of the hip and
posterior–anterior spine and
whole body; AEs, from
baseline in each group
Fractures: clinical fractures
were defined as one
diagnosed by a physician.
Self-reports of fractures were
confirmed by radiographic or
other tests (not described).
Traumatic fractures and
fractures of the face/skull were
excluded
Vertebral fractures were
assessed by radiographs.
Fracture was defined as 20%
decrease in height and 4mm
decrease in vertebral height
BMD: DXA – QDR-2000
(Hologic, Waltham, MA, USA)
Bone et al., 2000;57
countries not specified
RCT, number of centres
not specified
Merck Research
Laboratories
Inclusion: postmenopausal
osteoporotic women aged
42–82 years, with hysterectomy;
BMD < 0.862 g/cm2 on at least
three vertebra, LS T-score of
≤ –2.5 SDs
Exclusion: metabolic bone disease,
low vitamin D, oestrogen
replacement therapy > 6 months,
drugs that affect bone turnover,
renal insufficiency, cardiac disease,
upper GI disease
PBO, n= 50; ALN
10mg/day, n = 92
Adjuvant: both groups,
1000mg/day of calcium
24 months
BMD assessed at 3, 6,
12, 18 and 24 months
Primary: change BMD of the
LS, at 24 months
Secondary: change in BMD
of the TH, FN, trochanter
and total body; biochemical
markers of bone turnover;
fractures; AEs
Fractures: clinical fractures
recorded as AEs (assessment
method NR)
BMD: Hologic QDR
densitometers (QDR-1000,
-1000/W, -1500 or -2000;
Hologic Inc., Waltham, MA,
USA)
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Carfora et al., 1998;60
Italy
Single-centre RCT
Sponsor NR
Inclusion: postmenopausal women
(for ≥ 5 years); aged 44–80 years;
at least 2.5 SDs below the mean
value in premenopausal white
women
Exclusion: women with other
causes of OP or vitamin D
deficiency, Paget’s disease,
hyperparathyroidism, peptic ulcer,
abnormal renal/hepatic function,
abnormalities of LS
PBO, n= 34; ALN
10mg/day, n = 34
Adjuvant: both groups,
500mg/day of calcium
30 months
BMD assessed every
5 months, radiography
at baseline and end
treatment
Primary: change in BMD of
the spine at 2.5 years
Secondary: fractures;
biochemical markers of bone
turnover; and AEs
Fractures: radiography of the
thoracic and LS to evaluate
fractures. No further details
reported
BMD: DXA – QD|R1000
(Hologic)
Chesnut et al., 1995;61
USA
Multicentre RCT, seven
centres
Merck Research
Laboratories
Inclusion: women aged
42–75 years, at least 5 years
postmenopausal, with LS BMD
≤ 0.88 g/cm2 (approximately 2 SDs
below young, normal US white
female mean BMD values)
Exclusion: medications affecting
bone metabolism were excluded,
the presence of spine or hip
fractures attributable to OP
PBO, n= 31; ALN
10mg/day, n = 30
Also evaluated ALN
5mg/day, n = 32; 20 mg,
n= 32; 40 mg/PBO,
n= 32, 40 mg × 3 months
then 2.5 mg × 21 months,
n= 31
Adjuvant: both groups,
500mg/day of calcium
24 months
BMD assessed every
3 months
Primary: change in BMD
of the LS, FN, TH,
intertrochanter, Ward’s
triangle and the forearm;
bone markers; and AEs
Secondary: NR
Fractures: not an outcome
BMD: DXA 1000w (Hologic
Inc., Waltham, MA, USA)
Dursun et al., 2001;65
Turkey
Single-centre RCT
Sponsor NR
Inclusion: postmenopausal women,
with BMD of ≥ 2 SDs below young
adult mean at either the LS or FN
Exclusion: history of drug/alcohol
abuse, metabolic bone disease,
GI/liver disease, renal failure/calculi,
glucocorticoid therapy, malignancy,
disorder of calcium metabolism and
LS abnormalities preventing BMD
evaluation
Calcium 1000mg/day,
n= 50
ALN 10mg + calcium
1000mg/day, n= 51
Also evaluated calcitonin,
n= 50
12 months
BMD and radiographic
assessment at 6 and
12 months
Primary: change in BMD of
the LS, FN, trochanter and
Ward’s triangle in each
group at 12 months
Secondary: number of
factures; quality of life and
pain; fractures; AEs
Fractures: radiography of
thoracic and lumbar vertebrae.
A new vertebral fracture was
defined as a decrease of 20%
and at least 4 mm in any
vertebral height
BMD: DXA – model and
manufacturer NR
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Greenspan et al.,
2002;67 USA
Multicentre RCT,
25 centres
Merck Research
Laboratories
Inclusion: ambulatory women in
long-term care ≥ 65 years, LS or TH
BMD T-score of ≤ –2.0 SDs
Exclusion: disorders of bone
mineralisation, low vitamin D,
hyperthyroidism, GI disease, use of
bone-active agents
PBO, n= 164; ALN
10mg/day, n = 163
Adjuvant: both groups,
1000mg/day of calcium
and 400 IU/day of
vitamin D
24 months
BMD assessed at 6, 12,
18 and 24 months
Primary: change in BMD of
the LS, FN, hip and hip
trochanter; and biochemical
markers of bone turnover at
2 years
Secondary: AEs including
fractures
Fractures: clinical fractures
recorded as AEs (assessment
method NR)
BMD: DXA – Hologic
(Waltham, MA, USA)
Greenspan et al.,
2003;68 USA
Single-centre RCT
NIH grant
NR
Inclusion: community-dwelling
women aged ≥ 65 years
Exclusion: FN BMD ≥ 0.9 g/cm2
(0 SD of mean peak). Disease or
drugs affecting bone metabolism
PBO, n= 93; ALN
10mg/day, n = 93
Adjuvant: women with
low calcium intake,
calcium 600mg/day,
200 IU/day of vitamin D
Both groups, vitamin D
400–800 IU/day
36 months
BMD assessed at 6, 12,
18, 24 and 36 months
Primary: change in BMD of
the hip, spine, FN,
trochanter and ultradistal
radius
Secondary: fractures and AEs
Fractures: fracture reduction
was not a primary end point –
recorded as AEs (assessment
method NR)
BMD: DXA – QDR4500 A
(Hologic) (Bedford, MA, USA)
Ho and Kung 2005;71
China
RCT, number of centres
NR
Merck Sharp & Dohme
Ltd
Inclusion: women with OP aged
< 75 years, postmenopausal for
> 3 years and a BMD in the LS of
–2.5 SDs below local peak age
Exclusion: treatment with
bisphosphonates of fluorides,
SERMs or oestrogen, calcitonin or
any other drug that could affect
bone metabolism
Calcium 500mg/day,
n= 29; ALN
10mg+ calcium
500mg/day, n= 29
Adjuvant: calcium
500mg/day
12 months
BMD assessed at 3, 6
and 12 months
Primary: change in BMD of
the LS, FN and TH; bone
markers; AEs
Secondary: NR
Fractures: fracture not an
outcome
BMD: DXA – QDR (Hologic
Waltham, MA, USA)
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Klotz et al., 201373
(CORAL); Canada
Multicentre RCT,
30 centres
Abbot Laboratories
Inclusion: men with histologically
confirmed prostate cancer in whom
≥ 1 year of ADT was indicated
Exclusion: hypocalcaemia, abnormal
renal/liver function, metabolic bone
disease, bilateral hip replacement,
prior treatment with
bisphosphonates or therapy with
glucocorticoids
PBO, n= 102; ALN
70mg/week, n = 84
Adjuvant: both groups,
calcium 500mg/day and
vitamin D 400 IU/day
12 months
BMD assessed at
12 months
Primary: change in BMD of
the LS
Secondary: change in BMD
of the TH; changes in bone
markers
Fractures: not an outcome
BMD: DXA – model NR
Liberman et al., 1995;76
one multicentre study
was conducted in the
USA and the other in
Australia, Canada,
Europe, Israel, Mexico,
New Zealand and South
America
Phase III, multicentre
RCT
Merck Research
Laboratories
Inclusion: postmenopausal women
(for at least 5 years) aged
45–80 years, with a BMD in the LS
at least 2.5 SDs below the mean
value of in premenopausal white
women
Exclusion: other disorders of BMD,
abnormal hepatic function,
abnormality of LS precluding
assessment of BMD, history of hip
fracture, and prior bisphosphonates
treatment within 12 months
PBO, n= 397; ALN 5 mg,
10 mg and 20mg,
n= 526
Adjuvant: both groups
500mg/day of calcium
36 months
BMD and lateral spine
films assessed at 12, 24
and 36 months
Primary: new vertebral and
non-vertebral fractures;
change of BMD in the LS,
FN, trochanter and total
body, in each group at
3 years
Secondary: AEs
Fractures: the occurrence of
new vertebral fractures and
the progression of vertebral
deformities were determined
by an analysis of digitised
radiographs, and loss of
height was determined by
sequential height
measurements
BMD: DXA – Hologic
QDR-1000 or 1000/W
(Hologic, Waltham, MA, USA),
Lunar DPX-L (Lunar), or
Norland XR-26 (Norland)
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publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Orwoll et al., 2000;83
USA and 10 other
countries
Multicentre RCT,
20 centres
Merck Research
Laboratories
Inclusion: men with a BMD in the
FN of < 2 SDs below the mean
value in normal young men and a
BMD in the LS of < 1 SD below the
mean, or a BMD of at least 1 SD
below the mean in the FN and at
least one vertebral deformity or a
history of osteoporotic fracture
Exclusion: secondary causes of OP,
other bone diseases, vitamin D
deficiency, renal disease, cardiac
disease, cancer, peptic ulcer/
oesophageal disease
PBO, n= 95; ALN
10mg/day, n = 146
Adjuvant: both groups,
1000mg/day of calcium
and 400 IU/day of
vitamin D
24 months
BMD assessed at 6, 12,
18 and 24 months;
radiography at 24 months
Primary: changes in BMD of
the LS (L1–L4), FN, hip and
total body, between
treatment groups at 2 years
Secondary: incidence of
vertebral fractures;
biochemical markers of bone
turnover; AEs
Fractures: to detect both
vertebral fractures, X-ray films
were assessed. Both
semiquantitative and
quantitative morphometric
methods were used.
Non-vertebral (any site) from
patient reporting confirmed by
radiography
BMD: DXA – Hologic,
(Waltham, MA, USA) or Lunar
Pols et al.,199984
(FOSIT); Europe, Latin
America, Australia,
Canada, South Africa
and China
Multicentre RCT,
153 centres
Merck Research
Laboratories
Inclusion: women aged ≤ 85 years,
postmenopausal for ≥ 3 years with
a BMD in the LS of ≥ 2 SDs below
mean for postmenopausal woman
20–50% above the ideal weight
Exclusion: metabolic bone disease,
disturbed parathyroid/thyroid
function, GI disease myocardial
infarction, hypertension/angina,
organ disease, treatment with
bisphosphonates, fluoride, vitamin
A or vitamin D
PBO, n= 958; ALN
10mg/day, n = 950
Adjuvant: both groups,
1000mg/day of calcium
12 months
BMD assessed 3, 6 and
12 months
Primary: change in BMD of
the LS (L1–L4), FN,
trochanter, and TH, between
treatment groups at 1 year
Secondary: incidence of
vertebral fractures;
biochemical markers of bone
turnover; AEs
Fractures: the occurrence of
clinical fractures was captured
through AE reporting.
Documentation for each
fracture comprising
radiographs and/or radiology
reports, hospital discharge
reports with clinical diagnosis
and/or confirmation by the
investigator/treating physician
was sought after completion
of the study
BMD: Hologic QDR
densitometers (QDR-1000,
-1000/W, –1500 or –2000
(Hologic; Waltham, MA, USA)
or Lunar DPX densitometers
(DPX, DPX-L or DPX-a; Lunar)
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Saag et al., 1998;91 USA
and 15 other countries
Multicentre RCT, 15
centres in the USA and
22 in other countries
Merck & Co.
Inclusion: men and women aged
17–83 years, with underlying
diseases requiring long-term oral
glucocorticoid therapy at a daily
dose of at least 7.5 mg of
prednisone (Lodotra®, Napp
Pharmaceuticals) or its equivalent
irrespective of baseline BMD
Exclusion: metabolic bone disease,
a low serum vitamin D,
concomitant therapy with drugs
that affect bone turnover,
pregnancy or lactation, renal
insufficiency, severe cardiac disease
and a history of recent major upper
GI disease
PBO, n= 159; ALN
10mg/day, n = 157
Also evaluated ALN
5mg/day, n = 161
Adjuvant: all groups,
calcium 800–1000mg/
day and vitamin D
250–500 IU/day
48 weeks
BMD assessed at 4, 12,
24, 36 and 48 weeks;
radiography at 48 weeks
Primary: change in BMD of
the LS from baseline to
week 48 between the
groups
Secondary: changes in BMD
of the FN, trochanter and
total body; biochemical
markers of bone turnover;
and the incidence of new
vertebral fractures
Fractures: radiographs of the
lateral lumbar and thoracic
spine – semiquantitative visual
assessment: grade 0, normal;
grade 1, 20–25% reduction in
height, 10–20% area; grade 2,
25–40% reduction in height,
20–40% area; grade 3,
≥ 40% reduction in height
and area. Vertebral fractures
with grades of ≥ 2 were
defined as prevalent fractures,
and fractures that increased in
severity by at least one grade
were defined as incident
fractures
BMD: DXA – Hologic
(Waltham, MA, USA) or Lunar
(Madison, WI, USA)
Adachi et al., 200198
(Saag et al., 199891
extension)
Patients continued to receive the
double-blind study medication to
which they had been randomised
at the beginning of year 1
PBO, n= 61; ALN
10mg/day, n = 55
24 months Primary: change in BMD of
the LS, from baseline to
week 48 between the
groups
Secondary: changes in BMD
of the hip, FN, trochanter
and total body; biochemical
markers of bone turnover;
and the incidence of new
vertebral fractures
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Shilbayeh et al., 2004;93
Jordan
RCT, number of centres
NR
Sponsor NR
Inclusion: menopausal or early
menopausal women with OP –
BMD ≥ 2.5 SDs below the young
adult mean
Exclusion: NR
PBO, n= 27; ALN
10mg/day, n = 36
Adjuvant: both groups,
calcium 500mg/day and
vitamin D 10 IU/day
12 months
BMD assessed at
12 months
Primary: change in BMD of
the LS and FN; AEs
Secondary: NR
Fractures: not an outcome
BMD: DXA – Lunar DPX-L
densitometer (Lunar)
Smith et al., 2004;94
Australia
Multicentre RCT, three
centres
Merck, Sharp & Dohme
Inclusion: patients with asthma
and/or chronic obstructive airways
disease with the following risk
factors: > 2 courses of prednisolone
in the last 2 years, forced expiratory
volume in 1 second < 50%
predicted, any respiratory admission
in the last 5 years, severely limited
exercise tolerance (unable to walk
> 100m unaided), being a woman
aged over 50 years and sustaining
a bone fracture after the age of
40 years
Exclusion: known renal disease or
symptoms of dysphagia, dyspepsia,
use of proton pump inhibitors or
alcohol dependence or history of
bilateral hip replacements
PBO, n= 79 ALN
10mg/day, n = 66
Adjuvant: both groups,
calcium 600mg/day
12 months
BMD assessed at
12 months
Primary: change in BMD of
the LS, FN and whole femur
Secondary: NR
Fractures: not an outcome
BMD: DXA – Lunar (Lunar)
continued
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
IBN vs. PBO
Chesnut et al., 2004;45
Chesnut et al., 200546
(BONE); Europe and
North America
Multicentre RCT,
73 centres
Hoffman-La Roche Ltd
Inclusion: patients aged 55–80 years,
≥ 5 years postmenopausal, with 1–4
prevalent vertebral fractures (T4–L4),
and with a BMD T-score of –2.0 to
–5.0 SDs in at least one vertebra
(L1–L4)
Exclusion: upper GI disorders, a LS
T-score of 5.0 SDs, > 2 vertebral
fractures, disease or medication
affecting bone metabolism
PBO, n= 982; IBN
2.5 mg/day, n= 982
IBN 20mg eod,
12 doses/month, n = 982
Adjuvant: both groups,
calcium 500mg/day and
vitamin D 400 IU/day
36 months
Lateral radiography
performed annually,
BMD assessed every
6 months for 2 years,
then annually
Primary: new morphometric
vertebral fracture
Secondary: worsening
fractures, clinical vertebral
and osteoporotic non-
vertebral fractures; change
in BMD of the LS and femur;
biomarkers
Fractures: lateral radiography
of the thoracic spine
Diagnosis of fracture based
on morphometric criteria
confirmed by qualitative
assessment by radiologist.
Morphometric fracture –
height reduction at least 20%
and 4mm decrease
BMD: DXA (Hologic QDR)
Lester et al., 200874
(ARIBON); UK
Multicentre RCT,
two centres
AstraZeneca and Roche
Inclusion: postmenopausal women
with a histologically confirmed
diagnosis of oestrogen receptor-
positive breast cancer
Patients classified as osteopenic
(T-scores of > –2.5 SDs and < –1.0
SD of either the LS or TH) were
randomised
Exclusion: menopause was induced
by chemotherapy or drug therapy,
concurrent administration,
abnormal renal function, disorders
of bone metabolism and previous
bilateral hip fractures prostheses
PBO, n= 25; IBN
150mg/month, n= 25
Adjuvant: both groups,
anastrozole (Arimidex ®,
AstraZeneca UK Ltd,
London, UK) 1mg/day,
calcium 500mg/day and
vitamin D 400 IU/day
24 months
BMD assessed at 12 and
24 months
Primary: change in BMD of
the LS and TH
Secondary: changes in bone
resorption and formation
markers and AEs, including
any fracture
Fractures: recorded as AEs
(assessment method NR)
BMD: DXA – Lunar DPX
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
McClung et al., 2009;80
USA
Multicentre RCT,
10 centres
Roche
Inclusion: postmenopausal women
aged 45–60 years with a baseline
mean LS BMD T-score of between
–1.0 and –2.5 SDs and baseline
T-score of > –2.5 SDs in the TH,
trochanter and FN, with no prior
vertebral fractures
Exclusion: women with prevalent
vertebral or low-trauma
osteoporotic fractures; patients
receiving treatment affecting bone
metabolism
PBO, n= 83; IBN
150mg/month, n= 77
Adjuvant: both groups,
calcium 500mg/day and
vitamin D 400 IU/day
12 months
BMD assessed at
12 months
Primary: change in BMD of
the LS (L2–L4)
Secondary: change in BMD
of the FN, TH and
trochanter; change in bone
resorption marker serum
Fractures: fractures were
confirmed by radiography and
reported as AEs
BMD: DXA – (Hologic,
Bedford, MA, USA)
IBN-ranging trials
Delmas et al., 200649
(DIVA); USA, Canada,
Mexico, Europe,
Australia and South
Africa
Multicentre non-
inferiority RCT, 53
centres
Hoffman-La Roche and
GlaxoSmithKline
Inclusion: postmenopausal women
aged 55–80 years; at least 5 years
since menopause with OP [mean LS
(L2–L4) BMD T-score of < –2.5 to
–5.0 SDs]
Exclusion: prior treatment with
bisphosphonates or any other drug
affecting bone metabolism; upper
GI disease; renal impairment
IBN 2.5 mg/day, n = 470;
IBN 2mg/i.v. twice per
month, n= 454; IBN 3mg
i.v., three times per
month, n= 471
Adjuvant: all groups,
calcium 500mg/day and
vitamin D 400 IU/day
12 months
BMD assessed at
12 months
Primary: change in BMD of
the LS (L2–L4), year 1
Secondary: change in BMD
of the LS (L2–L4), year 2;
change in BMD of the
proximal femur; bone
markers
Fractures: clinical vertebral and
non-vertebral fractures were
monitored from AE reporting
(all fractures were confirmed
radiographically)
BMD: DXA on GE Lunar and
Hologic (Bedford, MA, USA)
Eisman et al., 200850
(DIVA); (year 2 data)
24 months
continued
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Miller et al., 200547
(MOBILE); involving 65
centres in the USA,
Canada, Europe,
Australia, South Africa,
Mexico and Brazil
Phase III RCT,
non-inferiority study
Hoffman-La Roche and
GlaxoSmithKline
Inclusion: postmenopausal women
aged 55–80 years; at least 5 years
since menopause with OP [mean LS
(L2–L4) BMD T-score of < –2.5 and
–5.0 SDs]
Exclusion: patients with
uncontrolled active or recurrent
peptic ulcer disease were excluded.
Additional exclusion criteria were a
disease, disorder or therapy known
to influence bone metabolism, prior
treatment with bisphosphonates,
fluoride treatment and renal
IBN 2.5 mg, n = 402; IBN
50mg two doses per
month, n= 402; IBN
100mg/month, n= 404;
IBN 150mg/month,
n= 401
Adjuvant: both groups,
calcium 500mg/day plus
vitamin D ≤ 400 IU
12 months
BMD assessed at
12 months
Primary: change in BMD of
the LS (L2–L4)
Secondary: change in BMD
of the TH, trochanter and FN
Fractures: clinical vertebral and
non-vertebral fractures were
recorded as AEs
BMD: DXA on GE Lunar and
Hologic (Bedford, MA, USA)
Reginster et al., 200648
(MOBILE); (year 2 data)
24 months
RIS vs. PBO
Boonen et al., 2009;58
Eastern and Western
Europe, Lebanon,
Australia and the USA
Phase III, multicentre
RCT
Procter & Gamble
Pharmaceuticals and
Sanofi-aventis
Pharmaceuticals
Inclusion: men aged ≥ 30 years,
with OP including a LS T-score of
≤ –2.5 SDs and a FN T-score of
≤ –1 SD or a LS T-score of ≤ –1 SD
and a FN T-score of ≤ –2 SDs
Exclusion: men with secondary
OP except those with primary
hypogonadism who declined
testosterone replacement therapy
PBO, n= 93; RIS
35 mg/week, n = 191
Adjuvant: both groups,
calcium 1000mg/day and
vitamin D 400–500 IU/day
24 months
Radiography completed
at 12 and 12 months;
BMD assessed at 6, 12
and 24 months
Primary: change in BMD of
the LS at month 24
Secondary: change in BMD
of the LS and proximal
femur at months 6, 12, and
24; incidence of new
vertebral fractures; incidence
of clinical fractures (vertebral
and non-vertebral) reported
as AEs at months 12 and 24
Fractures: new vertebral
fractures were determined by
radiography using a
semiquantitative method
Clinical vertebral and
non-vertebral fractures were
reported as AEs
BMD: DXA (Hologic, Bedford,
MA, USA)
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Choo et al., 2011;62
Canada
RCT, number of centres
NR
AstraZeneca
Pharmaceuticals
Inclusion: non-metastatic prostate
cancer patients receiving
radiotherapy plus 2–3 years of
androgen ablation therapy. All had
LS T-scores of > –2.5 SDs
PBO, n= 52; RIS
35 mg/week, n = 52
Adjuvant: both groups,
calcium and vitamin D
supplements (amount NR)
24 months
BMD assessed at 12 and
24 months
Primary: change in BMD of
the LS, FN and proximal
femur; and biomarkers for
bone turnover
Fractures: not an outcome
BMD of the LS, proximal
femur and FN were measured
by DXA at baseline, year 1 and
year 2
Cohen et al., 1999;63
USA
Multicentre RCT,
28 centres
Procter & Gamble/NIH
Inclusion: men and women aged
18–85 years on glucocorticoids
≥ 7.5 mg/day within 3 months;
women at least 1 year
postmenopausal
Exclusion: history of
hyperparathyroidism,
hyperthyroidism or osteomalacia,
use of drugs known to affect bone
metabolism
Premenopausal women:
PBO, n= 52; RIS
5 mg/day, n = 49
Postmenopausal women
PBO, n= 15; RIS
5 mg/day, n = 14
Adjuvant: both groups,
calcium 1000mg/day plus
vitamin D ≤ 500 IU/day for
women with low vitamin D
12 months
X-rays and BMD
assessed at 12 months
Primary: change in BMD of
the LS, FN and femoral
trochanter
Secondary: fractures;
biochemical markers of bone
turnover; AEs
Fractures: quantitative
morphometry was used to
identify prevalent (baseline)
and incident (new) vertebral
fractures. A new vertebral
fracture was defined as a
decrease of ≥ 15% (for intact
vertebrae at baseline) or a
decrease of ≥ 4 mm (for
fractured vertebrae at
baseline)
BMD: DXA – Hologic
(Waltham, MA, USA) or Lunar
Fogelman et al., 200066
(BMD-MN); France, UK,
the Netherlands,
Belgium and Germany
Multicentre RCT,
13 centres
Procter & Gamble and
Sanofi-aventis
Inclusion: women aged < 80 years,
postmenopausal for at least 1 year;
mean LS (L1–L4) T-score of –2 SDs
Exclusion: history of
hyperparathyroidism,
hyperthyroidism or osteomalacia,
use of drugs known to affect bone
metabolism
PBO, n= 180; RIS
5 mg/day, n = 179
Also evaluated: RIS
2.5 mg/day, n= 184
Adjuvant: both groups,
calcium 1000mg/day
24 months
BMD assessed at 6, 12,
18 and 24 months;
radiography at
24 months
Primary: incidence of
vertebral and non-vertebral
fractures, and percentage
change of BMD of the spine
Secondary: AEs; and
biochemical markers of bone
turnover
Fractures: non-vertebral
fractures and vertebral
fractures assessed as AEs by
radiography. A vertebral body
was considered to be
fractured if any of the
vertebral height ratios fell
below 3 SDs of the mean for
the study population
BMD: Lunar or Hologic
(Waltham, MA, USA)
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Hooper et al., 2005;72
Australia
Multicentre RCT,
11 centres
Procter & Gamble and
Sanofi-aventis
Inclusion: postmenopausal women
for 6–36 months with a LS BMD of
> –2.5 SDs (< 0.76 g/cm2)
Exclusion: history of
hyperparathyroidism,
hyperthyroidism or osteomalacia;
treatment with bone agents likely
to affect bone metabolism
PBO, n= 126; RIS
5 mg/day, n = 129
Adjuvant: both groups,
calcium 1000mg/day plus
vitamin D ≤ 500 IU/day for
women with low vitamin D
24 months
BMD assessed at 3, 6,
12, 18 and 24 months;
radiography at
24 months
Primary: changes in BMD of
the LS
Secondary: change in BMD
of the FN, and trochanter;
incidence of vertebral and
non-vertebral fractures; AEs
Fractures: prevalence and
incidence vertebral fractures
assessed by morphometric
analysis. An incident fracture
was considered evident if
anterior/middle vertebral
height was ≥ 15% of normal
vertebrae height
BMD: Hologic (Waltham, MA,
USA) or Lunar
Harris et al., 199970
(VERT-NA); USA
Multicentre RCT,
110 centres
Procter & Gamble
Inclusion: ambulatory women no
older than 85 years, ≥ 5 years since
menopause, with at least one
vertebral fracture at baseline
Exclusion: use of drugs known to
affect bone metabolism
PBO, n= 815; RIS
5 mg/day, n = 813
Adjuvant: both groups,
calcium 1000mg/day plus
vitamin D ≤ 500 IU/day for
women with low vitamin D
36 months
Radiography at 12, 24
and 36 months; BMD
assessed every 6 months
Primary: incidence of
vertebral and non-vertebral
fractures; and percentage
change of BMD of the spine
Secondary: AEs and
biochemical markers of bone
turnover
Fractures: quantitative and
semiquantitative assessment
was used to assess prevalent
(baseline) and incident
fractures. Fracture was
considered evident if anterior/
middle vertebral height was
≤ 0.8 of posterior
BMD: Lunar or Hologic
(Waltham, MA, USA)
Ste-Marie et al., 200499
(VERT-NA extension)
Women who had successfully
completed the original 3-year study
and who had undergone baseline
and month 36 iliac crest biopsies
were eligible to enrol. Women
continued on their assigned
treatments (PBO or RIS) for an
additional 2 years
PBO, n= 42; RIS
5 mg/day, n = 44
60 months Primary: histological and
histomorphometric
assessments
Secondary: change in BMD
Fractures: recorded as AEs
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Reginster et al., 200085
(VERT-MN); European
and Australian centres
Multicentre RCT,
number of centres NR
Procter & Gamble and
Hoechst Marion Roussel
Inclusion: ambulatory women
≤ 85 years and at least 5 years
postmenopausal; had at least two
radiographically confirmed vertebral
fractures
Exclusion: receiving treatment
known to affect bone metabolism
PBO, n= 407;
RIS 5 mg/day, n= 407
Adjuvant: both groups,
calcium 1000mg/day plus
vitamin D ≤ 500 IU/day
for women with low
vitamin D
36 months
BMD assessed every
6 months, radiography
every 12 months
Primary: changes in BMD of
the LS
Secondary: changes in the
BMD of the FN and
trochanter; incidence of
vertebral and non-vertebral
fractures; biochemical
markers of bone turnover;
and AEs
Fractures: quantitative and
semiquantitative assessment
was used to assess prevalent
(baseline) and incident
fractures. Fracture was
considered evident if anterior/
middle vertebral height was
≥ 15% of normal vertebrae
height
BMD: Lunar or Hologic
(Waltham, MA, USA)
Sorensen et al., 2003100
(VERT-MN extension);
USA
Multicentre RCT,
29 centres
Procter & Gamble
Inclusion: women remained on the
treatments (PBO or RIS, 5 mg daily)
to which they had originally been
assigned. Blinding was maintained
for the patients and clinical centre
personnel throughout the 5 years
of study
PBO, n= 130;
RIS 5 mg/day, n= 135
Adjuvant: both groups,
calcium 1000mg/day plus
vitamin D ≤ 500 IU/day
for women with low
vitamin D
60 months Primary: incidence of
vertebral fractures
Secondary: incidence of
non-vertebral fractures;
changes in BMD of the LS,
FN, femoral trochanter and
radius; biochemical markers
of bone turnover; and AEs
Leung et al., 2005;75
China
Multicentre RCT, four
centres
Aventis Pharma
Inclusion: postmenopausal for
≥ 5 years with a spine BMD at L1–4
of < 2.5 SDs of the local peak
young mean value
Exclusion: any medical conditions or
medication known to affect bone
metabolism
PBO, n= 34;
RIS 5 mg/day, n= 31
Adjuvant: both groups,
calcium 500mg/day plus
vitamin D 400 IU/day
12 months
BMD assessed at 3, 6
and 12 months
Primary: change in BMD of
the FN, LS, TH and
trochanter; and bone
markers
Secondary: NR
Fractures: not an outcome
BMD: DXA (QDR 4500 plus
Hologic, Hologic Waltham,
MA, USA)
continued
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
McClung et al., 2001;78
USA
Multicentre RCT,
183 centres
Procter & Gamble/
Aventis Pharma
Inclusion: women aged ≥ 70 years;
low BMD of the FN with a T-score
of < –4 or < –3 SDs, with at least
one non-skeletal risk factor for hip
fracture
Exclusion: any major illness, history
of another metabolic bone disease,
bilateral hip fracture, recent use of
drugs known to affect bone
metabolism
Women aged 70–79 years:
PBO, n= 1821;
RIS 2.5mg/day,
n= 1812; RIS 5mg/day,
n= 1812
Women aged ≥ 80
years:
PBO, n= 1313;
RIS 2.5mg/day,
n= 1281; RIS
5mg/day, n= 1292
Adjuvant: both
groups, calcium
1000mg/day plus
vitamin D ≤ 500 IU/
day for women with
low vitamin D
36 months
BMD assessed every
6 months
Primary: change in BMD of
the LS
Secondary: change in BMD
of the FN, proximal femur,
trochanter, radius; vertebral
fractures; biochemical
markers of bone turnover;
and AEs
Fractures: radiographically
confirmed hip fractures and
non-vertebral osteoporotic
fractures. Non-vertebral
osteoporotic fractures, defined
as all radiographically
confirmed fractures of the
wrist, leg, humerus, hip, pelvis,
or clavicle
BMD: DXA – Lunar or Hologic
(Waltham, MA, USA)
Reid et al. 2000;86 UK
Multicentre RCT,
23 centres
Procter & Gamble and
Hoechst Marion Roussel
Inclusion: ambulatory men and
women aged 18–85 years, who
have taken glucocorticoids for at
least 6 months
Exclusion: history of
hyperparathyroidism,
hyperthyroidism, or osteomalacia;
treatment with bone agents likely
to affect bone metabolism
PBO, n= 96;
RIS 5 mg/day, n= 100
Adjuvant: both groups,
calcium 1000mg/day and
vitamin D 400 IU/day
12 months
BMD assessed at 6 and
12 months; radiography
at 12 months
Primary: change in BMD of
the LS
Secondary: change in BMD
of the FN, proximal femur,
trochanter, radius; vertebral
fractures; biochemical
markers of bone turnover;
and AEs
Fractures: incident fractures
were identified using
quantitative morphometry
defined as a reduction of
≥ 15% in vertebral height in a
previously intact vertebra or
a reduction of ≥ 4mm in a
previously fractured vertebra
BMD: DXA – Lunar or Hologic
(Waltham, MA, USA)
A
S
S
E
S
S
M
E
N
T
O
F
C
L
IN
IC
A
L
E
F
F
E
C
T
IV
E
N
E
S
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
3
4
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Ringe et al., 2006;89
Germany
Single-centre RCT
Sponsor NR
Inclusion: men with primary or
secondary OP with or without
pre-existing prevalent vertebral
fractures. OP was defined as a LS
(BMD) T-score of ≤ –2.5 SDs and
FN BMD T-score of ≤ –2.0 SDs
relative to a healthy young adult
male. Primary OP; secondary OP:
PBO, 92 (58.2%); 66 (41.8%)
RIS 5 mg/day, 94 (59.5%); 64
(40.5%)
Exclusion: patients with known
hypersensitivity to bisphosphonates,
severe impairment of renal
function, hypocalcaemia and a
history of bisphosphonate or
fluoride pre treatment
PBO, n= 158;
RIS, 5 mg/day, n= 158
Adjuvant: PBO with
fractures, calcium
500mg/day and
alfacalcidol (One-Alpha®,
LEO Pharma) 1 µg/day
PBO without factures,
calcium 800mg/day and
vitamin D 1000 IU/day
12 months
BMD assessments and
radiography at
12 months
Primary: change in BMD of
the LS
Secondary: incidence of new
vertebral fractures; change
in BMD of the FN and TH;
change in body height;
course of back pain; and the
incidence of non-vertebral
fractures
Fractures: radiography of the
spine. Assessment of vertebral
fracture was performed using
the semiquantitative technique
BMD: DXA (Lunar)
Ringe et al., 2009;101
follow-up to
Ringe et al., 200689
PBO, n= 158;
RIS 5 mg/day, n= 158
24 months
Taxel et al., 2010;95 USA
RCT, number of centres
NR
Proctor and Gamble and
Aventis
Inclusion: men aged > 55 years and
within a month of receiving an
initial injection of ADT for prostate
cancer
Exclusion: metastatic bone disease,
chronic kidney, GI or liver diseases,
a previous cancer diagnosis,
metabolic bone disorders
medications that interfere with
bone metabolism
PBO, n= 20;
RIS 35 mg/week, n= 20
Adjuvant: both groups,
calcium 600mg/day and
vitamin D 400 IU/day
6 months
BMD assessed at
6 months
Primary: BMD of the FN and
TH
Secondary: change in bone
markers
Fractures: not an outcome
BMD: DXA (Lunar DXA-IQ)
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
ZOL vs. PBO
Black et al., 200756
(HORIZON-PFT);
international
Multicentre RCT,
number of centres NR
Novartis Pharmaceuticals
Inclusion: postmenopausal women
aged 65–89 years with a FN BMD
T-score of ≤ –2.5 SDs, with or
without evidence of existing
vertebral fracture, or a T-score
of –1.5 SDs, with radiological
evidence of at least two mild
vertebral fractures or one moderate
vertebral fracture. Use of hormone
therapy, raloxifene, calcitonin
(Miacalcic®, Novartis Pharmaceutical
UK Ltd), tibolone (Livial®, Merck
Sharp & Dohme Ltd), tamoxifen
(Nolvadex®, AstraZeneca UK Ltd),
dehydroepiandrosterone ipriflavone
and medroxyprogesterone
(Provera®, Pfizer Ltd) was allowed.
Patients in stratum I (n = 6113)
were not taking any OP
medications at the time of
randomisation, whereas patients in
stratum II (n = 1652) were all taking
an allowed medication
Exclusion: previous use of PTH,
sodium fluoride, anabolic steroids,
growth hormone, glucocorticoids,
or strontium
PBO, n= 3876;
ZOL 5mg/year, n = 3889
Adjuvant: both groups,
calcium 1000–1500mg/
day and vitamin D
400–1200 IU/day
36 months
Radiography at 12, 24
and 36 months in
stratum I; baseline and
36 months in stratum II;
BMD assessed at 6, 12,
24 and 36 months
Primary: stratum II, vertebral
fractures
Strata I and II, hip fracture
Secondary: any non-
vertebral fracture, any
clinical fracture, and clinical
vertebral fracture; changes
in BMD of the LS, FN and
TH; changes in markers of
bone resorption and
formation
Fractures: spinal lateral
radiographs from vertebrae
T4 to L4 were evaluated with
the use of quantitative
morphometry and standard
methods. Incident
morphometric vertebral
fractures were defined as a
reduction in vertebral height
of at least 20% and 4mm by
quantitative morphometry,
confirmed by an increase of
one severity grade or more on
semiquantitative analysis.
Clinical fracture reports were
obtained from patients at each
contact. Non-vertebral fracture
reports required central
confirmation. Excluded were
fractures of the toe, facial
bone and finger and those
caused by excessive trauma
BMD: DXA – model NR.
Measurements of BMD at the
LS were obtained for a
subgroup of patients
Reid et al., 2010102
(HORIZON-PFT)
AEs
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Lyles et al., 200777
(HORIZON-RFT);
international
Multicentre RCT,
number of centres NR
Novartis Pharmaceuticals
Inclusion: men and women aged
≥ 50 years, within 90 days after
surgical repair of a hip fracture
sustained with minimal trauma;
ambulatory prior to fracture
Exclusion: calculated low creatinine
clearance, low serum calcium
concentration, active cancer,
metabolic bone disease and a life
expectancy of < 6 months
PBO, n= 1062;
ZOL 5mg/year, n = 1065
Adjuvant: both groups,
calcium 1000–1500mg/
day and vitamin D
800–1200 IU/day
36 months
BMD assessed every
12 months
Primary: new clinical
fractures excluding facial
and digital fractures and
fractures in abnormal bone
(e.g. bone-containing
metastases)
Secondary: BMD of the non-
fractured hip; new vertebral,
non-vertebral and hip
fractures; safety
Fractures: lateral radiography
of the chest and LS. A non-
vertebral fracture (not a
vertebral, facial, digital or skull
fracture) was confirmed when
a radiograph, a radiographic
report or a medical record
documented a new fracture.
A new clinical vertebral
fracture was defined as new
or worsening back pain with a
reduction in vertebral body
height of 20% (grade 1) or
more, as compared with
baseline radiographs, or a
reduction in vertebral body
height of 25% (grade 2) or
more if no baseline radiograph
was available
BMD: DXA – model NR
Adachi et al., 2011103
(HORIZON-RFT)
Quality of life
continued
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Boonen et al., 2012;59
Europe, South America,
Africa and Australia
RCT, number of centres
NR
Novartis Pharmaceuticals
Inclusion: men aged 50–85 years
who had primary OP or OP
associated with low testosterone
levels with BMD T-score of
≤ –1.5 SDs in the TH or FN and
1–3 prevalent vertebral fractures.
Men without fractures were eligible
if they had a BMD T-score of
≤ –2.5 SDs in the TH, FN or LS
Exclusion: four or more prevalent
vertebral fractures, low serum
vitamin D concentration, renal
insufficiency, hypercalcaemia or
hypocalcaemia, hypersensitivity to
bisphosphonates, medication
affecting bone metabolism
PBO, n= 611;
ZOL 5mg/year, n = 588
Adjuvant: both groups,
calcium 1000–1500mg/
day and vitamin D
800–1200 IU/day
24 months
Radiography at 12 and
24 months; BMD
assessed at 6, 12 and
24 months
Primary: proportion of men
with one or more new
morphometric vertebral
fractures
Secondary: proportion of
men with one or more new
morphometric vertebral
fractures; one or more new
moderate to severe, or new
or worsening morphometric
vertebral fractures; change
in height; the time to first
clinical fracture (vertebral or
non-vertebral); change in
BMD of the LS, FN and TH;
bone-turnover markers; and
safety
Fractures: vertebral fractures
were assessed by means of
quantitative vertebral
morphometry performed on
lateral thoracic and LS, incident
vertebral fracture was assessed
by means of morphometry and
defined as a reduction in
vertebral height of 20% or
more and 4mm or more.
Clinical fractures (vertebral and
non-vertebral) were reported
by participants at each visit and
were verified by radiographic
report or surgical notes. Only
confirmed fractures were
included in the analysis
BMD: DXA – model NR
BMD and bone markers were
analysed in a subgroup of 100
or more participants
McClung et al., 2009;79
USA and France
Multicentre RCT,
25 centres
Novartis Pharmaceuticals
Inclusion: women aged ≥ 45 years,
who were postmenopausal, had a
LS BMD T-score of < –1.0 SD and
> –2.5 SDs and a FN T-score of
> –2.5 SDs
Exclusion: participants with more
than one vertebral fracture or any
grade 2 or 3 vertebral fracture.
Participants with low vitamin D
concentration, renal insufficiency,
hypercalcaemia or hypocalcaemia,
treatment medications affecting
bone metabolism
PBO, n= 202;
ZOL 5mg/year, n = 198
Adjuvant: both groups,
calcium 500–1200mg/
day and vitamin D
400–800 IU/day
24 months
BMD assessment time
points NR
Primary: change in BMD of
the LS at 12 months
Secondary: change in BMD
of the TH, FN, trochanter
and distal radius at 12 and
24 months; and bone
markers
Fractures: not an outcome
BMD: DXA Hologic or General
Electric Lunar machine
A
S
S
E
S
S
M
E
N
T
O
F
C
L
IN
IC
A
L
E
F
F
E
C
T
IV
E
N
E
S
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
3
8
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Head to head: ALD vs. IBN
Miller et al., 200881
(MOTION); North
America, Latin America,
America, Europe and
South Africa
Multicentre RCT,
65 centres
Hoffman La-Roche Ltd
and GlaxoSmithKline
Inclusion: postmenopausal women
aged between 55 and < 85 years
with a LS (L2–L4) BMD T-score of
between < –2.5 SD and ≥ –5.0 SD
Exclusion: upper GI disease, any
diseases or medications known to
influence bone metabolism
ALN 70mg/week,
n= 873; IBN 150mg/
month, n= 887
Adjuvant: both groups,
calcium 500mg/day and
vitamin D 400 IU/day
12 months
BMD assessed at
12 months
Primary: change in BMD of
the LS and TH
Secondary: change in BMD
of the trochanter; and bone
markers
Fractures: recorded as AEs
(assessment method NR)
BMD: DXA – model NR
Head to head: ALD vs. RIS
Atmaca and Gedick
2006;54 Turkey
RCT, number of centres
NR
Sponsor NR
Inclusion: late postmenopausal
women with osteoporosis with a
mean age of 66.3 years (range
60–85 years) and a T-score of
< 2.5 SDs
Exclusion: any medical conditions or
medication known to affect bone
metabolism
RIS 5 mg/day, n= 14;
ALN 10mg/day, n= 14
Adjuvant: both groups,
calcium 600mg/day and
vitamin D 400 IU/day
12 months
BMD assessment time
point NR
Primary: change in BMD of
the FN, LS and distal radius;
and bone markers
Secondary: NR
Fractures: not an outcome
BMD: DXA – Hologic QDR
(Waltham, MA, USA)
Muscoso et al., 2004;82
Italy
RCT, number of centres
NR
Sponsor NR
Inclusion: osteoporotic female
population submitted to a
treatment with antiresorption drugs
Exclusion: NR
RIS 5 mg/day, n= 1000;
ALN 10mg/day, n= 100
Other treatments were:
clodronic acid (Bonefos®,
Bayer plc.), n= 800 and
raloxifene, n= 100
Adjuvant: all groups,
calcium 1000mg/day and
vitamin D 800 IU/day
24 months
BMD assessment time
point NR
Primary: change in BMD of
the LS; and fractures
Secondary: NR
Fractures: NR
BMD: DXA – Lunar DPX
continued
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Sarioglu et al., 200692
Turkey
RCT, number of centres
NR
Sponsor NR
Inclusion: postmenopausal women
with OP
Exclusion: patients aged > 75 years
and taking treatment for OP. The
presence of any disease which
interferes with bone metabolism,
recent use of drugs known to
affect bone metabolism and history
of oesophagitis and peptic ulcer
RIS 5 mg/day, n= 25;
ALN 10mg/day, n= 25
Adjuvant: both groups,
calcium 1000mg/day and
vitamin D 400 IU/day
12 months
BMD assessment time
point NR
Primary: change in BMD of
the hip
Secondary: NR
Fractures: not an outcome
BMD: DXA – Lunar DPX
Rosen et al., 200590
(FACT); USA
Multicentre RCT,
78 centres
Merck & Co.
Inclusion: postmenopausal women
aged ≥ 40 years or ≥ 25 years if
surgically menopausal. BMD T-score
of ≤ –2.0 SDs in at least one of the
four sites (TH, hip trochanter, FN or
posterior LS)
Exclusion: hypocalcaemia,
hypovitaminosis D, metabolic bone
disease, bisphosphonates within
1 year or bisphosphonates for
≥ 2 years within 5 years, use of PTH
within 1 year, had taken oestrogen
or oestrogen analogues within
6 months
ALN 70mg/week,
n= 520; RIS 35 mg/week,
n= 533
Both groups, 1000
mg/day calcium and
400 IU/day vitamin D
12 months
BMD assessed at 6 and
12 months
Primary: change BMD of the
trochanter
Secondary: change in BMD
of the TH, FN and LS
Fractures: incidence of clinical
fracture recorded as AEs
(assessment method NR)
BMD: Hologic (Waltham, MA,
USA) or Lunar
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Bonnick et al., 2006104
(FACT); extension to
Rosen et al., 2005;90
USA
Multicentre RCT, 72 of
the original 78 centres
Merck & Co.
Inclusion: postmenopausal women
aged ≥ 40 years or ≥ 25 years if
surgically menopausal. BMD T-score
of ≤ –2.0 SDs in at least one of the
four sites (TH, hip trochanter, FN or
posterior LS)
Exclusion: hypocalcaemia,
hypovitaminosis D, metabolic bone
disease, bisphosphonates within
1 year or for ≥ 2 years within
5 years, use of PTH within 1 year,
had taken oestrogen or oestrogen
analogues within 6 months
ALN 70mg/week,
n= 411; RIS 35 mg/week,
n= 414
Adjuvant: both groups,
1000mg/day calcium and
400 IU/day vitamin D
Extension to 24 months Primary: change of BMD in
the trochanter
Secondary: change in BMD
of the TH, FN and LS
Fractures: clinical fractures that
occurred during the trial,
regardless of association with
trauma or skeletal site, were
reported by investigators as
clinical AEs (assessment
method NR)
BMD: Hologic (Waltham, MA,
USA) or Lunar
Reid et al., 200687
(FACTS); Europe, the
Americas and Asia-
Pacific
Multicentre RCT,
75 centres
Merck & Co.
Inclusion: postmenopausal women
aged > 40 years with low bone
density (–2.0 SDs below the young
normal mean) at LN, FN or TH
Exclusion: hypocalcaemia,
hypovitaminosis D, metabolic bone
diseases, use of oestrogen,
oestrogen analogues, tibolone or
anabolic steroids, bisphosphonates
or PTH
ALN 70mg/week,
n= 468; RIS 35 mg/week,
n= 468
Adjuvant: both groups,
calcium 1000mg/day and
vitamin D 400 IU/day
12 months
BMD assessed at 6 and
12 months
Primary: change of BMD in
the trochanter
Secondary: change in BMD
of the TH, FN and LS
Fractures: fractures were
reported as AEs whether or
not they were associated
with trauma and without
requirements of radiographic
confirmation or adjudication
BMD: DXA – using Hologic
(Waltham, MA, USA) or Lunar
densitometers
Reid et al., 2008105
(FACTS); extension to
Reid et al., 2006;87
72 of the original
75 international sites
Merck & Co.
Inclusion: all eligible women
maintained their original
randomised, blinded treatment
allocation from year 1
ALN 70mg/week,
n= 403; RIS 35 mg/week,
n= 395
Adjuvant: both groups,
calcium 1000mg/day and
vitamin D 400 IU/day
24 months
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TABLE 3 Characteristics of included studies: clinical effectiveness review (continued )
Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Head to head: ZOL vs. ALN
Hadji et al., 2010106
(ROSE)
Primary: quality of life and
compliance
Hadji et al., 201269
(ROSE); Germany
Multicentre RCT,
95 centres
Novartis Pharmaceuticals
Inclusion: women aged 55–90
years who were considered
postmenopausal with BMD T-score
of ≤ –2.0 SDs of the TH or LS
Exclusion: patients who had
received prior therapy with
bisphosphonates, PTH (Teriparatide,
Forsteo®, Eli Lilly and Company
Ltd), strontium ranelate,
raloxifene, calcitonin, high-dose
glucocorticoids, patients with
a fracture within 6 months,
secondary OP, primary
hyperparathyroidism and patients
with inappropriate blood chemistry
ZOL 5mg/year, n = 408;
ALN 70mg/week, n= 196
Adjuvant: both groups,
calcium 1200mg/day and
vitamin D 800 IU/day
12 months Primary: to assess if ZOL was
superior to ALN in reducing
serum NTx levels
Secondary: comparison of
P1NP levels; safety and
tolerability
Fractures and BMD: not
outcomes assessed by the trial
(assessed bone markers and
quality of life)
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Author, year of study
publication, country,
number of centres
and sponsor Inclusion and exclusion criteria
Numbers randomised
and adjuvant
supplements
Final follow-up and
assessment time
points
Primary and secondary
outcomes
Fracture and BMD
assessments
Head to head: ZOL vs. RIS
Reid et al., 200988
(HORIZON); Australia, EU
countries (including the
UK), China and the USA
Multicentre RCT, 54
centres
Novartis Pharmaceuticals
Inclusion: men and women aged
18–85 years receiving at least
7.5 mg oral prednisolone daily
(or equivalent) and were expected
to receive glucocorticoids for at
least another 12 months
Exclusion: previous treatment drugs
that affect the skeleton, low serum
vitamin D, history of cancer or
parathyroid disease and renal
impairment
ZOL 5mg/year: treatment
n= 272; prevention,
n= 144
RIS 5 mg/day: treatment,
n= 273; prevention,
n= 144
Adjuvant: both groups,
calcium 1000mg/day and
vitamin D 400–1200
IU/day
12 months
BMD assessed at 6 and
12 months; radiography
at 12 months
Primary: change in BMD of
the LS
Secondary: change in BMD
of the FN, TH, trochanter
and distal radius; and
occurrence of thoracic and
lumbar vertebral fractures
Fractures: thoracic and lumbar
vertebral fractures were
defined according to
semiquantitative methods
BMD: Hologic (Waltham, MA,
USA), GE or Lunar
ALN, alendronic acid; ARIBON, reversal of anastrozole (ARImidex) induced bone loss with oral monthly ibandronate (BONdronat) treatment during adjuvant therapy for breast cancer trial;
CORAL; Cancer and Osteoporosis Research with alendronic acid and Leuprolide trial; eod, every other day; FACT, Fosamax Actonel Comparison Trial; FACTS, Fosamax Actonel Comparison
Trial International Study; FIT, Fracture Intervention Trial; FN, femoral neck; FOSIT, FOSamax International Trial; HORIZON, Health Outcomes and Reduced Incidence with Zoledronic acid Once
Yearly trial; HORIZON-PFT; Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly – Pivotal Fracture Trial; HORIZON-RFT, Health Outcomes and Reduced Incidence with
Zoledronic acid Once Yearly – Recurrent Fracture Trial; IBN, ibandronic acid; IU, international unit; L1–L4, lumbar vertebrae 1–4; LS, lumbar spine; MOTION, Monthly Oral Therapy with
ibandronate for Osteoporosis iNtervention trial; NIH, National Institutes of Health; NR, not reported; NTx, N-telopeptide of collagen type I; OP, osteoporosis; P1NP, procollagen 1 C-terminal
extension peptide; PBO, placebo; PTH, parathyroid hormone; QDR, quantitative digital radiography; RIS, risedronic acid; ROSE, Rapid Onset and Sustained Efficacy trial; SERM, selective
oestrogen receptor modulator; TH, total hip; VERT-MN, Vertebral Efficacy with Risedronate Therapy – MultiNational trial; VERT-NA, Vertebral Efficacy with Risedronate Therapy – North
American trial; ZOL, zoledronic acid.
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TABLE 4 Characteristics of participants in included RCTs
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
ALN vs. PBO
Adami et al., 199553
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD), years since menopause (SD):
l PBO: 59 years (6 years); 11 years
(8 years)
l ALN 10mg/day: 59 years (6 years);
12 years (7 years)
Height (SD), weight (SD), BMI (estimated):
l PBO: 160 cm (6 cm); 60 kg (8 kg);
23.4 kg/m2
l ALN 10mg/day: 160 cm (7 cm); 60 kg
(7 kg); 23.4 kg/m2
None reported Current smokers:
l PBO: 7/71 (9.9%)
l ALN 10mg/day: 13/68
(19.1%)
Fractures: 5% of all participants had
prevalent vertebral fractures
FN BMD (SD):
l PBO: non-lunar: 0.65 cm3
(0.09 cm3); lunar, 0.76 cm3
(0.08 cm3)
l ALN 10mg/day: non-lunar,
0.65 cm3 (0.09 cm3); lunar,
0.71 cm3 (0.09 cm3)
Black et al., 199655 (FIT I)
Women with PMO
Male/female: 100% female
Race:
l Caucasian 97%
l Asian 1%
l African American 1%
Age (SD):
l PBO: 71.0 years (5.6 years)
l ALN 10mg/day: 70.1 years (5.6 years)
BMI (SD):
l PBO: 25.6 kg/m2 (4.2 kg/m2)
l ALN 10mg/day: 25.5 kg/m2 (4.2 kg/m2)
None reported Smokers:
l PBO: current 10%; ever
35%; never 54%
l ALN 10mg/day: current
10%; ever 35%;
never 52%
Fractures: percentage with one, two or
three or more:
l PBO: one, 68%; two, 17%; three
or more, 15%
l ALN 10mg/day: one, 70%; two,
17%; three or more, 13%
FN BMD (SD):
l PBO: 0.56 cm3 (0.07 cm3)
l ALN 10mg/day: 0.57 cm3
(0.07 cm3)
A
S
S
E
S
S
M
E
N
T
O
F
C
L
IN
IC
A
L
E
F
F
E
C
T
IV
E
N
E
S
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
4
4
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Cummings et al., 199864
(FIT II)
Women with PMO
Male/female: 100% female
Race: all, Caucasian 97%
Age (SD):
l PBO: 67.7 years (6.1 years)
l ALN 10mg/day: 67.6 years (6.2 years)
Height (SD); BMI (SD):
l PBO: 160 cm (6.0 cm); 25.0 kg/m2
(4.0 0 kg/m2)
l ALN 10mg/day: 161 cm (6.0);
24.90 kg/m2 (3.90 kg/m2)
None reported Smokers:
l PBO: current 10%; ever
35%; never 54%
l ALN 10mg/day: current
10%; ever 35%;
never 52%
Fracture since age 45 years:
l PBO: 776/2218 (35%)
l ALN 10mg/day: 797/2214 (36%)
FN BMD (SD):
l PBO: 0.59 cm3 (0.06 cm3)
l ALN 10mg/day: 0.59 cm3 (0.06 cm3)
FN SDs > 2.5 (SD); 2.0–2.5 (SD);
1.5–2.0 (SD) below peak:
l PBO: 36.6%, 32.0%, 31.4%
l ALN 10mg/day: 37.0%;
32.8%; 30.2%
Bone et al., 200057
Women with PMO
Male/female: 100% female
Race:
l PBO:
¢ Caucasian, 44/50 (88%)
¢ Other, 6/50 (12%)
l ALN 10mg/day:
¢ Caucasian, 85/92 (92%)
¢ Other, 7/92 (8%)
Age (SD); years since menopause (SD):
l PBO: 62 years (8 years); 23 years
(11 years)
l ALN 10mg/day: 61 years (8 years);
22 years (8 years)
Height, weight, BMI: not reported
None reported Not reported Not reported
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Carfora et al., 199860
Women with PMO
Male/female: 100% female
Race: not reported
Age; years since menopause: not reported
Height, weight, BMI: not reported
None reported Not reported Not reported
Chesnut et al., 199561
Women with PMO
Male/female: 100% female
Race, all:
l Caucasian: 184 (98%)
l Asian: 4 (2%)
Age (SD); years since menopause (SD):
l PBO: 63.6 years (7.1 years); 16.9 years
(7.7 years)
l ALN, all doses: 62.9 years (6.1 years);
15.0 years (6.9 years)
Height (SD), weight (SD):
l PBO: 160.6 cm (5.9 cm); 61.6 kg (9.8 kg)
l ALN, all doses: 161.6 cm (6.8 cm);
63.7 kg (9.4 kg)
None reported Not reported Not reported
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Dursun et al., 200165
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l Calcium 1000mg/day: 60.26 years
(8.58 years); 14.32 years (7.96 years)
l ALN 10mg/day + calcium: 60.26 years
(8.58 years); 14.88 years (7.60 years)
Height; weight; BMI:
l Calcium 1000mg/day: 154.10 cm
(4.78 cm); 66.41 kg (11.53 kg);
28.62 kg/m2 (5.52 kg/m2)
l ALN 10 kg/m2 mg/day + calcium:
154.10 cm (4.78 cm); 66.41 kg
(11.53 kg); 28.62 kg/m2 (5.52 kg/m2)
None reported Not reported FN BMD (SD):
l Calcium 1000mg/day: 0.77 cm3
(0.1 cm3)
l ALN 10mg/day+ calcium:
0.74 cm3 (0.08 cm3)
Greenspan et al., 200267
Women with PMO
Male/female: 100% female
l Race, all (n= 327): Caucasian, 95%
Age, all:
l 78.5 years (range 65–91 years)
Height; weight; BMI: not reported
None reported Not reported Fractures: 55% had a history of
fracture (type not reported)
FN BMD: not reported
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Greenspan et al., 200368
Women aged ≥ 65 years
Male/female: 100% female
Race: not reported
Age (SD):
l PBO: 72 years (5 years)
l ALN 10mg/day: 71 years (4 years)
Height (SD); weight (SD); BMI (SD):
l PBO: 159 cm (7 cm); 69 kg (18 kg);
27 kg/m2 (6 kg/m2)
l ALN 10mg/day: 159 cm (6 cm); 71 kg
(17 kg); 28 kg/m2 (7 kg/m2)
None reported Not reported Fracture since age 50 years:
l PBO: 31/93 (33%)
l ALN 10mg/day: 36/93 (39%)
FN BMD (SD):
l PBO: 0.66 cm3 (0.10 cm3)
l ALN 10mg/day: 0.66 cm3 (0.10 cm3)
Ho and Kung 200571
Women with PMO
Male/female: 100% female
Race:
l 100% East Asian
Age (SD); years since menopause (SD):
l Calcium 500mg/day: 62 years
(4 years); 12 years (4.8 years)
l ALN 10mg/day + calcium: 60.6 years
(5.5 years); 11.6 years (5.8 years)
Height (SD); weight (SD); BMI (estimated):
l Calcium 500mg/day: 1.5 m (0.3 m);
52 kg (7.4 kg); 23.1 kg/m2
l ALN 10+calcium: 1.52 m (4.4 m);
51.8 kg (8 kg); 22.4 kg/m2
None reported Not reported Prevalent vertebral fracture:
l Calcium 500mg/day: 10/29 (34%)
l ALN 10mg/day: 12/29 (41%)
FN BMD (SD):
l Calcium 500mg/day: 0.532 cm3
(0.069 cm3)
l ALN 10mg/day: 0.583 cm3
(0.054 cm3)
FN BMD T-score (SD):
l Calcium 500mg/day: –3.4 (0.7)
l ALN 10mg/day: –2.2 (0.6)
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Klotz et al., 201373
(CORAL)
Men with androgen
deprivation bone loss in
non-metastatic prostate
cancer
Male/female: 100% male
Race: not reported
Age (SD):
l PBO: 73.7 years (8.6 years)
l ALN 70mg/week: 73.5 years (8.1 year)
Height; weight, BMI: not reported
Gleason prostate cancer score:a
l PBO: Gleason score of 6, 15;
Gleason score of 7, 34; Gleason
score of 8, 18
l ALN 70mg/week: Gleason score
of 6, 17; Gleason score of 7, 26;
Gleason score of 8, 18
ADT: 42 prior ADT regimens were
reported in 34/183 (19%) of all
participants. Median duration of prior
ADT 6.1 months (range 1.0–16.2
months)
Years of smoking mean (SD);
packs per day (SD):
l PBO: 23.4 (14.6);
0.94 (0.48)
l ALN 70mg/week: 29.5
(16.2); 0.98 (0.49)
Fractures: of the 47% who reported
prior fracture, 1% had had a history
of hip or vertebral fracture. Four
participants in the ALN group reported
a family history of osteoporotic
fracture
FN BMD cm3: not reported. At
baseline, 63 subjects (38%) had
osteopenia (25 patients treated with
ALN and 38 treated with PBO) and 12
subjects (7%) had OP (three patients
treated with ALN and nine treated
with PBO). The remaining ITT
population was considered to have
normal BMD for their age
Liberman et al., 199576
Seeman 199997
Women with PMO
Male/female: 100% female
Race: not reported
Age; years since menopause:
l PBO: 64 years; 17 years
l ALN, all doses: 64 years; 16 years
BMI:
l PBO, 24.1 kg/m2
l ALN, all doses: 24.2 kg/m2
None reported Not reported Fractures at baseline:
l PBO: vertebral 75/355 (21.2%);
non-vertebral 187/355 (52.6%)
l ALN, all doses, vertebral 106/526
(20.2%); non-vertebral 300/526
(57.0%)
FN BMD:
l PBO: 0.6 cm3
l ALN, all doses: 0.6 cm3
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
0
7
8
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
6
V
O
L
.
2
0
N
O
.
7
8
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
6
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
D
a
vis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
4
9
TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Orwoll et al., 200083
Men with OP
Male/female: 100% male
Race: not reported
Age (SD):
l PBO: 63 years (12 years)
l ALN 10mg/day: 63 years (13 years)
BMI (SD):
l PBO: 25 kg/m2 (3 kg/m2)
l ALN 10mg/day: 25 kg/m2 (3 kg/m2)
None reported Current smokers:
l PBO: 23/95 (24.2%)
l ALN 10mg/day:
28/146 (19.2%)
Fractures at baseline:
l PBO: vertebral 52/95 (54.5%)
l ALN 10mg/day: vertebral 49/146
(33.7%)
FN BMD cm3: not reported
Pols et al., 199984 (FOSIT)
Women with PMO
Male/female: 100% female
Race:
l PBO:
¢ Caucasian 901/958 (94%)
l ALN 10mg/day:
¢ Caucasian 893/950 (94%)
Age (SD); years since menopause (SD):
l PBO: 62.8 years (7.4 years); 15.9 years
(8.4 years)
l ALN 10mg/day: 62.8 years (7.5 years);
15.8 years (8.5 years)
Height; weight; BMI (estimated):
l PBO: 158.5 cm (6.8 cm); 63.6 kg
(9.7 kg); 25.3 kg/m2
l ALN 10mg/day: 158.6 cm (7.0 cm);
63.8 kg (9.6 kg); 25.4 kg/m2
None reported Not reported Fractures: not reported
FN BMD:
l PBO: 0.62 cm3 (0.08 cm3)
l ALN 10mg/day: 0.63 cm3 (0.09 cm3)
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Saag et al., 1998;91
extension of Adachi 2001
et al.,98
Men and women with
glucocorticoid-induced OP
Male/female:
l PBO: men, 52/159 (33%);
premenopausal women, 40/159
(25%); PM women, 67/159 (42%)
l ALN 10mg/day: men, 44/157 (28%);
premenopausal women, 30/157
(19%); PM women, 83/157 (53%)
Race:
l PBO: Caucasian, 142/159 (89%);
other, 17/159 (11%)
l ALN 10mg/day: Caucasian, 138/157
(88%); other, 19/157 (12%)
Age (SD):
l PBO: 54 years (15 years)
l ALN 10mg/day: 55 years (15 years)
Height (SD); weight (SD); BMI (estimated):
l PBO: 158.5 cm (6.8); 63.6 kg
(9.7); 25.3
l ALN 10mg/day: 158.6 cm (7.0 cm);
63.8 kg (9.6 kg); 25.4 kg/m2
Comorbidities:
l PBO: rheumatoid arthritis,
43 (27%); polymyalgia,
24 (15%); lupus, 19 (12%);
pemphigus, 12 (8%); asthma,
15 (9%); inflammatory myopathy,
10 (6%); inflammatory bowel
disease, 8 (5%); giant-cell
arteritis, 6 (4%); sarcoidosis,
5 (3%); myasthenia gravis, 12
(8%); COPD, 3 (2%); nephritic
syndrome, 2 (1%)
l ALN 10mg/day: rheumatoid
arthritis, 52 (33%); polymyalgia,
30 (19%); lupus, 12 (8%);
pemphigus, 10 (6%); asthma,
12 (8%); inflammatory myopathy,
7 (4%); inflammatory bowel
disease, 10 (6%); giant-cell
arteritis, 5 (3%); sarcoidosis,
7 (4%); myasthenia gravis,
1 (1%); COPD, 4 (3%); nephritic
syndrome, 7 (4%)
Glucocorticoid dose – mg/day of
prednisone or equivalent median
(range):
l PBO: 11 mg/day of prednisone
(5–120mg/day)
l ALN 10mg/day: 10 mg/day
(7–95mg/day)
l All 34% of the PM women were
taking oestrogen replacement
therapy (not described)
Not reported Not reported
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Shilbayeh et al., 200493
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l PBO: 60.8 years (1.4 years); 12.6 years
(1.4 years)
l ALN 10mg/day: 57.8 years (1.4 years);
10.6 years (1.5 years)
BMI:
l PBO: 30.83 kg/m2 (0.73 kg/m2)
l ALN 10mg/day: 30.99 kg/m2
(1.08 kg/m2)
None reported Not reported Fractures: not reported.
FN BMD (SD):
l PBO: 0.73 cm3 (0.02 cm3)
l ALN 10mg/day: 0.73 cm3 (0.02 cm3)
Smith et al., 200494
Men and women with
asthma and/or chronic
obstructive airways disease
Male/female:
l PBO: 37/79 (47% male)
l ALN 10mg/day: 37/66 (56% male)
Race: not reported
Age, n (%):
l PBO: < 60 years, 21 (27%); 60–69
years, 19 (24%); ≥ 70 years, 39 (49%)
l ALN 10mg/day, < 60 years, 12 (18%);
60–69 years, 24 (36%); ≥ 70 years,
30, (46%)
Height; weight; BMI: not reported
Comorbidities: all had airways disease
(asthma and/or COPD)
Medications:
l PBO: inhaled glucocorticoids,
68 (86%); calcium, 27 (34%);
thyroxine, 6 (8%); maintenance
oral glucocorticoids, 15 (19%);
calcitriol, 6 (8%); theophylline,
12 (15%)
l ALN 10mg/day: inhaled
glucocorticoids, 60 (91%);
calcium, 28 (42%); thyroxine,
4 (6%); maintenance oral
glucocorticoids, 10 (15%);
calcitriol, 8 (12%); theophylline,
13 (20%)
Current smokers:
l PBO: 69 (87%)
l ALN 10mg/day:
54 (82%)
Not reported
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
IBN vs. PBO
Chesnut et al., 200445;
Chesnut et al., 200546
(BONE)
Women with PMO
Male/female: 100% female
Race: not reported
Age; years since menopause:
l PBO, 68.8 years; 20.8 years
l IBN 2.5 mg/day: 68.7 years; 20.9 years
l IBN 20mg eod: 12 doses/month:
68.7 years; 20.8 years
Height; weight; BMI:
l PBO: 159.7 cm; 66.8 kg; 26.2 kg/m2
l IBN 2.5 mg/day: 160.2 cm; 66.6 kg;
26.0 kg/m2
l IBN 20mg eod: 160.3 cm; 66.7 kg;
26.0 kg/m2
Comorbidities: reports pre-existing GI
disorders were similar across groups
Medications: reports use of
non-steroidal anti-inflammatory
agents was comparable across groups
Not reported Vertebral fractures: one; two:
l PBO: 906 (93%); 421 (43%)
l IBN 2.5 mg/day: 920 (94%);
433 (44%)
l IBN 20mg eod 12 doses/month:
917 (94%); 413 (42%)
FN BMD: not reported
FN BMD T-score (SD):
l PBO: –2.0 (0.9)
l IBN 2.5 mg/day: –1.7 (0.8)
l IBN 20mg eod: 12 doses/month:
–1.7 (0.9)
Lester et al., 200874
(ARIBON)
PM women with breast
cancer
Male/female: 100% female
Race: not reported
Age median (range):
l PBO: 67.5 years (63.6–71.0 years)
l IBN 150mg/month: 67.8 years
(58.9–73.4 years)
BMI median (range):
l PBO: 30.83 kg/m2 (0.73 kg/m2)
l IBN 150mg/month: 30.99 kg/m2
(1.08 kg/m2)
All had a histologically confirmed
diagnosis of oestrogen receptor-
positive breast cancer and
commenced anastrozole at study
entry
Not reported Not reported
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
McClung et al., 200980
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l PBO: 53.4 years (3.8 years); 5.5 years
(5.8 years)
l IBN 150mg/month: 53.7 years
(3.6 years); 5.3 years (6.0 years)
BMI:
l PBO: 27.4 kg/m2 (6.1 kg/m2)
l IBN 150mg/month: 27.2 kg/m2
(5.0 kg/m2)
None reported Not reported Fractures: not reported.
FN BMD (SD):
l PBO: 0.729 cm3 (0.082 cm3)
l IBN 150mg/month: 0.738 cm3
(0.085 cm3)
FN BMD T-score (SD):
l PBO: –1.1 (0.7)
l IBN 150mg/month: –1.0 (0.8)
IBN dose-ranging trials
Delmas et al., 2006;49
Eisman et al., 200850
(DIVA)
Women with PMO
Male/female: 100% female
Race: not reported
Age; years since menopause:
l IBN 2.5 mg/day: 65.5 years; 18.0 years
l IBN 2mg i.v. two times per month:
66.6 years; 19.3 years
l IBN 3mg i.v. three times per month:
65.6 years; 18.2 years
Height; weight; BMI:
l IBN 2.5 mg/day: 158.4 cm; 63.4 kg;
25.3 kg/m2
l IBN 2mg i.v. two times per month:
158.1 cm; 64.1 kg; 25.6 kg/m2
l IBN 3mg i.v. three times per month:
158.1 cm; 63.9 kg; 25.6 kg/m2
None reported Not reported Fractures:
l IBN 2.5 mg/day: 166/381 (43.7%)
l IBN 2mg i.v. two times per
month: 148/355 (41.8%)
l IBN 3mg i.v. three times per
month: 156/355 (41.8%)
FN BMD: not reported
FN BMD T-score: not reported
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Miller et al., 2005;47
Reginster et al., 200648
(MOBILE)
Women with PMO
Male/female: 100% female
Race: not reported
Age; years since menopause:
l IBN 2.5 mg: 65.8 years; 18.3 years
l IBN 50/50 mg (single 50-mg dose on
2 consecutive days): 66.0 years;
18.7 years
l IBN 100mg: 66.2 years; 19.1 years
l IBN 150mg: 66.2 years; 18.3 years
BMI:
l IBN 2.5 mg: 25.9 kg/m2
l IBN 50/50 mg (single 50-mg dose on
2 consecutive days): 25.8 kg/m2
l IBN 100mg: 25.9 kg/m2
l IBN 150mg: 25.5 kg/m2
None reported Not reported History of previous fractures:
l IBN 2.5 mg: 192 (48.9%)
l IBN 50/50 mg: 183 (46.3%)
l IBN 100mg: 180 (45.5%)
l IBN 150mg: 185 (46.7%)
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
RIS vs. PBO
Boonen et al., 200958
Men with OP
Male/female: 100% male
Race:
l PBO:
¢ Caucasian, 88 (95%)
¢ Unknown, 2 (2%)
¢ Asian, 1 (1%)
¢ Hispanic, 1 (1%)
¢ Indian, 1 (1%)
l RIS 35 mg/week:
¢ Caucasian, 181 (95%)
¢ Unknown, 7 (4%)
¢ Asian, 1 (1%)
¢ Hispanic, 1 (1%)
¢ Indian, 1 (1%)
Age (SD):
l PBO: 62 years (11 years)
l RIS 35 mg/week: 60 years (11 years)
Height; BMI:
l PBO: 1.708 m (0.74 m); 25 (4 kg/m2)
l RIS 35 mg/week: 1.727 m (0.72 m);
25 kg/m2 (4 kg/m2)
None reported Not reported Fractures: not reported
BMD:
l PBO: proximal femur (total
proximal femur, femoral neck,
femoral trochanter): BMD
0.763 cm3 (0.106 cm3); T-score:
–2.0 (0.7) SDs
l RIS 35 mg/week: proximal femur
(total proximal femur, FN, femoral
trochanter): 0.768 cm3 (0.111 cm3);
T-score: –2.0 (0.8) SDs
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Choo et al., 201162
Men with androgen
deprivation bone loss in
non-metastatic prostate
cancer
Male/female: 100% male
Race: not reported
Age:
l PBO: 66.8
l RIS 35 mg/week: 66.2 years
Height; weight; BMI: not reported
Comorbidities: all were non-
metastatic prostate cancer patients
undergoing radiotherapy
Medications:
l PBO: median duration androgen
ablation therapy, 2 years
l RIS 35 mg/week: median duration
androgen ablation therapy of
2.1 years
Not reported Not reported
Cohen et al., 199963
Men and women (≥ 1 year
PM) aged 18–85 years on
glucocorticoids
Male/female:
l PBO: 25/77 (32.5% male)
l RIS 5 mg/day: 27/76 (35.5% male)
Race: not reported
Age (SD):
l PBO: 57.2 years (14.7 years)
l RIS 5 mg/day: 66.2 years (14.3 years)
Height; weight; BMI: not reported
Underlying disease requiring
glucocorticoid treatment:
l PBO: rheumatoid arthritis,
31/77 (40.3%); polymyalgia
rheumatic, 19/77 (24.7%);
systemic lupus erythematosus,
10/77 (13.0%); giant-cell arteritis,
5/77 (6.5%); vasculitis, 8/77
(10.4%)
l RIS 5mg/day: rheumatoid arthritis,
27/76 (35.5%); polymyalgia
rheumatic, 25/76 (32.9%);
systemic lupus erythematosus,
12/76 (15.8%); giant-cell arteritis,
5/76 (6.6%); vasculitis, 3/76
(2.6%)
Medications: All patients had begun
taking moderate to high doses of
glucocorticoids (≥ 7.5 mg/day mean
daily dose of prednisone or prednisone
equivalent) within the previous
3 months and were expected to
continue treatment for another
12 months
Not reported Fractures:
l PBO: vertebral 22/77 (28.9%)
l RIS 5 mg/day: vertebral 27/76
(35.5%)
FN BMD cm3: not reported
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Fogelman et al., 200066
(BMD-MN)
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l PBO: 65 years (6.7 years); 17 years
(9.4 years)
l RIS 5 mg/day: 65 years (6.7 years);
18 years (9.3 years)
Height; weight; BMI (estimated):
l PBO: 157 cm (6.7 cm); 63 kg (9.4 kg);
25.6 kg/m2
l RIS 5 mg/day: 158 cm (5.3 cm); 62 kg
(9.3 kg); 24.8 kg/m2
Comorbidities: none reported
Previous OP medication:
l PBO: 43/180 (24%)
l RIS 5 mg/day: 56/177 (32%)
Not reported Fractures:
l PBO: vertebral 52/180 (30.0%)
l RIS 5 mg/day: vertebral 55/177
(32.0%)
FN BMD:
l PBO: 0.636 cm3 (0.094 cm3)
l RIS 5 mg/day: 0.637 cm3
(0.093 cm3)
Hooper et al., 200572
Early PM women with OP
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l PBO: 52 years (3.3 years); 3.9 years
(5.7 years)
l RIS 5 mg/day: 52 years (3.1 years);
3.6 years (4.8 years)
Height; weight; BMI: not reported
None reported Not reported Fractures:
l PBO: vertebral 24/125 (19%)
l RIS 5 mg/day: vertebral 26/129
(20%)
FN BMD (SD):
l PBO: 0.78 cm3 (0.01 cm3)
l RIS 5 mg/day: 0.76 cm3 (0.01 cm3)
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Harris et al., 199970
(VERT-NA); extension of
Ste-Marie et al., 200499
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD)
l PBO: 68 years (7.2 years); 24 years
(10 years)
l RIS 5 mg/day: 69 years (7.7 years);
24 years (10.1 years)
Height (SD); weight (SD); BMI (estimated):
l PBO: 159 cm (6.9 cm); 67 kg (13.3 kg);
26.5 kg/m2
l RIS 5 mg/day: 158 cm (6.8) cm;
66.5 kg (13.6 kg); 26.6 kg/m2
None reported Not reported Fractures:
l PBO: vertebral 639/820 (79%)
l RIS 5 mg/day: vertebral 645/821
(80%)
FN BMD (SD):
l PBO: 0.602 cm3 (0.102 cm3)
l RIS 5mg/day: 0.593 cm3 (0.105 cm3)
Reginster et al., 200085
(VERT-MN); extension of
Sorensen et al., 2003100
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l PBO: 71 years (7.0 years); 25 years
(8.7 years)
l RIS 5 mg/day: 71 years (7.0 years);
25 years (8.6 years)
Height (SD):
l PBO: 155.5 cm (7.1 cm)
l RIS 5 mg/day: 154.9 cm (7.3 cm)
None reported Not reported Median (range) number of vertebral
fractures:
l PBO: 3 (0–13)
l RIS 5 mg/day: 4 (0–13)
FN BMD (SD):
l PBO: 0.576 cm3 (0.093 cm3)
l RIS 5mg/day: 0.573 cm3 (0.098 cm3)
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Leung et al., 200575
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l PBO: 67 years (6 years); 15.1 years
(2.2 years)
l RIS 5 mg/day: 67 years (6 years);
15.5 years (1.6 years)
Height (SD); weight (SD); BMI (estimated):
l PBO: 1.5 m (0.05 m); 48.6 kg (8 kg);
21.6 kg/m2
l RIS 5 mg/day: 1.5 m (0.05 m); 49.5 kg
(6.3 kg); 22.0 kg/m2
None reported Not reported Fractures: not reported
FN BMD (SD):
l PBO: 0.50 cm3 (0.08 cm3)
l RIS 5 mg/day: BMD 0.5 cm3
(0.05 cm3)
FN BMD T-score (SD):
l PBO: –2.72 (0.85)
l RIS 5 mg/day: BMD –2.55 (0.58)
McClung et al., 200178
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l All women 70–79 years old (n not
reported) 74 years (3 years); 28 years
(8 years)
l All women ≥ 80 years (n not reported)
83 years (3 years); 37 years (7 years)
Date by group not reported
Height; weight; BMI: not reported
None reported Not reported Vertebral fractures:
l PBO, 70–79 years old: 562/1821
(39%)
l PBO, ≥ 80 years: 394/1313 (45%)
l RIS 2.5+ 5 mg groups, 70–79
years old: 1100/3624 (38%)
l RIS 2.5+ 5 mg groups, ≥ 80 years:
743/7543 (44%)
FN BMD: not reported
FN BMD T-score (SD):
l PBO, 70–79 years old: –3.7 (0.6)
l RIS 2.5+ 5 mg groups,
70–79 years old: –3.7 (0.6)
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Reid et al., 200086
Men and women taking
glucocorticoids for
≥ 6 months
Male/female:
l PBO: 36/96 (38% male)
l RIS 5 mg/day: 36/100 (36% male)
Race: not reported
Age (SD):
l PBO: 59 years (12 years)
l RIS 5 mg/day: 59 years (12 years)
Height; weight; BMI: not reported
Underlying disease requiring
glucocorticoid treatment:
l PBO: rheumatoid arthritis,
31/96 (41%); asthma, 19/96
(20%); polymyalgia rheumatic,
11/96 (12%); systemic lupus
erythematosus, 5/96 (5%);
temporal arteritis, 7/96 (7%);
vasculitis, 3/96 (3%); COPD, 1/96
(1%); polymyositis, 4/96 (4%);
chronic intestinal lung disease,
2/96 (2%); other, 5/96 (5%)
l RIS 5 mg/day: rheumatoid
arthritis, 44/100 (44%); asthma,
18/100 (18%); polymyalgia
rheumatic, 13/100 (13%);
systemic lupus erythematosus,
8/100 (8%); temporal arteritis,
4/100 (4%); vasculitis, 4/100
(4%); COPD, 3/100 (3%);
polymyositis, 2/100 (2%); chronic
intestinal lung disease, 1/100
(1%); other, 3/100 (3%)
Medications: all patients had been
receiving oral glucocorticoids (mean
daily dose of prednisone ≥ 7.5 mg, or
equivalent) for at least 6 months
Not reported Fractures:
l PBO: vertebral 35/96 (37%)
l RIS 5 mg/day: vertebral 34/100
(34%)
FN BMD: not reported
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Ringe et al., 2006;89
extension Ringe et al.,
2009101
Men with OP
Male/female: 100% male
Race: not reported
Age (SD):
l PBO: 58.0 years (10.3 years)
l RIS 5 mg/day: 55.8 years (10.5 years)
Height (SD); weight (SD); BMI (estimated):
l PBO: 174.2 cm (6.2 cm); 73.1 kg
(9.6 kg); 24.1 kg/m2
l RIS 5 mg/day: 174.7 cm (7.0 cm);
76.2 kg (13.5); 25 kg/m2
None reported Not reported One or more vertebral fracture:
l PBO: 81/158 (51.3%)
l RIS 5 mg/day: 84/158 (53.2%)
FN BMD: not reported
FN BMD T-score (SD):
l PBO: –2.59
l RIS 5 mg/day: –2.45
Taxel et al., 201095
Men aged > 55 years and
within 1 month of
receiving an initial injection
of ADT for prostate cancer
Male/female: 100% male
Race: not reported
Age:
l PBO: 70 years
l RIS 35 mg/week: 72 years
BMI (SD):
l PBO: 29.3 kg/m2 (5.4 kg/m2)
l RIS 35 mg/week: 28.0 kg/m2
(2.9 kg/m2)
None reported Not reported Fractures: not reported
FN BMD (SD):
l PBO: 0.98 cm3 (0.16 cm3)
l RIS 35 mg/week: 0.95 cm3
(0.91 cm3)
FN BMD T-score (SD):
l PBO: –0.67 (1.24)
l RIS 35 mg/week: –0.95 (0.91)
A
S
S
E
S
S
M
E
N
T
O
F
C
L
IN
IC
A
L
E
F
F
E
C
T
IV
E
N
E
S
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
6
2
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
ZOL vs. PBO
Black et al., 200756
(HORIZON-PFT)
Women with PMO
Male/female: 100% female
Race:
l ZOL 5mg/year:
¢ Caucasian, 973 (91.4%)
¢ Hispanic, 70 (6.6%)
¢ Black, 6 (0.6%)
¢ Other, 16 (1.5%)
Age (SD):
l PBO: 73.0 years (5.40 years)
l ZOL 5mg/year: 73.1 years (5.34 years)
BMI:
l PBO: 24.8 kg/m2 (4.5 kg/m2)
l ZOL 5mg/year: 24.7 kg/m2 (4.4 kg/m2)
None reported Not reported Number (%) vertebral fractures:
l PBO: none, 1383 (35.8); one,
1076 (27.9); two or more,
1401 (36.3)
l ZOL 5mg/year: none, 1457 (37.6);
one, 1093 (28.2); two or more,
1323 (34.1)
FN BMD (SD):
l PBO: 0.53 cm3 (0.064 cm3)
l ZOL 5mg/year: 0.53 cm3
(0.062 cm3)
Number (%) with FN BMD T-score:
l PBO: < –2.5, 2734 (70.8%); –2.5
to –1.5, 1073 (27.8%); > –1.5,
38 (1.0%)
l ZOL 5mg/year: < –2.5, 2814
(72.6%); –2.5 to –1.5, 1002
(25.9%); > –1.5, 35 (0.9%)
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Lyles et al., 200777
(HORIZON-RFT)
Men and women 50 years
of age or older within
90 days after surgical repair
of a hip fracture
Male/female:
l PBO: 260/1062 (24.5% male)
l ZOL 5mg/year: 248/1065
(23.3% male)
Race:
l PBO:
¢ Caucasian 965 (90.9%)
¢ Hispanic, 70 (6.6%)
¢ Black, 12 (1.1%)
¢ Other, 15 (1.4%)
ZOL 5mg/year:
l Caucasian, 973 (91.4%)
l Hispanic, 70 (6.6%)
l Black, 6 (0.6%)
l Other, 16 (1.5%)
Age (SD):
l PBO: 74.6 years (9.86 years)
l ZOL 5mg/year: 74.4 year (9.48 years)
BMI:
l PBO: 24.8 kg/m2 (4.5 kg/m2)
l ZOL 5mg/year: 24.7 kg/m2 (4.4 kg/m2)
Comorbidities: the most common
coexisting medical conditions at
baseline were hypertension, coronary
artery disease, osteoarthritis, previous
stroke, depression, and diabetes
mellitus. n/N (%) not reported. Active
tachyarrhythmia was present in 5.8%
of patients in the ZOL group and in
7.5% of patients in the PBO group
Not reported Fractures: all patients who were
enrolled in the trial had undergone
repair of a hip fracture
FN BMD (SD):
l PBO: 0.65 cm3 (0.122 cm3)
l ZOL 5mg/year: 0.65 cm3
(0.127 cm3)
Number (%) with FN BMD T-score:
l PBO: ≤ –2.5, 437 (41.1%);
> –2.5 to –1.5, 375 (35.3%);
> –1.5, 121 (11.4%)
¢ Missing data: 129 (12.1%)
l ZOL 5mg/year: ≤ –2.5, 451
(42.3%); >–2.5 to –1.5, 360
(33.8%); > –1.5, 123 (11.5%)
¢ Missing data: 131 (12.3%)
A
S
S
E
S
S
M
E
N
T
O
F
C
L
IN
IC
A
L
E
F
F
E
C
T
IV
E
N
E
S
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
6
4
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Boonen et al., 201259
Men with OP
Male/female: 100% male
Race:
l PBO:
¢ Caucasian, 578 (94.6%)
¢ Black, 3 (0.5%)
¢ Asian, 0 (0.0%)
¢ Other, 26 (4.4%)
l ZOL 5mg/year:
¢ Caucasian, 555 (94.4%)
¢ Black, 5 (0.9%)
¢ Asian, 2 (0.3%)
¢ Other, 30 (4.9%)
Age, median (range):
l PBO: 66 years (50–85 years)
l ZOL 5mg/year: 66 years (50–85 years)
Height; weight; BMI: not reported
Comorbidities: none reported
OP medications used before the first
infusion in the study:
l PBO: bisphosphonates, 7 (1.1%);
calcitonin, 1 (0.2%)
l ZOL 5mg/year: bisphosphonates,
8 (1.4%); calcitonin, 4 (0.7%)
Not reported Number of vertebral fractures:
l PBO: none, 409 (66.9%); one,
135 (22.1); two or more, 66 (10.8)
l ZOL 5mg/year: none, 404 (68.7);
one, 135 (22.1); two or more,
66 (10.8)
FN BMD: not reported
FN BMD T-score (SD):
l PBO: –2.44 (0.685)
l ZOL 5mg/year: –2.23 (0.677)
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
0
7
8
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
6
V
O
L
.
2
0
N
O
.
7
8
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
6
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
D
a
vis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
6
5
TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
McClung et al., 200979
Women with PMO
Male/female: 100% female
Race:
l PBO:
¢ Caucasian, 186 (92%)
¢ Other 16 (8%)
l ZOL 5mg/year:
¢ Caucasian, 184 (94%)
¢ Other 12 (6%)
Age (SD); years since menopause (SD):
l PBO: 60.5 years (8.0 years); 11.4 years
(9.5 years)
l ZOL 5mg/year: 59.6 years (8.0 years);
11.5 years (10.1 years)
BMI (SD):
l PBO: 27.2 kg/m2 (5.5 kg/m2)
l ZOL 5mg/year: 27.3 kg/m2 (5.8 kg/m2)
None reported Not reported Fractures: not reported
FN BMD (SD):
l PBO: 0.69 cm3 (0.07 cm3)
l ZOL 5mg/year: 0.69 cm3
(0.08 cm3)
FN BMD T-score (SD):
l PBO: –1.47 (0.63)
l ZOL 5mg/year: –1.40 (0.56)
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Head to head: ALN vs. IBN
Miller et al., 200881
(MOTION)
Women with PMO
Male/female: 100% female
Race:
l ALN 70mg/week:
¢ Caucasian, 705/873 (80.8%)
l IBN 150mg/month:
¢ Caucasian, 739/887 (83.3%)
Age; years since menopause:
l ALN 70mg/week: 65.6 years;
18.2 years
l IBN 150mg/month: 65.6 years;
18.5 years
Height; weight; BMI (estimated):
l ALN 70mg/week: 155 cm; 62.28 kg;
25.9 kg/m2
l IBN 150mg/month: 154.6 cm;
62.01 kg; 25.9 kg/m2
None reported Not reported Previous fractures (not described):
l ALN 70mg/week: to present age,
38.2%; since age 45 years,
31.6%
l IBN 150mg/month: to present
age, 39%; since age 45 years,
32.5%
FN BMD/T-score: not reported
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Head to head: ALN vs. RIS
Atmaca and Gedik, 200654
Women with PMO
Male/female: 100% female
Race: not reported
Age (SD); years since menopause (SD):
l RIS 5 mg/day: 65.7 years (4 years);
15 years (4.7 years)
l ALN 10mg/day: 66.3 years (3.8 years);
15.9 years (4.9 years)
Height; weight; BMI: not reported
None reported Not reported Fractures: not reported
FN BMD (SD):
l RIS 5mg/day: 0.603 cm3 (0.06 cm3)
l ALN 10mg/day: 0.601 cm3
(0.06 cm3)
FN BMD T-score: not reported
Muscoso et al., 200482
Women with PMO
Male/female: 100% female
Race: not reported
Age:
l RIS 5 mg/day: 71 years (8 years)
l ALN 10mg/day: 66 years (9 years)
Height; weight; BMI: not reported
None reported Not reported Not reported
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Rosen et al., 200590 (FACT);
extension of Bonnick et al.,
2005104
Women with PMO
Male/female: 100% female
Race:
l ALN 70mg/week:
¢ Caucasian, 491/520 (94.4%)
¢ Black, 8/520 (1.5%)
¢ Asian, 7/520 (1.3%)
¢ Other, 14/520 (2.8%)
l RIS 35 mg/week:
¢ Caucasian, 512/533 (96.1%)
¢ Black, 2/533 (0.4%)
¢ Asian, 8/533 (1.5%)
¢ Other, 11/533 (2.0%)
Age (SD); years since menopause (SD):
l ALN 70mg/week: 64.2 years
(9.9 years); 18.3 years (12.3 years)
l RIS 35 mg/week: 64.8 years
(9.7 years); 18.7 years (11.6 years)
BMI (SD):
ALN 70mg/week: 25.2 kg/m2 (4.7 kg/m2)
RIS 35 mg/week: 25.5 kg/m2 (4.5 kg/m2)
None reported Not reported Fracture history of hip, spine, or wrist
after age 45 years:
l ALN 70mg/week: 60/520 (11.5%)
l RIS 35 mg/week: 66/533 (12.4%)
FN BMD not reported
FN BMD T-score (SD):
l ALN 70mg/week: –2.12 (0.66)
l RIS 35 mg/week: –2.16 (0.67)
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Reid et al., 200687 (FACTS);
extension of Reid et al.,
2008105
Women with PMO.
Male/female: 100% female
Race:
l ALN 70mg/week:
¢ Caucasian, 371/468 (79.3%)
¢ Hispanic, 39/468 (8.3%)
¢ Asian, 35/468 (7.5%)
¢ Other, 23/468 (4.9%)
l RIS 35 mg/week:
¢ Caucasian, 364/468 (77.8%)
¢ Hispanic, 43/468 (9.2%)
¢ Asian, 36/468 (7.7%)
¢ Other, 25/468 (5.3%)
Age (SD); years since menopause (SD):
l ALN 70mg/week: 64.3 years
(8.1 years); 16.9 years (9.5 years)
l RIS 35 mg/week: 63.9 years
(8.3 years); 16.8 years (9.4 years)
BMI (SD):
l ALN 70mg/week: 25.2 kg/m2
(4.7 kg/m2)
l RIS 35 mg/week: 25.5 kg/m2
(4.5 kg/m2)
None reported Family history of OP:
l ALN 70mg/week:
152 (43.1%)
l RIS 3 5mg/week:
139 (39.0%)
Fracture history (not described):
l ALN 70mg/week: 166 (35.5%)
l RIS 35 mg/week: 149 (31.8%)
FN BMD: not reported
FN BMD T-score (SD):
l ALN 70mg/week: –2.06 (0.76)
l RIS 35 mg/week: –2.17 (0.75)
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TABLE 4 Characteristics of participants in included RCTs (continued )
Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Head to head: ZOL vs. ALN
Hadji et al., 2012;69 Hadji
et al., 2010106 (ROSE)
Women with PMO
Male/female: 100% female
Race:
l ZOL 5mg/year:
¢ Caucasian, 403 (98.8%)
188 (98.4%)
¢ Black, 1 (0.2%)
¢ Asian, 1 (0.2%)
¢ Other, 2 (0.5%)
¢ Missing, 1 (0.2%)
l ALN 70mg/week:
¢ Caucasian, 188 (98.4%)
¢ Black, 1 (0.5%)
¢ Asian, 0 (0%)
¢ Other, 2 (1.0%)
¢ Missing, 0 (0%)
Age (SD):
l ZOL 5mg/year: 67.6 years (8.05 years)
l ALN 70mg/week: 68.1 years
(7.86 years)
BMI (SD):
ZOL 5mg/year: 26.1 kg/m2 (4.12 kg/m2)
ALN 70mg/week: 26.3 kg/m2 (4.0 kg/m2)
None reported Current and previous
smokers:
l ZOL 5mg/year:
97/408 (23.8%)
l ALN 70mg/week:
40/194 (20.9%)
Fractures (not described):
l ZOL 5mg/year: 134/408 (32.8%)
l ALN 70mg/week: 65/194 (34.0%)
FN BMD: not reported
l ZOL 5mg/year: n= 408
l ALN 70mg/week: n= 196
FN BMD T-score:
l ZOL 5mg/year: n= 408
l ALN 70mg/week: n= 196
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Author, year of study
publication (trial
acronym) and population Characteristics
Comorbidities and associated
medication Medical history History of fractures
Head to head: ZOL vs. RIS
Reid et al., 200988
(HORIZON)
Men and women taking
glucocorticoids ≥ 3 months
and < 3 months
Male/female:
l ZOL 5mg/year:
¢ Treatment, 87 (32%) male
¢ Prevention, 44 (31%) male
l RIS 5 mg/day:
¢ Treatment, 90 (33%) male
¢ Prevention, 44 (31%) male
Race: not reported
Age (SD):
l ZOL 5mg/year:
¢ Treatment, 53.2 years (14.0 years)
¢ Prevention, 56.3 years (15.4 years)
l RIS 5 mg/day:
¢ Treatment, 52.7 years (13.7 years)
¢ Prevention, 58.1 years (14.7 years)
Height; weight; BMI: not reported
Medical disorders requiring
glucocorticoid use:
l ZOL 5mg/year:
¢ Treatment: rheumatoid
arthritis, 119 (44%);
polymyalgia, 13 (5%); lupus,
41 (15%); asthma, 23 (8%)
l ZOL 5mg/year:
¢ Prevention: rheumatoid
arthritis, 56 (39%);
polymyalgia, 29 (20%); lupus,
10 (7%); asthma, 7 (5%)
l RIS 5 mg/day:
¢ Treatment: rheumatoid
arthritis, 114 (42%);
polymyalgia, 13 (5%); lupus,
44 (16%); asthma, 20 (7%)
l RIS 5 mg/day:
¢ Prevention: rheumatoid
arthritis, 53 (37%);
polymyalgia, 29 (20%);
lupus, 15 (10%); asthma,
4 (3%)
Not reported Fractures: not reported
FN BMD/T-score: not reported
ALN, alendronic acid; ARIBON, reversal of anastrozole (ARImidex) induced bone loss with oral monthly ibandronate (BONdronat) treatment during adjuvant therapy for breast cancer trial;
COPD, chronic obstructive pulmonary disease; CORAL, Cancer and Osteoporosis Research with Alendronate and Leuprolide trial; eod, every other day; FACT, Fosamax Actonel Comparison
Trial; FACTS, Fosamax Actonel Comparison Trial international Study; FIT, Fracture Intervention Trial; FN, femoral neck; FOSIT, FOSamax International Trial; HORIZON, Health Outcomes and
Reduced Incidence with Zoledronic acid Once Yearly trial; HORIZON-PFT; Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly – Pivotal Fracture Trial; HORIZON-RFT,
Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly – Recurrent Fracture Trial; IBN, ibandronic acid; ITT, intention to treat; MOTION, Monthly Oral Therapy with
ibandronate for Osteoporosis iNtervention trial; OP, osteoporosis; PBO, placebo; PM, postmenopausal; PMO, postmenopausal osteoporosis; RIS, risedronic acid; ROSE, Rapid Onset and
Sustained Efficacy trial; ZOL, zoledronic acid.
a Gleason scores range from 2 to 10, with 2 representing the most differentiated tumours and 10 the least differentiated tumours.107
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Alendronic acid
Alendronic acid was compared with placebo in 17 RCTs reported across 19 publications.53,55,57,60,61,64,65,67,68,71,
73,76,83,84,91,93,94,97,98 Two RCTs65,71 did not include a placebo comparison, but evaluated alendronic acid
combined with calcium compared with calcium alone.
Randomised controlled trial location and funding Four RCTs were multicentre RCTs undertaken in the
USA55,61,64,67 and six RCTs were international multicentre RCTs.76,83,84,91,94,98 One multicentre RCT was
undertaken in Italy53 and one in Canada.73 Single-centre RCTs were undertaken in Italy,60 Turkey65 and
Jordan.93 The countries and number of participating centres was unclear for one RCT57 and the number of
participating centres was unclear for one RCT undertaken in China.71 RCT sponsor details were not reported
for four RCTs.53,60,65,93 The total numbers of participants randomised ranged from 6393 to 4432.64 Where
reported, RCTs typically excluded patients with underlying conditions or receiving medications that affect
bone metabolism, and patients either with upper GI tract disorders or receiving medication for the condition.
Populations recruited and treatment dosage Fourteen RCTs recruited postmenopausal women and
evaluated 10 mg per day of alendronic acid.53,55,57,60,61,64,65,67,68,71,76,84,91,93 Two of these RCTs also included
an evaluation of other doses of alendronic acid not currently licensed.76,91,98 Two of the RCTs in
postmenopausal women reported that participants were switched from a 5 mg daily dose of oral
alendronic acid to 10 mg per day after 24 months, spending the remaining 12 months of the RCT on
10 mg per day.55,64 One RCT evaluated a daily dose of 10 mg of oral alendronic acid in men with
osteoporosis,83 one RCT evaluated a daily 10 mg dose of oral alendronic acid in men and women
(51% male) with airways disease94 and one RCT evaluated 70 mg per week of oral alendronic acid in men
with ADT bone loss in non-metastatic prostate cancer.73 One RCT, in men and women (37.4% male) with
underlying diseases requiring long-term oral glucocorticoid therapy, evaluated 5 mg or 10 mg per day of
oral alendronic acid (two active treatment groups) and reported fracture outcomes for both groups
combined (data not used in the analysis for this assessment report).91
Adjuvant therapy Adjuvant treatment in the form of calcium alone or in combination with vitamin D was
reported for all RCTs. The doses varied across the RCTs (see Table 3).
Bone mineral density of recruited participants Inclusion criteria varied across the RCTs in terms of
baseline BMD and T-scores (skeletal site and cut-off). Seven RCTs53,57,60,71,76,84,93 reported inclusion criteria
that would identify women with osteoporosis according to the current WHO definition.1 Two RCTs
recruited women aged 55–81 years with a femoral neck BMD of ≤ 2 SDs below that of a normal young
adult,55,64 an additional inclusion criterion for one of these RCTs being the presence of at least one
vertebral fracture.55 One RCT recruited women aged 42–75 years with lumbar spine BMD approximately
2 SDs below the young normal value,61 and another RCT recruited women with BMD ≥ 2 SDs below
young adult mean at either lumbar spine or femoral neck.65 One RCT recruited ambulatory women aged
65 years in long-term care with a lumbar spine or total hip BMD T-score of ≤ –2.0 SDs.67 One RCT
recruited community-dwelling women aged 65 years.67 Femoral neck BMD above mean peak was an
exclusion criterion for one RCT.68 One RCT recruited men and women with underlying diseases requiring
long-term oral glucocorticoid therapy, irrespective of baseline BMD.91 One RCT recruited men with femoral
neck and lumbar T-scores of < 2 SDs and < 1 SD below the normal for young men, or femoral neck BMD
of ≤ 1 SD below the normal for young men plus vertebral deformity or fracture.83 The RCT in men and
women with airways disease included only participants with a T-score of < –2.5 SDs or z-score of < –1.0 at
hip or lumbar spine.94 The RCT in men with ADT bone loss reported that 38% of all participants had
osteopenia and 7% had osteoporosis.73
Age, race, years post menopause, body mass index and smoking status The mean age of
participants was in the sixth decade (between 51 and 60 years) in two RCTs.53,91 One RCT did not report
mean age, but recruited women aged 44–73 years.60 Another RCT not reporting mean age included
participants 61–69 years.94 In one RCT, the mean age of all included participants was 73.6 years73 and in
all others the mean age of included participants was between 61 and 70 years. Seven RCTs in women
ASSESSMENT OF CLINICAL EFFECTIVENESS
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reported on the number of years since menopause.53,57,61,65,70,84,93 The mean number of years since
menopause ranged from 10 to 15 years with the exception of one RCT recruiting women after
hysterectomy, in which the mean number of years since menopause was 22.57 BMI was available for
12 RCTs.53,55,61,64,65,68,71,76,83,84,91,93 Across these RCTs, all mean BMI values were > 18.5 kg/m2. In one RCT,93
the mean BMI was > 30 kg/m2. Race of included participants was reported by eight RCTs.55,57,61,64,67,71,84,91
One of these studies recruited 100% East Asian women.71 Across the other RCTs the proportion of
Caucasian participants was ≥ 90%.55,57,61,64,67,84,91 Smoking status was reported by five trials,53,55,64,73,94 with
four reporting that ≥ 10% of included participants were current smokers.53,55,64,94 Mean smoking duration
of 26.2 years and mean quantity of 0.98 packs per day were reported by one RCT.73
Fractures at baseline The presence of fractures or fracture history at baseline was reported by nine
RCTs.53,55,64,67,68,71,73,76,83 One reported that 5% of all participants had vertebral fractures,53 one that 37%
had vertebral fractures71 and one that 41.9% had vertebral fractures.83 One RCT reported that 64% of
participants had at least one vertebral fracture and that 14% had three or more vertebral fractures.55
One study reported that 21% of participants had vertebral fractures and 5% had non-vertebral fractures at
baseline.76 Fifty-five per cent of participants in one RCT had a history of fracture.67 One RCT reported that,
of the 47% who reported prior fracture, 1% had a history of hip or vertebral fracture.73 One RCT reported
that 36% had experienced fractures since age 50 years68 and another RCT reported that 35% had
experienced fractures since age 45 years.64
Assessment of treatment compliance Compliance with treatment in the form of a pill count was
assessed by three RCTs.53,55,64
Follow-up and participants completing randomised controlled trials Final follow-up was 12 months
in six RCTs,65,71,73,84,93,94 24 months in five RCTs,53,57,61,67,83 30 months in one RCT,60 36 months in three
RCTs55,68,76 and 48 months in one RCT.64 One RCT reported an initial follow-up of 12 months,91 with an
extension to 24 months.98
The number of participants completing was not reported for two RCTs60,67 (Table 5). Overall completion rates
of ≥ 90% were reported by seven RCTs53,55,64,68,71,73 (see Table 5). The highest rate of participant withdrawal
was reported by Shilbayeh et al. 2004,93 with 40% of participants withdrawing overall (see Table 5).
Post-treatment fracture assessment Fractures were not assessed as an outcome in four RCTs.53,61,71,93
Across the RCTs assessing fractures, classification of the fracture and the method of assessment was
diverse (see Table 3). Five RCTs recorded fractures as AEs,57,67,68,73,84 four of which did not report details of
the assessment method.57,67,68,73 Vertebral fractures were assessed by seven RCTs.55,60,64,65,76,83,91 All seven
RCTs reported that vertebral fractures were assessed radiographically. One of the RCTs also assessed
clinical fractures (non-spine clinical fractures, hip fractures, wrist fractures and clinical vertebral fractures,
and other clinical fractures) reported by participants and confirmed by radiography55 and one reported that
clinical fractures (clinical vertebral, hip or wrist) were assessed by participant self-reports and confirmed by
radiograph.64 One RCT reported that non-vertebral fractures were assessed from patient reporting and
confirmed by radiography.83
Post-treatment femoral neck bone mineral density assessment Femoral neck BMD assessment was
reported by all but one of the RCTs.60 Where assessed, BMD assessment was by DXA. With the exception
of one RCT that did not report on DXA manufacturer65 all studies assessed BMD using DXA Hologic or
Luner machines.
Ibandronic acid
Oral ibandronic acid at a dosage of 150 mg per month was evaluated against placebo in two RCTs,74,80
and 2.5 mg per day of oral ibandronic acid was evaluated against placebo in one RCT.45 This RCT also
evaluated oral ibandronic acid at a dosage of 20 mg every other day for 12 doses per month (unlicensed
dose). One RCT evaluated 2.5 mg per day of oral ibandronic acid, 2 mg i.v. every 2 months (unlicensed
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TABLE 5 Outcome data reported by included RCTs
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
ALN vs. PBO
Adami et al., 199553
24 months
Numbers completing: of the original
286 patients (all doses), 17 were lost
to follow-up and nine withdrew
consent during the study. Number of
participants by group: NR
Reasons for withdrawal: 13 patients
discontinued treatment because of a
clinical AE and two because of a
laboratory AE (not described). Number
of participants by group: NR
NR Not an outcome Mean per cent change (SD) from baseline:
l PBO: –2.58 (7.28)
l ALN 10mg/day: 1.19 (6.92)
Between-group difference: p ≥ 0.01 vs.
PBO
Numbers included in FN BMD analysis:
l PBO: 67/71 (86%)
l ALN 10mg/day: 62/68 (91%)
Black et al., 199655 (FIT I)
36 months
Numbers with radiograph at
follow-up:
l PBO: 965/1005 (96.0%)
l ALN 10mg/day: 981/1022
(96.0%)
Reasons for withdrawal:
l PBO: AE 96/1005 (9.6%)
l ALN 10mg/day: AE 78/1022
(7.6%)
Other reasons for withdrawal: NR
At closeout, 87% of those
assigned to PBO and 89% of
those assigned to ALN were
taking study medication and
96% in each treatment group
had taken at least 75% of
their pills since the last clinic
visit
PBO:
l New morphometric vertebral fractures,
192/965 (19.9%); 240 fractures
l One or more morphometric vertebral
fracture, 145/965 (15%)
l Two or more morphometric vertebral
fractures, 47/965 (4.9%); clinical
vertebral fractures 50/965 (5.2%);
l Any clinical fracture, 183/1005
(18.2%)
l Non-vertebral fracture, 148/1005
(14.7%)
l Hip 22 (2.2%), wrist 41 (4.1%), other
99 (9.9%)
Mean per cent change (SD) from baseline
(extracted from graph):
l PBO: –0.31 (5.7)
l ALN 10mg/day: 3.54 (5.43)
Between-group difference: 4.1%
difference; p< 0.001
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
ALN:
l New morphometric vertebral fractures,
83/981 (8.5%)
l One or more new morphometric
vertebral fractures, 78/981 (8%);
86 fractures
l Two or more new morphometric
vertebral fractures, 5/981 (0.5%)
l Clinical vertebral fracture, 23/981
(2.3%)
l Non-vertebral fracture, 122/1022
(11.9%)
l Hip, 11 (1.1%); wrist, 22; (2.2%); other
100 (8%)
Between-group difference:
l New morphometric vertebral fractures
47% lower (p< 0.001) in ALN
¢ One or more new morphometric;
RR 0.53 (95% CI 0.41 to 0.68)
¢ Two or more new morphometric
vertebral fractures; RR 0.10
(95% CI 0.05 to 0.22)
¢ Clinical vertebral fracture; RH 0.45
(95% CI 0.27 to 0.72)
¢ Non-vertebral; RR 0.80 (95% 0.63
to 1.01)
¢ Hip, RR 0.49 (95% CI 0.23 to 0.99);
wrist, RR 0.52 (95% CI 0.31 to
0.87); other, RR 0.99 (95% CI 0.75
to 1.31)
continued
D
O
I:
1
0
.3
3
1
0
/h
ta
2
0
7
8
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
6
V
O
L
.
2
0
N
O
.
7
8
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
6
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
D
a
vis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
7
7
TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Cummings et al., 199864
(FIT II)
36 months
Numbers with radiograph at
follow-up:
l PBO: 2077/2218 (93.6%)
l ALN 10mg/day: 2057/2214
(93.0%)
Reasons for withdrawal:
l PBO: died, 37 (1.7%); other
104 (4.7%)
l ALN 10mg/day: died, 35 (15.8%),
other, 122 (5.5%)
Stopped medication as rate of bone
loss exceeded predetermined limits:
l PBO: 22 (1.0%)
l ALN 10mg/day: 12 (0.5%)
At closeout 82.5% of those
assigned to PBO and 81.3%
of those assigned to ALN
were taking study medication
and 96% in each treatment
group had taken at least 75%
of their pills since the last
clinic visit
PBO:
l One or more vertebral fractures,
78/2077 (3.8%)
l Two or more vertebral fractures,
10/2077 (0.2%);
l Any clinical, 312/2218 (14.1%)
l Non-vertebral, 294/2218 (13.3%)
l Hip, 24 (1.1%); wrist, 70 (3.2%)
l Other clinical, 227/2218 (10.2%)
ALN 10mg/day:
l One or more vertebral fractures,
43/2057 (2.1%);
l Two or more vertebral fractures,
4/2057 (0.2%);
l Any clinical, 272/2214 (12.3%)
l Non-vertebral, 261/2214 (11.8%)
l Hip, 19/2214 (0.9%); wrist,
83/2214 (3.7%);
l Other clinical, 182/2214 (8.2%)
Between-group difference:
l One of more vertebral RH, 0.56
(95% CI 0.73 to 1.01); p = 0.002
l Two or more vertebral RHs, 0.40
(95% CI 0.13 to 12.4); p = 0.11
l Any clinical RH 0.86 (95% CI 0.73 to
1.01); p = 0.07
l Non-vertebral RH 0.88 (95% CI 0.74 to
1.04); p = 0.13
l Hip RH 0.79 (95% CI 0.43 to 1.44);
p = 0.44
l Wrist RH 1.19 (95% CI 0.87 to 1.64);
p = 0.28;
l Other clinical RH 0.79 (95% CI 0.65 to
0.96); p = 0.02
Mean per cent change (SD) from baseline
(extracted from graph):
l PBO: –0.8 (7.53)
l ALN 10mg/day: 3.6 (7.53)
Between-group difference: 4.6%
difference; p< 0.001
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Bone et al., 200057
24 months
Numbers completing:
l PBO: 34/50 (68%)
l ALN 10mg/day: 68/92 (73.9%)
Reasons for withdrawal:
l PBO: AE, 5 (10%); withdrew
consent, 7 (14%); lost to
follow-up, 4 (8%); protocol
violation, 0 (0%)
l ALN 10mg/day: AE, 6 (6%);
withdrew consent, 10 (11%); lost
to follow-up, 5 (5.5%); protocol
violation, 3 (3.3%)
NR Non-vertebral fractures (e.g. foot, ankle, rib)
reported as AE:
l PBO: 4/50 (8%)
l ALN 10mg/day: 5/92 (5.4%)
Between-group difference: reported as not
significant, p-value NR
Mean per cent change (SD) from baseline:
l PBO: –0.6 (6.78)
l ALN 10mg/day: 2.9 (4.66)
Between-group difference: ALN reported
as significant vs. baseline and PBO,
p-value NR
Carfora et al., 199860
30 months
Numbers completing: NR
Reasons for withdrawal: NR
NR Vertebral fractures:
l PBO: 4/34 (11.8%)
l ALN 10mg/day: 1/34 (2.94%)
Between-group difference: NR
NR
Chesnut et al., 199561
24 months
Numbers completing: reports that, of
188 enrolled (PBO; ALN 10mg, 20 mg
and 5 mg), 164 (87%) completed
12 months and 154 (82%) completed
24 months. Number of participants by
group: NR
Reasons for withdrawal: reports that,
of the 34 withdrawals, 18 were
due to an AE, one to an adverse
laboratory experience; five because
of protocol deviations and 10 were
voluntary. Number of participants
by group: NR
NR Not an outcome Mean per cent change (SD) from baseline:
l PBO: NR
l ALN 10mg/day: 5.03 (3.78)
Between-group difference: p-value vs.
PBO reported as < 0.01
continued
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Dursun et al., 200165
12 months
Radiographic follow-up available for:
l Calcium 1000mg/day: 35/50
(70.0%)
l ALN 10mg/day+ calcium, 38/51
(74.5%)
Reasons for withdrawal: NR
NR Vertebral fractures:
l Calcium 1000mg/day: 14/35 (40.0%)
l ALN 10mg/day+ calcium: 12/38
(31.6%)
Between-group difference: NR
Mean per cent change (SD) from baseline:
l Calcium 1000mg/day: 2.33 (4.32)
l ALN 10mg/day + calcium: 3.75 (6.16)
Between-group difference: p < 0.0001
Greenspan et al., 200267
24 months
Numbers completing: NR
Reasons for withdrawal: NR
NR Clinical fractures (not described):
l PBO: any, 18/164 (11.0%); hip,
4/164 (2.4%)
l ALN 10mg/day: any, 13/163 (8.0%);
hip, 2/163 (1.2%)
Between-group difference: reported as not
significant, p-value NR
Mean per cent change (SD) from baseline
(extracted from graph):
l PBO: –0.36 (0.82)
l ALN 10mg/day: 2.84 (4.43)
Between-group difference: 3.4%
(CI, 2.3% to 4.4%); p< 03.001
Greenspan et al., 200368
36 months
Numbers completing:
l PBO: 83/93 (89.3%)
l ALN 10mg/day: 85/93 (91.4%)
Reasons for withdrawal:
l PBO:
¢ Refused follow-up; 8 (8.6%)
¢ Medical contraindication,
1 (1.1%)
¢ Death, 1 (1.1%)
l ALN 10mg/day:
¢ Lost to follow-up, 2 (2.2%)
¢ Refused follow-up, 4 (4.3%)
¢ Medical contraindication,
1 (1.1%)
¢ Death 1 (1.1%)
Participants taking 80% of
medication during study:
l PBO: 63/93 (68%)
l ALN 10mg/day:
58/93 (62%)
Clinical fractures (not described):
l PBO: 9/93 (10.0%)
l ALN 10mg/day: 7/93 (8.0%)
Between-group difference: NR
Mean per cent change (SD) from baseline
(ALN extracted from graph):
l PBO: –0.65 (5.11)
l ALN 10mg/day: 4.2 (3.8)
Between-group difference: reported as
significantly different, p-value NR
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Ho and Kung 200571
12 months
Numbers completing:
l Calcium 500mg/day: 26/29 (89.7%)
l ALN 10mg+ calcium, 28/29
(96.5%)
Reasons for withdrawal:
l Calcium 500mg/day: personal
reasons, 3 (10.3%)
l ALN 10mg+ calcium, personal
reasons, 1 (3.5%)
NR Not an outcome Mean per cent change from baseline:
l Calcium 500mg/day: –0.2
l ALN 10+ calcium: 5.6
Variance estimates NR
Between-group difference: p < 0.05
Klotz et al., 201373
(CORAL)
12 months
Numbers completing:
l PBO: 92/102 (90%)
l ALN 70mg/week: 78/84 (92.8%)
Reasons for withdrawal:
l PBO:
¢ AE, 6 (6%)
¢ Withdrew consent, 2 (2%)
¢ Participant request, 2 (2%)
l ALN 70mg/week:
¢ withdrew consent, 3 (3.6%)
¢ disease progression, 1 (1.2%)
¢ lost to follow-up, 1 (1.2%)
¢ non-compliance, 1 (1.2%)
Reports that compliance (pill
count) was similar (99% and
100%) between the two
groups
AE fracture (not described):
l PBO: 3/102 (1.67%)
l ALN 70mg/week: 1/84 (0.7%)
Between-group difference: p= 0.4395
Mean per cent change (SD) from baseline:
l PBO: –2.06 (5.71)
l ALN 70mg/week: 1.65 (7.53)
Between-group difference: NR
continued
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Liberman et al., 199576
36 months
Numbers completing:
l PBO: 332/397 (83.6%)
l ALN 10mg/day: 170/196 (86.7%)
Reasons for withdrawal:
l PBO: AEs, 24 (6%); other reasons
NR, 41 (10.3%)
l LN 10mg/day: AEs, 8 (4.1%),
other reasons NR 18 (9.2%)
NR Fractures:
l PBO:
¢ Vertebral fractures, 22/355 (6.2%)
¢ Non-vertebral, 38/397 (9.6%)
¢ Hip, 3/397 (0.8%)
¢ Wrist, 16/397 (4.0%)
l ALN 5mg, 10 mg, 20 mg:
¢ vertebral fractures, 17/526 (3.2%)
¢ non-vertebral, 73/1012 (7.2%)
Between-group difference:
l Vertebral fractures, RR 0.52 (95% CI
0.28 to 0.95); p = 0.03
l Non-vertebral RR 0.79 (95% CI 0.52 to
1.22); hip and wrist NR
Fractures by ALN dose: NR
Between-group difference PBO vs. ALN
10mg/day: OR 0.45 (95% CI 0.18 to 1.13)
Mean per cent change (SD) from baseline
(extracted from graph):
l PBO: –1.28 (5.98)
l ALN 10mg/day: 4.65 (6.58)
Between-group difference: 5.9% (SE 0.5);
p < 0.001
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Orwoll et al., 200083
24 months
Numbers completing:
l PBO: 79/95 (83%)
l ALN 10mg/day: 125/146 (86%)
Reasons for withdrawal: NR
NR Fractures:
l PBO:
¢ New vertebral fractures, 7/94 (7.1%)
¢ Non-vertebral, 5/94 (5.3%)
l ALN 10mg/day:
¢ New vertebral fractures,
1/146 (0.8%)
¢ Non-vertebral, 6/146 (4.1%)
Between-group difference:
l New vertebral fractures: p = 0.02
l Non-vertebral: p= 0.8
Mean per cent change (SD) from baseline:
l PBO: –0.1 (4.5)
l ALN 10mg/day: 2.5 (4.52)
Between-group difference: 2.6%
(95% CI 1.6 to 3.7); p< 0.001
Pols et al. 199984 (FOSIT)
12 months
Numbers completing:
l PBO: 865/958 (90.0%)
l ALN 10mg/day: 832/950 (88.0%)
Reasons for withdrawal: NR
NR Non-vertebral fractures:
l PBO: 37/958 (3.9%)
l ALN 10mg/day: 19/950 (2.0%)
Between-group difference: 47% risk
reduction (95% CI 10% to 70%); p = 0.021
Mean per cent change (SD) from baseline:
l PBO: –2.0 (4.5)
l ALN 10mg/day: 2.3 (4.5)
Between-group difference: 2.4%
(95% CI 2.0 to 2.8); p< 0.001
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Saag et al., 199891
48 weeks
Adachi et al., 200198
24 months
Numbers BMD data reported for
12 months:
l PBO: 142/159 (89.3%)
l ALN 10mg/day: 145/157 (92.4%)
Numbers fracture data reported for
12 months:
l PBO: 134/159 (84.2%)
l ALN 5mg/10 mg: 266/318
(83.6%)
24 months: NR
Reasons for withdrawal 12 months:
l PBO: AEs, 8 (5%), other
withdrawals NR
l ALN 10mg/day: AEs, 6 (4%),
other withdrawals NR
24 months: NR
NR Fractures, 12 months:
l PBO:
¢ Vertebral, 5/134 (3.7%); men, 1/48
(2.1%); postmenopausal women,
4/53 (7.6%)
¢ Non-vertebral, 7/159 (4.4%)
l ALN 5/10 mg/day:
¢ Vertebral 6/266 (2.3%); men, 1/74
(1.4%); postmenopausal women,
5/134 (3.7%)
¢ Non-vertebral 14/318 (4.4%)
Between-group difference 48 weeks:
vertebral fractures all RR 0.6 (95% CI
0.1 to 4.4)
Fractures, 24 months:
l PBO:
¢ Vertebral fractures, 4/59 (6.8%); of
which women 4/40 (10.0%), men
0/19 (0%)
¢ Non-vertebral 6/61 (9.8%)
l ALN 5/10 mg/day:
¢ Vertebral fractures, 1/143 (0.7%),
of which women 1/97 (1.0%) and
men 0/46 (0%)
¢ Non-vertebral 8/147 (5.4%)
Between-group difference 24 months:
p= 0.026
Fractures by ALN dose NR
Mean per cent change (SD) from baseline,
12 months:
l PBO: –1.2 (4.77)
l ALN 10mg: 1.0 (4.82)
Mean per cent change (SD) from baseline,
24 months:
l PBO: –2.93 (6.26), n= 53
l ALN 10mg/day: 0.61% (4.71), n= 51
Between-group difference: p ≤ 0.001
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Shilbayeh et al., 200493
12 months
Numbers completing:
l PBO: 18/36 (50%)
l ALN 10mg/day: 20/27 (74%)
Reasons for withdrawal [all women
(osteoporotic and osteopenic),
n= 63]: AEs, 9 (14.2%); personal
reason, 21 (33.3%); lost to follow-up,
17 (27.0%); non-compliance, 6 (9.5%);
and other, 3 (4.8%)
NR Not an outcome Mean per cent change from baseline
(SD extracted from graph):
l ALN 10mg/day: 0.79 (7.82) vs.
young adult
l PBO: 0.00 (6.36) vs. young adult
l ALN 10mg/day: 1.84 (13.59) vs.
age-matched
l PBO: 1.71 (13.87) vs. age matched
Comparative values for young adult and
age matched: NR
Between-group difference: NR; p< 0.01
compared with baseline reported for ALN
10 mg/day group
Smith et al., 200494
12 months
Numbers completing:
l PBO: 55/79 (70%)
l ALN 10mg/day: 41/65 (36%)
Reasons for withdrawal (i.e. report
that of those who withdrew, main
reasons included): voluntary
withdrawal, 38%; AEs, 36%; loss to
follow-up, 16%; and protocol
violation, 10%.
Number of participants by group: NR
NR Not an outcome Change in T-score (SD):
l PBO ITT: –0.0031 (0.24)
l PBO PP: 0.0294 (0.29)
l ALN 10mg/day ITT: 0.0565 (0.25)
l ALN 10mg/day PP: 0.0644 (0.19)
Change in z-score (SD):
l PBO ITT: 0.0587 (0.24)
l PBO PP: 0.1021 (0.23)
l ALN 10mg/day ITT: 0.1328 (0.23)
l ALN 10mg/day PP: 0.1498 (0.24)
Between-group difference:
l T-score ITT: p= 0.816
l T-score PP: p = 0.811
l Z-score ITT: p= 0.091
l Z-score PP: p = 0.334
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
IBN vs. PBO
Chesnut et al., 200445;
Chesnut et al., 200546
(BONE)
36 months
Numbers completing treatment:
l PBO: 628/982 (64%)
l IBN 2.5 mg/day: 648/982 (66%)
l IBN 20mg eod, 12 doses/month:
662/982 (67.4%)
Reasons for withdrawal:
l PBO: did not receive medication,
7 (1%); AEs, 180 (18.3%); other,
167 (17%)
l IBN 2.5 mg/day: did not receive
medication, 5 (< 1%); AEs, 175
(17.8%); other, 154 (15.6%)
l IBN 20mg eod, 12 doses/month:
did not receive medication, 5
(< 1%); AEs, 178 (18.1%); other,
137 (14%)
Mean duration on treatment
(years):
l PBO: 2.42
l IBN 2.5 mg/day: 2.48
l IBN 20mg eod,
12 doses/month: 2.46
New vertebral:
l PBO: 93/975 (9.56%)
l IBN 2.5 mg/day: 46/977 (4.7%)
l IBN 20mg eod, 12 doses/month:
48/977 (4.9%)
Between-group difference vs. PBO:
l IBN 2.5 mg/day: RR 62 (95% CI
41 to 74); p= 0.0001
l IBN 20mg eod, 12 doses/month:
RR 50 (95% CI 26 to 66); p= 0.0006
Not an outcome
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
New or worsening vertebral:
l PBO: 101/975 (10.4%)
l IBN 2.5 mg/day: 50/977 (5.1%)
l IBN 20mg eod, 12 doses/month:
57/977 (5.8%)
Clinical vertebral:
l PBO: 52/975 (5.3%)
l IBN 2.5 mg/day: 27/977 (2.8%)
l IBN 20mg eod, 12 doses/month:
27/977 (2.8%)
Between-group difference vs. PBO:
l IBN 2.5mg/day: p= 0.00117
l IBN 20mg eod, 12 doses/month:
p = 0.0143
Clinical OP:
l PBO: 127/975 (13%)
l IBN 2.5 mg/day: 113/977 (11.6%)
l IBN 20mg eod, 12 doses/month:
109/977 (11.2%)
Between-group difference vs. PBO: NR
Clinical non-vertebral:
l PBO: 80/975 (8.2%)
l IBN 2.5 mg/day: 89/977 (9.1%)
l IBN 20mg eod, 12 doses/month:
87/977 (8.9%)
Between-group difference vs. PBO: NR
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Lester et al., 200874
(ARIBON)
24 months
Numbers completing:
l PBO: 19/25 (76%)
l IBN 150mg/month: 21/25 (84%)
Reasons for withdrawal:
l PBO: reduced BMD at year 1, 2
(8%); recurrent disease, 2 (8%),
bowel carcinoma, 1 (4%), CVA
(no definition provided), 1 (4%)
l IBN 150mg/month: vaginitis,
1 (4%); joint pain, 1 (4%)
Reports that tablet
compliance of the IBN was
very good, with > 90% of
study patients taking all of
their monthly doses
Reports that no fragility fractures were
reported. Three patients taking PBO
(wrist, n= 1; shoulder, n = 1; rib, n= 1)
experienced a traumatic fracture. Two
patients taking IBN (wrist, n= 1; hip,
n = 1) experienced a traumatic fracture
Between-group difference: NR
Not an outcome
McClung et al., 200980
12 months
Numbers completing:
l PBO: 73/83 (88%)
l IBN 150mg/month: 65/77 (84%)
Reasons for withdrawal: NR
NR Fracture AE:
l PBO: 2/83 (2%); both fractures of the
foot associated with traumatic events
l IBN 150mg/month: 2/77 (3%); one
subject had a fracture of the radius
while another subject had both a rib
fracture and an upper limb fracture
associated with traumatic events
Between-group difference: NR
Mean per cent change from baseline (SD):
l PBO: –0.73 (4.16)
l IBN 150mg/month: 1.09 (2.87)
Between-group difference: NR
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
IBN dose-ranging trials
Delmas et al., 200649
(DIVA)
12 months
Eisman et al., 200850
24 months
Numbers completing, 12 months:
l IBN 2.5 mg/day: 409/470 (87%)
l IBN 2mg/i.v., every 2 months:
382/454 (84%)
l IBN 3mg/i.v., every 3 months:
394/471 (84%)
Numbers completing, 24 months:
l IBN 2.5 mg/day: 384/470 (83%)
l IBN 2mg/i.v., every 2 months:
361/454 (81%)
l IBN 3mg/i.v., every 3 months:
372/471 (79%)
Reasons for withdrawal, 24 months:
l IBN 2.5 mg/day: AEs, 46 (9.8%);
death, 3 (< 1%); no follow-up,
2 (< 1%); refused treatment,
28 (6%); other, 2 (< 2%)
l IBN 2mg/i.v.: AEs, 41 (9%);
death, 3 (< 1%); no follow-up,
6 (1.3%); refused treatment,
30 (6.6%); other 7 (1.5%)
l IBN 3mg/i.v.: AEs, 53; (11.2%);
death, 2 (< 1%); no follow-up,
6 (1.9%); refused treatment,
35 (7.4%); other, 1 (< 1%)
12 months: reports poor
compliance with the oral
(n= 248) or i.v. (n= 165).
Number of participants by
group: NR
24 months: non-compliance
with the daily regimen
(≈18%), non-compliance with
the i.v. regimens (≈12%)
12 months: reports that, in total,
43 patients (3.1%) experienced clinical
fractures (radiographically confirmed),
including non-vertebral fractures;
13 fractures occurred in the every
2 months group, 13 fractures occurred in
the every 3 months group and
17 fractures occurred in the oral treatment
group. A total of 43 patients equals 3.1%
and is inconsistent with safety number
reported
24 months clinical osteoporotic fractures
(including fractures of the vertebrae,
clavicle, scapula, ribs, pelvis, sternum,
humerus, forearm, femur, patella, tibia,
fibula, ankle and carpus):
l IBN 2.5 mg/day: 29/465 (6.2%)
l IBN 2mg/i.v., every 2 months:
21/448 (4.7%)
l IBN 3mg/i.v., every 3 months:
23/469 (4.9%)
Between-group difference: NR
Mean per cent change from baseline (SD)
extracted from graph 12 months:
l IBN 2.5 mg/day: 1.6 (4.18)
l IBN 2 mg/i.v. every 2 months
2.0 (3.89)
l IBN 3 mg/i.v. every 3 months 2.3
(3.87)
Between-group difference: NR
Mean per cent change from baseline (SD)
extracted from graph 24 months:
l IBN 2.5 mg/day: 2.01 (5.65)
l IBN 2 mg/i.v. every 2 months
2.62 (4.21)
l IBN 3 mg/i.v. every 3 months 2.32
(4.70)
Between-group difference: NR
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Miller et al., 200547
Reginster et al., 200648
(MOBILE) 12 and
24 months
Numbers completing, 12 months:
l IBN 2.5 mg: 335/402 (83.3%)
l IBN 50/50 mg (single 50-mg dose
on 2 consecutive days):
347/402 (86.3%)
l IBN 100mg/month: 340/404
(84.2%)
l IBN 150mg/month: 344/401
(84.1%)
Numbers completing, 24 months:
l IBN 2.5 mg: 325 (80.8%)
l IBN 50/50mg (single 50-mg dose
on 2 consecutive days): 328 (81.6%)
l IBN 100mg/month: 316 (78%)
l IBN 150mg/month: 322 (80.3%)
Reasons for withdrawal, 24 months:
l IBN 2.5mg: death, 41 (10%); no
follow-up, 3 (< 1%); refused
treatment, 20 (5%); other, 6 (1.5%)
l IBN 50/50 mg (single 50-mg dose
on 2 consecutive days): death,
32 (8%); no follow-up, 2 (< 1%);
refused treatment, 29 (7%);
other, 5 (1.2%)
l IBN 100mg/month: death, 44
(11%); no follow-up, 4 (1%);
refused treatment, 29 (6.4%);
other, 3 (< 1%)
l IBN 150mg/month: death, 37
(9.2%); no follow-up, 5 (1.2%);
refused treatment, 32 (7.9%);
other, 0
Reports the measures of
compliance. Does not allow
conclusions on differences in
therapeutic adherence. Data
not presented
Reports clinical fractures identified as
AEs showed no statistically significant
differences between the treatment arms
after 1 year
Clinical osteoporotic fractures recorded as
AEs at 24 months:
l IBN 2.5 mg: 24 (6.1%)
l IBN 50/50 mg (single 50-mg dose on
2 consecutive days): 29 (7.3%)
l IBN 100mg/month: 24 (6.1%)
l IBN 150mg/month: 27 (6.8%)
Between-group difference: NR
Mean per cent change (SD) from baseline
(extracted from graph) 12 months:
l IBN 2.5 mg: 1.71 (3.68)
l IBN 50/50 mg (single 50-mg dose on
2 consecutive days): 1.84 (3.68)
l IBN 100mg/month: 1.92 (3.64)
l IBN 150mg/month: 2.22 (3.83)
Between-group difference: NR
Mean per cent change (SD) from baseline
(extracted from graph) 24 months:
l IBN 2.5 mg: 1.91 (4.45)
l IBN 50/50 mg (single 50-mg dose on
2 consecutive days): 2.08 (4.09)
l IBN 100mg/month: 2.65 (3.74)
l IBN 150mg/month: 3.12 (7.03)
Between-group difference: NR
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
RIS vs. PBO
Boonen et al., 200958
24 months
Numbers completing:
l PBO: 75/93 (80.6%)
l RIS 35 mg/week: 175/191
(91.6%)
Reasons for withdrawal:
l PBO: AEs, 9 (9.7%); protocol
violation, 1 (1.1%); voluntary
withdrawal, 7 (7.5); lost to
follow-up, 1 (1.1%)
l RIS 35 mg/week: AEs, 7 (4%);
voluntary withdrawal, 9 (5.1%)
Compliant with study drug:
l PBO: 91%
l RIS 35 mg/week: 98%
Fractures:
l PBO: new vertebral fractures, 0; clinical
fractures, 6/93 (6%)
l RIS 35 mg/week: new vertebral
fractures, 1/191 (0.5%); clinical
fractures, 9/191 (5%)
Between-group difference: reported as no
differences in fracture rates between groups
Mean per cent change from baseline (SD)
extracted from graph:
l PBO: 0.73 (3.28)
l RIS 35 mg/week: 1.71 (3.46)
Between-group difference:
It was reported that significantly greater
increases in FN BMD were observed at
month 24 and end point in the RIS group
compared with PBO
Choo et al., 201162
24 months
Numbers included in analysis:
l PBO: 52/52 (100%)
l RIS 35 mg/week: 52/52 (100%)
Reasons for withdrawal: NR
NR Not an outcome Percentage change from baseline (SD):
l PBO: –5.56 (21.06)
l RIS 35 mg/week: –2.55 (20.84)
Between-group difference: p = 0.4670,
unclear if from baseline or vs. PBO
Cohen et al., 199963
12 months
Numbers completing men and
women:
l PBO: 57/77 (74.0%)
l RIS 5 mg/day: 62/76 (81.6%)
Reasons for withdrawal men and
women (across all groups, including
RIS 2.5 mg): AEs, 12; protocol
violation, 21; voluntary withdrawal,
15; lost to follow-up, 3
NR Vertebral fracture:
l PBO: premenopausal women, 0/11
(0.0%); postmenopausal women,
5/24 (20.8%)
l RIS 5 mg/day: premenopausal women,
0/10 (0.0%); postmenopausal women,
2/24 (8.3%)
Between-group difference: men and
women, p= 0.072
Mean per cent change from baseline (SD):
l Premenopausal women:
¢ PBO: –1.2 (4.64)
¢ RIS 5 mg/day: –3.3 (4.74)
l Postmenopausal:
¢ PBO: –0.9 (5.75)
¢ RIS 5 mg/day: –2.8 (5.1)
Between-group difference:
l Women only, not significant
l Men and women, p< 0.001
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Fogelman et al., 200066
(BMD-MN)
24 months
Numbers completing:
l PBO: 143/180 (79.4%)
l RIS 5 mg/day: 139/177 (78.5%)
Reasons for withdrawal:
l PBO: AEs, 14 (8%); other
reasons, NR
l RIS 5 mg/day: AEs, 19 (11%);
other reasons, NR
NR Fractures recorded as AEs:
l PBO: vertebral fractures, 17/125
(14.0%); non-vertebral, 13/125 (9.0%)
l RIS 5 mg/day: vertebral fractures,
8/112 (7.0%); non-vertebral, 7/112
(5.0%)
Between-group difference: NR
Mean per cent change from baseline (SD):
l PBO: –1.0 (0.32)
l RIS 5 mg/day: 1.3% (0.44)
Between-group difference: p < 0.001
Hooper et al., 200572
24 months
Numbers completing:
l PBO: 93/125 (74.4%)
l RIS 5 mg/day: 103/129 (79.8%)
Reasons for withdrawal:
l PBO: voluntary withdrawal,
16 (12.8%); AEs, 8 (6.4%);
protocol violation, 5 (4%); lost to
follow-up, 1 (< 1%); other,
2 (1.6%)
l RIS 5 mg/day: voluntary
withdrawal, 12 (9.6%); AE,
7 (5.6%); protocol violation,
5 (3.9%); other, 2 (1.5%)
NR Fractures:
l PBO: new vertebral fractures,
10/125 (8.3%); non-vertebral,
6/125 (4.8%)
l RIS 5 mg/day: new vertebral fractures,
10/129 (7.7%); non-vertebral, 5/129
(3.9%)
Between-group difference: reported as not
significant, p-value NR
Mean per cent change (SD) from baseline
(extracted from graph):
l PBO: –2.43 (3.69)
l RIS 5 mg/day: 2.29 (2.24)
Between-group difference: 3.30%;
p ≤ 0.05
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Harris et al., 199970
(VERT-NA)
36 months
Ste-Marie et al., 200499
60 months
Numbers completing, 36 months:
l PBO: 450/815 (55.2%)
l RIS 5 mg/day: 489/813 (60.1%)
Numbers completing, 60 months:
l PBO: 33/42 (78.6%)
l RIS 5 mg/day: 41/44 (93.2%)
Reasons for withdrawal, 36 months:
l PBO: AEs, 136 (16.6%); voluntary
withdrawal, 144 (17.7%);
protocol violation, 39 (4.8%); lost
to follow-up, 21 (2.6%);
treatment failure, 8 (1%); other,
17 (2.9%)
l RIS 5 mg/day: AEs, 138 (17%);
voluntary withdrawal,
119 (14.6%); protocol violation,
32 (3.9%); lost to follow-up,
14 (17.2%); treatment failure,
3 (< 1%); other 18 (2.2%)
Reasons for withdrawal, 60 months:
l PBO: AEs, 3 (7.1%); voluntary,
4 (9.5%)
l RIS 5 mg/day: AEs, 0 (0%);
voluntary, 4 (9.1%)
55% in the PBO and 60% in
the RIS 5 mg/day group
completed 3 years of
medication
Fractures, 36 months:
l PBO: vertebral, 93/678 (16.3%); non-
vertebral fractures, 52/815 (8.4%); hip,
15/815 (1.8%); wrist, 22/815 (2.7%);
humerus, 10/815 (1.2%)
l RIS 5 mg/day: vertebral, 61/696
(11.3%); non-vertebral fractures,
33/812 (5.2%); hip, 12/812 (1.0%);
wrist, 14/812 (1.7%); humerus,
4/812 (0.5%)
Between-group difference: vertebral,
41% (95% CI 18% to 58%; p= 0.003);
non-vertebral 39% (95% CI 6% to 61%;
p= 0.02)
Fractures, 60 months:
l PBO: vertebral (7.1%);
non-vertebral fractures (16.7%)
l RIS 5 mg/day: vertebral (9.1%);
non-vertebral fractures (4.5%)
Between-group difference: NR
Per cent change from baseline (SD from
graph) 36 months:
l PBO: –1.2 (9.21)
l RIS 5 mg/day: 1.6 (12.83)
Between-group difference: p < 0.05
Between-group difference, 60 months
reported as: 4.7%, no variance estimate
or p-value reported
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Reginster et al., 200085
(VERT-MN)
36 months
Sorensen et al. 2003100
60 months
Numbers completing, 36 months:
l PBO: 221/407 (54.3%)
l RIS 5 mg/day: 251/407 (61.7%)
Numbers completing, 60 months:
l PBO:105/130 (80.8%)
l RIS 5 mg/day: 115/135 (85.2%)
Reasons for withdrawal, 36 months:
l PBO: AEs, 83 (19.7%); voluntary
withdrawal, 58 (14.2%); other,
45 (11%)
l RIS 5 mg/day: AEs, 65 (16%);
voluntary withdrawal, 56 (13.8%);
other, 35 (8.6%)
Reasons for withdrawal, 60 months:
l PBO: AEs, 16 (12.3%); protocol
violation, 2 (1.5%); voluntary
withdrawal, 3 (2.3%); other,
4 (3.1%)
l RIS 5 mg/day: AEs, 10 (7.4%);
protocol violation, 1 (0.7%);
voluntary withdrawal, 6 (4.4%);
other, 3 (2.2%)
NR Fractures, 36 months:
l PBO: new vertebral fractures,
89/346 (25.7%); non-vertebral,
51/406 (12.6%); hip, 11/406 (2.7%);
wrist, 21/406 (5.2%); humerus,
14/406 (3.4%)
l RIS 5 mg/day: new vertebral fractures,
53/344 (15.4%);
non-vertebral, 36/406 (8.9%); hip,
9/406 (2.2%); wrist, 15/406 (3.7%);
humerus, 7/406 (1.7%)
Between-group difference: new vertebral,
RR 0.51 (95% CI 0.36 to 0.73; p< 0.001);
non-vertebral, RR 0.67 (95% CI 0.44 to
1.04; p = 0.063)
Fractures, 60 months:
l PBO: vertebral, 29/103 (28.2%);
non-vertebral, 11/130 (8.5%); humerus,
6/130 (4.6%)
l RIS 5 mg/day: vertebral, 15/109
(13.8%); non-vertebral, 7/135 (5.2%);
humerus, 3/135 (2.2%)
Between-group difference: vertebral 59%
(95% CI 19% to 79%; p = 0.01)
Mean per cent change (SD) from baseline
(extracted from graph), 36 months:
l PBO: –0.97 (7.46)
l RIS 5 mg/day: 2.09 (7.67)
Between-group difference: 3.1%
(95% CI: 1.8, 4.5; p < 0.001)
Mean per cent change (SD) from baseline
(mean extracted from text; SD extracted
from graph), 60 months:
l PBO: –2.3 (6.84)
l RIS 5 mg/day: 2.2 (10.46)
Between-group difference: p < 0.05
Leung et al., 200575
12 months
Numbers completing: NR
Reasons for withdrawal: overall, 5;
migration, 1; stroke, 2; gastrointestinal
upset. Number of participants by
group: NR
NR Fractures: reports that there were no
symptomatic fractures in both groups
during the study
Mean per cent change from baseline
(SD estimated from graph):
l PBO: 1.1 (5.25)
l RIS 5 mg/day: 1.8 (3.9)
Between-group difference: p < 0.0001
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
McClung et al., 200178
12 months
Numbers completing:
l PBO: 1584/3134 (50.5%)
l RIS 2.5 mg + 5mg group:
4000/6197 (64.5%)
Reasons for withdrawal: NR
Hip fracture, all women:
l PBO: 95/3134 (3.0%)
l RIS 2.5 mg + 5mg groups: 317/6197
(5.1%)
Between-group difference: RR 0.7 (95% CI
0.6 to 0.9; p= 0.02)
Hip fracture, aged 70–79 years:
l PBO: 46/1821 (2.5%)
l RIS 2.5 mg + 5mg groups: 55/3624
(1.5%)
Between-group difference: RR 0.6 (95% CI
0.4 to 0.9; p= 0.009)
Between-group differences reported in text:
RR 0.7 (95% CI 0.4 to 1.1)
Hip fracture aged 80 years:
l PBO: 82/2573 (3.2%)
l RIS 2.5+ 5 mg groups: 49/1313 (3.7%)
Between-group difference: RR 0.8 (95% CI
0.6 to 1.2; p= 0.35)
Non-vertebral all women:
l PBO: 351/3134 (11.2%)
l RIS 2.5+ 5 mg groups: 317/6197
(5.1%)
Between-group difference: RR 0.8 (95% CI
0.7 to 1.0; p= 0.03)
Fractures by ALN dose for all women or
women 80+ years: NR
Between-group difference in women aged
70–79 years:
l PBO vs. RIS 5 mg/day: 3.4%
Data by group and p-value: NR
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Reid et al., 200086
12 months
Numbers completing:
l PBO: 70/96 (72.9%)
l RIS 5 mg/day: 81/100 (81.0%)
Reasons for withdrawal: AEs, 12%;
voluntary withdrawal, 7%; lost to
follow-up/protocol violation, 3%.
Number of participants by group: NR
NR New vertebral fractures, men and women:
l PBO: 9/60 (15%)
l RIS 5 mg/day: 3/60 (5%)
Between-group difference: NR
Mean per cent change (SD) from baseline:
l Premenopausal women:
¢ PBO: 1.3 (4.92)
¢ RIS 5 mg/day: 0.7 (3.39)
l Postmenopausal women:
¢ PBO: –0.5 (3.08)
¢ RIS 5 mg/day: 1.8 (4.64)
Between-group difference: NR
A p-value of < 0.05 was reported for RIS
5 mg/day in postmenopausal women vs.
baseline
Ringe et al., 200689
12 months
Ringe et al., 2009101
24 months
Numbers completing, 12 months:
study reports that all 316 patients
were re-examined
Numbers completing, 24 months:
l PBO: 152/158 (96%)
l RIS 5 mg/day: 148/158 (93.5%)
Reasons for withdrawal: all because of
personal reasons
NR New vertebral fracture, 12 months:
l PBO: 20/158 (12.7%)
l RIS 5 mg/day: 8/158 (50.6%)
Between-group difference: p= 0.028
New vertebral fracture, 24 months:
l PBO: 33/148 (22.3%)
l RIS 5 mg/day: 18/152 (11.8%)
Between-group difference: p= 0.032
Mean per cent change from baseline,
12 months:
l PBO: 0.2%
l RIS 5 mg/day: 1.8%
Between-group difference: p < 0.0001
Mean per cent change from baseline,
24 months:
l PBO: 0.6%
l RIS 5 mg/day: 3.2%
Between-group difference: p < 0.0001
Variance estimates: NR
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Taxel et al., 201095
6 months
l Numbers included in analysis:
l PBO: 20/20 (100%)
l RIS 35 mg/week: 20/20 (100%)
Reports compliance with the
study drug was 90–95% for
all patients
Not an outcome Mean per cent change (SD) from baseline:
l PBO: –2.0 (2.72)
l RIS 35 mg/week: 0.0 (2.72)
Between-group difference: p < 0.01
ZOL vs. PBO
Black et al., 200756
(HORIZON-PFT)
36 months
Numbers completing:
l PBO: 3248/3889 (83.5%)
l ZOL 5mg/year: 3269/3876
(84.3%)
Reasons for withdrawal: the study
reports that the primary reasons that
patients in both study groups did not
complete follow-up were AEs,
withdrawal of consent, loss to
follow-up, and death. Number of
participants by group: NR
A total of 6260 patients
(81%) received all three
infusions
Fractures:
l PBO:
¢ Morphometric vertebral fracture
[stratum 1 patients who are taking
no OP meds (N= 3039), proportion
of stratum 1 patients with a baseline
radiograph, at least one follow-up
radiograph, and a fracture,
n= 2853]: 310/2853 (10.9%)
¢ Hip fracture: 88/3861 (2.3%)
¢ Non-vertebral fracture: 388/3861
(10.0%)
¢ Any clinical fracture: 456/3861
(11.8%)
¢ Clinical vertebral fracture: 84/3861
(2.2%)
¢ Multiple (≥ 2%) morphometric
vertebral fractures [stratum
1 patients who are taking no OP
meds (N= 3039), proportion of
stratum 1 patients with a baseline
radiograph, at least one follow-up
radiograph, and a fracture,
n= 2853]: 66/2853 (2.3%)
Mean per cent change (SD) from baseline
(PBO extracted from graph):
PBO: –0.04 (8.88)
ZOL 5mg/year: 5.06 (8.48)
Between-group difference: 5.06%
(95% CI 4.76% to 5.36%; p< 0.001)
continued
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
l ZOL 5mg/year:
¢ Morphometric vertebral fracture
[stratum 1 patients who are taking
no OP meds (N = 3045), proportion
of stratum 1 patients with a
baseline radiograph, at least one
follow-up radiograph, and a
fracture, n= 2822]: 92/2822 (3.3%)
¢ Hip fracture: 52/3875 (1.3%)
¢ Non-vertebral fracture: 292/3875
(7.5%)
¢ Any clinical fracture: 308/3875
(8.0%)
¢ Clinical vertebral fracture: 19/3875
(0.5%)
¢ Multiple (≥ 2%) morphometric
vertebral fractures [stratum 1
patients who are taking no OP
meds (N = 3045), proportion of
stratum 1 patients with a baseline
radiograph, at least one follow-up
radiograph, and a fracture,
n= 2822]: 7/2822 (0.2%)
Between-group difference:
l Morphometric vertebral (stratum 1):
RR 0.30 (95% CI 0.24 to 0.38)
l Hip: HR 0.59 (95% CI 0.42 to 0.83)
l Non-vertebral fractures, all clinical
fractures, and clinical vertebral
fractures: p< 0.001
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Lyles et al., 200777
(HORIZON-RFT)
36 months
Numbers completing:
l PBO 746/1062 (70%)
l ZOL 5mg/year: 770/1065 (72.3%)
Reasons for withdrawal:
l PBO: died, 142 (13.4%);
withdrew consent, 108 (10.2%);
lost to follow-up, 28 (2.6%); AEs,
18 (1.7%); administrative
problem, 8 (< 1%); protocol
violation, 7 (< 1%); abnormal lab
vale, 3 (< 1%); unsatisfactory
therapeutic effect, 1 (< 1%)
l ZOL 5mg/year: died, 102 (9.5%);
withdrew consent, 120 (11.2%);
lost to follow-up, 35 (3.3%); AEs,
21 (1.9%); administrative
problem, 9 (1%); protocol
violation, 4 (< 1%); abnormal lab
value, 4 (< 1%)
NR Fractures:
PBO:
Any new clinical, 139/1062 (13.1%)
Non-vertebral, 107/1062 (10.1%)
Hip, 33/1062 (3.1%)
Vertebral, 39/1062 (3.7%)
ZOL 5 mg/year:
Any, 92/1065 (8.6%)
Non-vertebral, 79/1065 (7.1%)
Hip, 23/1065 (2.2%)
Vertebral, 21/1065 (2.0%)
Between-group difference:
Any new clinical, HR 0.65 (95% CI
0.50 to 0.84); p= 0.001
Non-vertebral, 0.73 (0.55 to 0.98); 0.03
Hip, 0.70 (0.41 to 1.19); 0.18
Vertebral, 0.72 (0.56 to 0.93); 0.01
Mean per cent change from baseline
l PBO: –0.7
l ZOL 5mg/year: 3.6
Between-group difference: p < 0.001
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Boonen et al., 201259
24 months
Numbers completing:
PBO: 540/611 (88.4%)
ZOL 5mg/year: 530/588 (90.1%)
Reasons for withdrawal:
l PBO: withdrew consent,
22 (3.6%); died, 18 (2.9%); AEs,
11 (1.8%); lost to follow-up,
12 (2.0%); protocol deviation,
4 (0.7%); and had unsatisfactory
therapeutic effects, 4 (0.7%);
l ZOL 5mg/year: withdrew consent,
25 (4.3%); died, 15 (2.6%); AEs,
11 (1.9%); lost to follow-up,
4 (0.7%); protocol deviation,
3 (0.5%); and did not have baseline
assessment and at least one
assessment of the primary efficacy
variable after baseline, 35 (6.0%)
NR One or more new morphometric vertebral
fractures:
l PBO: 28/574 (4.9%)
l ZOL 5mg/year: 9/553 (1.6%)
Between-group difference:
RR 0.33 (95% CI 0.16 to 07.70; p= 0.002)
Mean per cent change from baseline
(SD estimated from graph):
l PBO: 0.1 (4.6); n= 63
l ZOL 5mg/year 3.4 (4.49); n= 56
Between-group difference: p < 0.05
McClung et al., 200979
24 months
Numbers completing:
l PBO: 188/202 (93.1%)
l ZOL 5mg/year: 154/181 (85.1%)
Reasons for withdrawal:
l PBO: abnormal test result, 1
(< 1%); AEs, 1 (< 1%); lost to
follow-up, 2 (1.1%); protocol
violation, 1 (< 1%); withdrew
consent, 9 (4.8%)
l ZOL 5mg/year: AEs, 3 (1.9%); lost
to follow-up, 6 (3.3%); protocol
violation, 2 (1.3%); withdrew
consent, 16 (8.8%)
NR Not an outcome Mean per cent change from baseline (SD):
l PBO: –1.35 (4.09)
l ZOL 5mg/year: 1.64 (4.14)
Between-group difference: p < 0.001
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Head to head
Miller et al., 200881
(MOTION)
12 months
Numbers completing:
l ALN 70mg/week: 785/873 (90%)
l IBN 150mg/month: 863/874
(98.7%)
Reasons for withdrawal: NR
NR Osteoporotic fractures recorded as AEs:
l ALN 70mg/week: 17/859 (2.0)
¢ Vertebral: 5/859 (< 1)
¢ Non-vertebral: 12/859 (1.4)
l IBN 150mg/month: 18/874 (2.1)
¢ Vertebral: 5/874 (< 1)
¢ Non-vertebral: 14/874 (1.6)
Between-group difference: NR
Mean per cent change from baseline (SD):
l ALN 70mg/week: 2.1 (1.77)
l IBN 150mg/month: 2.3 (2.12)
Between-group difference: reports that
gains in FN BMD were similar with both
treatments. p-value: NR
Atmaca and Gedik, 200654
12 months
Outcomes reported for:
l RIS 5 mg/day: 14/14 (100%)
l ALN 10mg/day: 16/16 (100%)
NR Not an outcome End of study value (SD) [% change]:
l RIS 5 mg/day: 0.612 (0.06) [1.5]
l ALN 10mg/day: 0.609 (0.06) [1.5]
Between-group difference: p < 0.001
Variance estimates: NR for % change
Muscoso et al., 200482
24 months
Outcomes reported for:
l RIS 5 mg/day: 100/100 (100%)
l ALN 10mg/day: 1000/1000 (100%)
NR Fractures:
l RIS 5 mg/day: 4 (vertebral, 2; femoral, 1;
wrist, 1)
l ALN 10mg/day: 0
NR if unit of analysis is patient or fracture
Between-group difference: NR
Not an outcome
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Sarioglu et al., 200692
12 months
Outcomes reported for:
l RIS 5 mg/day: 25/25(100%)
l ALN 10mg/day: 25/25 (100%)
NR Fractures: the study reports that no fractures
were detected throughout the study period
Mean per cent change from baseline (SD):
l RIS 5 mg/day: 3.7 (4.82)
l ALN 10mg/day: 2.6 (3.02)
Between-group difference: reported as
not significant, p-value not given
Rosen et al., 200590 (FACT)
12 months
Bonnick et al., 2005104
24 months
Numbers completing, 12 months:
l ALN 70mg/week: 438/520
(84.2%)
l RIS 35 mg/week: 454/533
(85.2%)
Numbers completing, 24 months:
l ALN 70mg/week: 375/411
(91.2%)
l RIS 35 mg/week: 375/414
(90.6%)
Reasons for withdrawal, 12 months:
l ALN 70mg/week: AEs, 33 (6.3%);
withdrew consent, 29 (5.6%); lost
to follow-up, 14 (2.7%); moved,
4 (0.8%); protocol deviation,
2 (0.4%)
l RIS 35 mg/week: AEs, 33 (6.2%);
withdrew consent, 28 (5.3%); lost
to follow-up, 9 (1.7%); moved,
3 (0.6%); protocol deviation,
5 (0.9%); laboratory AEs, 1 (0.2%)
24 months: NR
NR Fractures recorded as AEs at
12 months:
l ALN 70mg/week: 26/520 (5.0%)
l RIS 35 mg/week: 20/533 (3.8%)
Between-group difference: NR
Fractures recorded as AEs at 24 months:
l ALN 70mg/week: 34/411 (8.3%)
l RIS 35 mg/week: 34/414 (8.2%)
Between-group difference: NR
Mean per cent change (SD) from baseline
(extracted from graph), 12 months:
l ALN 70mg/week: 1.6 (5.39)
l RIS 35 mg/week: 0.9 (4.39)
Between-group difference: 0.7%
(95% CI 0.1 % to 1.2%; p< 0.005)
Mean per cent change (SD) from baseline
(extracted from graph), 24 months:
l ALN 70mg/week: 2.8 (4.45)
l RIS 35 mg/week: 1.0 (5.23)
Between-group difference: 0.8%
(95% CI 0.3% to 1.4%; p< 0.005)
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Reid et al., 200687 (FACTS)
12 months
Reid et al., 2008105
24 months
Numbers completing, 12 months:
l ALN 70mg/week: 430/468
(91.9%)
l RIS 35 mg/week: 424/468
(90.6%)
Numbers completing, 24 months:
l ALN 70mg/week: 385/403
(95.5%)
l RIS 35 mg/week: 373/395
(94.4%)
Reasons for withdrawal, 12 months:
l ALN 70mg/week: AEs, 19 (4%);
withdrew consent, 12 (2.5%); lost
to follow-up, 2 (< 1%); protocol
deviation, 2 (< 1%); other
3 (< 1%)
l RIS 35 mg/week: AEs, 29 (6.1%);
withdrew consent, 6 (1.3%); lost
to follow-up, 6 (1.3%); protocol
deviation, 1 (< 1%); other,
2 (< 1%)
Reasons for withdrawal, 24 months:
l ALN 70mg/week: AEs, 19 (4.7%);
withdrew consent, 12 (3.0%); lost
to follow-up, 2 (0.5%); protocol
deviation, 2 (0.5%); other, 3 (0.7%)
l RIS 35 mg/week: AEs, 29 (7.4%);
withdrew consent, 6 (1.5%); lost
to follow-up, 6 (1.5%); protocol
deviation, 1 (0.3%); other,
2 (0.5%)
NR Fractures recorded as AEs at
12 months:
l ALN 70mg/week: 17/468 (3.6%)
l RIS 35 mg/week: 18/468 (3.8%)
Between-group difference: NR
Fractures recorded as AEs at
24 months:
l ALN 70mg/week: 23/403 (5.7%)
l RIS 35 mg/week: 25/395 (6.3%)
Between-group difference: NR
Mean per cent change (SD) from baseline
(extracted from graph), 12 months:
l ALN 70mg/week: 2.25 (3.73)
l RIS 35 mg/week: 1.67 (3.71)
Between-group difference: 0.56%
(95% CI 0.03% to 1.09%; p= 0.039)
Mean per cent change (SD) from baseline
(extracted from graph), 24 months:
l ALN 70mg/week, 3.49 (5.55)
l RIS 35 mg/week, 2.53 (3.74)
Between-group difference: 1.0%
(95% CI 0.3% to 1.6%; p= 0.002)
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TABLE 5 Outcome data reported by included RCTs (continued )
Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Hadji et al., 201269
Hadji et al., 2010106
(ROSE)
12 months
Numbers completing:
l ZOL 5mg/year: 389/408 (95%)
l ALN 70mg/week: 172/196
(87.8%)
Reasons for withdrawal:
l Overall: AEs (3.3%); withdrawal
of consent (1.3%); and loss to
follow-up (1.7%)
l ZOL 5mg/year: major protocol
violations, 59/408 (14.5%)
l ALN 70mg/week: discontinued
treatment without post-baseline
measurement, 3/196 (1.5%);
major protocol violations
45/196 (23%)
The study reports that 80.9%
of patients were compliant
with ALN therapy
Not an outcome Not an outcome
Reid et al., 200988
(HORIZON)
12 months
Numbers completing:
l ZOL 5mg/year:
– Treatment: 256/272 (94%)
– Prevention: 129/144 (90%)
l RIS 5 mg/day:
– Treatment: 255/273 (93%)
– Prevention: 131/144 (91%)
The study reports that the frequency of new
vertebral fractures was n = 5 for ZOL
5mg/year and n = 3 for RIS 5 mg/day, with
no significant difference between drug
groups
Data by subgroup: NR
Mean per cent change from baseline (SD):
l ZOL 5mg/year
¢ Treatment: 1.45 (4.87)
l RIS 5 mg/day
¢ Treatment: 0.39 (4.63)
Between-group difference: 1.06% (95%
CI 0.32% to 1.79%)
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Author, year of study
publication (trial
acronym) and follow-up
Numbers completing and reasons
for withdrawal Compliance
Fracture outcomes – n/N (%)
participants; reported
between-group difference
FN BMD outcomes; reported
between-group difference
Reasons for withdrawal:
l ZOL 5mg/year:
¢ Treatment:
– AEs, 3 (1.1%); withdrew
consent, 6 (2.2%); lost to
follow-up, 3 (1.1%);
death, 3 (1.1%); did not
receive drug, 1 (0.4%)
¢ Prevention:
– AEs, 6 (4.2%); withdrew
consent, 5 (3.5%); lost to
follow-up, 3 (2.1%);
death, 1 (0.7%)
l RIS 5 mg/day
¢ Treatment:
– AEs, 3 (1.1%); protocol
deviation, 1 (0.4%);
withdrew consent,
5 (1.8%); lost to
follow-up, 2 (0.7%);
death, 3 (1.1%); did not
receive drug, 4 (1.5%)
¢ Prevention:
– AEs, 3 (2.1%); consent,
5 (3.5%); lost to
follow-up, 4 (2.8%); did
not receive drug, 1 (0.7%)
Mean per cent change from baseline (SD):
l ZOL 5 mg/year:
¢ Prevention: 1.30 (5.05)
l RIS 5 mg/day:
¢ Prevention: –0.03 (5.34)
Between-group difference: 1.33%
(95% CI 0.41% to 2.25%)
ALN, alendronic acid; ARIBON, reversal of anastrozole (ARImidex) induced bone loss with oral monthly ibandronate (BONdronat) treatment during adjuvant therapy for breast cancer trial;
CORAL, Cancer and Osteoporosis Research with alendronic acid and Leuprolide trial; eod, every other day; FACT, Fosamax Actonel Comparison Trial; FACTS, Fosamax Actonel Comparison
Trial international study; FIT, Fracture Intervention Trial; FN, femoral neck; FOSIT, FOSamax International Trial; HORIZON, Health Outcomes and Reduced Incidence with Zoledronic acid Once
Yearly trial; HORIZON-PFT; Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly – Pivotal Fracture Trial; HORIZON-RFT, Health Outcomes and Reduced Incidence with
Zoledronic acid Once Yearly – Recurrent Fracture Trial; HR, hazard ratio; IBN, ibandronic acid; MOTION, Monthly Oral Therapy with ibandronate for Osteoporosis iNtervention trial; NR, not
reported; OP, osteoporosis; OR, odds ratio; PBO, placebo; RH, relative hazard; RIS, risedronic acid; ROSE, Rapid Onset and Sustained Efficacy; VERT-MN, Vertebral Efficacy with Risedronate
Therapy – MultiNational trial; VERT-NA, Vertebral efficacy with Risedronate Therapy-North American trial; ZOL, zoledronic acid.
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dose) and 3 mg i.v. every 3 months (current licensed dose).49 One RCT evaluated 2.5 mg per day, 50 mg
twice per month (unlicensed dose), 100 mg per month (unlicensed dose) and 150 mg per month (current
licensed dose) of oral ibandronic acid.47 Where reported, RCTs typically excluded patients with underlying
conditions or receiving medications that affect bone metabolism, and patients with upper GI tract disorders
or receiving medication for these conditions.
Randomised controlled trial location and funding All five RCTs were multicentre RCTs: one was
undertaken in the UK,74 one in the USA,80 one in Europe and the USA,45 one in the USA, Canada, Mexico,
Europe, Australia and South Africa,49 and one in the USA, Canada, Europe, Australia, South Africa, Mexico
and Brazil.47 The RCT sponsor details were reported for all five RCTs. The total numbers of participants
randomised ranged from 5074 to 2946.45
Populations recruited and treatment dosage All of the RCTs recruited postmenopausal women;
one recruited postmenopausal women with a histologically confirmed diagnosis of oestrogen
receptor-positive breast cancer.74
Adjuvant therapy Daily adjuvant treatment in the form of 500 mg of calcium and 400 IU (international
unit) of vitamin D was prescribed across all five RCTs.
Bone mineral density of recruited participants Four of the RCTs45,47,49,80 reported inclusion criteria that
would identify women with osteoporosis according to the current WHO definition.1 The RCT in women
with breast cancer recruited women classified as osteopenic (T-scores of > –2.5 SDs and < –1.0 SD at
either the lumbar spine or total hip).74
Age, race, years post menopause and body mass index Four RCTs recruited participants with a mean
age between 61 and 70 years.45,47,49,74 Mean age in the other RCT was 53.6 years.80 The mean number of
years since menopause, in one RCT recruiting early postmenopausal women, was 4.2 years.80 Mean years
since menopause was 20.8 in one trial,45 18.7 in one RCT49 and 18.6 in another RCT.47 One RCT did not
report on years since menopause.74 Mean BMI values were > 18.5 kg/m2 in all RCTs. One RCT reported a
median BMI of < 30 kg/m2 in both placebo and ibandronic acid participants.74 Race of included participants
was not reported by any RCT.
Fractures at baseline The presence of fractures at baseline was reported by three RCTs:45,47,49 one in
which 93% of participants had at least one vertebral fracture at baseline and 43% had two,45 one in
which 42.1% had fractures at baseline49 and one in which 4.9% had fractures at baseline.47
Assessment of treatment compliance Compliance with treatment in the form of a pill count was
assessed by one RCT.74
Follow-up and participants completing RCTs Final follow-up was 12 months in two RCTs,47,80
24 months in two RCTs49,74 and 36 months in one RCT.45 None of the RCTs reported a completion rate of
≥ 90% (see Table 5).
The highest rate of participant withdrawal was reported by the BONE trial,45 with 34% participants
withdrawing overall (see Table 5).
Post-treatment fracture assessment Fractures were recorded as AEs, but the assessment method was
not reported in two RCTs.47,74 Two RCTs also assessed fractures as AEs confirmed by radiography.49,80
The number of vertebral fractures confirmed by radiography was the primary outcome in one RCT.45
Post-treatment femoral neck bone mineral density assessment Femoral neck BMD assessment was
reported by all of the RCTs. BMD assessment was by DXA using Hologic or Lunar machines.
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Bone mineral density and antifracture efficacy of ibandronic acid pivotal randomised controlled
trials One of the three placebo-controlled RCTs in ibandronic acid was the pivotal 3-year BONE study, in
which the antifracture efficacy of daily oral ibandronic acid 2.5 mg and intermittent oral ibandronic acid
20 mg every other day for 12 doses every 3 months (unlicensed dose) was assessed over 36 months.45
The BONE RCT reported comparable vertebral antifracture efficacy of daily and intermittent administration,
suggesting that ibandronic acid could be administered at intervals longer than daily or weekly. A further
non-inferiority RCT, the MOBILE trial,47 evaluated a monthly dose of 100 mg of ibandronic acid
administered as two single 50-mg doses on consecutive days; a single monthly 100-mg dose; a single
monthly 150-mg dose; and a daily 2.5-mg dose (four ibandronic acid study groups). The 150-mg dose
(licensed dose) produced the greatest gains in BMD compared with a daily 2.5-mg dose of ibandronic acid
at 2 years (lumbar spine BMD: 6.6% vs. 5.0%, respectively; p < 0.001).47 The DIVA study then compared
the efficacy of two regimens of intermittent i.v. injections of ibandronic acid [2 mg every 2 months
(unlicensed dose) and 3 mg quarterly (licensed dose)] with a daily 2.5-mg dose of oral ibandronic acid.
The regimen of daily 2.5 mg oral ibandronic acid has proven antifracture efficacy.49 At 2 years, the 2- and
3-monthly i.v. regimens produced improvements in spinal BMD (6.4% and 6.3%, respectively) that were
superior to oral ibandronic acid (4.8%; p < 0.001). The MOBILE and the DIVA studies confirmed a
sustained efficacy of monthly oral and quarterly i.v. regimens, respectively, over 5 years.108,109
Risedronic acid
Risedronic acid was evaluated against placebo in 12 RCTs reported across 15 publications.58,62,63,66,70,72,75,78,85,
86,89,95,99–101
Randomised controlled trial location and funding Three RCTs were multicentre RCTs undertaken in
the USA.63,70,78 One multicentre RCT was undertaken in Australia,72 one was undertaken in China75 and one
was undertaken in the UK.86 Three RCTs were international multicentre RCTs.58,66,85 One single-centre RCT
was undertaken in Germany.89 The number of participating centres was unclear for one RCT undertaken in
Canada62 and one RCT undertaken in the USA.95 With the exception of one RCT (two publications),89,101
sponsor details were reported for all included studies. The total numbers of participants randomised
ranged from 4095 to 9331.78
Populations recruited and treatment dosage Six RCTs recruited postmenopausal women and
evaluated 5 mg per day of risedronic acid.66,70,72,75,78,85 Two of these RCTs also included an evaluation of
other doses of risedronic acid not currently licensed.66,78 Both of these RCTs reported fracture outcomes for
participants in the 2.5-mg and 5-mg groups combined (data not used in the analysis for this assessment
report). One RCT evaluated oral risedronic acid at a dosage of 35 mg per week in men with osteoporosis58
and one RCT evaluated oral risedronic acid at 5 mg per day in men with osteoporosis.89 Two RCTs
evaluated 35 mg of oral risedronic acid per week in men with non-metastatic prostate cancer receiving
ADT.62,95 Two RCTs in men and women63,86 (32.5% male63 and 38% male,86 respectively) receiving
glucocorticoids evaluated oral risedronic acid at a dosage of 5 mg per day. Where reported, RCTs typically
excluded patients with underlying conditions or receiving medications that affect bone metabolism, and
patients with upper GI tract disorders or receiving medication for these conditions.
Adjuvant therapy Adjuvant treatment in the form of calcium alone or in combination with vitamin D was
reported for all RCTs. The dosages varied across the RCTs (see Table 3).
Bone mineral density of recruited participants Inclusion criteria varied across the RCTs in terms of
baseline BMD and T-scores (skeletal site and cut off). Six RCTs58,66,72,75,78,89 reported inclusion criteria that
would identify men and women with osteoporosis according to the current WHO definition.1 One RCT
recruited women aged ≤ 85 years with at least one vertebral fracture at baseline70 and another RCT
recruited women aged ≤ 85 years with at least two radiographically confirmed vertebral fractures.85
Baseline BMD was not an inclusion criterion for either of the two RCTs in men and women receiving
glucocorticoids63,86 or the two RCTs in men with prostate cancer receiving ADT.62,95
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Age, race, years post menopause and body mass index The mean age of participants was between
51 and 60 years in three RCTs.72,86,89 One RCT categorised women by age into two groups: those aged
70–79 years and those aged ≥ 80 years.78 In two RCTs, the mean age of all included participants was
71 years.85,95 In all other RCTs the mean age of included participants was between 61 and 70 years.
Five RCTs in women reported on the number of years since menopause.66,70,72,75,85 The mean number of years
since menopause was 15 years in one RCT,75 17 years in another RCT66 and ranged from 24 to 25 years in
two RCTs.70,85 The mean number of years since menopause was < 5 years in one RCT.72 In the RCT
categorising women by age into two groups (those aged 70–79 years and those ≥ 80 years), the mean
number of years since menopause was 28 years and 37 years, respectively.78 The mean years since
menopause in one RCT recruiting early postmenopausal women was 3.7 years.72 BMI was available
for five RCTs.58,66,70,75,89 Across these RCTs, all mean BMI values were > 18.5 kg/m2. Race of included
participants was reported by only one of the RCTs in which proportion of Caucasian participants was 95%.58
Fractures at baseline The presence of fractures or fracture history at baseline was reported by eight
RCTs,63,66,70,72,78,85,86,89 with 20% of women in one RCT having vertebral fractures at baseline.72 In two RCTs
approximately 31% of all participants had baseline vertebral fractures,63,66 and in one RCT 35% had
vertebral fractures.86 One RCT reported that 42% had vertebral fractures at baseline78 and one that 52%
had vertebral fractures.89 In one trial, 80% of all participants had vertebral fractures at baseline.70 One RCT
reported the median number of vertebral fractures at baseline, which was three in the placebo group and
four in the risedronic acid group.85
Assessment of treatment compliance Compliance with treatment in the form of a pill count was
assessed by two RCTs.58,95
Follow-up and participants completing randomised controlled trials Final follow-up was 12 months
in three RCTs63,75,86 and 24 months in four RCTs.58,62,66,72 One RCT reported a final follow-up of 6 months95
and another reported a follow-up of 36 months.78 One RCT reported an initial follow-up of 12 months,89
with an extension to 24 months.101 Two RCTs reported an initial follow-up of 36 months,70,85 with an
extension to 60 months.99,100
The number of participants completing the trial was not reported by three RCTs62,75,95 (see Table 5). Only
one RCT reported a completion rate of ≥ 90%89 (see Table 5). The highest rate of participant withdrawal
was reported by McClung et al.,78 with 40% participants withdrawing overall (see Table 5).
Post-treatment fracture assessment Fractures were not assessed as an outcome in four RCTs.62,75,86,95
Across the RCTs assessing fractures, classification of the fracture and the method of assessment were
diverse (see Table 3). One recorded clinical fractures (non-vertebral and vertebral fractures) confirmed by
radiography as AEs.99 This was an extension to a RCT in which vertebral fractures were the primary
outcome and were assessed radiographically.70 One RCT recorded non-vertebral fractures (not described)
and vertebral fractures as AEs, with vertebral fractures assessed radiographically.66 Vertebral fractures were
assessed by six other RCTs.58,63,72,85,86,89 All six RCTs reported that vertebral fractures where assessed
radiographically. One of these RCTs also assessed clinical vertebral and non-vertebral fractures reported
as AEs; vertebral fractures reported as AEs included symptomatic and asymptomatic radiographically
confirmed fractures.58 One RCT assessed radiographically confirmed hip fractures and non-vertebral
osteoporotic fractures; non-vertebral osteoporotic fractures were defined as all radiographically confirmed
fractures of the wrist, leg, humerus, hip, pelvis or clavicle.78
Post-treatment femoral neck bone mass density assessment Femoral neck BMD assessment was
reported by all of the RCTs. BMD assessment was by DXA using Hologic or Lunar machines.
Zoledronic acid
Zoledronic acid was evaluated against placebo in four RCTs.56,59,77,79
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Randomised controlled trial location and funding All four RCTs were international multicentre RCTs.
Sponsor details were reported for all trials and it was the same sponsor across the RCTs. The total number
of participants randomised ranged from 40079 to 7765.56
Populations recruited, bone mass density of participants and treatment dosage Two RCTs recruited
postmenopausal women with osteoporosis56,79 and one recruited men with osteoporosis.59 Across these
RCTs, baseline BMD and T-scores would identify men and women with osteoporosis according to the
current WHO definition.1 One RCT recruited ambulatory men (24.5%) and women who had undergone
repair of a hip fracture.77 Baseline BMD was not an inclusion criterion for this RCT. All RCTs evaluated
5 mg per year of i.v. zoledronic acid.
Adjuvant therapy Adjuvant treatment in the form of calcium in combination with vitamin D was
reported for all RCTs. The dosages varied across the RCTs (see Table 3).
Age, race, years post menopause and body mass index The mean age of participants in the Health
Outcomes and Reduced Incidence with Zoledronic acid Once Yearly (HORIZON) RCTs was between 61 and
70 years.56,77 The mean age of all participants was 66 years in one trial59 and 60 years in another trial.79
The mean number of years since menopause was reported for only one RCT and was 11.4.79 BMI was
available for three RCTs,56,77,79 and across these RCTs, all mean BMI values were > 18.5 kg/m2. The race of
included participants was reported by all four RCTs, and > 90% of the participants were Caucasian.
Fractures at baseline The presence of fractures at baseline was reported by three of the RCTs,56,59,77 one
of which reported all patients who were enrolled in the RCT had undergone repair of a hip fracture.77
One RCT reported that 28% of participants had one vertebral fracture at baseline and 35% had more
than two.56 One RCT reported that 22.1% of participants had one vertebral fracture at baseline and
10.8% had more than two.59
Assessment of treatment compliance An assessment method of compliance was not reported by any
RCT evaluating zoledronic acid with placebo.
Follow-up and participants completing randomised controlled trials Final follow-up was 24 months
in two RCTs59,79 and 36 months in the other two RCTs.56,77 The proportion of participants completing each
of the RCTs was 83.9%,56 71.1%,77 89.2%59 and 89.3%.79 (see Table 5).
Post-treatment fracture assessment Fractures were assessed as an outcome in three RCTs.56,59,77 One
RCT assessed vertebral fractures from radiographs.56 In this RCT, clinical fracture reports were also obtained
from patients at each visit and non-vertebral fracture reports required central confirmation. Fractures of
the toe, facial bone, finger and those caused by excessive trauma were excluded. In another RCT,
non-vertebral fractures (not a vertebral, facial, digital or skull fracture) were confirmed when a radiograph,
a radiographic report or a medical record documented a new fracture.77 In this RCT, a new clinical
vertebral fracture was defined as new or worsening back pain with a reduction in vertebral body height.
The third RCT assessed vertebral fractures from radiographs.59 In this RCT, clinical fractures (vertebral and
non-vertebral) were reported by participants at each visit and were verified centrally by means of a
radiographic report or surgical notes.
Post-treatment femoral neck bone mineral density assessment Femoral neck BMD assessment by
DXA was reported by all of the RCTs. Only one RCT reported the DXA model (Hologic or Lunar machines).79
Head to head
Alendronic acid versus ibandronic acid One RCT compared alendronic acid with monthly oral
ibandronic acid (at a dose of 150 mg) in postmenopausal women;81 there was no placebo arm in this trial.
This was a multicentre non-inferiority RCT conducted in North America, Latin America, Europe and South
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Africa, with sponsor details reported. In total, 1760 women were randomised. Mean age was 65.6 years,
mean years since menopause was 18.3 years, mean BMI was 25.9 kg/m2 and race of participants was
reported as 82% Caucasian. BMD inclusion criteria were based on lumbar spine [lumbar vertebrae 2–4
(L2–L4)] BMD T-score of < –2.5 and ≥ –5.0 SDs. Previous fractures (not described) were experienced by
38.2% of the alendronic acid group and 39% of the ibandronic acid group. Patients with either upper GI
tract disorders or diseases affecting bone metabolism were excluded. The alendronic acid dosage was
70 mg per week and the ibandronic acid dosage was 150 mg per month. Both groups also received
500 mg of calcium and 400 IU of vitamin D per day. For compliance assessment, returned study tablets
were counted. Fractures were recorded as AEs and follow-up was 12 months. Overall, 90% of participants
completed the 12-month follow-up (see Table 5).
Alendronic acid vs. risedronic acid Five RCTs across seven publications compared alendronic acid with
risedronic acid in postmenopausal women.54,82,87,90,92,104,105 There was no placebo arm in any of these RCTs.
Three RCTs evaluated 10 mg per day of alendronic acid and 5 mg per day of risedronic acid.54,82,92 Two of
these RCTs were undertaken in Turkey54,92 and the other in Italy.82 The number of participating centres and
RCT sponsor details were not reported for any of the RCTs. One trial randomised 28 participants (14 in
each group)54 and one randomised 50 participants (25 in each group).92 The third trial randomised 2000
participants to treatment groups also including clodronic acid and raloxifene. In total, 1000 participants
were randomised to risedronic acid and 100 to alendronic acid82 (10 : 1 randomisation ratio). All three
RCTs reported osteoporosis to be an inclusion criterion, but only one reported a BMD T-score inclusion
criterion.54 Mean ages were 66 years,54 70.5 years82 and 58.8 years.92 One RCT reported on mean years
since menopause, which was 15.6 years,54 and one RCT92 reported on mean BMI, which was 27.3 kg/m2.
Race was not reported by any of the three RCTs. All three RCTs prescribed a daily adjuvant of calcium and
vitamin D. Fractures at baseline were not reported by two of the RCTs;54,82 however, in the other trial,
approximately 10% of participants in both groups had vertebral fractures at baseline.92 Two of the RCTs
reported fracture as an outcome82,92 and one reported fracture as an AE;92 however, details of the
assessment method were not reported by either RCT. Final follow-up was at 12 months in two RCTs54,92
and 24 months in the third.82 Two of the RCTs reported 12-month femoral neck BMD assessment by DXA,
using either a Hologic54 or Lunar machine.92 None of the three RCTs reported on numbers withdrawing,
but all reported that 100% of participants randomised were included in the analysis (see Table 5). Where
reported, conditions or medications affecting bone metabolism were exclusion criteria, with one RCT also
considering upper GI conditions as an exclusion criterion.92
Two further RCTs undertaken by the same study group compared 70 mg per week of alendronic acid with
35 mg per week of risedronic acid in postmenopausal women.87,90 One was undertaken as a 12-month
multicentre RCT in the USA,90 with a 12-month extension to 24 months,104 and the other was a 12-month
multicentre RCT across 75 centres in 27 countries in Europe, the Americas and the Asia-Pacific region,87
with a 12-month extension to 24 months.105 Sponsor details were the same across these RCTs. The
number randomised was 1053 in the US study90 and 936 in the multinational study.87 Both RCTs recruited
postmenopausal women with osteoporosis according to the current WHO definition.1 Mean age, years
since menopause and BMI was 64.5 years, 18.5 years and 25.3 kg/m2, respectively, in the US study90 and
64.1 years, 16.9 years and 25.3 kg/m2, respectively, in the international study.87 The last RCT reported that
participants with conditions or medications affecting bone metabolism were excluded. Both RCTs reported
that > 90% of participants were Caucasian and both RCTs prescribed a daily adjuvant of 1000 mg of
calcium and 400 IU of vitamin D.
The study undertaken in the USA reported that 12% of participants had a history of hip, spine or wrist
fracture after the age of 45 years.90 The multinational study reported that 33.7% of participants had a
history of fractures (not described), and that 41% had a family history of osteoporosis.87 Across both RCTs,
clinical fractures that occurred during the trial, regardless of association with trauma or skeletal site, were
reported by investigators as clinical AEs. Femoral neck BMD was assessed in both RCTs using DXA
(Hologic). Both RCTs reported a completion rate of > 90% at the 12-month follow-up87,90 (see Table 5).
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Zoledronic acid versus alendronic acid One RCT evaluated 5 mg once per year of i.v. zoledronic acid
with 70 mg per week of alendronic acid.69 There was no placebo arm in this trial and the sponsor was
reported. In total, 604 postmenopausal women aged 55–90 years with a BMD T-score of ≤ –2.0 SDs
at total hip or lumbar spine were randomised. Both groups were prescribed a daily adjuvant of 1200 mg
of calcium and 800 IU of vitamin D. The mean age of participants was 67.8 years and mean BMI was
26.2 kg/m2. Of all the participants, 33% had fractures (not described) at baseline and the proportion of
participants who were current or previous smokers was 22.9%. Participants with conditions affecting bone
metabolism were excluded. Fractures and femoral neck BMD were not outcomes for this RCT. Quality of
life was assessed using a visual analogue scale (VAS) and compliance was assessed by investigator or study
personnel at each visit.106 The triallists reported that > 90% of participants completed the 12-month
follow-up (see Table 5).
Zoledronic acid versus risedronic acid One RCT reported as the HORIZON study [i.e. not the HORIZON –
Pivotal Fracture Trial (HORIZON-PFT) or HORZON – Recurrent Fracture Trial (HORIZON-RFT), which
compared zoledronic acid vs. placebo] recruited men and women aged 18–85 years receiving at least
7.5 mg of oral prednisolone daily (or equivalent) and who were expected to receive glucocorticoids for at
least another 12 months.88 There was no placebo arm in this trial. The RCT, which was an international
multicentre RCT, categorised 416 participants receiving steroids for > 3 months as a ‘treatment’ subgroup
and 417 participants receiving steroids for ≤ 3 months as a ‘prevention’ subgroup; both subgroups were
randomised to receive 5 mg of i.v. zoledronic acid once annually or 5 mg per day of risedronic acid. The
RCT sponsor was reported. All treatment groups were prescribed a daily adjuvant of 1200 mg of calcium
and 800 IU of vitamin D. Across treatment groups, 31% were male, the mean age of all participants was
54.4 years and race was not reported. Participants with conditions or previous treatments affecting bone
metabolism were excluded. Follow-up was at 12 months. Vertebral fractures were assessed by radiography
and femoral neck BMD by DXA (Hologic or Lunar). EuroQol (EQ-5D) HRQoL was assessed.110 The triallists
reported that > 90% of participants completed the 12-month follow-up (see Table 5).
Quality of the available research
Of the 46 included RCTs,45,47,49,53–95 21 were considered to be at low risk of selection bias;47,49,55–57,59,64,
67–70,72,73,77,79,81,87,88,90,93,94 however, the majority (25/46) of the included RCTs did not report a method of
random-sequence generation and were therefore classified as being at unclear risk of selection
bias.45,53,54,58,60–63,65,66,71,74–76,78,80,82–86,89,91,92,95 A summary of all risk-of-bias criteria judgements by RCT is
reported in Figure 4. A summary about each risk-of-bias item presented as percentages across all included
RCTs is presented in Figure 5.
Of the 46 included RCTs, 12 reported appropriate methods for concealment of treatment allocation and
were therefore judged to be at low risk of bias for this domain.55,56,59,64,68,70,77,79,81,87,88,90 The remaining 34
RCTs did not report on allocation concealment and were therefore judged as being at unclear risk of bias
for this domain.
Thirty-four of the included RCTs45,55–58,61–64,66–68,70,72–77,79–81,83–91,93–95 reported that participants and personnel
were blind to treatment allocation and were therefore judged at low risk of performance bias. Five RCTs
were reported as either open label or single blind and were judged as being at high risk of bias.53,71,82,92,106
The remaining RCTs did not report on blinding and were considered to be at unclear risk of bias for
this domain.
Blinding of the outcome assessment was reported by 13 RCTs,55,56,59,64,68,70,76,77,83,87–89,94 which were
therefore classified as being at low risk of detection bias. The remaining RCTs were considered at unclear
risk of bias for this domain.
In 29 of the RCTs,45,47,49,56–59,63,65,66,69,70,72,73,76–81,83–85,89–91,93,94,111 attrition was reported to be ≥ 10% across
treatment groups and, therefore, these RCTs were judged to be at high risk of attrition bias. In eight of the
included RCTs,53,55,64,68,86–88,95 attrition across treatment groups was reported as < 10% and these RCTs
were judged at low risk of attrition bias. In the remaining nine RCTs,54,60–62,67,71,75,82,92 numbers withdrawing
were not reported; these RCTs were therefore considered at unclear risk of bias for this domain.
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FIGURE 4 Risk-of-bias summary: judgements about each risk-of-bias item for each included RCT.?, unclear risk
of bias; +, low risk of bias, –, high risk of bias; ALN, alendronic acid; IBD, ibandronic acid; RIS, risedronic acid;
ZOL, zoledronic acid.
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Thirty-four of the included RCT reports45,55–59,63–72,74–80,83–85,87–91,93–95 contained either reference to a RCT
protocol or a RCT registration number, and were therefore judged as being at low risk of selection bias.
The remaining included RCTs did not contain this information and were therefore judged to be at unclear
risk of bias for this domain.
Assessment of effectiveness
Outcome measures prespecified in the final protocol reported across the included RCTs are presented in
Table 5.
Fracture
A total of 27 RCTs provided suitable fracture data for inclusion in the NMA reported in Results from the
network meta-analyses: nine RCTs compared alendronic acid with placebo;55,57,61,64,65,67,76,83,84 two compared
monthly oral ibandronic acid with placebo;74,80 one compared 2.5 mg per day of oral ibandronic acid with
placebo;45 nine compared risedronic acid with placebo;58,63,66,70,72,78,85,86,89 three compared zoledronic acid
with placebo;56,59,77 one compared alendronic acid with 150 mg per month of oral ibandronic acid;81
one compared alendronic acid with risedronic acid;82 and one compared zoledronic acid with
risedronic acid.88
Alendronic acid
In the Fracture Intervention Trial (FIT) I, Black et al.55 reported a RR of 0.53 (95% CI 0.41 to 0.68) for
morphometric vertebral fractures, and a relative hazard of 0.45 (95% CI 0.27 to 0.72) for clinical vertebral
fractures and 0.72 (95% CI 0.58 to 0.90) for the risk of any clinical fracture at the 36-month follow-up.
The relative hazards for hip fracture and wrist fracture were reported as 0.49 (95% CI 0.23 to 0.99) and
0.52 (95% CI 0.31 to 0.87), respectively. In FIT II, Cummings et al.64 reported a RR for radiographically
detected vertebral fractures at 36 months of 0.65 (95% CI 0.39 to 0.80). The relative hazard of clinical
fractures (vertebral, hip or wrist) was reported as 0.64 (95% CI 0.50 to 0.82) in women with osteoporosis
and 1.08 (95% CI 0.87 to 1.35) in those without osteoporosis. In the RCT by Carfora et al.,60 vertebral
fractures were reported for 8.82% of placebo participants, compared with 2.94% of alendronic acid
participants. The RCT by Dursun et al.65 reported vertebral fractures at 12 months in 40.0% of the group
assigned to calcium and 31.6% in the alendronic acid combined with calcium group. The difference
between treatments in these RCTs was not reported. Orwoll et al.83 reported a significant difference
between treatments at 24 months in new vertebral fractures (p = 0.02) but not non-vertebral fractures
(p = 0.8) in men.
Across the RCTs assessing fractures as AEs, Bone et al.57 reported that the difference between treatments
in non-vertebral fractures (foot, ankle, rib) was not significant (p-value not reported). Greenspan et al.67,68
reported that the difference between treatments in clinical fractures (not described) was not significant
(p-values not reported). In the FOSamax International Trial, Pols et al.84 reported a 47% risk reduction in
non-vertebral fractures (95% CI 10% to 70%; p = 0.021) and, in the Cancer and Osteoporosis Research
with Alendronate and Leuprolide (CORAL) trial, Klotz et al.73 reported no statistically significant difference
in fractures (not described) between treatments (p-value 0.4395).
Two RCTs pooled fracture data from different alendronic acid dosing arms (licensed and unlicensed doses).
Liberman et al.76 reported that by 36 months participants treated with alendronic acid (5 mg, 10 mg and
20 mg groups combined) had experienced fewer fractures than those treated with placebo (vertebral
fractures: RR 0.52, 95% CI 0.28 to 0.95; p = 0.03; non-vertebral fractures: RR 0.79, 95% CI 0.52 to 1.22;
p-value not reported). A difference between placebo and 10 mg per day of alendronic acid was reported
for this RCT as an odds ratio (OR) of 0.45 (95% CI 0.18 to 1.13; p-value not reported);97 however,
numbers by group were not reported. Saag et al.91 reported a difference in vertebral fractures at 12 months
between the alendronic acid 5 mg and 10 mg groups combined and the placebo group as a RR of 0.6
(95% CI 0.1 to 4.4).
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Ibandronic acid
Lester et al.,74 in the reversal of anastrozole (ARImidex) induced bone loss with oral monthly ibandronate
(BONdronat) treatment during adjuvant therapy for breast cancer (ARIBON) trial,74 reported that three
patients in placebo group and two patients in the ibandronic acid group (monthly oral dose) experienced
fractures as AEs. McClung et al.80 also reported fractures as AEs, with 2% in placebo group and 3% in the
ibandronic acid group (monthly oral dose) experiencing fractures. A difference between treatments was
not reported by either RCT. In the BONE trial, Chesnut et al.45 reported that the risk of new vertebral
fractures at 36 months was 62% lower in the group treated with 2.5 mg of oral ibandronic acid daily than
the placebo-treated group (95% CI 41% to 74%; p = 0.0001). Clinical non-vertebral fractures were
experienced by 8.2% of the placebo group compared with 9.1% of the group receiving 2.5 mg per day of
oral ibandronic acid. A difference between treatments was not reported. In the DIVA trial, Delmas et al.49
reported that 43 (3.1%) participants experienced clinical fractures, including non-vertebral fractures
recorded as AEs, at 12 months: 17 in the 2.5 mg per day of oral ibandronic acid group and 13 in the 3 mg
i.v. every 3 months group. The corresponding numbers at the 24-month follow-up were 29 (6.2%) and
23 (4.9%).50 Differences between treatments were not reported. In the MOBILE trial, Miller et al.47 reported
that there was no statistically significant difference between treatments in clinical fractures recorded as AEs
at 12 months. At the 24-month follow-up, 24 (6.1%) participants receiving 2.5 mg per day of oral
ibandronic acid and 27 (6.8%) receiving 150 mg per month had clinical fractures.48 Differences between
treatments were not reported.
Risedronic acid
Boonen et al.58 reported no differences in new vertebral or clinical fractures (recorded as AEs) at
24 months between those treated with 35 mg per week of risedronic acid and those receiving placebo.
Cohen et al.63 found no statistically significant difference in vertebral fractures in both men and women at
12 months between those treated with 5 mg per day of risedronic acid and those receiving placebo
(p = 0.072). In the RCT assessing fractures as AEs,66 14% of the placebo group experienced vertebral
fractures and 9% experienced non-vertebral fractures at 24 months. Corresponding numbers in the
risedronic acid 5 mg per day group were 7% and 5%, respectively.66 A difference between treatments was
not reported. The difference between treatments in new vertebral fractures or non-vertebral fractures
between 5 mg per day of risedronic acid and placebo at 24 months was reported as not significant
(p-value not reported) by one RCT.72
In the Vertebral efficacy with Risedronate Therapy – North American (VERT-NA) trial, Harris et al.70 reported a
difference between treatments in favour of risedronic acid in the incidence of vertebral fractures at 36 months
of 41% (95% CI 18% to 58%; p = 0.003) and in the incidence of non-vertebral fractures of 39% (95% CI
6% to 61%; p = 0.02). In the 60-month extension, fractures were recorded as AEs, the triallists reporting that
AEs were similar across groups.99 A difference between treatments for fractures was not reported. In the
Vertebral Efficacy with Risedronate Therapy – MultiNational (VERT-MN) trial, Reginster et al.85 reported a
difference between treatment groups in fractures at the 36-month follow-up (vertebral fractures: RR 0.51,
95% CI 0.36 to 0.73; p < 0.001; non-vertebral fractures: RR 0.67, 95% CI 0.44 to 1.04; p = 0.063). In the
extension study,100 a difference in vertebral fractures of 59% (95% CI 19% to 79%; p = 0.01) was reported.
The triallists reported that fracture results observed in the study extension were consistent with those
observed in the first 3 years.
In the subgroup of women aged 70–79 years, McClung et al.78 reported a difference in hip fractures at
12 months between those treated with 5 mg per day of risedronic acid and those treated with placebo
(RR 0.7, 95% CI 0.4 to 1.1). In the subgroup of women aged ≥ 80 years, hip fracture data were reported for
the combined 2.5 mg risedronic acid per day group (unlicensed) and the 5 mg risedronic acid per day group
and compared with data for the placebo-treated group (p = 0.35). The hip fracture results in all women
were also reported for the combined 2.5 mg risedronic acid per day group and 5 mg risedronic acid per day
group and compared with the placebo-treated group, risedronic acid was favoured (RR 0.7, 95% CI 0.6
to 0.9; p = 0.02).
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Reid et al.86 reported a p-value of 0.042 for the difference between treatments in vertebral fractures at
12 months across men and women for the 2.5 mg risedronic acid per day group and the 5 mg per day
group combined compared with placebo. The difference between treatments for 5 mg risedronic acid per
day compared with placebo was not reported. The triallists reported that the RCT was not powered to
demonstrate fracture efficacy.
Ringe et al.89 reported a significant difference between treatment groups in new vertebral fractures at
12 months in men (p = 0.028). At 24 months, the significant difference persisted (p = 0.032).101
Zoledronic acid
In the HORIZON-PFT, Black et al.56 reported a difference in morphometrically assessed vertebral fractures at
36 months between women treated with 5 mg of zoledronic acid annually and those treated with placebo
(RR 0.30, 95% CI 0.24 to 0.38; p < 0.001). The women were not taking any osteoporosis medications at
baseline (stratum I). Significant between-group differences in hip fracture, non-vertebral fractures, clinical
fractures and clinical vertebral fractures in all women were also reported (p < 0.001).
In the HORIZON-RFT, Lyles et al.77 reported a difference in any new clinical fracture at 36 months between
men and women treated with 5 mg of zoledronic acid annually and those treated with placebo [hazard
ratio (HR) 0.65, 95% CI 0.50 to 0.84; p = 0.001]. The difference in clinical non-vertebral fractures was
reported as a HR of 0.73 (95% CI 0.55 to 0.98; p = 0.03), the difference in clinical hip fractures as a HR of
0.70 (95% CI 0.41 to 1.19; p = 0.18) and the difference in clinical wrist fractures as a HR of 0.72 (95% CI
0.56 to 0.93; p = 0.01).
Boonen et al.59 reported a difference in the number of male participants experiencing one or more new
morphometric vertebral fractures at 24 months depending on treatment group (RR 0.33, 95% CI 0.16 to
07.70; p = 0.002).
Alendronic acid versus risedronic acid
In the Monthly Oral Therapy with Ibandronate for Osteoporosis iNtervention (MOTION) trial, Miller et al.,81
reported that, at 12 months, 18 out of 874 (2.1%) participants in the ibandronic acid group (monthly oral
dose) had experienced osteoporotic fractures recorded as AEs, of which five were vertebral fractures and
14 non-vertebral, compared with 17 (comprising five vertebral and 12 non-vertebral) out of 859 (2%)
participants in the alendronic acid group. A difference between treatments was not reported.
Muscoso et al.82 reported that at 24 months there were four fractures in the risedronic acid group,
compared with none in the alendronic acid group; however, it was unclear if the unit of analysis was the
participant or the fracture. A difference between treatments was not reported.
In the Fosamax Actonel Comparison Trial (FACT), Rosen et al.90 reported that at 12 months 5.0% of the
alendronic acid group had an AE fracture, compared with 3.8% in the risedronic acid group. At 24
months, 8.3% of the alendronic acid group had an AE fracture, compared with 8.2% in the risedronic acid
group.104 In the FACT international Study (FACTS), Reid et al.87 reported that at 12 months 3.6% of the
alendronic acid group had an AE fracture, compared with 3.8% in the risedronic acid group. A difference
between treatments was not reported. The corresponding values at 24 months105 were 5.7% and 6.3%.
Zoledronic acid versus risedronic acid
In the HORIZON trial, Reid et al.88 reported that the frequency of new vertebral fractures was five in the
zoledronic acid group and three in the risedronic acid group, with no significant difference between drug
groups. Data by steroid use subgroup were not reported.
Femoral neck bone mineral density
A total of 35 RCTs provided suitable femoral neck BMD data for inclusion in the NMA reported in Results
from the network meta-analyses: 12 RCTs compared alendronic acid with placebo;53,55,57,64,65,67,68,73,76,83,84,91
one compared 2.5 mg per day of oral ibandronic acid with placebo;45 one compared 150 mg per month of
oral ibandronic acid with placebo;80 one compared 2.5 mg per day of oral ibandronic acid with 3 mg
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i.v. ibandronic acid every 3 months;49 one compared 2.5 mg per day of oral ibandronic acid with 150 mg
ibandronic acid per month;47 10 compared risedronic acid with placebo;58,62,63,66,70,72,75,85,86,95 four compared
zoledronic acid with placebo;56,59,77,79 three compared alendronic acid with risedronic acid;87,90,92 one
compared alendronic acid with 150 mg per month of oral ibandronic acid;81 and one compared zoledronic
acid with risedronic acid.88
Alendronic acid
Statistically significant differences in femoral neck BMD between treatments for 10 mg per day of
alendronic acid were reported at 48 weeks by one trial,91 at 12 months by three trials,65,71,84 at 24 months
by four trials53,57,61,83 and at 36 months by three trials.55,64,76 The variance estimates were reported as a
standard error in FIT I;55 however, FIT II64 reported that the variance estimates were SDs. These triallists
were contacted for confirmation of the variance estimate (Professor Dennis Black, University of California,
2015, personal communication) but no reply was received to 29 June 2016. For this assessment report it
was assumed that the femoral neck BMD variance estimate was reported as standard error in both RCTs
because of the sample sizes and apparent comparability of the reported values. A mean difference
between treatments at 24 months of 3.4% (95% CI 2.3% to 4.4%) was reported by one RCT67 (p-value
not reported). One RCT did not report the difference between treatments at 36 months (data by group
presented in graphical format only)68 and one RCT reported mean per cent change from baseline
compared with age-matched and young adult reference values (source not reported).93 Significant changes
from baseline were reported in the alendronic acid group (p < 0.01). One RCT reported differences
between treatments in femoral neck T-scores and z-scores at 12 months,94 but no statistically significant
differences between treatments were reported. One RCT assessing 70 mg per week of alendronic acid
reported a mean change from baseline in femoral neck BMD at 12 months of –2.06% (SD ± 5.71%) in
the placebo group, compared with 1.65% (SD ± 7.53%) in the alendronic acid group.73 No difference
between treatments was reported by this RCT.73
Ibandronic acid
One RCT assessing 150 mg per month of ibandronic acid reported a mean change from baseline in
femoral neck BMD at 12 months of –0.73% (SD ± 4.16%) in the placebo group compared with 1.09%
(SD ± 2.87%) in the ibandronic acid group,80 but a between-group difference between treatments was not
reported by this RCT. In the DIVA trial, Delmas et al.49 reported a mean change from baseline at 12 months
of 1.6% (SD ± 4.18%) for 2.5 mg per day of oral ibandronic acid compared with 2.3% (SD ± 3.87%) for
3 mg of i.v. ibandronic acid every 3 months. Corresponding values at 24 months were 2.01% (SD ± 5.65%)
and 2.32% (SD ± 4.70%);50 differences between treatments were not reported. In the MOBILE trial, Miller
et al.47 reported a mean change in femoral neck BMD from baseline at 12 months of 1.71% (SD ± 3.68%)
for 2.5 mg per day of oral ibandronic acid compared with 2.22% (SD ± 3.83%) for 150 mg per month of
ibandronic acid. Corresponding values at 24 months were 1.91% (SD ± 4.45%) and 3.12% (SD ± 7.03%),
respectively.48 Between-group differences between treatments were not reported.
Risedronic acid
Statistically significant differences in femoral neck BMD between women receiving 5 mg of risedronic acid
per week and those receiving placebo were found at 12 months,75 24 months,66,72 36 months70,85 and
60 months.100 Statistically significant differences at 6 months95 and at 24 months58 were reported in men
receiving 35 mg per week risedronic acid and at 12 months89 and 24 months in men receiving 5 mg per
week risedronic acid compared with placebo treatment.101 One RCT reported a p-value of 0.4670 for 35 mg
per week of risedronic acid, but it was unclear whether this was compared with baseline or the placebo
group.62 One RCT reported a statistically significant difference at 12 months among men and women
between those treated 5 mg per day of risedronic acid and those treated with placebo (p < 0.001);63
however, the difference between treatments was not significant when only women were considred.63 In a
subgroup of women aged 70–79 years McClung et al.78 reported a 3.4% difference in femoral neck BMD
between those treated with 5 mg per week of risedronic acid and those treated with placebo;78 data by
group or a p-value were not reported. Reid et al.86 reported a p-value < 0.05 for 5 mg/day of risedronic acid
in postmenopausal women compared with baseline.
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Zoledronic acid
In the HORIZON-PFT, Black et al.56 reported a difference in femoral neck BMD between treatment groups at
36 months of 5.06% (95% CI 4.76% to 5.36%; p< 0.001). In the HORIZON-RFT trial, Lyles et al.77 also
reported a statistically significant between-group difference at 36 months (p< 0.001). Boonen et al.59 reported a
statistically significant between-group difference in men at 24 months (p< 0.05) and McClung et al.79 reported
a statistically significant between-group difference in postmenopausal women at 24 months (p< 0.001).
Alendronic acid versus ibandronic acid
In the MOTION trial, Miller et al.81 reported a mean change in femoral neck BMD from baseline to 12 months
of 2.1% (SD ± 1.77) in the 70 mg per week of alendronic acid group compared with 2.3% (± 2.12 SD) in
the 150mg per month oral ibandronic acid group; the difference between treatments was not reported.
Alendronic acid versus risedronic acid
In the RCT by Sarioglu et al.,92 data and variance estimates by group were reported. The triallists reported
that the difference in femoral neck BMD between treatments was not significant (p-value or difference
between treatments not reported). In the FACT trial, Rosen et al.90 reported that, at 12 months, the
difference between treatments was 0.7% (95% CI 0.1% to 1.2%; p < 0.005) in favour of alendronic acid.
The difference between treatments at 24 months104 was reported as 0.8% (95% CI 0.3% to 1.4%;
p < 0.005) in favour of alendronic acid. In the FACTS trial, Reid et al.87 reported that, at 12 months, the
difference between treatments was 0.56% (95% CI 0.03% to 1.09%; p = 0.039) in favour of alendronic
acid. The difference between treatments at 24 months105 was reported as 1.0% (95% CI 0.3% to 1.6%;
p = 0.002) in favour of alendronic acid.
Zoledronic acid versus risedronic acid
In the HORIZON trial, Reid et al.88 reported that, in the treatment subgroup, the difference in femoral neck
BMD between treatments at 12 months was 1.06% (95% CI 0.32% to 1.79%) and the difference
between treatments in the prevention subgroup was 1.33% (95% CI 0.41% to 2.25%); both were in
favour of zoledronic acid.
Mortality
Details of all AEs reported for alendronic acid, ibandronic acid, risedronic acid and zoledronic acid, across
all included RCTs, are presented in Appendix 4.
Nine RCTs45,55,56,58,59,64,77,81,88 reported deaths in participants treated with bisphosphonates: two RCTS
compared 10 mg per day of alendronic acid with placebo;55,64 one compared 2.5 mg per day of ibandronic
acid with placebo;45 one compared risedronic acid with placebo;58 four compared 5 mg per year of
zoledronic acid with placebo;56,59,77,88 and one was a head-to-head comparison between alendronic acid
and a monthly oral dose of ibandronic acid.81 The frequencies of deaths in each treatment group in the
included RCTs are tabulated in Appendix 4.
Alendronic acid
Two RCTs55,64 reporting AEs in postmenopausal women for 24 months55 and 48 months64 were included.
Data from the two RCTs show that there were 122 deaths: 61/3236 (1.9%) in the alendronic acid group
and 61/3223 (1.9%) in the placebo group (pooled RR 1.0, 95% CI 0.70 to 1.41; p = 0.98). The difference
between treatments was not statistically significant (Figure 6).
Ibandronic acid
The BONE trial45 compared 2.5 mg per day of oral ibandronic acid (n = 977) with placebo (n = 975) for
36 months in postmenopausal women. No association between any treatment and risk of death was
found. In total, 22 deaths occurred: 11 (1.1%) in the ibandronic acid group and 10 (1.0%) in the placebo
group (RR 1.1, 95% CI 0.47 to 2.5; p = 0.83). The difference between treatments was not statistically
significant (Figure 7).
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FIGURE 6 Deaths in postmenopausal women on alendronic acid compared with placebo. M–H, Mantel–Haenszel.
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FIGURE 7 Deaths in postmenopausal women on ibandronic acid compared with placebo. M–H, Mantel–Haenszel.
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Risedronic acid
Boonen et al.58 compared 35 mg per week of risedronic acid with placebo in osteoporotic men (risedronic
acid, n = 191; placebo, n = 93). After 24 months, there were five deaths: two (1%) in the risedronic acid
group and three (3%) in the placebo group (RR 0.32, 95% CI 0.06 to 1.91; p = 0.21). The difference
between treatments was not statistically significant (Figure 8).
Zoledronic acid
Three RCTs reported mortality: Black et al.56 compared 5mg of zoledronic acid with placebo in
postmenopausal women at 36 months; Boonen et al.59 compared 5mg of zoledronic acid with placebo in
men for 36 months; and Lyles et al.77 compared 5 mg of zoledronic acid with placebo in men and women
following hip fracture at 36 months. The pooled number of deaths across these RCTs was 517, of which 246
(out of 5504; 4.5%) were in the 5 mg of zoledronic acid groups and 271 (out of 5520 participants,4.9%)
were in the placebo groups (pooled RR 0.91, 95% CI 0.77 to 1.08; p= 0.28). The difference between
treatments was not statistically significant; however, the difference between treatments for the HORIZON-RFT77
alone was statistically significant (p= 0.007), with a higher mortality rate in the placebo arm (Figure 9).
Head to head: zoledronic acid compared with risedronic acid
Reid et al.88 compared 5 mg of zoledronic acid per year with 5 mg per day of risedronic acid for 12 months
in both men and women receiving steroids and divided the participants into treatment of osteoporosis and
prevention of osteoporosis subgroups. In the treatment subgroup the RR of mortality for zoledronic acid
compared with risedronic acid was 0.33 (95% CI 0.04 to 3.20; p = 0.34) and in the prevention subgroup
the RR of mortality was 3.06 (95% CI 0.13 to 74.57; p = 0.49). The differences between treatments were
not statistically significant. A forest plot is not presented for this comparison.
Head to head: alendronic acid compared with ibandronic acid
One head-to-head RCT in postmenopausal women, comparing 70 mg per week of alendronic acid
(n = 859) with 150 mg per month of oral ibandronic acid (n = 874), reported mortality at 12 months.81 In
total, six deaths were reported: two (0.2%) in the active treatment group and four (0.5%) in the placebo
group (RR 0.51, 95% CI 0.09 to 2.77; p = 0.43) (Figure 10).
Adverse effects of treatment
Details of all AEs reported for alendronic acid, ibandronic acid, risedronic acid and zoledronic acid, across
all included RCTs, are presented in Appendix 4, Table 47.
A total of 30 of the included RCTs reported AEs;20,45,55–59,64,66–70,72,76–81,83–85,88,90,91,100,102,104,105 of these,
25 reported on any AE45,55–59,66,67,69,70,72,77–81,83–85,87,88,90,91,104,105 and 19 reported on any serious AEs.45,56–59,66,69,70,
72,77,78,80,81,83–85,87,88,90 Twenty RCTs reported the number of participants withdrawing because of AEs45,55–58,64,66,
69,70,72,76–78,80,83–85,87,88,90 and 20 reported data on upper GI events.45,55–58,64,66,69,70,72,76–78,80,83–85,87,88,90 Six RCTs
compared alendronic acid with placebo,55,57,64,67,83,84 six compared risedronic acid with placebo,58,66,70,72,78,85
one compared ibandronic acid (monthly oral dose) with placebo,80 one compared zoledronic acid with
placebo,102 two compared alendronic acid with risedronic acid87,90 and one compared alendronic acid with
zoledronic acid.69 A total of 10 RCTs reported influenza-like symptoms,56,58,59,69,77,79–81,83,88 of which five evaluated
zoledronic acid,56,59,77,79,88 one evaluated alendronic acid,83 one evaluated ibandronic acid (monthly oral dose)80
and one evaluated risedronic acid.58 Two RCTs reporting influenza-like symptoms were head-to-head
comparisons of 70 mg per week of alendronic acid with 150mg per month of ibandronic acid 81 and 70 mg
per week of alendronic acid with 5 mg per year of zoledronic acid.69
Any adverse events, serious adverse events and withdrawals owing to adverse events
Alendronic acid. Five RCTs reported any AE associated with 10 mg of alendronic acid and placebo in
postmenopausal women treated for periods ranging from 12 to 36 months.55,57,67,84,91 Across these RCTs
there were 3535 AEs; among participants on alendronic acid the incidence of AEs was 73.3% (1749/
2384), compared with 76.5% (1786/2336) among those treated with placebo (pooled RR 0.98, 95% CI
0.90 to 1.06; p = 0.63). The difference between treatments was not statistically significant (Figure 11).
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FIGURE 9 Deaths of men or women on 5mg per year of zoledronic acid compared with placebo. M–H, Mantel–Haenszel.
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FIGURE 10 Head-to-head comparison of 70mg of alendronic acid with 150mg of ibandronic acid in postmenopausal women and deaths. M–H, Mantel–Haenszel.
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FIGURE 11 Any AE in the alendronic acid group compared with placebo. M–H, Mantel–Haenszel.
D
O
I:
1
0
.3
3
1
0
/h
ta
2
0
7
8
0
H
E
A
L
T
H
T
E
C
H
N
O
L
O
G
Y
A
S
S
E
S
S
M
E
N
T
2
0
1
6
V
O
L
.
2
0
N
O
.
7
8
©
Q
u
e
e
n
’s
P
rin
te
r
a
n
d
C
o
n
tro
lle
r
o
f
H
M
S
O
2
0
1
6
.
T
h
is
w
o
rk
w
a
s
p
ro
d
u
ce
d
b
y
D
a
vis
e
t
a
l.
u
n
d
e
r
th
e
te
rm
s
o
f
a
co
m
m
issio
n
in
g
co
n
tra
ct
issu
e
d
b
y
th
e
S
e
cre
ta
ry
o
f
S
ta
te
fo
r
H
e
a
lth
.
T
h
is
issu
e
m
a
y
b
e
fre
e
ly
re
p
ro
d
u
ce
d
fo
r
th
e
p
u
rp
o
se
s
o
f
p
riva
te
re
se
a
rch
a
n
d
stu
d
y
a
n
d
e
xtra
cts
(o
r
in
d
e
e
d
,
th
e
fu
ll
re
p
o
rt)
m
a
y
b
e
in
clu
d
e
d
in
p
ro
fe
ssio
n
a
l
jo
u
rn
a
ls
p
ro
vid
e
d
th
a
t
su
ita
b
le
a
ck
n
o
w
le
d
g
e
m
e
n
t
is
m
a
d
e
a
n
d
th
e
re
p
ro
d
u
ctio
n
is
n
o
t
a
sso
cia
te
d
w
ith
a
n
y
fo
rm
o
f
a
d
ve
rtisin
g
.
A
p
p
lica
tio
n
s
fo
r
co
m
m
e
rcia
l
re
p
ro
d
u
ctio
n
sh
o
u
ld
b
e
a
d
d
re
sse
d
to
:
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry,
N
a
tio
n
a
l
In
stitu
te
fo
r
H
e
a
lth
R
e
se
a
rch
,
E
va
lu
a
tio
n
,
T
ria
ls
a
n
d
S
tu
d
ie
s
C
o
o
rd
in
a
tin
g
C
e
n
tre
,
A
lp
h
a
H
o
u
se
,
U
n
ive
rsity
o
f
S
o
u
th
a
m
p
to
n
S
cie
n
ce
P
a
rk
,
S
o
u
th
a
m
p
to
n
S
O
1
6
7
N
S
,
U
K
.
1
2
3
Three RCTs reported the proportion of AEs that were considered serious in postmenopausal
women.57,84,91 One reported events at 48 weeks,91 one at 12 months84 and one at 24 months.57 One RCT
in osteoporotic men reported events at 24 months.83 Across the three RCTs in women, 205 serious AEs
were observed: 103 (out of 1199 participants) in the alendronic acid groups (8.6%) and 102 (out of
1167 participants) in the placebo groups (8.7%) (pooled RR 0.96, 95% CI 0.74 to 1.25; p = 0.70). The
difference between treatments was not statistically significant (Figure 12). In osteoporotic men, the
number of AEs was not significantly different in different treatment groups (RR 0.80, 95% CI 0.48 to
1.32; p = 0.38).83
Seven RCTs reported on withdrawals as a result of AEs.55,57,64,76,83,84,91 Across all RCTs the difference
between treatments was not statistically significant. There were 807 withdrawals in total, and the
incidence was 7.8% (376/4777) in the alendronic acid groups, compared with 8.8% (431/4882) in the
placebo groups (pooled RR 0.86, 95% CI 0.73 to 1.07; p = 0.07). There was no statistically significant
between-group difference across six RCTs in postmenopausal women55,57,64,84,91 ranging in duration
from 48 weeks91 to 48 months.64 There were 793 withdrawals in total and the incidence was 8.0%
(372/4631) in the alendronic acid groups, compared with 8.8% (421/4787) in placebo groups (pooled RR
0.90, 95% CI 0.79 to 1.03; p = 0.13). However, in osteoporotic men, placebo treatment was associated
with a significantly higher rate of withdrawals at 24 months (10/95, 10.5%) than alendronic acid
(4/146, 2.7%) (RR 0.26, 95% CI 0.08 to 0.81; p = 0.02).83 However, a statistically significant
difference between treatments was not evident when RCTs were pooled by RCT duration (p = 0.68)
(Figure 13).
Ibandronic acid Both Chesnut et al.45 and McClung et al.80 reported on the number of AEs of any type in
an ibandronic acid group (unlicensed 2.5 mg daily oral dose45 and licensed monthly 150 mg oral dose80)
and a placebo group. Both recruited postmenopausal women and follow-up duration was 36 months and
12 months, respectively. The proportion of participants who experienced any AE did not differ by
treatment group. A total of 1870 participants experienced AEs, 939 (out of 1054 participants; 89.9%) in
the ibandronic acid groups and 931 (out of 1058 participants; 88.0%) in the placebo groups (pooled RR
1.01, 95% CI 0.98 to 1.04; p = 0.45), and this did not vary by dosage of ibandronic acid (p = 0.99)
(Figure 14).
The same RCTs45,80 also reported the number of AEs that were considered serious. The difference between
treatments across these trials was not statistically significant. A total of 449 participants experienced
serious AEs: 237 (out of 1054 participants; 22.5%) in the ibandronic acid groups and 212 (out of 1058
participants; 20.0%) in the placebo groups (pooled RR 1.11, 95% CI 0.95 to 1.31; p = 0.20). The
difference between treatments by dosage was also not statistically significant (Figure 15).
The same RCTs also reported the number of withdrawals as a result of AEs.45,80 Overall, the proportion of
withdrawals was similar among participants who were on ibandronic acid [17.8% (188/1054)] and those
on placebo [17.6% (186/1058)] (374 AEs in total; pooled RR 1.24, 95% CI 0.56 to 2.75; p = 0.59). The
difference between treatments across these RCTs was not statistically significant and results did not vary by
ibandronic acid dosage (p = 0.17) (Figure 16).
Risedronic acid Six RCTs compared AEs in a risedronic acid-treated group and a placebo group.58,66,70,72,78,85
Five of these were in postmenopausal women, with treatment duration ranging from 12 to 24 months,66,70,72,78,85
and one was in osteoporotic men with a follow-up at 24 months.58 Pooled data across all six RCTs (8674 AEs)
showed that the proportion of participants experiencing an AE was the same in the risedronic acid group
[90.6% (4370/4821)] and the placebo group [90.5% (4304/4754)] (pooled RR 0.95, 95% CI 0.84 to 1.08;
p= 0.44). The difference between treatments was not statistically significant and the results did not vary by age,
sex, drug dosage (p= 0.67) or duration of follow-up (p= 0.64) (Figure 17).
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0.001 0.1 1 10 1000
More in placebo More in alendronic acid
Study or subgroup
Alendronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
FOSIT Pols 199984 – 12 months
Bone 200057 – 24 months
Saag 199891 – 48 weeks
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.71, df = 2 (p = 0.70); I2 = 0%
Test for overall effect: z = 0.29 (p = 0.77)
60
13
30
103
63
5
34
102
950
92
157
1199
958
50
159
1167
45.5%
5.6%
27.6%
78.7%
0.96 (0.68 to 1.35)
1.41 (0.53 to 3.74)
0.89 (0.58 to 1.39)
0.96 (0.74 to 1.25)
Alendronic acid 10 mg/day postmenopausal women and any serious AE
Orwoll 200083 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.88 (p = 0.38)
27
27
22
22
146
146
95
95
21.3%
21.3%
0.80 (0.48 to 1.32)
0.80 (0.48 to 1.32)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 1.14, df = 3 (p = 0.77); I2 = 0%
Test for overall effect: z = 0.66 (p = 0.51)
Test for subgroup differences: χ2 = 0.42, df = 1 (p = 0.52); I2 = 0%
130 124
1345 1262 100.0% 0.93 (0.73 to 1.17)
Alendronic acid 10 mg/day men > 40 years and any serious AE
FIGURE 12 Any serious AE in the alendronic acid group compared with placebo. M–H, Mantel–Haenszel.
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0.001 0.1 1 10 1000
More in placebo More in alendronic acid
Study or subgroup
Alendronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
Bone 200057 – 24 months
FIT I Black 199655 – 36 months
FIT II Cummings 199864 – 48 months
FOSIT Pols 199984 – 12 months
Liberman 199576 – 36 months
Saag 199891 – 48 weeks
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 2.43, df = 5 (p = 0.79); I2 = 0%
Test for overall effect: z = 1.53 (p = 0.13)
6
78
221
53
8
6
372
5
96
227
61
24
8
421
92
1022
2214
950
196
157
4631
50
1005
2218
958
397
159
4787
2.1%
25.0%
46.2%
17.7%
4.3%
2.5%
97.9%
0.65 (0.21 to 2.03)
0.80 (0.60 to 1.06)
0.98 (0.82 to 1.16)
0.88 (0.61 to 1.25)
0.68 (0.31 to 1.48)
0.76 (0.27 to 2.14)
0.90 (0.79 to 1.03)
Orwoll 200083 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.33 (p = 0.02)
4
4
10
10
146
146
95
95
2.1%
2.1%
0.26 (0.08 to 0.81)
0.26 (0.08 to 0.81)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.01; χ2 = 7.00, df = 6 (p = 0.32); I2 = 14%
Test for overall effect: z = 1.80 (p = 0.07)
Test for subgroup differences: χ2 = 4.57, df = 1 (p = 0.03); I2 = 78.1%
376 431
4777 4882 100.0% 0.86 (0.73 to 1.01)
Alendronic acid 10 mg postmenopausal women and withdrawals due to an AE
Alendronic acid 10 mg men > 40 years and withdrawals due to an AE
FIGURE 13 Withdrawals as a result of an AE in the alendronic acid group compared with placebo. M–H, Mantel–Haenszel.
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0.01 0.1 1 10 100
More in placebo More in ibandronic acid
Study or subgroup
Ibandronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
BONE Chesnut 200445 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.75 (p = 0.45)
879
879
867
867
977
977
975
975
96.8%
96.8%
1.01 (0.98 to 1.04)
1.01 (0.98 to 1.04)
Ibandronic acid 2.5 mg/day postmenopausal women and any AE
McClung 200980 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.12 (p = 0.90)
60
60
64
64
77
77
83
83
3.2%
3.2%
1.01 (0.86 to 1.19)
1.01 (0.86 to 1.19)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.00, df = 1 (p = 0.99); I2 = 0%
Test for overall effect: z = 0.76 (p = 0.45)
Test for subgroup differences: χ2 = 0.00, df = 1 (p = 0.99); I2 = 0%
939 931
1054 1058 100.0% 1.01 (0.98 to 1.04)
Ibandronic acid 150 mg/month postmenopausal women and any AE
FIGURE 14 Any AE in the ibandronic acid group compared with placebo. M–H, Mantel–Haenszel.
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0.001 0.1 1 10 1000
More in placebo More in ibandronic acid
Study or subgroup
Ibandronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
BONE Chesnut 200445 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.22 (p = 0.22)
234
234
211
211
977
977
975
975
99.5%
99.5%
1.11 (0.94 to 1.30)
1.11 (0.94 to 1.30)
Ibandronic acid 2.5 mg postmenopausal women and any serious AE
McClung 200980 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.03 (p = 0.30)
3
3
1
1
77
77
83
83
0.5%
0.5%
3.23 (0.34 to 30.43)
3.23 (0.34 to 30.43)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.88, df = 1 (p = 0.35); I2 = 0%
Test for overall effect: z = 1.29 (p = 0.20)
Test for subgroup differences: χ2 = 0.87, df = 1 (p = 0.35); I2 = 0%
237 212
1054 1058 100.0% 1.11 (0.95 to 1.31)
Ibandronic acid 150 mg/month postmenopausal women and any AE
FIGURE 15 Any serious AE in the ibandronic acid group compared with the placebo group. M–H, Mantel–Haenszel.
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0.001 0.1 1 10 1000
More in placebo More in ibandronic acid
Study or subgroup
Ibandronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
BONE Chesnut 200445 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.14 (p = 0.89)
181
181
183
183
977
977
975
975
75.2%
75.2%
0.99 (0.82 to 1.19)
0.99 (0.82 to 1.19)
Ibandronic acid 2.5 mg/day postmenopausal women and withdrawals due to an AE
McClung 200980 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.37 (p = 0.17)
7
7
3
3
77
77
83
83
24.8%
24.8%
2.52 (0.67 to 9.38)
2.52 (0.67 to 9.38)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.21; χ2 = 1.91, df = 1 (p = 0.17); I2 = 48%
Test for overall effect: z = 0.54 (p = 0.59)
Test for subgroup differences: χ2 = 1.90, df = 1 (p = 0.17); I2 = 47.4%
188 186
1054 1058 100.0% 1.24 (0.56 to 2.75)
Ibandronic acid 150 mg/month postmenopausal women and withdrawals due to an AE
FIGURE 16 Withdrawals as a result of an AE in the ibandronic acid group compared with the placebo group. M–H, Mantel–Haenszel.
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0.005 0.1 1 10 200
More in placebo More in risedronic acid
Study or subgroup
Risedronic acid
Events Total Weight
Placebo RR (non-event)
M – H, random, 95% Cl
RR (non-event)
M – H, random, 95% ClEvents Total
BMD-NA Fogelman 200066 – 24 months
McClung 200178 – 36 months
Hooper 200572 – 24 months
VERT-MN Reginster 200085 – 36 months
VERT-NA Harris 199970 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 2.54, df = 4 (p = 0.64); I2 = 0%
Test for overall effect: z = 0.99 (p = 0.32)
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2805
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1.8%
7.6%
7.0%
90.4%
1.02 (0.39 to 2.65)
0.98 (0.84 to 1.13)
0.68 (0.27 to 1.73)
0.89 (0.57 to 1.40)
0.68 (0.43 to 1.10)
0.94 (0.82 to 1.07)
Risedronic acid 5 mg postmenopausal women and any adverse event
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68
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93
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9.6%
9.6%
1.11 (0.74 to 1.66)
1.11 (0.74 to 1.66)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 3.18, df = 5 (p = 0.67); I2 = 0%
Test for overall effect: z = 0.78 (p = 0.44)
Test for subgroup differences: χ2 = 0.63, df = 1 (p = 0.43); I2 = 0%
4370 4304
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Boonen 200958 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.51 (p = 0.61)
Risedronic acid 35 mg/week men and any adverse event
FIGURE 17 Any AE in the risedronic acid group compared with the placebo group. BMD-NA, Bone Mineral Density – North America trial; M–H, Mantel–Haenszel.
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Pooled data from the same RCTs revealed that the proportions of participants experiencing serious AEs
was also similar in both treatment groups; of the total of 2789 serious AEs reported, 1398 occurred in the
risedronic acid group (of 4821 participants; 29.0%) and 1391 (of 4754 participants; 29.3%) in the placebo
group (pooled RR 1.01, 95% CI 0.93 to 1.11; p = 0.76). The difference between treatments was not
statistically significant. There were no statistically significant differences between treatments evident by
age, sex or dosage (p = 0.27) or treatment duration (p = 0.18) (Figure 18).
Pooled data from these six RCTs58,66,70,72,78,85 also showed that there were no statistically significant
differences between treatments in withdrawals as a result of AEs [1596 withdrawals: 784 (of 4820
participants; 16.3%) in the risedronic acid group and 812 (of 4754 participants; 17.1%) in the placebo
group (pooled RR 0.94, 95% CI 0.81 to 1.10; p = 0.45). However, the difference between treatments for
the one RCT in osteoporotic men with follow-up at 24 months58 was statistically significant (p = 0.05)
(Figure 19).
Zoledronic acid Four RCTs reported AEs for zoledronic acid compared with placebo.56,59,77,79 Two RCTs
evaluated postmenopausal women who were followed up for 3656 and 24 months,79 one evaluated men
and women with hip fracture who were followed up for 36 months77 and one RCT evaluated osteoporotic
men who were followed up for 36 months.59
Pooled data across the two RCTs in postmenopausal women56,79 showed that zoledronic acid was
associated with a statistically significant increase in the incidence of AEs (total 7663 AEs): the incidence
was 94.5% (3861/4043) in the zoledronic acid group and 93.8% (3802/4054) in the placebo group
(pooled RR 1.02, 95% CI 1.01 to 1.03; p = 0.0007). In one RCT in osteoporotic men,59 in which a total of
1000 AEs were reported, the incidence of AEs was 19% higher in the zoledronic acid group [90.8% (534
AEs in 588 participants)] than in the placebo group [76.3% (466 AEs in 611 participants) (RR 1.19, 95% CI
1.13 to 1.25; p < 0.00001]; the difference between treatments was statistically significant. Another RCT in
men and women found no statistically significant difference between treatments.77 A total of 1719 AEs
effects were reported, 867 (in 1054 participants; 82.3%) in the zoledronic acid group and 852 (in 1057
participants; 80.6%) in the placebo group (RR 1.02, 95% CI 0.98 to 1.02; p = 0.33). Pooled data across
all four RCTs indicated that the incidence of AEs did not differ significantly by treatment group. The total
number of AEs was 10,382, and 92.5% of study participants (5262/5685) treated with zoledronic acid
group experienced an AE, compared with 89.5% of placebo-treated participants (5120/5722) (pooled RR
1.06, 95% CI 1.00 to 1.13; p = 0.06) (Figure 20).
The number of serious AEs was reported by four RCTs.56,59,77,88 Across these RCTs the difference between
treatments was not statistically significant. There were a total of 3427 serious AEs: 1679/5504 (30.5%)
in the zoledronic acid groups and 1748/5520 (32.2%) in the placebo groups (pooled RR 0.96, 95% CI
0.91 to 1.02; p = 0.16). The incidence of serious AEs did not differ by sex (p = 0.86) or by RCT duration
(p = 0.68) (Figure 21).
Two RCTs reported data on withdrawals as a result of AEs.56,77 Pooled data across these RCTs showed that
the rates of withdrawal were similar in the two treatment groups. There were a total of 189 withdrawals:
101/4961 (2.0%) in the 5 mg per year of zoledronic acid group and 88/4909 (1.8%) in the placebo groups
(pooled RR 1.15, 95% CI 0.86 to 1.52; p = 0.35). The difference between treatments was not statistically
significant. The number of withdrawals was the same for both sexes (p = 0.12) (Figure 22).
Head to head: alendronic acid versus ibandronic acid The MOTION trial81 compared 70 mg per week
of alendronic acid with 150 mg per month of oral ibandronic acid in postmenopausal women for 12 months.
The total number of AEs was 1291 and the proportion of participants experiencing an AE was higher in
the alendronic acid group than in the ibandronic acid group [75.4% (659/859) versus 73.6% (632/874);
RR 1.06, 95% CI 1.0 to 1.12; p = 0.04]; the difference between treatments was statistically significant
(Figure 23).
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BMD-NA Fogelman 200066 – 24 months
McClung 200178 – 36 months
Hooper 200572 – 24 months
VERT-MN Reginster 200085 – 36 months
VERT-NA Harris 199970 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.01; χ2 = 6.34, df = 4 (p = 0.18); I2 = 37%
Test for overall effect: z = 0.33 (p = 0.74)
26
943
12
151
237
1369
27
973
22
135
219
1376
177
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129
407
813
4630
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3134
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4661
3.3%
50.3%
1.9%
18.2%
23.8%
97.5%
0.98 (0.60 to 1.61)
0.98 (0.91 to 1.05)
0.53 (0.27 to 1.02)
1.12 (0.93 to 1.35)
1.08 (0.93 to 1.27)
1.02 (0.91 to 1.13)
Risedronic acid 5 mg postmenopausal women and any serious AE
29
29
15
15
191
191
93
93
2.5%
2.5%
0.94 (0.53 to 1.67)
0.94 (0.53 to 1.67)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 6.39, df = 5 (p = 0.27); I2 = 22%
Test for overall effect: z = 0.31 (p = 0.76)
Test for subgroup differences: χ2 = 0.07, df = 1 (p = 0.79); I2 = 0%
1398 1391
4821 4754 100.0% 1.01 (0.93 to 1.11)
Boonen 200958 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.21 (p = 0.84)
Risedronic acid 35 mg/week men and any serious AE
FIGURE 18 Any serious AE in the risedronic acid group compared with the placebo group. BMD-NA, Bone Mineral Density – North America trial; M–H, Mantel–Haenszel.
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More in placebo More in risedronic acid
Study or subgroup
Risedronic acid
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Placebo RR
M – H, random, 95% Cl
RR
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BMD-NA Fogelman 200066 – 24 months
McClung 200178 – 36 months
Hooper 200572 – 24 months
VERT-MN Reginster 200085 – 36 months
VERT-NA Harris 199970 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 3.53, df = 4 (p = 0.47); I2 = 0%
Test for overall effect: z = 0.56 (p = 0.57)
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7
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8
81
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4629
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4.3%
45.8%
2.3%
17.8%
26.8%
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1.38 (0.71 to 2.67)
0.98 (0.89 to 1.10)
0.85 (0.32 to 2.27)
0.78 (0.58 to 1.05)
1.02 (0.82 to 1.26)
0.97 (0.89 to 1.07)
Risedronic acid 5 mg postmenopausal women and withdrawals due to an AE
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93
93
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2.4%
0.38 (0.15 to 0.99)
0.38 (0.15 to 0.99)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.01; χ2 = 7.25, df = 5 (p = 0.20); I2 = 31%
Test for overall effect: z = 0.76 (p = 0.45)
Test for subgroup differences: χ2 = 3.72, df = 1 (p = 0.05); I2 = 73.1%
784 812
4820 4754 100.0% 0.94 (0.81 to 1.10)
Boonen 200958 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.99 (p = 0.05)
Risedronic acid 35 mg/week men and withdrawals due to an AE
FIGURE 19 Withdrawals as a result of an AE in the risedronic acid group compared with placebo. BMD-NA, Bone Mineral Density – North America trial; M–H, Mantel–Haenszel.
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FIGURE 20 Any AE in the zoledronic acid group compared with placebo. M–H, Mantel–Haenszel.
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Zoledronic acid 5 mg/year men and any serious AE
FIGURE 21 Any serious AE in the zoledronic acid group compared with placebo. M–H, Mantel–Haenszel.
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Test for overall effect: z = 0.49 (p = 0.62)
Zoledronic acid 5 mg men and women and withdrawal due to AE
FIGURE 22 Withdrawals as a result of an AE in the zoledronic acid group compared with placebo. M–H, Mantel–Haenszel.
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FIGURE 23 Head-to-head comparison of alendronic acid with ibandronic acid and any AE. M–H, Mantel–Haenszel.
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Head to head: alendronic acid versus risedronic acid Two RCTs compared 70 mg per week of
alendronic acid with 35 mg per week of risedronic acid in postmenopausal women treated for
12 months.87,90 Pooled data across these RCTs indicate that the risk of AEs was similar in both groups.
The total number of AEs was 1413 and the proportion of participants experiencing an AE was 71.2%
(700/983) in the alendronic acid group and 71.7% (713/995) in the risedronic acid group (pooled RR 1.0,
95% CI 0.94 to 1.05; p = 0.93); the difference between treatments was not statistically significant
(Figure 24).
Head to head: alendronic acid versus zoledronic acid The Rapid Onset and Sustained Efficacy (ROSE)
trial69 compared 70 mg per week of alendronic acid with 5 mg per year of zoledronic acid. The total
number of AEs was 465 and the risk of AEs was similar in the two treatment groups [74.7% (145/194)
in the alendronic acid group, compared with 78.4% (320/408) in the zoledronic acid group; RR 0.95,
95% CI 0.87 to 1.05; p = 0.33]; the difference between treatments was not statistically significant
(Figure 25).
Head to head: zoledronic acid versus risedronic acid The HORIZON trial88 compared 5 mg per year of
zoledronic acid with 5 mg per day of risedronic acid in both men and women receiving steroids; the
participants were divided into treatment and prevention subgroups for 12 months. The difference between
treatments in any AE in the treatment subgroup was a RR of 1.14 (95% CI 1.06 to 1.26; p = 0.01) and the
difference between treatments in the prevention subgroup was a RR of 1.19 (95% CI 1.03 to 1.26;
p = 0.01), with more AEs in the zoledronic acid groups in both cases. The differences between treatments
were statistically significant. No forest plot is presented for these data.
Serious adverse events
Head to head: alendronic acid versus ibandronic acid The MOTION trial81 also reported the number of
AEs experienced by participants receiving weekly alendronic acid (n = 859) or monthly oral ibandronic acid
(150 mg/month) (n = 874). There were 94 serious AEs and the risk of experiencing a serious AE was similar
in the two groups [4.5% (39/859) in the alendronic acid group and 6.4% (55/874) in the ibandronic acid
group; RR 0.72, 95% CI 0.48 to 1.08; p = 0.11]. The difference between treatments was not statistically
significant (Figure 26).
Head to head: alendronic acid versus risedronic acid Pooled data across two RCTs87,90 indicate no
statistically significant difference in the incidence of serious AEs between the two treatments [157 serious
AEs; 7.0% (69/983) in the alendronic acid group and 8.8% (88/995) in the risedronic acid group; RR 0.76,
95% CI 0.35 to 1.66; p = 0.50] (Figure 27).
Head to head: alendronic acid versus zoledronic acid In the ROSE trial,69 the proportion of participants
experiencing a serious AE was not significantly different between the group receiving 70 mg per week of
alendronic acid and the group receiving 5 mg per year of zoledronic acid [64 serious AEs: 21/194 (10.8%)
in the alendronic acid group and 43/403 (10.5%) in the zoledronic acid group; RR 1.03, 95% CI 0.63 to
1.68, p = 0.92] (Figure 28).
Head to head: zoledronic acid versus risedronic acid In the HORIZON trial,88 in which men and women
receiving steroids were divided into treatment and prevention subgroups for 12 months, the difference
between treatments in serious AEs in the treatment subgroup was a RR of 0.93 (95% CI 0.66 to 1.31;
p = 0.68) and the difference between treatments in the prevention subgroup was a RR of 1.13 (95% CI
0.68 to 1.88; p = 0.64). The differences between treatments were not statistically significant. No forest plot
is presented for these data.
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Alendronic acid 70 mg/week vs. risedronic acid 35 mg/week postmenopausal women and any AE
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Total events
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FIGURE 24 Head-to-head comparison of alendronic acid with risedronic acid and any AE. M–H, Mantel–Haenszel.
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Alendronic acid 70 mg/week vs. zoledronic acid 5 mg/year postmenopausal women and any AE
FIGURE 25 Head-to-head comparison of alendronic acid with zoledronic acid and any AE. M–H, Mantel–Haenszel.
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Alendronic acid 70 mg/week vs. ibandronic acid 150 mg/month postmenopausal women and any serious AE
FIGURE 26 Head-to-head comparison of alendronic acid with ibandronic acid and any serious AE. M–H, Mantel–Haenszel.
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FIGURE 27 Head-to-head comparison of alendronic acid with risedronic acid and any serious AE. M–H, Mantel–Haenszel.
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ROSE Hadji 201269 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.11 (p = 0.92)
Test for subgroup differences: not applicable
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FIGURE 28 Head-to-head comparison of alendronic acid with zoledronic acid and any serious AE. M–H, Mantel–Haenszel.
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Withdrawals as a result of adverse events
Head to head: alendronic acid versus risedronic acid Two RCTs reported withdrawals as a result of
AEs.87,90 Pooled data across these RCTs indicate no statistically significant difference between treatments
[114 withdrawals: 53/983 (5.4%) in the alendronic acid group and 61/995 (6.1%) in the risedronic acid
group; pooled RR 0.88, 95% CI 0.62 to 1.26; p = 0.50] (Figure 29).
Head to head: alendronic acid versus zoledronic acid The difference between treatments in withdrawals
as a result of AEs was statistically significant for one trial69 comparing 70mg per week of alendronic acid with
5 mg per year of zoledronic acid [21 withdrawals: 19/194 (9.8%) in the alendronic acid group and (2/408
(0.5%) in the zoledronic acid group; RR 19.98, 95% CI 4.70 to 84.92; p< 0.0001] (Figure 30).
Head to head: zoledronic acid versus risedronic acid In the HORIZON trial,88 in which men and women
receiving steroids were divided into treatment and prevention subgroups for 12 months, the difference
between treatments in the number of withdrawals as a result of AEs was a RR of 1.00 (95% CI 0.20 to
4.93; p = 1.00) in the treatment subgroup and a RR of 2.00 (95% CI 0.51 to 7.84; p = 0.32) in the
prevention subgroup; the differences between treatments were not statistically significant. No forest plot is
presented for these data.
Any upper gastrointestinal adverse events
The types of upper GI events greatly varied in different RCTs. Among six RCTs55,57,64,76,83,84 that investigated
alendronic acid and reported specific AEs (1738 upper GI events), abdominal pain was the most common,
accounting for 32% (557/1738) of all upper GI events, followed by acid regurgitation at 17.5% (304/1738),
dyspepsia at 11.2% (195/1738) and nausea at 8.1% (140/1738). Other events included peptic ulcers (i.e.
oesophageal and stomach ulcers), gastritis, oesophagitis, belching, diarrhoea, dysphagia, constipation,
heartburn and gastroenteritis.
In the six RCTs that administered 5 mg of risedronic acid (1076 upper GI events),66,70,72,78,85 abdominal pain
was also the most common, accounting for 43.1% (464/1076) of all upper GI events, followed by
dyspepsia (38.9%, 419/1076), oesophagitis (7.6%, 82/1076) and gastritis (4.0%, 43/1076). Similar results
were observed in the BONE trial45 and the trial by McClung et al.,80 in which abdominal pain and dyspepsia
were the most common upper GI events, accounting for 11.4% (111/977) of upper GI events in the group
receiving 5 mg ibandronic acid daily and 31.2% (24/77) in the group receiving 150 mg ibandronic acid
monthly. Of the 300 upper GI events occurring in participants on 5 mg of zoledronic acid in two RCTs,88,102
nausea was the major event, with 168 reports (56.0%), followed by vomiting with 76 (25.3%), diarrhoea
with 67 (22.3%), abdominal pain with 48 (16.0%) and anorexia with 45 (15.0%). However, the
proportion of these upper GI events was similar in the treatment group and the placebo group, but less
frequent in the zoledronic acid group.102
Alendronic acid Six RCTs reporting upper GI AEs evaluated 10 mg per day of alendronic acid in
postmenopausal women55,57,64,67,84,91 and one investigated 10 mg per day of alendronic acid in men
with osteoporosis.83
Pooled data across all seven RCTs indicated no statistically significant difference between treatments in the
incidence of upper GI AEs. There were a similar incidence of upper GI events reported in patients receiving
alendronic acid (38.6%) and placebo (37.6%) when pooling data across trials (pooled RR 1.03, 95% CI
0.98 to 1.08; p = 0.30) (Figure 31). There was also no statistically significant difference between
treatments according to sex (see Figure 31) or RCT duration (p = 0.83).
Ibandronic acid Only one trial80 using ibandronic acid reported upper GI events. The difference between
treatments was not statistically significant [44 upper GI events: 24/77 (31.2%) in the ibandronic acid
(monthly oral dose) group and 20/83 (24.1%) in the placebo group; RR 1.29 95% CI 0.78 to 2.15;
p = 0.32] (Figure 32).
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FIGURE 29 Head-to-head comparison of alendronic acid with risedronic acid and withdrawals as a result of AEs. M–H, Mantel–Haenszel.
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FIGURE 30 Head-to-head comparison of alendronic acid with zoledronic acid and withdrawals as a result of AEs. M–H, Mantel–Haenszel.
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FIGURE 31 Any upper GI AEs in the alendronic acid group compared with placebo. M–H, Mantel–Haenszel; UGI, upper GI.
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FIGURE 32 Any upper GI AEs in the ibandronic acid group compared with placebo. M–H, Mantel–Haenszel; UGI, upper GI.
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Risedronic acid Five RCTs evaluated 5 mg per day of risedronic acid in postmenopausal women66,70,72,78,85
and one evaluated 35 mg per week of risedronic acid in osteoporotic men.58 Pooled data across the five
RCTs in postmenopausal women showed that the overall risk of upper GI AEs was similar in the two
treatment groups [2150 upper GI events: 1076/4630 (23.2%) in the risedronic acid group and 1074/4661
(23.0%) in the placebo group; pooled RR 1.04, 95% CI 0.97 to 1.13; p = 0.75]. The difference between
treatments was not statistically significant. Pooled results across all the six RCTs showed that there was no
statistically significant difference between treatments in upper GI events in the risedronic acid treatment
group or placebo [2183 upper GI events; 1092/4821 (22.7%) in the risedronic acid group and 1091/4754
(22.9%) in the placebo group; RR 0.99, 95% CI 0.87 to 1.14; p = 0.93] and this did not vary with RCT
duration (p = 0.45). However, in the RCT in osteoporotic men,58 in which 33 upper GI events were
reported, the risk was significantly higher (16/191, 8.4%) in the risedronic acid group than in the placebo
group (19/93, 20.4%) (RR 0.46, 95% CI 0.24 to 0.87; p = 0.02) (Figure 33).
Alendronic acid versus risedronic acid Pooled data across two RCTs87,90 revealed no statistically significant
difference in the number of upper GI events between the alendronic acid treatment group and the risedronic
acid treatment group [411 upper GI events: 211/983 (21.5%) in the alendronic acid group and 00/995
(20.1%) in the risedronic acid group; pooled RR 1.07, 95% CI 0.90 to 1.27; p = 0.45] (Figure 34).
Alendronic acid versus zoledronic acid One RCT reporting upper GI events as an outcome69 found a
significantly higher incidence of upper GI events in the 70 mg per week alendronic acid treatment group
than in the 5 mg per year zoledronic acid group [132 upper GI events: 57/194 (29.4%) in the alendronic
acid group, compared with 75/408 (18.4%) in the zoledronic acid group; RR 1.60, 95% CI 1.19 to 2.16;
p = 0.002] (Figure 35).
Head to head: zoledronic acid versus risedronic acid The HORIZON trial88 compared 5 mg per year of
zoledronic acid with 5 mg per day of risedronic acid in both men and women receiving steroids and
divided the participants into treatment and prevention subgroups for 12 months. The p-values for the
differences between treatments in upper GI AEs reported between the treatment subgroup were as
follows: upper abdominal pain, p = 0.158; abdominal pain, p = 0.16; dyspepsia, p = 0.70; nausea,
p = 0.19; vomiting, p = 0.04; gastritis, p = 0.68; and gastro-oesophageal reflux, p = 0.37. The p-values for
the differences between treatments reported between the prevention subgroup were as follows: upper
abdominal pain, p = 1.00; abdominal pain, p = 1.00; dyspepsia, p = 0.57; nausea, p = 0.52; vomiting,
p = 1.00; gastritis, p = 1.00; and gastro-oesophageal reflux, p = 0.44.
Any gastrointestinal event
Zoledronic acid In HORIZON-PFT102 the proportion of participants experiencing any GI event (abdominal
pain, anorexia, diarrhoea, nausea, vomiting) in the first 3 days following i.v. administration was significantly
higher in the zoledronic acid group than in the placebo group [380 GI events: 300/3862 (7.8%) in the
zoledronic acid group and 80/3852 (2.1%) in the placebo group; RR 3.74, 95% CI 2.93 to 4.77;
p < 0.00001] (Figure 36).
Influenza-like symptoms
The reporting of influenza-like symptoms, including upper respiratory infections, influenza, pyrexia,
headache, chills, nasopharyngitis, bronchitis, pneumonia, cough and fatigue, varied across RCTs. Some
RCTs reported only the occurrence of influenza-type symptoms, whereas others documented a number of
potentially associated symptoms.
Alendronic acid One RCT83 reported the incidence of influenza-like symptoms in osteoporotic men:
146 treated with alendronic acid and 95 treated with placebo.83 Overall, 113 participants experienced
influenza-like symptoms [66/146 (45.2%) in the alendronic acid group and 47/95 (49.5%) in the
placebo group; RR 0.91, 95% CI 0.70 to 1.20; p = 0.51]. The difference between treatments was not
statistically significant.
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0.01 0.1 1 10 100
More in placebo More in risedronic acid
Study or subgroup
Risedronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
BMD-NA Fogelman 200066 – 24 months
McClung 200178 – 36 months
Hooper 200572 – 24 months
VERT-MIN Reginster 200085 – 36 months
VERT-NA Harris 199970 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 3.70, df = 4 (p = 0.45); I2 = 0%
Test for overall effect: z = 0.27 (p = 0.78)
40
657
25
109
245
1076
47
684
20
104
219
1074
177
3104
129
407
813
4630
180
3134
125
407
815
4661
10.1%
34.7%
5.5%
18.7%
27.0%
96.0%
0.87 (0.60 to 1.25)
0.97 (0.88 to 1.07)
1.21 (0.71 to 2.07)
1.05 (0.83 to 1.32)
1.12 (0.96 to 1.31)
1.01 (0.94 to 1.09)
Risedronic acid 5 mg/day postmenopausal women and any UGI AE
16
16
17
17
191
191
93
93
4.0%
4.0%
0.46 (0.24 to 0.87)
0.46 (0.24 to 0.87)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.01; χ2 = 9.56, df = 5 (p = 0.09); I2 = 48%
Test for overall effect: z = 0.09 (p = 0.93)
Test for subgroup differences: χ2 = 5.86, df = 1 (p = 0.02); I2 = 82.9%
1092 1091
4821 4754 100.0% 0.99 (0.87 to 1.14)
Boonen 200958 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.40 (p = 0.02)
Risedronic acid 35 mg/week men and any UGI AE
FIGURE 33 Any upper GI AEs in the risedronic acid group compared with placebo. M–H, Mantel–Haenszel; UGI, upper GI.
0.01 0.1 1 10 100
More in risedronic acid More in alendronic acid
Study or subgroup
FACT Rosen 200590 – 12 months
FACTS Reid 200687 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.00; χ2 = 0.34, df = 1 (p = 0.56); I2 = 0%
Test for overall effect: z = 0.75 (p = 0.45)
Test for subgroup differences: not applicable
116
95
211
106
94
200
515
468
983
527
468
995
54.3%
45.7%
100.0%
1.12 (0.89 to 1.41)
1.01 (0.78 to 1.30)
1.07 (0.90 to 1.27)
Alendronic 
acid 70 mg
Events Total Weight
Risedronic 
acid 35 mg RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
Alendronic acid 70 mg/week vs. risedronic acid 35 mg/week postmenopausal women and any UGI AE
FIGURE 34 Any upper GI AEs in the alendronic acid group compared with the risedronic acid group. M–H, Mantel–Haenszel; UGI, upper GI.
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0.001 0.1 1 10 1000
More in zoledronic acid More in alendronic acid
Study or subgroup
ROSE Hadji 201269 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 3.07 (p = 0.002)
Test for subgroup differences: not applicable
57
57
75
75
194
194
408
408
100.0%
100.0%
1.60 (1.19 to 2.16)
1.60 (1.19 to 2.16)
Alendronic acid
Events Total Weight
Zoledronic acid RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
Alendronic acid 70 mg/week vs. zoledronic acid 5 mg/year postmenopausal women and any UGI AE
FIGURE 35 Any upper GI AEs in the alendronic acid group compared with the zoledronic acid group.
0.002 0.1 1 10 500
More in placebo More in zoledronic acid
Study or subgroup
HORIZON-PFT Reid 2010102 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 10.66 (p < 0.00001)
Test for subgroup differences: not applicable
300
300
80
80
3862
3862
3852
3852
100.0%
100.0%
3.74 (2.93 to 4.77)
3.74 (2.93 to 4.77)
Zoledronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
Zoledronic acid 5 mg men and any UGI AE
FIGURE 36 Any GI AEs in the zoledronic acid group compared with placebo. M–H, Mantel–Haenszel; UGI, upper GI.
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Ibandronic acid In the RCT by McClung et al.,80 4.8% (4/83) of participants receiving 150 mg per month
of oral ibandronic acid developed influenza-like symptoms, whereas none of the 83 (0%) participants
receiving placebo developed symptoms. The difference between treatments was not statistically
significant (p = 0.12).
Risedronic acid Boonen et al.58 reported the number of participants treated with 35 mg per week of
risedronic acid or placebo who developed influenza and nasopharyngitis. The differences between treatment
groups were not statistically significant. There were 15 influenza cases: 11 (among 191 participants, 5.8%)
in the risedronic acid group and five (among 93 participants, 5.4%) in the placebo group (RR 1.07, 95% CI
0.38 to 2.99; p = 0.90). There were also 15 cases of nasopharyngitis: 11/191 (5.8%) in the risedronic acid
group and 5/93 (5.4%) in the placebo group (RR 1.07, 95% CI 0.38 to 2.99; p = 0.90).
Zoledronic acid Five of the included RCTs using zoledronic acid reported on influenza-like symptoms.56,59,77,79,88
Across these RCTs, zoledronic acid was associated with a significantly higher incidence of pyrexia, headache and
chills than placebo. There were 1048 reports of pyrexia: 907 (in 5957 participants, 15.2%) in the zoledronic
acid group and 141 (among 5866 participants, 2.4%) in the placebo group (pooled RR 4.36, 95% CI 1.91 to
9.98; p< 0.0005) (Figure 37). There were 554 cases of headache: 405 (among 4903 participants, 8.3%) in the
zoledronic acid group and 149 (among 4809 participants, 3.1%) in the placebo group (pooled RR 2.14, 95% CI
1.36 to 3.39; p= 0.001) (Figure 38). There were 53 reports of chills: 44/453 (9.7%) in the zoledronic acid group
and 9/346 (2.6%) in the placebo group (pooled RR 3.81, 95% CI 1.25 to 11.60, p< 0.02) (Figure 39). The
incidence of pyrexia and headache significantly differed by sex (p< 0.00001 and p= 0.004, respectively).
Alendronic acid versus ibandronic acid In the MOTION trial,81 the incidence of neither influenza
nor nasopharyngitis differed significantly between treatment groups [influenza (85 events): 36 (among 859
participants, 4.2%) in the alendronic acid group and 49 (among 874 participants, 5.6%) in the ibandronic
acid group (monthly oral dose, 150 mg) (RR 0.75, 95% CI 0.49 to 1.14; p = 0.17); nasopharyngitis (92 events):
41 among 859 participants, 4.8%) in the alendronic acid group and (51 among 874 participants, 5.8%) in the
ibandronic acid group (RR 0.82, 95% CI 0.55 to 1.22; p= 0.33)].
Alendronic acid versus zoledronic acid The ROSE trial69 found that 5 mg per year of zoledronic acid
was associated with significantly more influenza-like symptoms than 70 mg per week of alendronic acid
[137 cases: 5/194 (2.6%) in the alendronic acid group and 132/408 (32.4%) in the zoledronic acid group;
RR 1.44, 95% CI 1.34 to 1.55; p < 0.00001]. It was also associated with a slight increase in pyrexia
[23 cases: 2/194 (1.0%) in the alendronic acid group and 21/408 (5.2%) in the zoledronic acid group;
RR 1.04, 95% CI 1.02 to 1.07; p = 0.002] and an increase in chills [26 cases: 3/194 (1.5%) in the
alendronic acid group and 13/408 (3.2%) in the zoledronic acid group; RR 1.02, 95% CI 0.99 to 1.04;
p = 0.19] (Figure 40).
Head to head: zoledronic acid compared with risedronic acid The HORIZON trial88 compared 5 mg
per year of zoledronic acid with 5 mg per day of risedronic acid in both men and women receiving
steroids, and divided the participants into treatment and prevention subgroups for 12 months. The
difference between treatments in influenza-like symptoms in the treatment subgroup was a RR of 5.02
(95% CI 1.47 to 17.14; p = 0.01) and the difference between treatments in the prevention subgroup was
a RR of 10.00 (95% CI 1.30 to 77.09; p = 0.03); the differences between treatments were statistically
significant (more events with zoledronic acid). No forest plot is presented for these data.
Risk of hospitalisation
Alendronic acid Three RCTs in postmenopausal women reported on hospitalisation.55,64,68 A total of
1850 participants were hospitalised during 36 months55,68 or 48 months of follow-up.64 Across these RCTs
there was no statistically significant difference in the risk of hospitalisation between participants receiving
alendronic acid (27.9%, 928/3329) than those on placebo (27.8%, 922/3316) (pooled RR 1.01, 95% CI
0.79 to 1.28; p = 0.96) (Figure 41).
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0.001 0.1 1 10 1000
More in placebo More in zoledronic acid
Study or subgroup
Zoledronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
HORIZON-PFT Black 200756 – 36 months
McClung 200980 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.06; χ2 = 1.85, df = 1 (p = 0.17); I2 = 46%
Test for overall effect: z = 8.34 (p < 0.00001)
621
38
659
79
9
88
3862
181
4043
3852
202
4054
21.4
18.9
40.3%
7.84 (6.23 to 9.87)
4.71 (2.34 to 9.47)
6.79 (4.33 to 10.65)
Zoledronic acid 5 mg postmenopausal women and pyrexia
73
32
105
9
21
30
1054
272
1326
1057
144
1201
19.0%
20.1%
39.1%
8.13 (4.09 to 16.17)
0.81 (0.48 to 1.35)
2.53 (0.24 to 27.25)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.82; χ2 = 65.98, df = 4 (p < 0.00001); I2 = 94%
Test for overall effect: z = 3.49 (p < 0.0005)
Test for subgroup differences: χ2 = 0.64, df = 2 (p = 0.73); I2 = 0%
907 141
5957 5866 100.0% 4.36 (1.91 to 9.98)
HORIZON-RFT Lyles 200777 – 36 months
HORIZON Reid 200988 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 2.84; χ2 = 30.73, df = 1 (p < 0.0001); I2 = 97%
Test for overall effect: z = 0.77 (p = 0.44)
Zoledronic acid 5 mg men and women and pyrexia
143
143
23
23
588
588
611
611
20.6%
20.6%
6.46 (4.22 to 9.89)
6.46 (4.22 to 9.89)
Boonen 201259 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 8.59 (p < 0.00001)
Zoledronic acid 5 mg men and pyrexia
FIGURE 37 Pyrexia: zoledronic acid compared with placebo. M–H, Mantel–Haenszel.
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0.001 0.1 1 10 1000
More in placebo More in zoledronic acid
Study or subgroup
Zoledronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
HORIZON-PFT Black 200756 – 36 months
McClung 200980 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: τ2 = 0.10; χ2 = 3.69, df = 1 (p = 0.05); I2 = 73%
Test for overall effect: z = 3.44 (p = 0.0006)
273
37
310
90
23
113
3862
181
4043
3852
202
4054
31.8%
25.1%
56.8%
3.03 (2.39 to 3.82)
1.80 (1.11 to 2.90)
2.43 (1.47 to 4.04)
Zoledronic acid 5 mg/year postmenopausal women and headache
13
13
9
9
272
272
144
144
16.3%
16.3%
0.76 (0.33 to 1.75)
0.76 (0.33 to 1.75)
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.16; χ2 = 13.17, df = 3 (p = 0.004); I2 = 77%
Test for overall effect: z = 3.26 (p = 0.001)
Test for subgroup differences: χ2 = 9.01, df = 2 (p = 0.01); I2 = 77.8%
405 149
4903 4809 100.0% 2.14 (1.36 to 3.39)
HORIZON Reid 200988 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 0.64 (p = 0.52)
Zoledronic acid 5 mg/year men and women and headache
82
82
27
27
588
588
611
611
26.8%
26.8%
3.16 (2.07 to 4.80)
3.16 (2.07 to 4.80)
Boonen 201259 – 36 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 5.36 (p < 0.00001)
Zoledronic acid 5 mg/year men and headache
FIGURE 38 Headache: zoledronic acid compared with placebo. M–H, Mantel–Haenszel.
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0.001 0.1 1 10 1000
More in placebo More in zoledronic acid
Study or subgroup
Zoledronic acid
Events Total Weight
Placebo RR
M – H, random, 95% Cl
RR
M – H, random, 95% ClEvents Total
McClung 200980 – 24 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 4.20 (p < 0.0001)
33
33
6
6
181
181
202
202
58.5%
58.5%
6.14 (2.63 to 14.31)
6.14 (2.63 to 14.31)
Zoledronic acid 5 mg postmenopausal women and chills
Total (95% Cl)
Total events
Heterogeneity: τ2 = 0.36; χ2 = 2.22, df = 1 (p = 0.14); I2 = 55%
Test for overall effect: z = 2.35 (p = 0.02)
Test for subgroup differences: χ2 = 2.21, df = 1 (p = 0.14); I2 = 54.7%
44 9
453 346 100.0% 3.81 (1.25 to 11.60)
11
11
3
3
272
272
144
144
41.5%
41.5%
1.94 (0.55 to 6.85)
1.94 (0.55 to 6.85)
HORIZON Reid 200988 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.03 (p = 0.30)
Zoledronic acid 5 mg men and women and chills
FIGURE 39 Chills: zoledronic acid compared with placebo. M–H, Mantel–Haenszel.
A
S
S
E
S
S
M
E
N
T
O
F
C
L
IN
IC
A
L
E
F
F
E
C
T
IV
E
N
E
S
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
1
5
0
0.001 0.1 1 10 1000
More in alendronic acid More in zoledronic acid
Study or subgroup
Alendronic acid
Events Total Weight
Zoledronic acid RR (non-event)
M – H, random, 95% Cl
RR (non-event)
M – H, random, 95% ClEvents Total
ROSE Hadji 201269 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 10.08 (p < 0.00001)
5
5
132
132
194
194
408
408
100.0%
100.0%
1.44 (1.34 to 1.55)
1.44 (1.34 to 1.55)
Alendronic acid 70 mg/week vs. zoledronic acid 5 mg/year and influenza-like illness
2
2
21
21
194
194
408
408
100.0%
100.0%
1.04 (1.02 to 1.07)
1.04 (1.02 to 1.07)
ROSE Hadji 201269 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 3.11 (p = 0.002)
Alendronic acid 70 mg/week vs. zoledronic acid 5 mg/year and pyrexia
3
3
13
13
194
194
408
408
100.0%
100.0%
1.02 (0.99 to 1.04)
1.02 (0.99 to 1.04)
ROSE Hadji 201269 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 1.32 (p = 0.19)
Alendronic acid 70 mg/week vs. zoledronic acid 5 mg/year and chills
4
4
24
24
194
194
408
408
100.0%
100.0%
1.04 (1.01 to 1.07)
1.04 (1.01 to 1.07)
ROSE Hadji 201269 – 12 months
Subtotal (95% Cl)
Total events
Heterogeneity: not applicable
Test for overall effect: z = 2.46 (p = 0.01)
Zoledronic acid 5 mg/year men and women and chills
FIGURE 40 Influenza-like symptoms: 70mg per week of alendronic acid compared with 5mg per year of zoledronic acid.
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FIGURE 41 Forest plot for hospitalisation in postmenopausal women on 10mg per day of alendronic acid compared with placebo.
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Atrial fibrillation
Atrial fibrillation was reported as an AE outcome across the two HORIZON RCTs comparing zoledronic acid
with placebo56,77 and in the HORIZON RCT in men and women receiving glucocorticoids.88 Across these
RCTs no statistically significant differences between treatments were evident [HORIZON-PFT: RR 1.28
(95% CI 0.95 to 1.74; p = 0.10); HORIZON-RFT: RR 1.21 (95% CI 0.80 to 1.85; p = 0.37); HORIZON
glucocorticoid – prevention group: RR 7.00 (95% CI 0.36 to 134.31; p = 0.20); HORIZON glucocorticoid –
treatment group: zero events in both arms]. No forest plot is presented for these data.
Bone pain
Bone pain was reported as an AE outcome by two RCTs.69,88
Head to head: zoledronic acid compared with risedronic acid The HORIZON trial88 compared 5 mg
per year of zoledronic acid with 5 mg per day of risedronic acid in both men and women receiving
steroids, and divided the participants into treatment and prevention subgroups for 12 months. The
difference between treatments in bone pain in the treatment subgroup was a RR of 2.61 (95% CI 0.94 to
7.22; p = 0.06). The difference between treatments was not statistically significant. There were zero events
in both arms of the prevention subgroup. No forest plot is presented for these data.
Head to head: alendronic acid compared with zoledronic acid The ROSE RCT69 compared 70 mg per
week of alendronic acid with 5 mg per year of zoledronic acid. The difference between treatments in bone
pain was a RR of 6.91 (95% CI 3.02 to 15.83; p < 0.00001). The difference between treatments was
statistically significant (more events with zoledronic acid). No forest plot is presented for these data. There
were zero events in both arms of the prevention subgroup.
Conjunctivitis
Zoledronic acid The HORIZON-PFT102 reported on eye inflammation as an AE in the first 3 days following
administration of 5 mg per year of zoledronic acid or placebo in osteoporotic women. The difference
between treatments in eye inflammation was a RR of 6.98 (95% CI 1.59 to 30.70; p = 0.01). The
difference between treatments was statistically significant (more events with zoledronic acid). No forest
plot is presented for these data.
Stroke
Zoledronic acid The HORIZON-RFT77 reported on stroke as an AE in men and women with history of hip
fracture receiving 5 mg per year of zoledronic acid or placebo over 5 years. The difference between
treatments in stroke was a RR of 1.21 (95% CI 0.80 to 1.85; p = 0.37); the difference between treatments
was not statistically significant. No forest plot is presented for these data.
Osteonecrosis of the jaw
Zoledronic acid Four placebo-controlled RCTs evaluated zoledronic acid,56,59,77,79 one compared zoledronic
acid with risedronic acid88 and one compared zoledronic acid with alendronic acid;69 all studies reported that
no cases of spontaneous osteonecrosis were observed during the course of the RCT. The HORIZON-PFT56
reported that cases of osteonecrosis in both the zoledronic acid and placebo groups following dental surgery
(one case in each group) resolved with antibiotic therapy.
Hypocalcaemia and atypical femoral fracture
None of the included RCTs reported on these AE outcomes.
Systematic review evidence for adverse events
A supplementary search in MEDLINE (via Ovid) and EMBASE (via Ovid) for systematic reviews reporting AEs
of treatment was undertaken on 6 January 2015. Keywords and subheadings for AEs and safety with the
drug names, and a reviews search filter were used. The MEDLINE search strategy is presented in Appendix 1.
A total of 177 additional citations were identified, which were then sifted by a single reviewer (FC).
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Fourteen reviews summarising evidence for AEs across studies in bisphosphonates were identified.112–125
A summary of these reviews and their findings is presented in Table 48, Appendix 5.
Any AE/upper gastrointestinal events The review by Bobba et al.112 evaluated the evidence from
14 studies of alendronic acid, eight studies of risedronic acid, 10 studies of ibandronic acid and nine
studies in zoledronic acid. RCTs and observational studies were included. Summarising the evidence base,
the reviewers reported that the rates of GI toxicity associated with alendronic acid, risedronic acid and oral
ibandronic acid are similar to those associated with placebo. In addition, no significant difference in renal
toxicity was evident for i.v. ibandronic acid compared with placebo; however, a decrease in renal function
was evident with zoledronic acid. Osteonecrosis of the jaw was rarely described in participants receiving
oral bisphosphonates, but it was more commonly reported in participants with malignancy receiving
zoledronic acid. The authors concluded that the AEs associated with alendronic acid, risedronic acid and
oral ibandronic acid are minimal; however, zoledronic acid may be compromised by renal toxicity. Myalgias
and arthralgias were evident in the acute phase following i.v. administration.
In a review of clinical efficacy of risedronic acid for postmenopausal osteoporosis, Paget’s disease, breast
cancer and participants taking glucocorticoids, Crandall113 evaluated the evidence across nine RCTs and
seven clinical trials. Safety data from six RCTs of risedronic acid for any condition indicated that the safety
of risedronic acid is similar to that of placebo; none of the trials found a notable rate of upper GI AEs.
In a comparative review of pivotal trials of alendronic acid and risedronic acid including a meta-analysis,
Kherani et al.114 concluded that both alendronic acid and risedronic acid result in similar rates of AEs
as placebo.
In a review of clinical studies and review articles concerning the use of risedronic acid, Umland and
Boyce115 observed that, although post-marketing surveillance studies reported an increase in serious or
severe upper GI side effects with alendronic acid, similar findings were not evident for risedronic acid. The
reviewers concluded that risedronic acid has been associated with a lower incidence of gastric ulcers than
alendronic acid; however, the number of AEs associated with risedronic acid is generally similar to those
observed with placebo in most clinical trials.
As part of a NICE report on adverse effects and persistence with oral bisphosphonates, Lloyd-Jones and
Wilkinson116 reported that across UK prescription event monitoring studies, treatment with daily alendronic
acid or risedronic acid is associated with a high level of reporting of a number of conditions in the first
month of therapy, particularly those affecting the upper GI tract. There were around 30 reports of
dyspepsia, the most commonly reported condition, per 1000 patient-months of exposure. However, RCTs
of tolerability found no increased incidence of AEs in patients randomised to alendronic acid.
The Actavis consultee submission for this assessment reported that the patients who switched from
risedronic acid to alendronic acid experienced a significant increase in the risk of GI side effects. In a
retrospective cohort study evaluating anonymous medical records from 390 general practices in the UK,
Ralston et al.126 reported that the risk of developing a GI AE was higher in patients who switched to
alendronic acid than in those who remained on risedronic acid (HR 1.85, 95% CI 1.26 to 2.72). The
authors also reported that the risk was even greater in the subgroup of patients with a history of upper GI
events (HR 3.18, 95% CI 2.79 to 3.63), but was also observed in patients with no history of GI events
(HR 1.76, 95% CI 1.15 to 2.69). The authors concluded that switching patients who are stabilised on
risedronic acid to alendronic acid is associated with an increased risk of GI AEs.
Osteonecrosis of the jaw In a review specifically of bisphosphonate-induced osteonecrosis of the jaw,
Krueger et al.117 reviewed the evidence from 11 case reports and 26 case series studies reporting actual cases
linking osteonecrosis of the jaw with bisphosphonate use, the majority of which reported on zoledronic acid.
The available literature showed that i.v. bisphosphonates, especially zoledronic acid, are more likely to
predispose patients to osteonecrosis of the jaw. However, in addition to bisphosphonate use, there appears
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to be several other factors involved in the development of osteonecrosis of the jaw. Other risk factors noted
from the included studies were dental extraction or trauma to the jaw exposing part of the bone.
Van den Wyngaert et al.118 also reviewed the evidence of an asssociation between bisphosphonates and
osteonecrosis of the jaw across 22 studies based on retrospective chart reviews without a control, of
which three included patients with osteoporosis. Zoledronic acid and pamidronic acid (Aredia®, Novartis
Pharmaceuticals Ltd) were the main bisphosphonates covered. Of the patients included in the studies, 69.3%
had undergone a dental extraction prior to the development of osteonecrosis, confirming the importance of
trauma in the initiation of the disease. However, not enough evidence is available to prove a causal link.
Woo et al.119 reviewed the evidence of a link between bisphosphonates and osteonecrosis of the jaw
across 29 case reports. Zoledronic acid, aledronic acid and pamidronic acid were the main bisphosphonates
covered and 94% of patients were treated with zoledronic acid or pamidronic acid or both; 85% of
affected patients had multiple myeloma or metastatic breast cancer and 4% had osteoporosis. The authors
concluded that the prevalence of osteonecrosis in patients with cancer is 6–10% and the prevalence in
those taking alendronic acid for osteoporosis is unknown. The authors also concluded that more than half
of all cases (60%) occur after dentoalveolar surgery (such as tooth extraction) to treat infections, and the
remaining 40% are probably related to infection, denture trauma or other physical trauma.
Recently, Lee et al.120 undertook a meta-analysis of 12 cohort and case–control studies evaluating oral
and i.v.-administered bishphosphonates. An inclusion criterion was that the studies were carried out in
non-cancer patients. The pooled effect estimate indicated that the use of bisphosphonates was associated
with a significantly increased risk of jaw osteonecrosis (OR 2.32, 95% CI 1.38 to 3.91). The reviewers
concluded that the use of bisphosphonates in non-cancer patients is associated with a substantial risk of
jaw osteonecrosis and that patients receiving i.v. bisphosphonates are at highest risk.
Atypical fracture Giusti et al.121 reviewed the evidence from 39 publications reporting on women treated
with a bisphosphonate in a regimen used for the prevention or treatment of osteoporosis. Twenty-seven of
the publications were case series or case reports (one abstract), four were retrospective studies and one
was a prospective article including three new cases. In most cases, the bisphosphonate was alendronic
acid, prescribed for prevention or treatment of osteoporosis. Across the included studies, there were
58 femoral shaft fractures and 41 subtrochanteric fractures; the precise fracture site was not specified in
42 cases. Nineteen fractures were diagnosed at presentation as insufficiency fractures, with 12 of these
progressing to a complete fracture. Overall, 53 (44.2%) of the 120 patients for whom data were available
had a contralateral fracture (32 of which were insufficiency fractures), either concurrently with or
subsequent to the initial fracture, of which 34 (64.2%) occurred in the same anatomical location as the
first fracture. The authors concluded that the analysis allowed the clinical identification of patients at risk
of developing atypical fractures; however, the reviewers also concluded that long-term bisphosphonate
therapy is not a prerequisite for development of atypical fractures. Moreover, the use of glucocorticoids
and proton pump inhibitors is an important risk factor for atypical fracture.
Recently, Gedmintas et al.122 undertook a meta-analysis of atypical fractures reported in five case–control
studies and six cohort studies. The studies were mainly carried out in women and evaluated mainly
alendronic acid but also ibandronic acid, risedronic acid, zoledronic acid and other bisphosphonates. The
overall pooled estimate for atypical fractures associated with bisphosphonates using data from the five
case–control and six cohort studies was a RR of 1.70 (95% CI 1.22 to 2.37). Gedmintas et al.122 concluded
that there is an increased risk of atypical fracture among bisphosphonate users but that atypical fractures
are rare events, even in bisphosphonate users.
Oesophageal cancer Andrici et al.123 undertook a meta-analysis of seven cohort or case–control studies
investigating oral bisphosphonates and the risk of oesophageal cancer. Participants were anyone who had
filed a prescription for any antiresorptive drug. The authors found a positive relationship between exposure
to bisphosphonates and oesophageal cancer, with an OR of 1.74 (95% CI 1.19 to 2.55). An increased risk
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of oesophageal cancer was also found in the group exposed to bisphosphonates for a longer period of
time. According to the authors, the results suggest a possible association between oral bisphosphonates
and oesophageal cancer, and this risk is increased with a longer exposure period. An increased risk was
observed for etidronic acid, but not alendronic acid.
Recently, Sun et al.124 undertook a a meta-analysis of observational studies. Seven epidemiological studies,
four cohort studies and three case–control studies, were included and, where reported, alendronic acid
was the main bisphosphonate. The underlying conditions for which patients were being treated with a
bisphosphonate were not reported. In the primary analysis, bisphosphonate treatment was not associated
with a risk of oesophageal cancer in either the cohort studies (pooled RR 1.23, 95% CI 0.79 to 1.92) or
the case–control studies (pooled OR 1.24, 95% CI 0.98 to 1.57). The authors also observed no significant
increased risk of oesophageal cancer in users of alendronic acid alone across cohort studies (RR 1.08, 95%
CI 0.67 to 1.75) or across case–control studies (OR 1.16, 95% CI 0.82 to 1.63). They concluded that
bisphosphonate treatment is not significantly associated with an excess risk of oesophageal cancer.
Atrial fibrillation Loke et al.125 evaluated the risk of atrial fibrillation associated with biphosphonate use
in patients with osteoporosis or fractures. RCTs of any biphosphonate compared with placebo and
case–control and prospective or retrospective cohort studies in patients with osteoporosis that reported on
the association between biphosphonate exposure and atrial fibrillation were eligible for inclusion.
Interventions in the included RCTs included alendronic acid, risedronic acid and zoledronic acid.
Interventions in the included case–control studies were mostly alendronic acid or etidronic acid. Across
nine RCTs, biphosphonates significantly increased the risk of atrial fibrillation compared with placebo
(OR 1.47, 95% CI 1.01 to 2.14). Biphosphonates did not significantly increase the risk of stroke or
cardiovascular mortality (three RCTs). One case–control study found that patients with atrial fibrillation
were more likely than control patients to have used biphosphonates (OR 1.86, 95% CI 1.09 to 3.15),
but the second case–control study found no association. Neither study found a greater likelihood of
current use of bisphosphonates among patients with atrial fibrillation. The authors concluded that
bisphosphonates were associated with atrial fibrillation, but heterogeneity of the existing evidence and a
paucity of information on some agents precluded any definitive conclusions with respect to risk.
Mortality Only one review reported on mortality.116 The authors did not report an overall conclusion on
this outcome, but did say that one cohort study found no difference in all-cause mortality, cancer mortality
or mortality from cancer of the lung or GI tract between patients treated with risedronic acid and those
treated with placebo. A non-statistically significant reduction in deaths from cardiovascular causes in the
risedronic acid group was largely caused by a statistically significant reduction in stroke mortality in the
combined risedronic acid groups (p = 0.015); and from one prescription event monitoring study that serious
upper GI events included gastric, duodenal and peptic ulceration, gastritis, and duodenitis. However, only 9
of the 502 reported deaths for which the cause of death was established were attributed to GI causes.
Summary of reviews of adverse events The 14 reviews were published from 2001 to 2014.112–125 One
review considered any antresorptive therapy,123 10 considered any bisphosphonate therapy112,114,117–122,124,125 and
three reported on AEs associated with specific bisphosphonates (two in risedronic acid113,115 and one in
alendronic acid or risedronic acid116). Four reviews included evidence from both observational studies and
RCTs112,116,117,125 and seven included only observational studies.118–124 Five reviews reported on any AE,112–115
whereas nine reported on specific AEs (four in jaw osteonecrosis,117–120 two in atypical fracture,121,122 two in
oesophogeal cancer123,124 and one in atrial fibrillation125). Four reviews pooled data across studies in a
meta-analysis.120,122–124
Evidence from these reviews indicates that rates of GI toxicity are similar following treatment with
alendronic acid, risedronic acid, oral ibandronic acid and placebo. However, observational data suggest a
high level of reporting of a number of conditions in the first month of therapy with alendronic acid or
risedronic acid, particularly those affecting the upper GI tract. Zoledronic acid may be compromised by
renal toxicity, and myalgia and arthralgia are evident in the acute phase following i.v. administration of the
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drug. Intravenous bisphosphonates, especially zoledronic acid, are more likely to predispose patients to
osteonecrosis of the jaw, although absolute risk is very low. In addition to bisphosphonate use, there
appears to be several other factors involved in the development of osteonecrosis of the jaw. There is an
increased risk of atypical fracture among bisphosphonate users; however, events are rare and long-term
bisphosphonate therapy is not a prerequisite for development of atypical fractures. Moreover, the use of
glucocorticoids and proton pump inhibitors are important risk factors. Bisphosphonates are associated
with serious atrial fibrillation, but heterogeneity of the existing evidence and a paucity of information on
some agents preclude any definitive conclusions with respect to risk. The review evidence for the use of
bisphosphonates and oesophogeal cancer is equivoval; no overlaps in this evidence either across the
included reviews or with the RCT evidence base included in this assessment report were identified.
Continuance and concordance
Alendronic acid
Two trials reported that at the end of treatment (36 months) > 80% of participants were still taking study
medication.55,64 One trial reported that > 60% of participants took 80% of their study medication.68
Ibandronic acid
The ARIBON74 trial reported that > 90% of participants took all of their monthly doses for 24 months. In
the BONE trial,45 the mean duration on treatment was reported as 2.42 years in the placebo group and
2.48 years in the group receiving 2.5 mg per day of ibandronic acid.
Risedronic acid
Boonen et al.58 reported that, at 24 months, 91% of placebo and 98% of 35 mg per week of risedronic
acid participants were compliant with the study drug. In the VERT-NA trial, Harris et al.70 reported that
55% of placebo and 60% of 5 mg per month risedronic acid groups completed 3 years of medication and
Taxel et al.95 reported that compliance with the study drug was 90–95% for all participants.
Zoledronic acid versus alendronic acid
Hadji et al.106 reported that, in the ROSE trial, at 12 months, 80.9% of patients were compliant with
alendronic acid therapy, but compliance with zoledronic acid was not reported.
Systematic review evidence for compliance and concordance
A supplementary search in MEDLINE (via Ovid) and EMBASE (via Ovid) for systematic reviews reporting on
compliance and continuance was undertaken on 6 January 2015. Keywords for ‘compliance’ were
combined with the named drug intervention terms and a reviews search filter. The MEDLINE search
strategy is presented in Appendix 1. From this search, 57 additional citations were identified. These records
were sifted by a single reviewer (MMSJ). Seven reviews were identified that summarised evidence for
compliance and concordance across studies in bisphosphonates for osteoporosis and a summary of these
reviews and their findings is presented in Appendix 6.116,127–132
The review by Cramer et al.127 included studies reporting one measure of compliance or persistence derived
from administrative databases of patient demographic and prescription information. Compliance was
measured as the medication possession ratio (MPR) and persistence was measured as the number of days of
possession without a gap in refills, and the percentage of patients persisting with therapy for 1 year. Most
of the therapies in the 14 included studies obtained were oral daily or weekly bisphosphonates (alendronic
acid and risedronic acid). Studies had observation periods of mainly 12 months. The reviewers reported that
the mean MPR was consistently higher for weekly therapy (0.58–0.76) than for daily therapy (0.46–0.64).
Patients receiving weekly bisphosphonates exhibited better persistence (length of persistence 194–269 days;
35.7–69.7% persistent) than those receiving daily therapy (length of persistence 134–208 days;
26.1–55.7% persistent). The reviewers concluded that, although patients using weekly bisphosphonate
medication follow their prescribed regimens better than those using daily therapy, overall compliance and
persistence rates were suboptimal.
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Imaz et al.128 examined observational studies that prospectively analysed administrative databases of
pharmacy refills for measures of persistence and compliance in patients who were prescribed either
bisphosphonates (mainly alendronic acid and risedronic acid) or other anti-osteoporosis medications.
Follow-up periods needed to be 1–2.5 years and compliance was to be measured by the MPR. Studies
were pooled in meta-analyses, with 15 studies included in the review. The pooled persistence mean was
184.1 days (95% CI 163.9 to 204.3 days; five studies) and the pooled MPR mean was 66.9% (95% CI
63.3% to 70.5%; five studies) at the 1-year follow-up. Low compliance when compared with high
compliance was significantly associated with increased overall fracture risk (RR 1.46, 95% CI 1.34 to 1.60;
six studies) from 1 to 2.5 years after starting treatment. Compared with high compliance, low compliance
was significantly associated with increased non-vertebral fracture risk (RR 1.16, 95% CI 1.07 to 1.26; three
studies) from 1.9 to 2.2 years’ follow-up, increased hip fracture risk (RR 1.28, 95% CI 1.06 to 1.53; four
studies) from 1.9 to 2.4 years’ follow-up and increased vertebral fracture risk (RR 1.43, 95% CI 1.26 to
1.63; two studies) from 2 to 2.2 years’ follow-up. The reviewers concluded that persistence and
compliance were suboptimal for postmenopausal women who underwent bisphosphonate therapy for the
treatment of osteoporosis.
Kothawala et al.129 reviewed 24 observational studies assessing pharmacological drug adherence in
patients with osteoporosis. Among the included studies, bisphosphonates were the most frequently
assessed drug. Treatment duration ranged from 1 month to > 24 months and a higher proportion of
included patients were new users. However, the types of bisphosphonates were not reported. The
outcomes of interest were grouped according to standardised definitions: persistence (how long a patient
received therapy after initiating treatment), compliance (how correctly, in terms of dose and frequency,
patients took their medication) and adherence (a combined measure of persistence and compliance).
Outcome rates were pooled in a random-effects meta-analysis. Compliance data were extracted as the
percentage of patients who reported that they followed the dosing recommendations. Adherence data
were extracted as the percentage of patients who achieved a predefined MPR threshold. Across seven
studies the pooled refill compliance rate was 68% at both 7–12 months (95% CI 63% to 72%) and at
13–24 months (95% CI 67% to 69%). The pooled estimate from self-reported data (four studies) was
62% (95% CI 48% to 75%) of patients following the recommended instructions within 6 months of
starting treatment. Across six studies, the pooled estimate of patients achieving a MPR > 66% (one study)
and > 80% (five studies) ranged from 53% (95% CI 52% to 54%) for treatment lasting 1–6 months to
43% (95% CI 32% to 54%) for treatment lasting 13–24 months. The authors concluded that one-third to
one-half of patients being treated with pharmacological drugs for osteoporosis did not take their
medication as directed.
Lee et al.130 reviewed 10 RCTs and observational studies. Compliance and persistence were evaluated, but
data were not pooled. Studies in osteoporosis medications including alendronic acid were evaluated. These
reviewers reported that adherence at 12 months was higher with weekly than with daily bisphosphonates
(≥ 84% preference for weekly, MPR 60–76% vs. 46–64%; persistence 43.6–69.7% vs. 31.7–55.7%). The
MPRs reported for oral bisphosphonates were 68–71% at 12 months. At 2 years, only 43% of patients
had a MPR ≥ 80% for daily and weekly bisphosphonates. Observational studies (6–12 months’ duration)
reported discontinuation rates of 18–22% for daily and 7% for weekly bisphosphonates. The studies
suggested that patient prefer annual zoledronic acid infusions to weekly bisphosphonates (66.4–78.8% vs.
9.0–19.7%, respectively), but no data on compliance or persistence were available. The reviewers
concluded that adherence is difficult to quantify and may not be exclusively influenced by the frequency of
medication administration.
As part of a NICE report on AEs and persistence with oral bisphosphonates, Lloyd-Jones and Wilkinson116
reported that, across UK prescription event monitoring studies, 24.5% of patients prescribed alendronic
acid by general practitioners (GPs) discontinued therapy within 1 year. The two most common reasons for
stopping treatment were dyspeptic conditions (6.3%) and non-compliance (3.0%). These authors
concluded that persistence might be improved by weekly rather than daily regimens.
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Mikyas et al.131 reviewed treatment adherence in studies in male osteoporosis. Eighteen retrospective or
prospective observational studies were included in the analysis. The reviewers reported that the definition
and measure of medication adherence varied among studies; however, adherence was measured in terms
of the MPR in most studies that reported adherence. The majority of treatments were bisphosphonates, of
which the majority were alendronic acid; data were not pooled. Across studies, the percentage of males
adherent to bisphosphonates [MPR > 0.8] over 12 months ranged from 32% to 64%. The reviewers
concluded that one-third to two-thirds of men do not adhere to bisphosphonates.
Vieira et al.132 reviewed 27 mainly observational studies of bisphosphonates (alendronic acid, ibandronic
acid, risedronic acid and zoledronic acid) covering a wide range of outcomes regarding adherence and
associated factors. No data were pooled and a narrative summary of the included studies was reported.
Among the included studies, the reviewers summarised evidence from one cohort study in which the
proportion of days covered (described as equivalent of a MPR) was 82% with i.v. zoledronic acid and
58–62% with i.v. ibandronic acid; one cohort study in which overall compliance with oral alendronic
acid, risedronic acid or ibandronic acid was 43%; one cohort study in which persistence with therapy
declined from 63% at 1 year to 46% at 2 years and 12% at 9 years among patients receiving
alendronic acid and risedronic acid; one RCT in which the MPR was 93–100% among women taking
weekly alendronic acid or monthly ibandronic acid; and one retrospective observational study in women
taking weekly (alendronic acid or risedronic acid) or monthly ibandronic acid. Patients treated with a
monthly regimen were 37% less likely to be non-persistent and were more compliant, with a 5% higher
absolute MPR, than women treated with weekly regimens; and one cohort study in patients taking
weekly risedronic acid or weekly alendronic acid in which patients initiated on weekly oral generic
alendronic acid showed a significantly lower persistence with bisphosphonate therapy than patients
initiated on weekly oral branded risedronic acid and weekly oral branded alendronic acid. Across all
studies, the reviewers concluded that a monthly dose is associated with better adherence than a
weekly dose.
Summary of reviews of continuance and concordance Seven reviews were identified, published
between 2006 and 2014.116,127–132 These are summarised in Appendix 6, Table 49. The majority of these
reviews reported on aledronic acid and risedronic acid. One review also included studies in ibandronic
acid132 and two included zoledronic acid.130,132 The majority of reviews evaluated compliance as a MPR and
persistence measured as the number of days of possession. Data were pooled across studies by
three reviews.128–130
Evidence across these reviews indicates that although patients using weekly bisphosphonate medication
follow their prescribed regimens better than those using daily therapy, overall compliance and persistence
rates are suboptimal for postmenopausal women receiving bisphosphonate therapy for the treatment
of osteoporosis. Furthermore, one-third to one-half of patients, including men being treated with
bisphosphonates for osteoporosis, did not take their medication as directed. No overlaps in this evidence
either across the included reviews or with the RCT evidence base included in this assessment report
were identified.
Health-related quality of life
Alendronic acid
A quality-of-life assessment was reported by one RCT65 using the Nottingham Health Profile.133 Statistically
significant improvements in all of the instrument’s domains were reported with alendronic acid.
Differences between treatments with placebo were not reported.
Ibandronic acid
Health-related quality of life was not reported by any trial evaluating ibandronic acid.
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Risedronic acid
Health-related quality of life was not reported by any trial evaluating risedronic acid.
Zoledronic acid
In the HORIZON-RFT trial, quality-of-life outcomes were reported by Adachi et al.103 Quality of life was
assessed at 6, 12, 24 and 36 months using the EQ-5D VAS and utility scores.134 The authors report that, at
the end of the study, mean change from baseline in EQ-5D VAS was greater (higher score better) in the
zoledronic acid-treated group than in the placebo group (7.67 ± 0.56 vs. 5.42 ± 0.56; p = 0.0034). A
statistically significant difference between treatments in EQ-5D VAS was also evident in the subgroup of
patients experiencing clinical vertebral fractures (8.86 ± 4.91 vs. –1.69 ± 3.42; p = 0.0456), non-vertebral
fractures (5.03 ± 2.48 vs. –1.07 ± 2.16; p = 0.0393) and clinical fractures (5.19 ± 2.25 vs. –0.72 ± 1.82;
p = 0.0243) in favour of zoledronic acid. EQ-5D utility scores were comparable for zoledronic acid and
placebo groups, but more participants in the placebo group consistently had extreme difficulty in mobility
(1.74% vs. 2.13%; p = 0.6238), self-care (4.92% vs. 6.69%; p = 0.1013) and usual activities (10.28% vs.
12.91%; p = 0.0775).
Zoledronic acid versus alendronic acid
In the ROSE trial, Hadji et al.69 assessed quality of life using the quality of life questionnaire of the
European Foundation for Osteoporosis questionnaire.135 Hadji et al.106 reported that in the alendronic acid
group only the pain domain showed a significant improvement as compared with baseline. However,
across all domains the differences between the treatments were not statistically significant.
Health resource use
Alendronic acid
The FIT I55 reported that the rate of hospital admissions for fracture was 9.2% in the placebo group,
compared with 6.3% in the alendronic acid groups.
No other included RCT reported any hospitalisation and service use following fracture.
Systematic review evidence for health-related quality of life
A summary of reviews of HRQoL is presented in Chapter 4, Independent economic assessment.
Methods for the network meta-analyses
A NMA was conducted for each of the four main fracture types and for femoral neck BMD. Details of the
statistical methods are provided in Appendix 3.
Selection of evidence contributing to the network meta-analysis
For RCTs to be eligible for inclusion in the NMA, the interventions were required to be assessed in line
with the licensing indications. RCTs that included both licensed and unlicensed dose groups were included
where outcome data for the licensed group could be isolated. RCTs that reported only results pooled
across RCT groups were not included.
An assumption of the NMA is that RCTs are exchangeable, that is we would be prepared to treat any
patient with any one of the treatments. Strictly, the RCTs included in this evidence synthesis are not
exchangeable because not all of the treatments are licensed in all patient populations but the analysis
follows the agreed scope.
Two RCTs reported that participants were switched from 5 mg per day alendronic acid to 10 mg per day
alendronic acid after 24 months of the 36-month trial.55,64 A sensitivity analysis was performed to explore
the impact on the results of excluding these RCTs from the analysis.
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Vertebral fractures were assessed using either clinical/symptomatic (four RCTs56,77,81,89) or morphometric/
radiographic (15 RCTs45,55,58–60,63–66,70,72,76,83,85,86) techniques, with two RCTs82,88 not stating the assessment
method. A sensitivity analysis was performed to assess the impact on the results of including in the analysis
those RCTs with only clinical assessment of fractures.
Femoral neck BMD data were presented either numerically or in graphical format. Nine RCTs55,56,64,68,72,76,85,87,90
presented results for each treatment group in graphical format but in the text presented the mean between-
group differences in the percentage change in femoral neck BMD in numerical form. Two of the included
RCTs45,77 reported only data on mean differences in percentage change between treatments. The remaining
24 RCTs presented sample estimates for each treatment group separately, with 20 reporting in numerical
format53,57,59,62,63,65,66,70,73,75,79–81,83,84,86,88,91,95 and four graphically.47,49,58,67 Where both formats were provided,
numerical estimates were selected as the most accurate summaries of means and variances. Given potential
inaccuracy and inconsistency between the numerical and graphical sample estimates, a sensitivity analysis
was performed to explore the impact on the results of excluding the graphically extracted sample estimates
from the analysis.
Results from the network meta-analyses
A summary of the data used in the NMA is provided in Tables 42–46 in Appendix 3. The results for each
of the four fracture types are presented in Vertebral fractures, class-effects model to wrist fractures,
class-effects model. Results for femoral neck BMD are presented in Femoral neck bone mineral density,
class-effects model. As described earlier (see Methods for the network meta-analyses), three sensitivity
analyses were undertaken. Sensitivity analysis 1 is presented below (see Sensitivity analysis 1) and assesses
the robustness of the results to the inclusion of RCTs that altered dose over the study duration. Sensitivity
analysis 2, which considers clinically assessed vertebral fractures, is presented in Sensitivity analysis 2.
Sensitivity analysis 3 is presented in Sensitivity analysis 3, excluding RCTs for which femoral neck BMD
results were provided in graphical format only. Results using the standard random-effects model are
presented in Appendix 3, Figures 131–136.
Vertebral fractures, class-effects model
An NMA was used to compare the effects of alendronic acid, risedronic acid, zoledronic acid, 150 mg per
month oral ibandronic acid and 2.5 mg per day oral ibandronic acid relative to placebo on the occurrence
of vertebral fractures. Data were available from 21 RCTs,45,55,56,58–60,63–66,70,72,76,77,81–83,85,86,88,89 each comparing
two treatments. Figure 42 presents the network of evidence for vertebral fractures.
Placebo
Risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
One study
Three studies
Six studies
Eight studies
FIGURE 42 Vertebral fractures: network of evidence.
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The network provided seven direct treatment comparisons (edges in the network diagram). For the placebo
versus 2.5 mg per day oral ibandronic acid comparison there is no direct evidence. The risedronic acid
versus alendronic acid comparison is contributed by one small study, with a zero count in the control arm.
Three contrasts were checked for inconsistency between direct and indirect evidence. None of the
comparisons showed significant evidence of inconsistency, as assessed using Bayesian p-values (Figure 43).
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FIGURE 43 Vertebral fractures: class-effects model. Assessing inconsistency using node splitting. (a) Nodes 1 and 2,
placebo–risedronic acid; (b) nodes 1–4, placebo–zoledronic acid; and (c) nodes 2–4, risedronic acid–zoledronic acid.
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Figure 44 presents the effects of each treatment relative to placebo, and the probabilities of treatment
rankings are presented in Figure 45. The model fitted the data well, with a total residual deviance of 41.05
being close to the number of data points included in the analysis, which was 42. The deviance information
criterion (DIC) was 69.28. The between-study SD was estimated to be 0.19 [95% credible interval (CrI)
0.01 to 0.49], implying mild heterogeneity in treatment effects between RCTs.
Versus placebo
Risedronic acid 0.50 (0.38 to 0.66)
0.51 (0.27 to 0.84)
Versus risedronic acid
Alendronic acid 0.45 (0.35 to 0.58)
0.45 (0.25 to 0.79)
Zoledronic acid 0.41 (0.28 to 0.56)
0.41 (0.23 to 0.76)
Ibandronic acid 150 mg/month 0.45 (0.24 to 0.81)
0.45 (0.21 to 0.96)
Ibandronic acid 2.5 mg/day 0.46 (0.32 to 0.67)
0.47 (0.25 to 0.86)
Bisphosphonate 0.45 (0.31 to 0.65)
0.45 (0.19 to 1.12)
Alendronic acid 0.92 (0.63 to 1.23)
0.89 (0.43 to 2.01)
Zoledronic acid 0.84 (0.50 to 1.14)
0.80 (0.38 to 1.91)
Ibandronic acid 150 mg/month 0.94 (0.46 to 1.58)
0.91 (0.36 to 2.20)
Ibandronic acid 2.5 mg/day 0.95 (0.60 to 1.37)
0.93 (0.42 to 2.12)
Versus alendronic acid
Zoledronic acid 0.93 (0.59 to 1.25)
0.90 (0.41 to 2.05)
Ibandronic acid 150 mg/month 1.00 (0.55 to 1.82)
1.00 (0.41 to 2.43)
Ibandronic acid 2.5 mg/day 1.01 (0.69 to 1.57)
1.03 (0.45 to 2.31)
Versus zoledronic acid
Ibandronic acid 150 mg/month 1.06 (0.63 to 2.28)
1.10 (0.44 to 2.86)
Versus ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day 1.01 (0.55 to 1.99)
1.03 (0.41 to 2.60)
Ibandronic acid 2.5 mg/day 1.09 (0.77 to 1.92)
1.14 (0.48 to 2.58)
– 0.25 0.31 0.88 1.44 2.00
Treatment comparison HR (95% Crl)
FIGURE 44 Vertebral fractures: class-effects model – HRs and 95% credible intervals. Note that the mean effects
estimates are plotted in black and predictive effects in a new study are plotted in green beneath. Points to the
right of the line favour the reference treatment (shown in green text).
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The between-treatment SD was estimated to be 0.18 (95% CrI 0.01 to 0.86), which is indicative of mild
heterogeneity in treatment effects between treatments (i.e. the effects of the bisphosphonates are
relatively similar) but with considerable uncertainty.
All treatments were associated with beneficial treatment effects relative to placebo, and all treatment
effects were statistically significant at a conventional 5% level. Zoledronic acid was associated with the
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FIGURE 45 Vertebral fractures: class-effects model – probability of treatment rankings. (a) Placebo, mean
rank = 5.99; (b) risedronic acid, mean rank = 3.89; (c) alendronic acid, mean rank = 2.91; (d) zoledronic acid,
mean rank = 2.08; (e) 150mg per month of ibandronic acid, mean rank = 2.97; and (f) 2.5 mg per day of ibandronic
acid, mean rank = 3.16.
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greatest effect (HR 0.41, 95% CrI 0.28 to 0.56) and was most likely to be the most effective treatment
(probability of 0.44 of being the most effective). Pairwise comparisons between treatments indicated that
no active treatments are significantly more effective than other active treatments. The HR for a randomly
chosen study for a new bisphosphonate is 0.45 (95% CrI 0.19 to 1.12), allowing for both between-study
and between-treatment heterogeneity.
The effect of baseline risk as a potential treatment effect modifier was explored using metaregression. The
model fitted the data well, with a total residual deviance of 41.11 (compared with 42 data points). The
between-study SD was estimated to be 0.21 (95% CrI 0.02 to 0.57) and the between-treatment SD was
estimated to be 0.18 (95% CrI to 0.01 to 0.92). The between-study SD from fitting a random-effects
model to the placebo baseline data was 1.23 (95% CrI 0.86 to 1.90), indicating substantial heterogeneity
between RCTs. However, there was no evidence that treatment effect varied according to baseline risk,
with the interaction term estimated to be 0.02 (95% CrI –0.25 to 0.22). In fact, including baseline risk did
not improve the fit of the model to the data according to a comparison of DICs (70.53 vs. 69.28), and
actually increased the estimate of the between-study SD of the treatment effect. Exchangeable and related
treatment–specific interactions were also considered. The model did not provide a better fit to the data,
with a DIC of 71.50.
Non-vertebral fractures: class-effects model
An NMA was used to compare the effects of alendronic acid, risedronic acid, zoledronic acid, 150 mg per
month of oral ibandronic acid and 2.5 mg per day of oral ibandronic acid relative to placebo on the
occurrence of non-vertebral fractures. Data were available from 14 RCTs,45,55–57,64,66,70,72,77,81,83–85,89 each
comparing two treatments. Figure 46 presents the network of evidence for non-vertebral fractures.
As the network provided no indirect evidence, an assessment of inconsistency was not performed.
Figure 47 presents the effects of each treatment relative to placebo. The probabilities of treatment
rankings are presented in Figure 48. The model fitted the data well, with a total residual deviance of 22.80
compared with the number of data points included in the analysis, which was 28. The DIC was 42.32.
The between-study SD was estimated to be 0.08 (95% CrI 0.00 to 0.31), implying mild heterogeneity in
treatment effects between RCTs.
Placebo
Risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
One study
Two studies
Five studies
FIGURE 46 Non-vertebral fractures: network of evidence.
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The between-treatment SD was estimated to be 0.17 (95% CrI 0.01 to 0.80), which is indicative of mild
heterogeneity in treatment effects between treatments (i.e. the effects of the bisphosphonates are
relatively similar) but with considerable uncertainty.
All treatments were associated with beneficial treatment effects relative to placebo, with risedronic acid,
alendronic acid and zoledronic acid being statistically significant at a conventional 5% level. Risedronic acid
was associated with the greatest effect (HR 0.72, 95% CrI 0.53 to 0.89) and was most likely to be the
most effective treatment (with a probability of being the most effective of 0.46). No active treatments were
statistically significantly more effective than other active treatment. The HR for a randomly chosen study
for a new bisphosphonate is 0.79 (95% CrI 0.38 to 1.69), allowing for both between-study and
between-treatment heterogeneity.
Versus placebo
Risedronic acid 0.72 (0.53 to 0.89)
0.71 (0.49 to 1.02)
0.80 (0.65 to 0.94)
0.80 (0.54 to 1.07)
0.75 (0.61 to 0.91)
0.75 (0.53 to 1.05)
0.80 (0.53 to 1.36)
0.80 (0.49 to 1.43)
0.91 (0.67 to 1.35)
0.92 (0.59 to 1.43)
0.79 (0.58 to 1.11)
0.79 (0.38 to 1.69)
Versus risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Bisphosphonate
Alendronic acid 1.09 (0.86 to 1.55)
1.12 (0.67 to 1.79)
1.04 (0.80 to 1.45)
1.05 (0.66 to 1.74)
1.09 (0.76 to 2.07)
1.12 (0.64 to 2.27)
1.26 (0.92 to 2.16)
1.29 (0.72 to 2.35)
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus alendronic acid
Zoledronic acid 0.95 (0.74 to 1.21)
0.94 (0.61 to 1.55)
1.01 (0.67 to 1.68)
1.01 (0.58 to 1.89)
1.13 (0.88 to 1.74)
1.15 (0.69 to 1.97)
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus zoledronic acid
Ibandronic acid 150 mg/month 1.05 (0.70 to 1.87)
1.07 (0.61 to 2.07)
1.20 (0.90 to 1.90)
1.23 (0.71 to 2.11)
Versus ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day 1.08 (0.72 to 2.01)
1.11 (0.62 to 2.19)
Ibandronic acid 2.5 mg/day
– 0.25 0.31 0.88 1.44 2.00
Treatment comparison HR (95% Crl)
FIGURE 47 Non-vertebral fractures: class-effects model – HRs and 95% CrIs. Note that the mean effect estimates
are plotted in black; predictive effects in a new study are plotted in green beneath. Points to the right of the line
favour the reference treatment (shown in green text).
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The effect of baseline risk as a potential treatment effect modifier was explored using metaregression. The
model fitted the data well, with a total residual deviance of 23.65 (compared with 28 data points).
The between-study SD was estimated to be 0.11 (95% CrI 0.01 to 0.37) and the between-treatment SD
was estimated to be 0.17 (95% CrI 0.01 to 0.81). The between-study SD from fitting a random-effects
model to the placebo baseline data was 0.48 (95% CrI 0.32 to 0.83), indicating moderate heterogeneity
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FIGURE 48 Non-vertebral fractures: class-effects model – probability of treatment rankings. Note that the most
efficacious = 1, and the least efficacious = 6. (a) Placebo, mean rank = 5.52; (b) risedronic acid, mean rank = 2;
(c) alendronic acid, mean rank = 3.14; (d) zoledronic acid, mean rank = 2.46; (e) 150mg per month of ibandronic
acid, mean rank = 3.34; and (f) 2.5 mg per day of ibandronic acid, mean rank = 4.55.
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between RCTs. However, there was no evidence that treatment effect varied according to baseline risk,
with the interaction term estimated to be –0.07 (95% CrI –0.44 to 0.22). In fact, including baseline risk did
not improve the fit of the model to the data according to a comparison of DICs (44.27 vs. 44.32), and
actually increased the estimate of the between-study SD of the treatment effect. Exchangeable and related
treatment-specific interactions were also considered. The model did not provide a better fit to the data,
with a DIC of 45.84.
Hip fractures: class-effects model
A NMA was used to compare the effects of alendronic acid, risedronic acid, zoledronic acid and 150 mg
per month of oral ibandronic acid relative to placebo on the occurrence of hip fractures. Data were
available from 10 RCTs,55,56,64,68,70,74,77,78,82,85 each comparing two treatments. Figure 49 presents the
network of evidence for hip fractures.
Figure 50 presents the effects of each treatment relative to placebo. The probabilities of treatment
rankings are presented in Figure 51. The model fitted the data well, with a total residual deviance of 18.46
(compared with the total number of data points included in the analysis of 18). The DIC was 33.82. The
between-study SD was estimated to be 0.43 (95% CrI 0.23 to 0.74), implying moderate heterogeneity in
treatment effects between RCTs.
The between-treatment SD was estimated to be 0.19 (95% CrI 0.01 to 0.61), which is indicative of mild
heterogeneity in treatment effects between treatments (i.e. the effects of the bisphosphonates are
relatively similar) but with reasonable uncertainty.
All treatments were associated with beneficial treatment effects relative to placebo, although the
treatment effects were not statistically significant at a conventional 5% level. Alendronic acid was
associated with the greatest effect, with a HR of 0.79 (95% CrI 0.44 to 1.30) and was most likely to be
the most effective treatment (probability 0.36 of being the most effective). The HR for a randomly chosen
study for a new bisphosphonate is 0.85 (95% CrI 0.26 to 2.77).
Placebo
Risedronic acid
Alendronic acidZoledronic acid
Ibandronic acid 150 mg/month One study
Two studies
Three studies
FIGURE 49 Hip fractures: network of evidence. Owing to the limited power of indirect evidence, assessment for
inconsistency was not performed.
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The effect of baseline risk as a potential treatment effect modifier was explored using metaregression.
For the model using standard reference priors there was evidence of poor convergence, and so weakly
informative priors were used for placebo arms of two RCTs.74,82 The model fitted the data well, with a total
residual deviance of 18.78 (compared with 18 data points). The between-study SD was estimated to be
0.40 (95% CrI 0.06 to 0.75) and the between-treatment SD was estimated to be 0.19 (95% CrI 0.01 to
0.63). The between-study SD from fitting a random-effects model to the placebo baseline data was 0.46
(95% CrI 0.23 to 1.05), indicating moderate heterogeneity between RCTs. However, there was no
evidence that treatment effect varied according to baseline risk, with the interaction term estimated to be
0.43 (95% CrI –0.79 to 1.67). In fact, including baseline risk did not improve the fit of the model to the
data according to a comparison of DICs (33.48 vs. 33.82), and actually increased the estimate of the
between-study SD of the treatment effect. Exchangeable and related treatment-specific interactions were
also considered but did not provide a better fit to the data.
Versus placebo
Risedronic acid 0.81 (0.49 to 1.32)
0.82 (0.28 to 2.37)
0.79 (0.44 to 1.30)
0.78 (0.26 to 2.28)
0.92 (0.56 to 1.60)
0.94 (0.32 to 2.72)
0.87 (0.43 to 1.98)
0.87 (0.27 to 2.92)
0.85 (0.51 to 1.44)
0.85 (0.25 to 2.8)
0.98 (0.53 to 1.60)
0.95 (0.23 to 4.03)
1.08 (0.72 to 2.22)
1.15 (0.27 to 4.84)
1.03 (0.56 to 2.47)
1.07 (0.25 to 4.92)
1.11 (0.75 to 2.49)
1.21 (0.28 to 5.12)
1.05 (0.59 to 2.83)
1.12 (0.26 to 5.17)
0.98 (0.43 to 1.90)
0.93 (0.22 to 4.22)
Versus risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Bisphosphonate
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Versus alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Versus zoledronic acid
Ibandronic acid 150 mg/month
0.00 0.75 1.50 3.002.25
Treatment comparison HR (95% Crl)
FIGURE 50 Hip fractures: class-effects model – HRs and 95% CrIs. Note that the mean effect estimates are plotted
in black; predictive effects in a new study are plotted in green beneath. Points to the right of the line favour the
reference treatment (shown in green text).
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Wrist fractures: class-effects model
A NMA was used to compare the effects of alendronic acid, risedronic acid, zoledronic acid and 150 mg
per month of oral ibandronic acid relative to placebo on the occurrence of wrist fractures. Data were
available from seven RCTs,55,64,70,74,80,82,85 each comparing two treatments. Figure 52 presents the network
of evidence for wrist fractures.
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FIGURE 51 Hip fractures: class-effects model. Probability of treatment rankings. Note that the most efficacious = 1
and the least efficacious = 6. (a) Placebo, mean rank = 3.97; (b) risedronic acid, mean rank = 2.5; (c) alendronic acid,
mean rank = 2.25; (d) zoledronic acid, mean rank = 3.34; and (e) 150mg per month of oral ibandronic acid, mean
rank = 2.95.
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Owing to the limited indirect evidence, an assessment for inconsistency was not performed. Figure 53
presents the effects of each treatment relative to placebo. The probabilities of treatment rankings are
presented in Figure 54. The model fitted the data well, with a total residual deviance of 13.32 (compared
with the total number of data points included in the analysis of 12). The DIC was 23.23. The between-study
SD was estimated to be 0.28 (95% CrI 0.03 to 0.66), implying mild to moderate heterogeneity in treatment
effects between RCTs.
Placebo
Risedronic acid
Alendronic acid
Ibandronic acid 150 mg/month
One study
Two studies
FIGURE 52 Wrist fractures: network of evidence.
Versus placebo
Risedronic acid
Versus risedronic acid
Alendronic acid
Ibandronic acid 150 mg/month
Bisphosphonate
Alendronic acid
Ibandronic acid 150 mg/month
Versus alendronic acid
Ibandronic acid 150 mg/month
0.77 (0.44 to 1.24)
0.76 (0.32 to 1.78)
0.83 (0.51 to 1.29)
0.83 (0.34 to 1.86)
0.82 (0.41 to 1.88)
0.83 (0.31 to 2.39)
0.80 (0.46 to 1.44)
0.81 (0.28 to 2.34)
1.04 (0.68 to 1.91)
1.08 (0.35 to 3.23)
1.03 (0.60 to 2.53)
1.07 (0.34 to 3.77)
1.00 (0.52 to 2.17)
1.00 (0.32 to 3.42)
0.00 0.75 1.50 3.002.25
Treatment comparison HR (95% Crl)
FIGURE 53 Wrist fractures: class-effects model – HRs and 95% CrIs. Note that the mean effect estimates are plotted
in black; predictive effects in a new study are plotted in green beneath. Points to the right of the line favour the
reference treatment (shown in green text).
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The between-treatment SD was estimated to be 0.17 (95% CrI 0.01 to 0.62), which is indicative of mild
heterogeneity in treatment effects between treatments (i.e. the effects of the bisphosphonates are
relatively similar) but with reasonable uncertainty.
All treatments were all associated with beneficial treatment effects relative to placebo, although the
treatment effects were not statistically significant at a conventional 5% level. Risedronic acid was
associated with the greatest effect, with a HR of 0.77 (95% CrI 0.39 to 1.28), and was most likely to be
the most effective treatment (probability of 0.42 of being the most effective). No active treatment was
statistically significantly more effective than another active treatment. The HR for a randomly chosen study
for a new bisphosphonate was 0.81 (95% CrI 0.28 to 2.34).
The effect of baseline risk as a potential treatment effect modifier was explored using metaregression.
For the model using standard reference priors there was evidence of poor convergence, and so weakly
informative priors were used for placebo arms of two RCTs.79,82 The model fitted the data well, with a total
residual deviance of 15.21 (compared with 12 data points). The between-study SD was estimated to be
0.35 (95% CrI 0.04 to 0.75) and the between-treatment SD was estimated to be 0.17 (95% CrI 0.01 to
0.61). The between-study SD from fitting a random-effects model to the placebo baseline data was 0.44
(95% CrI 0.12 to 1.52), indicating moderate heterogeneity between RCTs. However, there was no
evidence that treatment effect varies according to baseline risk, with the interaction term estimated to be
–0.40 (95% CrI –2.58 to 1.38). In fact, including baseline risk did not improve the fit of the model to
the data according to a comparison of DICs (25.85 vs. 23.23), and actually increased the estimate of the
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FIGURE 54 Wrist fractures: class-effects model. Probability of treatment rankings. Note that the most
efficacious = 1 and the least efficacious = 6. (a) Placebo, mean rank = 3.44; (b) risedronic acid, mean rank = 1.9;
(c) alendronic acid, mean rank = 2.3; and (d) 150mg per month oral ibandronic acid mean rank = 2.35.
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between-study SD of the treatment effect. Exchangeable and related treatment-specific interactions were
also considered, but did not provide a better fit to the data.
Femoral neck bone mineral density: class-effects model
An NMA was used to compare the effects of alendronic acid, risedronic acid, zoledronic acid, 2.5 mg per
day of oral ibandronic acid, 150 mg per month of oral ibandronic acid and 3 mg every 3 months of i.v.
ibandronic acid relative to placebo, on the percentage change in femoral neck BMD. Data were available
from 35 RCTs,45,47,49,53,55–59,62–68,70,72,73,75–77,79–81,83–88,90–92,95 each comparing two treatments. An assessment of
inconsistency between direct and indirect evidence is presented in Figure 55. The network provided
21 direct treatment comparisons (edges in the network diagram). For 12 of these comparisons there is no
direct evidence, leaving nine treatment comparisons to assess for consistency.
Figure 56 presents the network of evidence for femoral neck BMD. Nine RCTs55,56,64,68,72,76,85,87,90 presented
summary statistics for each treatment group in graphical format while presenting the mean differences in
percentage change in femoral neck BMD between treatments numerically in the text. A comparison of the
numerical results and the graphically extracted results is presented in Figure 57, showing generally good
but not identical correspondence between the two sample estimates.
An assessment of inconsistency between direct and indirect evidence is presented in Figure 55. The
network provided 21 direct treatment comparisons (edges in the network diagram). For 12 of these
comparisons there is no direct evidence, leaving nine treatment comparisons to assess for consistency.
Figure 58 presents the effects of each treatment relative to placebo on percentage change in femoral neck
BMD. The probabilities of treatment rankings are presented in Figure 59. The model fitted the data well,
with a total residual deviance of 53.65 (compared with the number of data points included in the analysis
of 59). The DIC was 96.5. The between-study SD was estimated to be 0.53 (95% CrI 0.30 to 0.86),
implying moderate heterogeneity in treatment effects between RCTs.
The between-treatment SD was estimated to be 0.56 (95% CrI 0.19 to 1.70), which is indicative of
moderate heterogeneity in treatment effects between RCTs (i.e. the effects of the bisphosphonates are
more dissimilar) but with considerable uncertainty.
The estimated interaction term for duration of study, assuming a common interaction for each treatment,
was 0.89 (95% CrI 0.48 to 1.18). The estimated interaction term implies that treatment effects increase
with duration of study. Exchangeable and related treatment-specific interactions were also considered.
The model did not provide a better fit to the data (DIC = 97.36).
All treatments were associated with a beneficial effect relative to placebo on percentage change in femoral
neck BMD, and all treatment effects were statistically significant at a conventional 5% level. Zoledronic
acid was associated with the greatest effect, with a treatment effect of 3.21 (95% CrI 2.52 to 3.86), and
was most likely to be the most effective treatment (a probability of 0.48 of being the most effective). The
treatment effect for a randomly chosen study for a new bisphosphonate is 2.79 (95% CrI 0.72 to 4.75),
allowing for both between-study and between-treatment heterogeneity.
The sample mean ages of the participants in each study ranged from 50.5 to 78.5 years, with an overall
mean of 64.1 years. The effect of age as a potential treatment effect modifier was explored using
metaregression. The model fitted the data well, with a total residual deviance of 53.97 (compared with
59 data points). The DIC was 97.99, suggesting that including age as a covariate in the model did not
improve the model fit. The between-study SD was estimated to be 0.55 (95% CrI 0.31 to 0.88), and the
between-treatment SD was estimated to be 0.56 (95% CrI 0.18 to 1.73). The interaction term for study
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FIGURE 55 Femoral neck BMD: class-effects model – assessing inconsistency using node splitting. (a) Nodes 1 and 2,
placebo–alendronic acid; (b) nodes 1–3, placebo–risedronic acid; (c) nodes 1–4, placebo–zoledronic acid; (d) nodes 1–5,
placebo–150mg per month of oral ibandronic acid; (e) nodes 1–6, placebo–2.5 mg per day of oral ibandronic acid;
(f) nodes 2–3, alendronic acid–risedronic acid; (g) nodes 2–5, alendronic acid–2.5mg per day of oral ibandronic acid;
(h) nodes 3–4, risedronic acid–zoledronic acid; and (i) nodes 5–6, 150mg per month of oral ibandronic acid –2.5mg
per day of oral ibandronic acid. RE, random effects. (continued )
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FIGURE 55 Femoral neck BMD: class-effects model – assessing inconsistency using node splitting. (a) Nodes 1 and 2,
placebo–alendronic acid; (b) nodes 1–3, placebo–risedronic acid; (c) nodes 1–4, placebo–zoledronic acid; (d) nodes 1–5,
placebo–150mg per month of oral ibandronic acid; (e) nodes 1–6, placebo–2.5 mg per day of oral ibandronic acid;
(f) nodes 2–3, alendronic acid–risedronic acid; (g) nodes 2–5, alendronic acid–2.5mg per day of oral ibandronic acid;
(h) nodes 3–4, risedronic acid–zoledronic acid; and (i) nodes 5–6, 150mg per month of oral ibandronic acid –2.5mg
per day of oral ibandronic acid. RE, random effects.
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FIGURE 56 Bone mineral density: network of evidence.
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FIGURE 57 Mean difference in percentage change in femoral neck BMD between treatments. Comparison of
reported vs. computed (from graph estimates) values.
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Versus placebo
Alendronic acid 3.11 (2.69 to 3.53)
3.11 (1.90 to 4.32)
2.37 (1.90 to 2.84)
2.37 (1.16 to 3.60)
3.21 (2.52 to 3.86)
3.22 (1.86 to 4.43)
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FIGURE 58 Femoral neck BMD: class-effects model – treatment effects and 95% CrIs. Note that the mean effect
estimates are plotted in black; predictive effects in a new study are plotted in green beneath. Points to the left of
the line favour the reference treatment (shown in green text). Treatment effects (TE) represent percentage change
in BMD for a study of average duration (1.8 years).
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FIGURE 59 Femoral neck BMD: class-effects model. Probability of treatment rankings. Note that the most efficacious= 1
and the least efficacious= 6. (a) alendronic acid, mean rank = 2.13; (b) risedronic acid, mean rank = 5.14; (c) zoledronic
acid, mean rank = 1.9; (d) ibandronic acid, mean rank = 3.48; (e) 2.5mg per day of oral ibandronic acid, mean rank
= 5.18; (f) 3mg per 3 months of oral ibandronic acid, mean rank = 3.16; and (g) placebo, mean rank = 7.
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duration in this model was 0.86 (95% CrI 0.47 to 1.25). There was no evidence that treatment effect
varied according to age, with the interaction term estimated to be 0.01 (95% CrI –0.04 to 0.06). A model
in which the treatment effect modifier for age was treated as separate but related (i.e. exchangeable) for
each treatment was fitted, but this did not improve the model fit, with a DIC of 98.86.
Of the 35 RCTs included in the network, six RCTs58,59,62,73,83,95 included only male participants, 26 only
female participants45,47,49,53,55–57,63–68,70,72,75,76,79–81,84–87,90,92 and three included both.77,88,91 A metaregression was
conducted to test for different treatment effects according to the proportion of male participants. In line
with the licensing indications, interaction terms were not included for ibandronic acid treatments that are
not licensed in men. The model fitted the data well, with a total residual deviance of 55.98 (compared
with 59 data points). The between-study SD was estimated to be 0.51 (95% CrI 0.24 to 0.87). The
between-treatment SD was estimated to be 0.45 (95% CrI 0.20 to 0.79) and the interaction term for study
duration in this model was 0.81 (95% CrI 0.48 to 1.14). There was no evidence that treatment effect
varied according to sex, with the interaction term estimated to be –0.79 (95% CrI –1.64 to 0.14). In fact,
including sex did not improve the fit of the model to the data according to a comparison of DICs (98.24
vs. 96.5). Exchangeable and related treatment-specific interactions were also considered; the model did not
provide a better fit to the data, with a DIC of 99.30.
The relationship between baseline response and treatment effect was also assessed. For the class-effects
model with baseline response adjustment, there was evidence for poor convergence using standard
reference priors, and so weakly informative priors were used for placebo arms of the RCTs with active
treatment. The model fitted the data well, with a total residual deviance of 55.25 and DIC of 99.33.
The between-study SD was estimated to be 0.51 (95% CrI 0.49 to 0.97) and the between-treatment SD
was estimated to be 0.50 (95% CrI 0.19 to 1.38).
The between-study SD from fitting a random-effects model to the placebo baseline data was 1.05
(95% CrI 0.61 to 1.78). There was evidence of an interaction between baseline response and treatment
effect, with the interaction term estimated to be –0.46 (95% CrI –0.76 to –0.13). Figure 57 presents the
relationship between baseline response and treatment effect assuming a common interaction for each
treatment. Including baseline response did not improve the fit of the model to the data according to a
comparison of DICs, but did reduce the estimate of the between-study SD of the treatment effect.
Exchangeable and related treatment-specific interactions were also considered. The model did not provide
a better fit to the data, with a DIC of 100.43.
Sensitivity analysis 1
Sensitivity analysis 1 was conducted by excluding RCTs for which participants were switched from 5 mg per
day of alendronic acid to 10 mg per day during the course of the study.55,64 This affected the networks for
vertebral and non-vertebral outcomes only.
Sensitivity analysis 1: vertebral outcomes – class-effects model A NMA was used to compare the
effects of alendronic acid, risedronic acid, zoledronic acid, 150 mg per month of oral ibandronic acid and
2.5 mg per day of oral ibandronic acid relative to placebo on the occurrence of vertebral fractures. Data
were available from 19 RCTs comparing two treatments.45,56,58–60,63,65,66,70,72,76,77,81–83,85,86,88,89 The network of
evidence is the same as that presented in Figure 42, except for the exclusion of the two alendronic acid
RCTs,55,64 so that the modified network contains only four direct estimates between placebo and
alendronic acid rather than six. Figure 60 presents the effects of each treatment relative to placebo. The
model fitted the data well, with a total residual deviance of 36.78 (compared with the total number of
data points included in the analysis of 38). The between-study SD was estimated to be 0.23 (95% CrI 0.02
to 0.59) and the between-treatment SD was estimated to be 0.20 (95% CrI 0.01 to 0.96). On exclusion of
the two RCTs,55,64 a treatment effect of 0.45 (95% CrI 0.28 to 0.68) was estimated for alendronic acid.
The estimated treatment effect was the same as before, but with an increase in uncertainty.
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Sensitivity analysis 1: non-vertebral outcomes An NMA was used to compare the effects of alendronic
acid, risedronic acid, zoledronic acid, 150 mg per month of oral ibandronic acid and 2.5 mg per day of
oral ibandronic acid relative to placebo on the occurrence of non-vertebral fractures. Data were available
from 12 RCTs comparing two treatments.45,56,57,66,70,72,77,81,83–85,89 The network of evidence is the same as
that presented in Figure 46, except for the exclusion of the two alendronic acid RCTs,55,64 so that the
modified network contains only three direct estimates between placebo and alendronic acid rather than
five. Figure 61 presents the effects of each treatment relative to placebo. The model fitted the data well,
with a total residual deviance of 18.02 (compared with the total number of data points included in
the analysis of 24). The between-study SD was estimated to be 0.10 (95% CrI 0.00 to 0.38) and the
between-treatment SD was estimated to be 0.23 (95% CrI 0.01 to 1.00). On exclusion of the two
RCTs,55,64 a more pronounced treatment effect of 0.68 (95% CrI 0.45 to 0.94) is observed for alendronic
acid, compared with a value of 0.80 (95% CrI 0.65 to 0.94) estimated in the main analyses, Non-vertebral
fractures: class-effects model, and there is an increase in uncertainty.
Versus placebo
Risedronic acid 0.50 (0.36 to 0.67)
0.51 (0.24 to 0.94)
0.45 (0.28 to 0.68)
0.45 (0.21 to 0.91)
0.41 (0.27 to 0.58)
0.40 (0.20 to 0.83)
0.45 (0.22 to 0.84)
0.45 (0.18 to 1.03)
0.46 (0.30 to 0.70)
0.47 (0.22 to 0.95)
0.45 (0.29 to 0.68)
0.45 (0.16 to 1.23)
Versus risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Bisphosphonate
Alendronic acid 0.93 (0.53 to 1.37)
0.90 (0.34 to 2.40)
0.84 (0.50 to 1.19)
0.80 (0.33 to 2.31)
0.94 (0.42 to 1.67)
0.90 (0.30 to 2.57)
0.95 (0.57 to 1.45)
0.92 (0.36 to 2.52)
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus alendronic acid
Zoledronic acid 0.94 (0.52 to 1.44)
0.90 (0.35 to 2.52)
1.00 (0.51 to 1.93)
1.00 (0.35 to 2.90)
1.01 (0.62 to 1.83)
1.03 (0.38 to 2.83)
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus zoledronic acid
Ibandronic acid 150 mg/month 1.05 (0.58 to 2.34)
1.09 (0.36 to 3.21)
1.10 (0.73 to 2.01)
1.15 (0.41 to 3.00)
Versus ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day 1.01 (0.52 to 2.22)
1.03 (0.35 to 3.14)
Ibandronic acid 2.5 mg/day
– 0.25 0.31 0.88 1.44 2.00
Treatment comparison HR (95% Crl)
FIGURE 60 Sensitivity 1: vertebral outcomes – class-effects model (HRs and 95% CrIs). Note that the mean effect
estimates are plotted in black; predictive effects in a new study are plotted in green beneath. Points to the right of
the line favour the reference treatment (shown in green text).
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Sensitivity analysis 2
Sensitivity analysis 2 assessed vertebral fractures, including only the RCTs that used clinical/symptomatic
assessment techniques. The network provides two comparisons for placebo against zoledronic acid and
one comparison of placebo against risedronic acid.
Figure 62 presents the effects of each treatment relative to placebo. The model fitted the data well,
with a total residual deviance of 6.32 being close to the six data points included in the analysis and a
DIC of 11.68. The between-study SD was estimated to be 0.29 (95% CrI 0.02 to 0.72) and the
between-treatment SD was estimated to be 0.18 (95% CrI 0.01 to 0.64). Both treatments are associated
with beneficial treatment effects relative to placebo, significant at the 5% level. The HR for risedronic acid
is 0.35 (95% CrI 0.17 to 0.72), compared with the HR of 0.50 (95% CrI 0.38 to 0.67) for all vertebral
fractures. For zoledronic acid, the estimated HR is 0.34 (95% CrI 0.20 to 0.61), compared with 0.41
(95% CrI 0.28 to 0.56) for all vertebral fractures. No evidence was observed to suggest differential
treatment effects according to assessment method.
Versus placebo
Risedronic acid
Versus risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 2.5 mg/day
Bisphosphonate
Alendronic acid
Zoledronic acid
Zoledronic acid
Ibandronic acid 2.5 mg/day
Versus alendronic acid
Ibandronic acid 2.5 mg/day
Ibandronic acid 2.5 mg/day
0.69 (0.53 to 0.89)
0.69 (0.45 to 1.07)
0.68 (0.45 to 0.94)
0.68 (0.40 to 1.10)
0.74 (0.59 to 0.92)
0.74 (0.48 to 1.11)
0.88 (0.62 to 1.32)
0.89 (0.51 to 1.44)
0.74 (0.36 to 1.50)
0.99 (0.63 to 1.43)
0.98 (0.52 to 1.80)
1.05 (0.81 to 1.47)
1.06 (0.59 to 1.86)
1.26 (0.90 to 2.11)
1.29 (0.64 to 2.42)
1.06 (0.78 to 1.69)
1.09 (0.59 to 2.06)
1.27 (0.89 to 2.43)
1.31 (0.65 to 2.71)
1.18 (0.87 to 1.85)
1.22 (0.62 to 2.18)
Versus zoledronic acid
– 0.25 0.31 0.88 2.001.44
Treatment comparison HR (95% Crl)
FIGURE 61 Sensitivity 1: non-vertebral outcomes – class-effects model (HRs and 95% CrIs). Note that the mean
effect estimates are plotted in black; predictive effects in a new study are plotted in green beneath. Points to the
right of the line favour the reference treatment (shown in green text).
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Sensitivity analysis 3
Sensitivity analysis 3 assessed percentage change in femoral neck BMD, excluding the RCTs for which only
graphically extracted results were available.47,49,58,67 An NMA was used to compare the effects of alendronic
acid, risedronic acid, zoledronic acid, 2.5 mg per day of oral ibandronic acid and 150 mg per month of oral
ibandronic acid relative to placebo on the percentage change in femoral neck BMD. Data were available
from 31 RCTs,45,53,55–57,59,62,66,68,70,72,73,75–77,79–81,83–88,90–92,95 each comparing two treatments. Figure 63 presents
the network of evidence for femoral neck BMD.
Figure 64 presents the effects of each treatment relative to placebo. The model fitted the data well, with a
total residual deviance of 46.41 (compared with the number of data points included in the analysis of 55).
The DIC was 81.56. The between-study SD was estimated to be 0.43 (95% CrI 0.16 to 0.77), implying
moderate heterogeneity in treatment effects between RCTs. The between-treatment SD was estimated to
be 0.65 (95% CrI 0.15 to 2.81). The estimated interaction term for duration of study, assuming a common
interaction for each treatment, was 0.86 (95% CrI 0.55 to 1.18).
One study
Three studies
Four studies
Nine studies
Eleven studies
Ibandronic acid 150 mg/month
Zoledronic acid
Risedronic acid
Alendronic acid
Placebo
Ibandronic acid 2.5 mg/day
FIGURE 63 Sensitivity analysis 3: femoral neck BMD excluding graphically extracted results – network of evidence.
Treatment comparison HR (95% Crl)
Versus placebo
Versus risedronic acid
Risedronic acid 0.35 (0.17 to 0.72)
0.35 (0.12 to 0.98)
Zoledronic acid 0.34 (0.20 to 0.61)
0.34 (0.13 to 0.88)
Zoledronic acid 0.99 (0.51 to 1.78)
0.98 (0.28 to 3.16)
– 0.25 0.31 0.88 1.44 2.00
FIGURE 62 Sensitivity 2: clinically assessed vertebral outcomes – class-effects model (HRs and 95% CrIs).
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All treatments were still associated with a beneficial effect relative to placebo, and all treatment effects
were statistically significant at a conventional 5% level. As in the full NMA presented in Femoral neck bone
mineral density: class-effects model, zoledronic acid was associated with the greatest effect, with a
treatment effect of 3.37 (95% CrI 2.69 to 3.97).
Discussion
A total of 46 RCTs were identified that provided data for the clinical effectiveness systematic
review.45,47,49,53–95 Alendronic acid was evaluated against placebo in 17 RCTs,53,55,57,60,61,64,65,67,71,73,76,83,
84,91,93,94,98 while 2.5 mg per day of oral ibandronic acid was evaluated against placebo in three RCTs45,47,49
Versus placebo
Alendronic acid 3.16 (2.77 to 3.54)
3.16 (2.11 to 4.18)
2.56 (2.10 to 3.00)
2.56 (1.47 to 3.60)
3.37 (2.69 to 3.97)
3.40 (2.14 to 4.41)
2.87 (2.13 to 3.54)
2.87 (1.68 to 4.03)
2.39 (0.44 to 3.48)
2.34 (0.31 to 3.88)
2.87 (1.69 to 3.82)
2.88 (0.18 to 5.31)
Versus alendronic acid
Risedronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Bisphosphonate
Risedronic acid – 0.59 (– 1.10 to – 0.09)
– 0.60 (– 2.02 to 0.86)
0.21 (– 0.49 to 0.84)
0.24 (– 1.38 to 1.61)
– 0.28 (– 1.01 to 0.35)
– 0.29 (– 1.81 to 1.22)
– 0.76 (– 2.73 to 0.32)
– 0.84 (– 3.08 to 1.01)
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus risedronic acid
Zoledronic acid 0.81 (0.04 to 1.47)  
0.84 (– 0.80 to 2.24)
0.29 (– 0.44 to 1.07)
0.31 (– 1.25 to 1.87)
– 0.16 (– 2.08 to 0.94)
– 0.24 (– 2.43 to 1.61)
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus zoledronic acid
Ibandronic acid 150 mg/month – 0.50 (– 1.38 to 0.37)
– 0.53 (– 2.04 to 1.19)
– 0.97 (– 3.05 to 0.24)
– 1.05 (– 3.33 to 0.95)
Versus ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day – 0.46 (– 2.50 to 0.69)
– 0.53 (– 2.81 to 1.36)
Ibandronic acid 2.5 mg/day
– 2.50 – 0.62 1.25 3.12 5.00
Treatment comparison TE (95% Crl)
FIGURE 64 Sensitivity analysis 3: femoral neck BMD excluding graphically extracted results – class-effects model
[treatment effects (TEs) and 95% CrIs]. Note that the mean effect estimates are plotted in black; predictive effects
in a new study are plotted in green beneath. Treatment effects to the left of the reference line favour the
comparator treatment.
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and against 3 mg per 3 months of i.v. ibandronic acid in one RCT.49 Daily administration of 2.5 mg of oral
ibandronic acid was compared with 150 mg per month oral administration in one RCT.47 risedronic acid was
compared with placebo in 12 RCTs58,62,63,66,70,72,75,78,85,86,89,95 and zoledronic acid was compared with placebo
in four RCTs.56,59,77,79 One RCT evaluated alendronic acid compared with 150 mg per month of oral
ibandronic acid,81 five RCTs evaluated alendronic acid compared with risedronic acid,54,82,87,90,92 one RCT
evaluated zoledronic acid compared with alendronic acid69 and one RCT evaluated zoledronic acid
compared with risedronic acid.88 The maximum trial duration was 48 months.64
The risk of bias associated with the included RCTs was assessed using the Cochrane risk-of-bias
instrument. Attrition ≥ 10% across treatment groups was evident for 29 (63%) of the included
RCTs.45,47,49,56,58,59,63,66,69,70,73,76,78–81,83–85,89,91,93,94,111 Five trials were reported as either open label or single blind,
and were considered at high risk of bias of performance bias.53,71,82,92,106 Blinded outcome assessment was
reported by only 13 (28%) trials.55,56,59,64,68,70,76,77,83,87–89,94
The outcome measures prespecified in the final NICE scope23 were addressed by the included trial evidence
to varying degrees. Femoral neck BMD was the most widely reported outcome and fracture was the
second most widely reported outcome. The majority of included trials reported AEs. Across the included
trials there was limited reporting on outcomes of compliance (adherence and persistence), hospitalisation
and service use, and quality of life.
A total of 27 RCTs provided suitable fracture data for inclusion in the fracture NMA:45,55–59,61,63–67,70,72,74,76–78,80–89
nine compared alendronic acid with placebo,55,57,61,64,65,67,76,83,84 two compared 150mg per month of oral
ibandronic acid with placebo,74,80 one compared 2.5 mg per day of oral ibandronic acid with placebo,45 nine
compared risedronic acid with placebo,58,63,66,70,72,78,85,86,89 three compared zoledronic acid with placebo,56,59,77
one compared alendronic acid with risedronic acid;45 one compared 150 mg per month of oral ibandronic
acid with alendronic acid82 and one compared zoledronic acid with risedronic acid.88
A total of 35 RCTs provided suitable femoral neck BMD data for inclusion in the BMD NMA: 45,47,49,53,55–59,62–68,
70,72,73,75–77,79–81,83–88,90–92,95 12 evaluated alendronic acid compared with placebo,53,55,57,64,65,67,68,73,76,83,84,91 one
evaluated 2.5 mg per day of oral ibandronic acid compared with placebo;45 one evaluated 150mg per month
of oral ibandronic acid compared with placebo;80 one evaluated 2.5 mg per day of oral ibandronic acid
compared with 3 mg every 3 months of i.v. ibandronic acid;49 one evaluated 2.5 mg per day of oral
ibandronic acid compared with 150 mg per month of oral ibandronic acid;47 10 evaluated risedronic acid
compared with placebo;58,62,63,66,70,72,75,85,86,95 four evaluated zoledronic acid compared with placebo;56,57,77,79
three evaluated alendronic acid compared with risedronic acid;56,77,79 one evaluated alendronic acid compared
with 150 mg per month of oral ibandronic acid;81 and one evaluated zoledronic acid compared with
risedronic acid.88
Femoral neck BMD may be considered as a surrogate for fracture outcomes. Analysis of the femoral neck
BMD data was of interest in order to confirm that the treatment effects were qualitatively the same.
The analysis provided no evidence to suggest different treatment effects according to age or sex, with
respect to percentage change in femoral neck BMD.
Based on the NMA, all treatments were associated with beneficial effects on each outcome measure relative
to placebo. HRs for fracture varied from 0.41 to 0.92 depending on treatment and fracture site. All
treatments resulted in statistically significant changes (at a conventional 5% level) in both vertebral fractures
and percentage change in femoral neck BMD. Pairwise comparisons between treatments indicated that no
active treatments were statistically significantly different from any other active treatment. For vertebral
fractures and percentage change in femoral neck BMD, zoledronic acid had the greatest effect based on the
midpoint estimates although in general the ranking of treatments varied for the different outcomes.
Assessment of vertebral fractures within the studies was based on both clinical and morphometric
fractures. Ideally, the effect of assessment method would be assessed through metaregression; however,
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data for clinical fractures were limited. Consideration of the studies reporting clinical fractures did not
provide any evidence to suggest different treatment effects according to assessment method.
The main analyses were based on a class-effects model such that the effects of each of the treatments
are assumed to be related but not identical. The treatment effects estimated using the class-effects model
were broadly similar qualitatively (i.e. direction of effect) and quantitatively (i.e. magnitude of effect) to
those estimated using the standard random-effects model, but with the treatment effects in the
class-effects model shrunk towards the overall bisphosphonate treatment effect. The qualitative effects
of treatment (i.e. direction of effect) were the same for the majority of outcome types and treatments from
the class effects and standard random-effects models with the exception of zoledronic acid (hip fractures),
150 mg per month of oral ibandronic acid (hip and wrist fractures) and 2.5 mg per day of oral ibandronic
acid (non-vertebral fractures). Although the point estimates changed from being relative increases in effect
in the standard random-effects model to relative decreases in effect in the class-effects model, there was
considerable uncertainty about the true effects as reflected in the CrIs.
Non-vertebral fractures are used as a proxy for fractures of the proximal humerus, as fractures of the
proximal humerus are not commonly reported. Two studies presented results for proximal humerus
fractures, both considering the effects of risedronic acid against placebo.70,85 A standard random-effects
meta-analysis of these two studies provided a HR of 0.45 (95% CrI 0.13 to 1.41), which was greater than
that estimated for non-vertebral fractures from the standard random-effects NMA, (HR 0.65, 95% CrI
0.47 to 0.88), and from the class-effects NMA (HR 0.71, 95% CrI 0.52 to 0.89), but with considerably
more uncertainty.
There were no statistically significant differences between treatments in the incidence of upper GI events
associated with any oral bisphosphonate compared with placebo when data were pooled across RCTs for
each bisphosphonate. However, evidence from one RCT indicated a statistically significant risk of upper GI
events in men receiving risedronic acid compared with those treated with placebo.58 Where reported
across the RCTs, treatments were prescribed in accordance with the SmPC for oral bisphosphonates to
minimise gastric irritation. There was no evidence of significant differences between treatments in mortality
across the RCT evidence when data were pooled by bisphosphonate. However, evidence from one RCT
indicated that the proportion of men and women dying following hip fracture was significant higher
in the placebo group than in the zoledronic acid group.77 There was also no evidence of significant
between-treatment differences in participants withdrawing because of AEs across the RCT evidence when
data were pooled by bisphosphonate. However, in one RCT the proportion of men withdrawing because
of AEs was significantly higher in the alendronic acid group than in the placebo group.83
In agreement with the SmPC, there was evidence that zoledronic acid is associated with influenza-like
symptoms . There was no statistically significant difference in the incidence of atrial fibrillation between
those treated with zoledronic acid and those receiving placebo56,77 or risedronic acid.88 There was no
statistically significant difference in the incidence of bone pain between those treated with zoledronic acid
and those receiving placebo88 or alendronic acid.88 There was evidence that the risk of eye inflammation in
the first 3 days following drug administration was significantly greater in those receiving zoledronic acid
than in those receiving placebo.102 Evidence from a single RCT indicated that the incidence of stroke over
36 months does not differ significantly among individuals receiving zoledronic acid and those receiving
placebo.77 All RCTs evaluating zoledronic acid reported no cases of spontaneous osteonecrosis of the jaw
in any treatment group during the trial period.
Adverse events of hypocalcaemia and atypical femoral fracture were not reported as outcomes by any RCT
of any bisphosphonate.
A summary of evidence from systematic reviews that include observational data indicates that alendronic
acid, risedronic acid and oral ibandronic acid have similar rates of GI toxicity when compared with placebo.
However, prescription event monitoring study data suggest a high level of reporting of a number of
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conditions in the first month of therapy with alendronic acid or risedronic acid, particularly those affecting
the upper GI tract. Retrospective cohort data also suggest that switching patients who are stabilised on
risedronic acid to alendronic acid is associated with an increased risk of GI AEs. Zoledronic acid may be
compromised by renal toxicity, and myalgias and arthralgias are evident in the acute phase following i.v.
administration. Intravenous bisphosphonates, especially zoledronic acid, are more likely to predispose
patients to osteonecrosis of the jaw. However, in addition to bisphosphonate use, several other factors
appear to be involved in the development of osteonecrosis of the jaw (e.g. dental trauma). There is an
increased risk of atypical fracture among bisphosphonate users, but events are rare, and long-term
bisphosphonate therapy might not be a prerequisite for development of atypical fractures. Moreover, the
use of glucocorticoids and proton pump inhibitors is a potentially important risk factor for atypical fracture.
Bisphosphonates are associated with serious atrial fibrillation, but heterogeneity of the existing evidence
and a paucity of information on some agents preclude any definitive conclusions with respect to risk. The
review evidence for the use of bisphosphonates and oesophogeal cancer is equivocal.
Evidence for persistence and adherence reported by RCTs was very limited. Where reported, high levels
of compliance reported as a pill count were evident over the trial duration. A summary of evidence
from systematic reviews including observational data indicates that, although patients using weekly
bisphosphonate medication follow their prescribed regimens better than those using daily therapy, overall
compliance and persistence rates are suboptimal for postmenopausal women receiving bisphosphonate
therapy for the treatment of osteoporosis. Furthermore, one-third to one-half of patients, including men,
being treated with bisphosphonates for osteoporosis do not take their medication as directed.
With the exception of the RCTs evaluating bisphosphonates in steroid users, the majority of RCTs included
in the clinical effectiveness systematic review typically excluded people with underlying conditions that
affect bone metabolism or people receiving medications that affect bone metabolism. Furthermore,
people with history of, or receiving medication for, upper GI tract disorders were also excluded by the
majority of included trials. Therefore, the effects of alendronic acid, ibandronic acid, risedronic acid and
zoledronic acid are unknown in these populations.
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Chapter 4 Assessment of cost-effectiveness
Systematic review of existing cost-effectiveness evidence
Methods
The review of the published evidence surrounding the cost-effectiveness of bisphosphonates in the
patient groups eligible for risk assessment within CG14616 was started by analysing the likely quantity of
evidence available. A published systematic review by Müller et al.136 included cost-effectiveness studies
of screen-and-treat strategies for preventing osteoporotic fractures published between January 2006
and November 2011. Of the 24 papers included by Müller et al.,136 22 examined the cost-effectiveness
of bisphosphonates. However, only seven of these considered a UK setting.137–143 Given the large
number of published articles identified from this single systematic review, it was decided to limit the
review to those papers reporting cost-effectiveness analyses for a UK setting as they would be more
applicable to the decision problem defined in Chapter 2. None of the consultee submissions contained
a de novo economic evaluation, so the review of existing cost-effectiveness evidence is limited to
published sources.
Identification of studies
A comprehensive search was undertaken until 26 September 2014 to identify papers published in 2006 or
later that evaluated the cost-effectiveness of alendronic acid, risedronic acid, oral ibandronic acid, i.v.
ibandronic acid or zoledronic acid in any of the patient groups eligible for risk assessment within CG146.16
Subject headings and keywords for ‘osteoporosis’ were combined with each of the named interventions
and an economics search filter. The search strategy is provided in Appendix 1.
The following databases were searched:
l MEDLINE In-Process & Other Non-Indexed Citations and MEDLINE (via Ovid) 2006 to
23 September 2014
l EMBASE (via Ovid) 2006 to 23 September 2014
l Cochrane Database of Systematic Reviews (via Wiley Online Library) 2006 to 23 September 2014
l Database of Abstracts of Reviews of Effects (via Wiley Online Library) 2006 to 23 September 2014
l Health Technology Assessment Database (via Wiley Online Library) 2006 to 23 September 2014
l NHS Economic Evaluation Database (via Wiley Online Library) 2006 to 23 September 2014
l EconLit (via Ovid) 2006 to 23 September 2014
l Cumulative Index to Nursing and Allied Health Literature (via EBSCOhost) 2006 to 23 September 2014
l Science Citation Index Expanded (via Web of Science) 2006 to 23 September 2014
l Conference Proceedings Citation Index – Science (via Web of Science) 2006 to 23 September 2014
l Bioscience Information Service (via Web of Science) 2006 to 23 September 2014.
Published economic evaluations cited within the consultee submissions were cross-checked with those
identified from the search.
Inclusions/exclusion criteria
Studies were included in the review if they reported full economic evaluations comparing alendronic acid,
risedronic acid, oral ibandronic acid, i.v. ibandronic acid or zoledronic acid with each other or with no
treatment. Studies were included if any of the population considered would be eligible for risk assessment
within CG146.16 For example, studies on postmenopausal women were included whether or not they
specified that the women had risk factors, as those aged > 65 years would be eligible for risk assessment
under CG146 even without risk factors being present. Studies that did not assess outcomes using QALYs or
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report the incremental cost per QALY of alternative treatment strategies were excluded. Studies that did
not assess the cost-effectiveness of bisphosphonates within a UK setting were also excluded, as discussed
above. Studies that assessed the cost-effectiveness of treatment with bisphosphonates at non-licensed
doses were also excluded, as were studies that used bisphosphonates for other indications, such as the
treatment of Paget’s disease or metastatic bone disease. Studies published prior to 2006 were excluded
on the basis that the estimates of cost-effectiveness from older published studies are unlikely to be
directly applicable to the decision problem outlined in the scope because of the availability of generic
bisphosphonates, which has reduced the price of bisphosphonates over recent years. Studies were
included only if they were reported as full papers, with conference abstracts being excluded from the
review as they present insufficient detail to allow for a rigorous assessment of study quality. Studies not
reported in English were also excluded.
Review methods
The results of the economic searches were sifted by title and abstract by one reviewer (AR). The full papers
of studies that potentially met the inclusion criteria were retrieved for further inspection. Studies included
in the systematic review were examined to determine whether or not they met the NICE reference case.144
They were also critically appraised using the checklist published by Phillips et al.145
Results
The study selection process is summarised in the form of a PRISMA diagram96 in Figure 65.
Potentially relevant health economic studies
identified through the systematic searches
(n = 1058)
Studies excluded at title and
abstract sift
(n = 1013)
Potentially relevant studies retrieved for
detailed inspection
(n = 45)
Relevant economic studies included in the
economic review
(n = 8)
Studies excluded at full paper
stage
(n = 37)E
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FIGURE 65 Flow diagram of study selection process (adapted from PRISMA): cost-effectiveness review.
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Quantity of evidence identified
The search identified 1058 unique articles, of which 1013 were excluded at the title and abstract stage.
A further 37 were excluded at the full-paper stage, with the most common reasons being that they were
conference abstracts presenting limited data. Table 50 in Appendix 7 provides the reasons for exclusion
for those papers that were not excluded based on title or abstract. None of the consultee submissions
identified any published analyses not already picked up through the systematic search.
Study characteristics
The characteristics of the included studies are summarised in Table 6. Six of the included
studies137–141,146 were in postmenopausal women, with the remaining two being in populations with
steroid-induced osteoporosis.142,143
Three studies137–139 compared a single bisphosphonate with no treatment, one study140 compared multiple
bisphosphonate strategies head to head and with no treatment, and four studies141–143,146 compared a
strategy of bisphosphonates with no treatment without specifying the exact bisphosphonate used.
All of the included studies assumed that treatment with bisphosphonates lasts 5 years.
Six studies137–140,142,146 used a Markov model framework, with four137–139,146 using a cohort-level modelling
approach and two140,142 using a patient-level Markov simulation based on the same underlying model.
The remaining two papers141,143 described an individual patient-based pharmacoeconomic model using
patient-level data from two large GP record databases [General Practice Research Database (GPRD) and
The Health Improvement Network].
Two studies140,142 explicitly reported using a NHS and Personal Social Services (PSS) perspective, while a
further three studies137–139 reported using a health-care perspective and one reported a societal
perspective.146 The remaining two studies141,143 did not explicitly report their perspective although many
of the costs used were taken from Stevenson et al.140 which used a NHS and PSS perspective. Discounting
consistent with the current NICE reference case144 (3.5% for both costs and QALYs) was applied in four
of the studies,137–139,146 whereas alternative discounting at rates (6% for costs and 1.5% for QALYs) were
used in the remaining four papers.140–143 The time horizon varied from 6 years to a lifetime horizon or age
of 100 years.
Evidence sources used
The study conducted by Stevenson et al.140 was a systematic review of the literature to estimate the
costs associated with osteoporotic fractures. The remaining studies used various sources including
personal communication and pre-exiting literature, with two studies137,138 quoting the same source,
Stevenson et al.147
For all published cost-effectiveness studies the costs of the pharmaceutical agents were ultimately taken
from the appropriate version of the British National Formulary for their cost year. The costs of case finding,
BMD testing and consultations with GPs were obtained from various sources including the appropriate
versions of the NHS reference costs and the Unit Costs of Health and Social Care or were assumed.
Health-related quality of life was obtained using utility multipliers for fracture states taken from the
literature. The studies use different categories of fracture, with hip fracture, vertebral fracture, forearm/
wrist fracture and humerus fracture being the most common. One study had the additional categories
of pelvic fracture, tibia fracture, clavicle, scapula or sternum fracture and rib fracture.142 Three studies
further split hip fracture into hip fracture leading to nursing home admission and hip fracture not leading
to nursing home admission.140,141,143 Seven studies split utility multipliers for fractures into those for the year
of fracture and those in subsequent years.137–143 The remaining study split multipliers for fractures into
those for the year of fracture and those in the year following fracture and those in subsequent years.146
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TABLE 6 Characteristics of included studies: cost-effectiveness review
Author, year of
study
publication and
location
Population
and
interventions
Type of
evaluation Perspective Time horizon
Cost year
and cost
discount
rate Cost source
Location of
population
and benefits
discount
rate
Benefits
source and
benefits
instrument
Effectiveness
data
van Staa et al.,
2007143
UK
Oral
glucocorticoid
users aged ≥ 40
years
5 years’
bisphosphonate
treatment vs. no
treatment
Individual
patient-based
model
Not reported 6 years 2003/4
6%
Analysis of resource
allocation and
standard UK
reference sources
UK
1.50%
Observational
data
EQ-5D
Retrospective
survey of
medical notes
Kanis et al.,
2008138
UK
Postmenopausal
women with
risk factors
5 years’
alendronic acid
treatment vs. no
treatment
Markov
cohort model
Health care 10 years and
lifetime
Not reported
3.50%
UK HES data
combined with
Swedish data
Sweden,
Europe and
the UK
3.50%
Observational
data
EQ-5D
Recent
meta-analysis
of trial results
van Staa et al.,
2007141
UK
Postmenopausal
women
5 years’
risedronic acid/
alendronic acid
treatment vs. no
treatment
Individual
patient-based
model
Not reported 10 years Not reported
6%
Analysis of resource
allocation and
standard UK
reference sources
UK
1.50%
See
Stevenson
et al.140
EQ-5D
Retrospective
survey of
medical notes
Borgström et al.,
2010137
UK
Postmenopausal
women
5 years’
risedronic acid
treatment vs. no
treatment
Markov
cohort model
Health care Set according to
the patient’s
starting age so that
the simulation ends
at age 100 years
2006
3.50%
Standard UK and
Swedish reference
sources
Sweden and
UK
3.50%
Observational
data
EQ-5D
Recent
meta-analysis
of trial results
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Author, year of
study
publication and
location
Population
and
interventions
Type of
evaluation Perspective Time horizon
Cost year
and cost
discount
rate Cost source
Location of
population
and benefits
discount
rate
Benefits
source and
benefits
instrument
Effectiveness
data
Stevenson et al.,
2005140
UK
Postmenopausal
women
Multiple
interventionsa
Patient-level
Markov model
NHS and PSS Patients lifetime 2001/2
6%
Standard UK
reference sources
Not reported
1.50%
Observational
data
EQ-5D
Meta-analysis
conducted by
authors
Ström et al.,
2007139
UK
Patients from
the fracture
intervention trial
5 years’
alendronic acid
treatment vs. no
treatment
Markov
cohort model
Health payer Set according to
the patient’s
starting age so that
the simulation ends
at age 100 years
2004
3.50%
Standard UK
reference sources,
academic papers
personal
communication
Sweden and
the UK
3.50%
Observational
data
EQ-5D
Results of
the fracture
intervention
trial
Kanis et al.,
2007142
UK
Oral
glucocorticoid
users age
≥ 40 years
5 years’
bisphosphonate
treatment vs. no
treatment
Patient-level
Markov model
NHS and PSS 10 years and
lifetime
2004/5
(drugs 2006)
6%
Analysis of resource
allocation and
standard UK
reference sources
Sweden
1.50%
Observational
data
EQ-5D
Meta-analysis
conducted by
authors
Borgström et al.,
2006146
Australia,
Germany, Japan,
Spain, Sweden,
the UK and the
USA
Postmenopausal
women
5 years’
bisphosphonate
treatment vs. no
treatment
Markov
cohort model
Societal Set according to
the patient’s
starting age so that
the simulation ends
at age 100 years
2004
3.50%
Standard UK
reference sources
and academic
papers
Sweden
3.50%
Observational
data
EQ-5D
Assumption
HES, Hospital Episode Statistics.
a No treatment; raloxifene; HRT; calcium; calcium plus vitamin D; calcitonin; alendronic acid; alfacalcidol; fluoride; pooled bisphosphonate.
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The National Institute for Health and Care Excellence reference case
Both studies by van Staa et al.141,143 used data from a retrospective analysis of patient notes rather than
RCT evidence, as required by the NICE reference case.144 These authors also reported results using a
10-year time horizon rather than the lifetime horizon, which is required by the NICE reference case.
The study by Borgström et al.146 failed to meet the requirements of the NICE reference case as the RR
reduction used in the study was based on an assumption involving the expected distribution of
osteoporotic fractures dependent on age and the subsequent utility loss rather than on the evidence.
Additionally, the study by Ström et al.139 failed to meet the requirements of the NICE reference case by
using efficacy data from a single RCT, but the study did present the results of a sensitivity analysis using
data from a published meta-analysis. Two papers, by Stevenson et al.140 and Kanis et al.,142 which used
the same underlying model but applied it in two different populations, used differential discount rates
of 6% for future costs and 1.5% for future benefits rather than 3.5% for both future costs and
future benefits as required by the NICE reference case. However, Kanis et al.142 did report that using
discount rates of 3.5% for both future costs and future benefits had only a minor effect on the results.
In addition to the points above, none of the included studies compared all four bisphosphonates
specified within the scope of this appraisal in a fully incremental analysis as required by the NICE
reference case.
Quality of studies
The quality of the studies was generally good when appraised using the checklist published by Phillips
et al.145 Responses for each individual study are provided in Table 7. Five of the studies met > 50% of the
checklist criteria.137–140,142 The studies commonly performed badly on the questions related to internal and
external consistency, with none of the models providing an adequate description of the quality assurance
processes used to demonstrate internal validity and none demonstrating that the model had been
calibrated against external data sources. All of the models assessed patient-level heterogeneity by running
the model for subgroups of patients with different characteristics. However, none of the papers adequately
addresses all types of uncertainty (structural, parameter, methodological). Three of the models139,140,142
assessed parameter uncertainty using analysis [probabilistic sensitivity analysis (PSA)], but in the other five
cases this was either not done or not clearly reported. Only two of the studies140,142 adequately addressed
the quality of the input data and there was limited discussion of the methods used to derive the utility
weights applied in the model.
Study conclusions
All of the studies report a range of incremental cost-effectiveness ratios (ICERs) for patients with different
characteristics. Patient age, BMD, the presence of prior fracture and the presence of other clinical risk
factors all appear to have a significant influence on the ICER based on the included studies. The duration
of treatment and the offset duration (the time over which the treatment still has an effect on fracture
risk following discontinuation), as well as patient adherence to treatment, may have a lesser influence on
the cost-effectiveness. Given that none of the studies used current prices for bisphosphonates and these
have fallen substantially since the time these studies were published, further details on the ICERs are
not reported.
Summary of existing cost-effectiveness evidence
Although a number of published studies were identified that assessed the cost-effectiveness of
bisphosphonates, and the quality of those studies was generally good, none of the included studies
compared all the bisphosphonate treatments specified within the scope of this appraisal in a fully
incremental analysis as required by the NICE reference case.144 Furthermore, the cost of generic
formulations of bisphosphonates has fallen since these studies were conducted. The results reported by
these studies were, therefore, considered to have limited applicability to the decision problem described in
Chapter 2. However, these studies were used as a source of model parameters and assumptions for the
independent economic assessment described in Independent economic assessment.
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TABLE 7 Quality assessment of the included studies: cost-effectiveness
Criterion Question
Author and year of study publication
van Staa
et al.,
2007143
Kanis
et al.,
2008138
van Staa
et al.,
2007141
Borgström
et al.,
2010137
Stevenson
et al.,
2005 140
Ström
et al.,
2007139
Kanis
et al.,
2007142
Borgström
et al.,
2006146
S1: statement
of decision
problem/objective
Is there a clear statement of the decision
problem?
Yes Yes Yes Yes Yes Yes Yes Yes
Is the objective of the evaluation and model
specified consistent with the stated decision
problem?
Yes Yes Yes Yes Yes Yes Yes Yes
Is the primary decision-maker specified? No Yes No Yes Yes No Yes No
S2: statement of
scope/perspective
Is the perspective of the model clearly stated? No Yes No Yes Yes Yes Yes Yes
Are the model inputs consistent with the stated
perspective?
NA Yes NA Yes Yes Yes Yes Yes
Has the scope of the model been stated and
justified?
No Yes Yes Yes Yes Yes Yes No
Are the outcomes of the model consistent with
the perspective, scope and overall objective of the
model?
Yes Yes NA Yes Yes Yes Yes Yes
S3: rationale for
structure
Is the structure of the model consistent with a
coherent theory of the health condition under
evaluation?
Yes Yes Yes Yes Yes Yes Yes Yes
Are the sources of data used to develop the
structure of the model specified?
No Yes No Yes Yes Yes Yes No
Are the causal relationships described in the
model structure justified appropriately?
Yes Yes Yes Yes Yes Yes Yes Yes
S4: structural
assumptions
Are the structural assumptions transparent and
justified?
Yes Yes Yes Yes Yes Yes Yes Yes
Are the structural assumptions reasonable given
the overall objective, perspective and scope of the
model?
Yes Yes NA Yes Yes Yes Yes Yes
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TABLE 7 Quality assessment of the included studies: cost-effectiveness (continued )
Criterion Question
Author and year of study publication
van Staa
et al.,
2007143
Kanis
et al.,
2008138
van Staa
et al.,
2007141
Borgström
et al.,
2010137
Stevenson
et al.,
2005 140
Ström
et al.,
2007139
Kanis
et al.,
2007142
Borgström
et al.,
2006146
S5: strategies/
comparators
Is there a clear definition of the options under
evaluation?
No Yes Yes Yes Yes Yes Yes Yes
Have all the feasible and practical options been
evaluated?
No No No No Yes Yes Yes No
Is there justification for the exclusion of feasible
options?
No No No No NA NA NA No
S6: model type Is the chosen model type appropriate given the
decision problem and specified causal
relationships within the model?
Yes Yes Yes Yes Yes Yes Yes Yes
S7: time horizon Is the time horizon of the model, the duration of
treatment and the duration of treatment effect
described and justified?
No Yes No Yes Yes Yes Yes Yes
S8: disease states/
pathways
Do the disease states (state transition model) or
the pathways (decision tree model) reflect the
underlying biological process of the disease in
questions and the impact of interventions?
Yes Yes Yes Yes Yes Yes Yes Yes
S9: cycle length Is the cycle length defined and justified in terms of
the natural history of the disease?
NA Yes NA Yes Yes Yes Yes No
D1: data
identification
Are the data identification methods transparent
and appropriate given the objective of the model?
Yes Yes Yes Yes Yes Yes Yes No
Where choices have been made between data
sources, are these justified appropriately?
No Yes No No Yes Yes Yes No
Has particular attention been paid to identifying
data for the important parameters in the model?
Yes No Yes Yes Yes Yes Yes No
Has the quality of data been assessed
appropriately?
No No No No Yes No Yes No
Where expert opinion has been used, are the
methods described and justified?
NA NA NA NA NA NA NA NA
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Criterion Question
Author and year of study publication
van Staa
et al.,
2007143
Kanis
et al.,
2008138
van Staa
et al.,
2007141
Borgström
et al.,
2010137
Stevenson
et al.,
2005 140
Ström
et al.,
2007139
Kanis
et al.,
2007142
Borgström
et al.,
2006146
D2: pre-model data
analysis
Is the data modelling methodology based on
justifiable statistical and epidemiological
techniques?
Yes Yes Yes Yes Yes Yes Yes No
D2a: baseline data Is the choice of baseline data described and
justified?
Yes Yes Yes Yes Yes Yes Yes No
Are transition probabilities calculated appropriately? NA Unknown NA Unknown Unknown Unknown Unknown Unknown
Has half-cycle correction been applied
appropriately to both costs and outcomes?
NA Unknown NA Yes Unknown Unknown Unknown Unknown
If not, has the omission been justified? NA NA NA NA NA NA NA NA
D2b: treatment
effects
If relative treatment effects have been derived
from trial data, have they been synthesised
correctly using appropriate techniques?
NA NA NA Yes Yes Yes Yes NA
Have the methods and assumptions used to
extrapolate short-term results to final outcomes
been documented and justified?
NA NA NA NA NA NA NA NA
Have alternative extrapolation assumptions been
explored through sensitivity analysis?
NA NA NA NA NA NA NA NA
Have assumptions regarding the continuing effect
of treatment once treatment is completed been
documented and justified?
No Yes Unknown Yes Yes Yes Yes Yes
Have alternative assumptions regarding the
continuing effect of treatment been explored
through sensitivity analysis?
Yes Yes NA Yes No Yes Yes Yes
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TABLE 7 Quality assessment of the included studies: cost-effectiveness (continued )
Criterion Question
Author and year of study publication
van Staa
et al.,
2007143
Kanis
et al.,
2008138
van Staa
et al.,
2007141
Borgström
et al.,
2010137
Stevenson
et al.,
2005 140
Ström
et al.,
2007139
Kanis
et al.,
2007142
Borgström
et al.,
2006146
D2c: costs Are the costs incorporated in the model justified? Yes Yes Yes Yes Yes Yes Yes No
Has the source of all costs been described? No No No Yes Yes Yes Yes No
Have discount rates been described and justified
given the target decision-maker?
NA Yes NA Yes Yes Yes Yes Yes
D2d: quality-of-life
weights (utilities)
Are the utilities incorporated into the model
appropriate?
Yes Yes Yes Yes Yes Yes Yes Yes
Is the source of utility weights referenced? Yes Yes Yes Yes Yes Yes Yes Yes
Are the methods of derivation of the utility
weights justified?
No Yes No No Yes No Yes No
D3: data
incorporation
Have all data incorporated into the model been
described and referenced in sufficient detail?
No Yes No Yes Yes Yes Yes No
Has the use of mutually inconsistent data been
justified (i.e. are the assumptions and choices
appropriate)?
No No No No No No No No
Is the choice of data incorporation transparent? Yes Yes Yes Yes Yes Yes Yes No
If data have been incorporated as distributions,
has the choice of distribution for each parameter
been described and justified?
No Unknown No No No No No No
If data have been incorporated as distribution, is it
clear that second order uncertainty is reflected?
No Yes No Yes Yes Yes Yes No
D4: assessment of
uncertainty
Have the four principal types of uncertainty been
addressed?
No No No No No No No No
If not, has the omission of particular forms of
uncertainty been justified?
No No No No No No No No
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Criterion Question
Author and year of study publication
van Staa
et al.,
2007143
Kanis
et al.,
2008138
van Staa
et al.,
2007141
Borgström
et al.,
2010137
Stevenson
et al.,
2005 140
Ström
et al.,
2007139
Kanis
et al.,
2007142
Borgström
et al.,
2006146
D4a: methodological Have the methodological uncertainties been
addressed by running alternative versions of the
model with different methodological
assumptions?
No No No No No No No No
D4b: structural Is there evidence that structural uncertainties have
been addressed via sensitivity analysis?
No No No No No Yes No Yes
D4c: heterogeneity Has heterogeneity been dealt with by running the
model separately for different subgroups?
Yes Yes Yes Yes Yes Yes Yes Yes
D4d: parameter Are the methods of assessment of parameter
uncertainty appropriate?
No Unknown No Unknown Yes Yes Yes No
If data are incorporated in the point estimates, are
the ranges used for sensitivity analysis stated
clearly and justified?
No No No Unknown No Unknown Unknown No
C1: internal
consistency
Is there evidence that the mathematical logic of
the model has been tested thoroughly before
use?
No No No No No No No No
C2: external
consistency
Are any counterintuitive results from the model
explained and justified?
No No No No No No No No
If the model has been calibrated against
independent data, have any differences been
explained and justified?
No No No No No No No No
Have the results of the model been compared
with those of previous models and any difference
in results explained?
No Yes Yes Yes No No No No
C; dimensions of quality that relate to consistency; D, dimensions of quality that relate to data; NA, not applicable; S, dimensions of quality that relate to structure.
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Independent economic assessment
Modelling rationale and overview
A de novo economic analysis was considered necessary in order to properly address the decision problem
outlined in the scope, as none of the economic evaluations identified in Systematic review of existing
cost-effectiveness evidence compared all five bisphosphonate treatments specified within the scope of this
appraisal in a fully incremental analysis as required by the NICE reference case.144
In the scope for this appraisal23 it was stated that this MTA would ‘develop the framework to link absolute
fracture risk with intervention thresholds, based on cost effectiveness’. Therefore, in order to provide
information that might inform intervention thresholds, expressed in terms of absolute risk, the aim of
the de novo economic evaluation was to estimate the cost-effectiveness of the five bisphosphonates
treatments compared with no treatment for patients at varying levels of absolute fracture risk. The overall
population is those eligible for risk assessment under CG146,16 but it is divided into risk categories based
on the estimates of fracture risk provided by the QFracture and FRAX risk assessment tools.
Discrete event simulation (DES) was used to estimate lifetime costs and QALYs for each bisphosphonate
treatment strategy and a strategy of no treatment for a simulated cohort of patients with heterogeneous
characteristics. The model was populated with effectiveness evidence from the systematic review and NMA
described in Chapter 3. All other parameters were estimated from published sources. Evidence on the
impact of fracture on HRQoL was identified from a systematic review. The published economic evaluations
described in in Systematic review of existing cost-effectiveness evidence were used to identify other data
sources that could be used to inform model parameters. A NHS and PSS perspective was taken and costs
and benefits were discounted at 3.5% per annum. A brief summary of the modelling methodology and
key data sources is provided in Table 8 alongside information of where further details can be found in
Methods below.
Methods
Model structure
The model is a DES that simulates the clinical events occurring over the lifetimes of individual patients
who are allowed to have heterogeneous characteristics. When designing the model structure, we
constructed a conceptual model to explore the relationships between patient characteristics, absolute
risks and cost-effectiveness, which is summarised in Figure 66 and discussed in more detail in the section
Specifying the model population. Based on this conceptual model we anticipated that an unbiased
estimate of the average cost-effectiveness for groups selected according to their level of absolute risk
could only be obtained by calculating the mean cost-effectiveness across a population with heterogeneous
characteristics. This is because we expected certain characteristics, such as age, which are not uniform
across cohorts selected based on absolute risk, to have a non-linear relationship with cost-effectiveness.
For example, age was expected to affect both life expectancy and the probability of a new admission to
a residential care setting following fracture, both of which would alter the cost and QALY implications
of fracture. Therefore, we decided to use a patient-level simulation approach in which the patient
characteristics were allowed to vary stochastically in a manner that reflects our beliefs about their
distribution within the general population. Having decided to use a patient-level simulation approach,
we then decided that a DES approach would be more efficient than a patient-level state transition
approach. This is because a DES approach updates the calculation of costs and benefits only when a
patient experiences an event rather than making calculations for every model cycle. The cohort modelled
included a substantial proportion of low-risk patients, as not all patients eligible for fracture risk
assessment under CG14616 are at high risk of fracture. In a low-risk cohort it would be common for there
to be no fracture events experienced during a patient’s lifetime. Calculating costs and QALYs every model
cycle is much less efficient in low-risk populations than in high-risk populations, in which events may occur
every few cycles. The main disadvantage of using a DES approach is that the risk factor tools (FRAX and
QFracture), which are recommended for assessing fracture risk in CG146,16 provide estimates of the
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TABLE 8 Overview of the modeling methodology and key data sources
Model feature Summary Chapter and section heading
Decision problem To assess the cost-effectiveness of bisphosphonates
compared with no treatment at varying levels of
absolute fracture risk, as defined by the FRAX and
QFracture risk assessment tools
Chapter 2, Chapter 4, Modelling rationale
and overview, and Chapter 4, Specifying
the model population
Type of economic
evaluation
Cost-effectiveness analysis, with benefits expressed
as QALYs
Chapter 4, Modelling rationale and
overview
Population/subgroups The model simulates the heterogeneous patient
population eligible for risk assessment under
CG14616
The population is stratified into 10 risk categories
and results presented for each risk category. This is
done once using FRAX and once using QFracture
Chapter 4, Specifying the model
population
Interventions Oral alendronic acid
Oral risedronic acid
Oral ibandronic acid
i.v. ibandronic acid
i.v. zoledronic acid
Chapter 4, Treatment strategies
Comparators No treatment Chapter 4, Treatment strategies
Perspective NHS and PSS Chapter 4, Age- and sex-specific utility
values in the absence of clinical events;
and Chapter 4, Resource use and costs for
bisphosphonates treatment
Model type Discrete-event simulation with heterogeneous
patient population
Chapter 4, Model structure
Model events Clinical events are fracture, death (all-cause
mortality and fracture-related mortality) and nursing
home admission. There are four possible fracture
events (hip, wrist, vertebral and proximal humerus),
with fracture at other sites included by increasing
the incidence of these events
Dummy events are used to update attributes 1 year
after fracture and to update the fracture risks once
treatment finishes
Chapter 4, Model structure
Time horizon Lifetime (up to age of 100 years) Chapter 4, Model structure
Duration of treatment Mean duration of persistence with treatment from
observational studies
Chapter 4, Treatment strategies
Natural history Time to fracture is based on the estimate of
absolute fracture risk for major osteoporotic
fractures (hip, wrist, proximal humerus and
vertebral) provided by either QFracture or FRAX,
which are uplifted to include fractures at additional
sites. The distribution of fractures across different
sites is based on incidence data from Sweden.148
The increased risks of fracture following incident
fracture are based on a published systematic review
by Klotzbuecher et al.149
Chapter 4, Estimating time to event from
absolute fracture risk; Chapter 4,
Incorporating the risk of fracture at other
site; Chapter 4, Risk of subsequent
fracture after incident fracture
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DOI: 10.3310/hta20780 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 78
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Davis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
199
TABLE 8 Overview of the modeling methodology and key data sources (continued )
Model feature Summary Chapter and section heading
Effectiveness The HRs from the systematic review and NMA are
applied for the duration of treatment. Some
effectiveness is assumed to persist beyond
treatment. A linear decline in treatment effect
assumed
Chapter 4, Application of hazard ratios to
incorporate treatment both during and
beyond treatment period and Chapter 4,
Efficacy estimates
AEs Upper GI side effects for oral bisphosphonates
and flu-like symptoms for i.v. bisphosphonates
are included by applying one-off cost and
QALY deductions in the first month of
treatment
Chapter 4, Adverse event estimates
Mortality All-cause mortality is based on UK life tables
Fracture-related mortality is based on estimates of
excess mortality attributable to hip and vertebral
from a case–control study using routine data from
UK general practice
Chapter 4, Estimating time to non-
fracture-related mortality to Chapter 4,
Excess mortality risk at fracture sites other
than hip or vertebrae
Utility data Utility decrements based on EQ-5D scores pre and
post fracture were obtained from a systematic
review (see Health-related quality of life: review
of utility values following fracture). Utility
decrement for nursing home admission was
based on a single study identified from the
literature that used EQ-5D. Variation in baseline
utility by age and sex was based on UK EQ-5D
population estimates
Chapter 4, Health-related quality of life:
review of utility values following fracture
to Chapter 4, Age- and sex-specific utility
values in the absence of clinical events
Resource use and unit
costs
The analysis includes drug costs, administration
costs and costs of fracture including those falling
on primary care, secondary care and PSS
Post-fracture costs were based on a case–control
study that used routine data from UK general
practice. Nursing home admission following hip
fracture was based on a UK observational study of
discharge destinations
Unit costs are taken from NHS reference costs,150
PSSRU unit costs,26 the primary care national drug
tariff151 and the eMIT database152 of generic drug
costs in secondary care
Costs are reported in pounds sterling (£)
Cost year is 2014
Chapter 4, Risk of nursing home admission
following hip fracture; Chapter 4, Risk
of nursing home admission following
vertebral fracture; Chapter 4, Resource use
and costs for bisphosphonates treatment;
and Chapter 4, Resource use and costs of
fracture
Discounting 3.5% per annum for both costs and QALYs Chapter 4, Model structure
Sensitivity analysis PSA was undertaken for the base-case
scenario to estimate the mean costs and
benefits when taking into account parameter
uncertainty
Structural uncertainty was assessed through
scenario analysis. For most of the scenario
analyses parameters were set to their mid-point
values
Chapter 4, Approach to sensitivity analysis
eMIT, electronic market information tool.
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Absolute fracture risk
Residential status
Mortality after fracture Proportion of fractures occuring at various sites Life expectancy
Residential status after fracture Baseline utility
Efficacy estimates
Age
Smoking status History of falls Alcohol use
Medications (other than steroids, e.g. antidepressants, HRT, anti-convulsants) Parental history of fracture
BMI BMD Ethnicity
Prior fracture Gender Steroid use
Cost-effectiveness of bisphosphonates vs. no treatment
Comorbidities (e.g. cancer, CVD, dementia, Parkinson’s disease, liver disease, kidney disease, rheumatoid arthritis or lupus, malabsorption, endocrine, diabetes, asthma or COPD)
Factors assumed to have no impact on cost-effectiveness independent of absolute fracture risk
Factors that may affect cost-effectiveness independently of absolute fracture risk
FIGURE 66 Relationships assumed between individual risk factors and cost-effectiveness. COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease.
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cumulative risk over a defined time frame (10 years for FRAX and 1–10 years for QFracture). In order to
convert these estimates of absolute cumulative risk to time-to-event estimates, it was necessary to assume
some functional form for event-free survival, and this required some additional data or assumptions
regarding the hazard function.
In general, within a DES model, patients’ experience as they progress through the model is determined by
the events that occur rather than by the health states they occupy. Figure 67 shows the clinical events that
can occur over a patient’s lifetime, with the arrows showing which events can occur following other
events. (Note that this is not a state transition diagram, as patients do not reside in the state defined by
the most recent event until the next event is experienced.) In our model, the main clinical events were
fracture, death and new admission to residential care. Fractures at different sites were processed using
separate fracture events for hip, wrist, and vertebral and proximal humerus. These are the sites most
strongly associated with osteoporosis and these are the fracture sites included by both the QFracture and
FRAX risk calculators. Fractures at additional sites (femoral shaft, humeral shaft, pelvis, scapula, clavicle,
sternum, ribs, tibia and fibula) have been incorporated by increasing the incidence of these four event
types rather than by adding additional competing events.
Separate events are shown in Figure 67 for all-cause mortality and fracture-related deaths to show that
fracture-related deaths can occur only following hip and vertebral fracture. However, in practice in the
model code, a single event was used to process both all-cause mortality and fracture-related deaths. If a
particular fracture was sampled to be fatal, then the time to death was set equal to the time of fracture
plus an additional time assumed to be 3 months. At all other times, the time to death was determined by
age- and sex-specific estimates for all-cause mortality from the general population. As the data provided by
the life tables allowed only the year of death to be sampled and not the exact time point, we assumed
that all deaths occurred exactly 6 months through the year in which death was sampled to occur. All-cause
mortality estimates were not adjusted to remove deaths following fracture and, therefore, the model may
have marginally overestimated the total mortality risk.
Fracture-related death
Residential care admission
Wrist fracture
Vertebral fracture
Proximal humerus fracture
Hip fracture
All-cause mortality
FIGURE 67 Clinical events that can occur during a patient’s lifetime in the DES.
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A schematic of the model logic used to implement the DES is provided in Figure 68. In a DES, the patient’s
progress is driven by a list of times at which each event has been sampled to occur. The model steps
forward from one event to the next and the list of event times can be updated when events are processed,
to allow the patient’s event history to affect their future progress. In a DES no changes are made to the
patient’s attributes between events. Therefore, dummy events were used to ensure that certain patient
attributes were updated at times other than when experiencing a clinical event (death or fracture, or new
admission to residential care home). For example, dummy events were used to recalculate fracture risks at
the end of treatment and at the end of the period when treatment effect is assumed to reach zero. The
time between the end of treatment and the end of any remaining treatment effect is called the fall-off
period. If these two events occurred prior to 5 and 10 years, respectively, then additional dummy events
are scheduled for 5 and 10 years to ensure that all patients have their risk updated at these time points.
Dummy events were also used to allow the patient’s health utility values to be updated 1 year after a
fracture event to allow the acute (< 1 year) and chronic (> 1 year) consequences of fracture to be
incorporated separately. Finally, a time horizon event was also included to process final patient outcomes
Go to next patient in cohort
Set patient attributes (e.g. age, gender, risk factors, BMI,
QFracture score, utility in absence of fracture,
life expectancy, time horizon)
Initialise event list (e.g. set
time to event for each
event type)
Determine next event type
Process event
Patient died or
time horizon
exceeded?
Last patient?
End simulation of cohort
Yes
YesNo
No
Update costs and QALYs
Update patient history, and utility value and attributes
Update event list (e.g. resample events where necessary)
Add dummy event to update utility 1 year after fracture
FIGURE 68 Schematic of the DES model.
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for those patients who do not die before reaching the age of 100 years. The individual’s risk of fracture is
updated each time a clinical event, or dummy event, occurs. The model incorporates the following
structural assumptions:
l The maximum number of hip fractures that can be experienced is limited to one per bone with an
additional limit of four vertebral fractures, four rib fractures and two pelvic fractures.
l There are no restrictions on the sequence of fractures that can be experienced.
l Death attributable to fracture occurs 3 months after fracture (see Mortality after hip fracture), with
other fracture events possible during this period but no mortality from non-fracture-related causes.
l No further events can be experienced after death.
l A fracture event occurring < 1 year after a previous event supersedes the dummy event used to update
patient attributes 1 year after fracture, thus reducing the acute period for the earlier fracture.
l Nursing home admission can only occur following fracture and, therefore, patients who are community
dwelling at the start of the simulation do not transfer to nursing home care as they age, unless this is
simulated to occur following a fracture.
Utility in the model is based on a combination of sex, age, fracture history and residential status
(community dwelling or institutionalised). Every time an event occurs the patient’s utility value is updated
and this utility value is used to calculate the QALYs accrued between one event and the next. Furthermore,
when calculating the QALYs accrued between events an adjustment is made for age-related utility
decrements over the intervening years so that the utility value applied does not remain artificially high
when the time between events is long. This is done by assuming a linear fall in utility over the intervening
years between events. The utility impact for each fracture type is separated into an acute utility multiplier
applied in the first year after fracture and a chronic utility multiplier which is applied in all subsequent
years. If more than one fracture has occurred then the chronic multiplier for each fracture is applied but no
more than one acute utility multiplier is applied at any one time. A utility multiplier is also applied for
institutional versus community living. Owing to the use of multipliers the absolute utility decrement for
each subsequent fracture is smaller and the patient’s utility never falls to below zero. Patients who have a
prior fracture (as defined by either the FRAX or QFracture risk calculators) at baseline have the chronic
utility multiplier for that fracture type applied for rest of their lifetime.
Two types of costs are applied within the model to capture the consequences of fracture. Acute costs,
which represent the cost of acute care such as hospitalisations, are assumed to occur at the time of the
event and are applied for both fatal and non-fatal fractures. Chronic costs, which are used to represent the
ongoing costs of care in the months and years after fracture, such as nursing home care or medication
costs for chronic pain, are accrued gradually over the time period between events. The chronic cost is set
to the maximum chronic cost for all fracture events experienced so far, with the maximum chronic cost for
any individual being the cost for institutionalised patients. Drug costs are applied from the start of the
simulation until the end of the treatment period and are assumed to accrue at a constant rate across time.
Death does not incur any additional costs within the model. For patients who suffer a fatal fracture, the
full costs of acute care in the year following fracture are still incurred despite the reduced survival period of
3 months under the assumption that that majority of acute costs are incurred close the time of fracture.
Patients are assumed to stay in the same residential setting (community or institution) unless they
experience a fracture event. So while some patients reside in an institutional setting at the start of the
simulation, and this proportion is higher in older patients, no patients are simulated to move from the
community into an institutional residential setting for reasons other than fracture. This may slightly
overestimate the cost savings of preventing fractures, as in reality people may enter an institutional
residential setting prior to a fracture occurring and, therefore, will not be at risk of incurring additional
costs for residential care following fracture. However, this assumption avoids the need for regular events
updating the patient’s residential status, which would reduce the computational efficiency of the
DES approach.
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The simulation for each individual ends when a fracture-related or non-fracture-related death occurs or
when the time horizon is reached. The time horizon is set according to the patient’s starting age so that
the simulation ends at age 100 years for all patients. This is because the all-cause mortality data are limited
to patients aged ≤ 100 years. Costs and benefits have been discounted within the analysis at 3.5% per
annum in accordance with NICE reference case.144
As CG146 recommends that either FRAX or QFracture is used to estimate the absolute risk of fracture,16
the simulation is run once using each of these tools to estimate fracture risk. First, it is run using QFracture
to estimate the absolute risk of fracture. During this run the patient characteristics are stored. The model
is then rerun using the same set of patients with identical characteristics but with the absolute risk of
fracture being defined by FRAX rather than QFracture. This ensures that an identical patient cohort
is simulated when using either QFracture or FRAX to estimate the absolute risk of fracture. In the
deterministic model, random number control is used to ensure that the random numbers used are identical
when running the same patient using both FRAX and QFracture. This eliminates the possibility that results
achieved using the different risk calculators are different purely through chance. The same cohort of
patients is run for each treatment and for each parameter sample during the PSA. This means that the
100th patient has the same characteristics and the same set of random numbers determining their path
through the model regardless of the parameter samples selected for the PSA or the treatment being
simulated.144 The DES model structure is represented in Figure 68.
Specifying the model population
The population included in the economic analysis is the whole population eligible for risk assessment
within CG146. A heterogeneous population has been simulated and then stratified into risk categories
based on absolute fracture risk, as predicted by either the FRAX or QFracture risk assessment tool.
A heterogeneous population was simulated because we expected certain characteristics, such as age,
which are not uniform across cohorts selected based on absolute risk, to have a non-linear relationship
with cost-effectiveness. The population was stratified into risk categories to allow the variation in
cost-effectiveness across absolute risk to be examined.
The NICE guideline on assessing the risk of fragility fracture (CG146)16 recommends that FRAX17 or
QFracture18,19 should be used to assess the 10-year absolute risk of fragility fracture. Therefore, our analysis
assumes that absolute fracture risk is measured using one of these two tools. (It is assumed that FRAX web
version 3.9 and QFracture 2012 open-source revision 38 were used, as these were the versions available
online at the time this report was prepared.) In both of these tools, absolute fracture risk is dependent on
the patient’s age, sex, BMI and the presence or absence of a number of clinical risk factors. In the case
of QFracture, ethnicity is also taken into account. In the case of FRAX, the patient’s BMD can also be
incorporated if it is known, but CG146 recommends that BMD is measured only in patients whose absolute
fracture risk falls close to a treatment threshold. Therefore, our model assumes that BMD is not known, as
treatment thresholds must be defined for those without a BMD measurement for the recommendations in
CG146 to be implemented. The FRAX tool estimates the individual’s 10-year absolute risk of hip fracture and
their 10-year absolute risk of major osteoporotic fracture (clinical spine, hip, forearm and humerus fracture).
The QFracture tool provides the absolute risk of hip and the absolute risk of major osteoporotic fracture (hip,
spine, wrist or shoulder), but with the option to vary the timeframe from 1 year to 18 years (the web tool is
limited to 10 years). Table 9 summarises the risk factors used by the FRAX and QFracture tools.
A particular level of absolute fracture risk, as measured by FRAX or QFracture, can be achieved in different
ways by different individuals. For example, a young patient with many clinical risk factors may have the
same absolute risk of fracture as an older patient who has no clinical risk factors. Although the absolute
risk of fracture is likely to be an important determinant of the cost-effectiveness of treatment with
bisphosphonates, other factors may affect cost-effectiveness independently of absolute fracture risk.
For example, the cost and QALY consequences of fracture may be more severe in older patients, who may
be more likely to die or be admitted to a nursing home following fracture. Therefore, in a group of
patients who have been selected to have the same absolute fracture risk there may be variation in the
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TABLE 9 Summary of risk factors included in FRAX (web v3.9) and QFracture (2012) tools
Patient
characteristic
Absolute fracture risk tool
FRAX17 QFracture18,19
Y/N Notes Y/N Notes
Age Y Y
Sex Y Y
BMI Y Y
BMD Y (Optional) T-score or femoral neck BMD
in g/cm2
N
Ethnicity N Y Categories are white or not stated,
Indian, Pakistani, Bangladeshi, other
Asian, black Caribbean, black African,
Chinese, other
Previous fracture Y Fragility fracture at any site in adult life Y Hip, wrist, spine or shoulder
Parental history of
fracture
Y Hip fracture in mother or father Y Hip fracture or osteoporosis in parent
Alcohol use Y ≥ 3 units daily Y Categorised as daily units of < 1, 1–2,
3–6, 7–9, > 9
Smoking status Y Current smoking Y Categorised as non-smoker, ex-smoker,
light smoker (< 10 cigarettes per day),
moderate smoker (10–19 cigarettes per
day) or heavy smoker (> 20 cigarettes
per day)
Steroid use Y Currently exposed to oral glucocorticoids
or past exposure > 3 months at a
dosage equivalent to 5 mg per day of
prednisolone
Y Taking steroid tablets regularly
Rheumatoid arthritis
or systemic lupus
erythematosus
Y Rheumatoid arthritis only Y
Secondary
osteoporosis
Y Any disorder strongly associated with
osteoporosis. Examples given are type 1
(insulin-dependent) diabetes mellitus,
osteogenesis imperfecta in adults,
untreated long-standing
hyperthyroidism, hypogonadism or
premature menopause (< 45 years),
chronic malnutrition, or malabsorption
and chronic liver disease
N Several causes of secondary
osteoporosis are included as separate
risk factors (see rows below)
Diabetes N Type 1 diabetes mellitus included under
secondary osteoporosis
Y Type 1 and type 2 diabetes mellitus
specified separately
Living in nursing or
care home
N Y
History of falls N Y
Dementia N Y
Cancer N Y
Asthma or COPD N Y
Heart attack, angina,
stroke or TIA (CVD)
N Y
Chronic liver disease N Included under secondary osteoporosis Y
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cost-effectiveness of treatment. If there is a linear relationship between patient characteristics
and cost-effectiveness, then it is possible to estimate the average cost-effectiveness by calculating
the cost-effectiveness for a patient with average characteristics. However, previous work in this area
suggests that cost-effectiveness may be non-linearly associated with patient characteristics, such as age.153
In such cases, an unbiased estimate of the mean cost-effectiveness can be achieved by simulating a patient
population with heterogeneous patient characteristics and estimating the average cost-effectiveness across
that population.154
In this analysis we have simulated a heterogeneous patient cohort that is representative of all patients
eligible for risk factor assessment within CG146.16 We have limited the population to patients > 30 years,
as neither the FRAX nor the QFracture tool has been validated in patients aged < 30 years. Initially, a
population of patients aged ≥ 30 years is simulated, but only those eligible for risk factor assessment with
CG146 are included within the cohort used within the cost-effectiveness analysis. For example, simulated
patients without clinical risk factors (any included in QFracture or FRAX) are excluded from the analysis if
they are female and aged < 65 years or male and aged < 75 years, and simulated patients are also
excluded if they are aged < 50 years and do not have either a prior history of fragility fracture or current
steroid use. This approach of sampling the whole population and then excluding those not recommended
for risk factor assessment by CG146 was necessary, as data were not available on the distribution of
clinical risk factors within the specific population eligible for risk assessment under CG146.
Once the cohort eligible for risk factor assessment was defined from within the general population, we
estimated FRAX and QFracture scores for each individual (where ‘score’ refers to the absolute risk of fracture
over 10 years for the four main fracture sites: hip, wrist, vertebra and proximal humerus). Lifetime costs and
QALYs for each patient are then estimated using the cost-effectiveness model. This step is repeated once
for no treatment and once for each bisphosphonate treatment strategy. We then stratified the patients into
10 risk categories based on their absolute fracture risk and estimated the average cost-effectiveness of
each bisphosphonate compared with no treatment within each risk score category. The cut-off points
for each risk category have been set using deciles to ensure that a sufficient number of patients fall into
each category to allow the cost-effectiveness to be estimated accurately. The stratification into risk
TABLE 9 Summary of risk factors included in FRAX (web v3.9) and QFracture (2012) tools (continued )
Patient
characteristic
Absolute fracture risk tool
FRAX17 QFracture18,19
Y/N Notes Y/N Notes
Chronic kidney
disease
N Y
Parkinson’s disease N Y
Malabsorption N Included under secondary osteoporosis Y For example, Crohn’s disease, ulcerative
colitis, coeliac disease, steatorrhoea or
blind loop syndrome
Endocrine problems N Long-standing hyperthyroidism included
under secondary osteoporosis
Y For example, thyrotoxicosis,
hyperparathyroidism, Cushing’s
syndrome
Epilepsy or taking
anticonvulsants
N Y
Taking
antidepressants
N Y
Taking oestrogen-
only HRT
N Y
COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; N, no; TIA, transient ischaemic attack; Y, yes.
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categories is done independently for QFracture and FRAX. As there is not necessarily agreement between
the risk scores calculated by these two different risk assessment tools at the patient level, the same patients
may not end up in the same risk category when using different tools to define absolute risks.
In order to stochastically sample patient characteristics we needed data on the prevalence of each clinical
risk factor and the distribution of continuous factors, such as age and BMI. As well as considering the
prevalence of individual risk factors, it is also important to determine whether or not there are correlations
between any of the patient characteristics so that the sampling process can allow for the fact that some
risk factors may be more likely to occur in the same patient than in separate patients. It is difficult to fully
characterise the correlation structure of all of the risk factors that go into both the QFracture and FRAX
tools without access to a database containing information on all of the risk factors in a large sample of
patients. However, it is most important to capture the correlations between those characteristics that
are likely to be significant determinants of cost-effectiveness independently of their impact on absolute
fracture risk. This is because the prevalence of these factors will determine the distribution of
cost-effectiveness within groups who have the same absolute fracture risk.
We developed a conceptual model outlining which risk factors are likely to significantly impact
cost-effectiveness independently of their impact on absolute fracture risk. This was based on the
relationships assumed in published models in this area, advice from our clinical advisors and rapid literature
searches (Table 10). A summary of this conceptual model is shown in Figure 66. Age, sex, prior fracture,
TABLE 10 Patient characteristics expected to affect cost-effectiveness independently of absolute fracture risk
Patient characteristic Rationale
Age Age is predictive of the following factors that affect cost-effectiveness independently of absolute
fracture risk:
l life expectancy155
l utility156
l proportion of fractures occurring at various sites148
l mortality after hip fracture157
l residential status after hip fracture158
Steroid use Efficacy data for steroid-induced osteoporosis may differ from non-steroid-induced osteoporosisa
All-cause mortality may be higher in steroid users, which will affect cost-effectiveness
independently of absolute fracture risk
Sex Efficacy data for males and females may differa
Sex is predictive of the following factors that affect cost-effectiveness independently of absolute
fracture risk:
l life expectancy155
l proportion of fractures occurring at various sites148
l mortality after hip fracture157
l residential status after hip fracture158
Prior fracture Utility at baseline may be lower in those with significant prior fractures (e.g. hip fracture)
Residential status Residential status is predictive of the following factors that affect cost-effectiveness independently
of absolute fracture risk:
l utility at baseline
l mortality after hip fracture157
l cost of additional social care following fracture (these will be higher in community-dwelling
patients who move to an institutional residential setting following fracture than in those
already living in an institutional residential setting)
a The conceptual model allowed for this possibility, but after considering the efficacy evidence it was decided that these
data would be pooled across sexes, and steroid and non-steroid users.
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steroid use and residential status were identified as risk factors thought to affect cost-effectiveness
independently of absolute fracture risk. Further details on the rationale for selecting these risk factors are
given in Table 10. Ethnicity, family history of fracture and BMD were excluded, as these are expected to
affect cost-effectiveness solely through their impact on absolute fracture risk. Although some of the
remaining risk factors included in either FRAX or QFracture (e.g. alcohol use, smoking status, comorbidities,
secondary causes of osteoporosis, medications, BMI and history of falls) might be expected to affect an
individual’s baseline utility, life expectancy or likelihood of living in an institutional residential setting, these
relationships were felt to be too weak to include within the model without adding unnecessary complexity
to the model structure. Furthermore, many of these conditions are likely to be more prevalent within older
patients or those living in residential care and, therefore, their impact on utility, all-cause mortality or
outcomes following a fracture may already be captured by the relationship between these variables and age
or residential status. We have therefore focused on trying to capture the correlations between age, sex,
steroid use, prior fracture and residential status. This was achieved by looking for age- and sex-specific
estimates of steroid use, prior fracture and residential status, as these were considered to be where the
most significant correlations would lie. The conceptual model was developed to allow for the possibility
that different efficacy data may be applied for different sexes and for steroid- and non-steroid-induced
osteoporosis, but in the final analysis efficacy evidence was pooled across all included trials reporting
fracture outcomes. The potential for increased all-cause mortality in steroid users was noted at the
conceptual modelling stage, but no difference in life expectancy was applied in the final model.
The primary data source used to characterise the patient population was the cohort used to derive the
2012 QFracture algorithm. This study used a large (n = 3,142,673) prospective cohort aged 30–100 years
drawn from a large, validated primary care electronic database.18 This study was chosen as the primary
source of data on patient characteristics as it was considered to be representative of the general UK
population and provided data on all of the risk factors included within the QFracture algorithm. For the
majority of the clinical risk factors, we used the prevalence within the 2012 QFracture cohort and applied
the same prevalence across all ages and across both sexes. These risk factors are listed in Table 11 along
with the prevalence reported for the 2012 QFracture cohort. Although many of these risk factors are
expected to have varying prevalence across different sexes and age groups, it was not considered
necessary to capture their correlation with age or sex, as they are assumed to influence cost-effectiveness
through only their impact on absolute fracture risk.
Although data were available on the age distribution for patients within the 2012 QFracture cohort, these
data were not provided separately for males and females and the age profile of the UK population is
known to differ slightly by sex.159 Therefore, sex-specific 2013 mid-year population estimates for England
from the Office for National Statistics (ONS) were used to provide an empirical distribution for patient
age.159 Figure 69 shows how the proportion falling within each band compares between the ONS data and
the 2012 QFracture cohort. The data appear to be reasonably well matched except that the QFracture
cohort appears to have a lower proportion in the 30–39 years category. The ONS data were considered to
be more representative of the population in England and, therefore, the age of each individual patient was
sampled using the sex-specific ONS data.
The proportion of patients living in an institutional residential setting was estimated from the 2011 census
data.160,161 Sex-specific data were available for 5-year age bands for all people who are usual residents in
communal establishments.160 However, these 5-year estimates included people resident in other types
of communal establishments such as children’s homes and prisons. Data were also available on specific
types of establishments for 10-year age bands.161 We selected data for people resident in medical and care
establishments, which included NHS, local authority and other establishments both with and without
nursing care. We then used the 5-year data on all communal establishments to divide up the 10-year data
into 5-year age bands. These data, shown in Figure 70, were used to sample whether or not an individual
was living in an institution according to their age and sex.
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For steroid use, data published by van Staa et al.162 suggest that the prevalence of current steroid use
increases with age. Their estimates were based on analysis of the GPRD (which is now called Clinical
Practice Research Datalink), which is a large database of GP records for UK patients. This provided a large
retrospective cohort that is likely to be representative of the general population of England and Wales.
TABLE 11 Clinical risk factors that were assumed to have a constant prevalence across the cohort
Clinical risk factors aPrevalence in 2012 QFracture cohort18
Dementia 0.6%
History of falls 1.2%
Malabsorption 0.5%
Endocrine disorders 0.5%
Asthma or chronic obstructive airways disease 7.6%
Any cancer 1.9%
Cardiovascular disease 5.3%
Epilepsy diagnosis or prescribed anticonvulsants 1.8%
Chronic liver disease 0.2%
Parkinson’s disease 0.2%
Rheumatoid arthritis or systemic lupus erythematosus 0.7%
Chronic renal disease 0.2%
Type 1 diabetes mellitus 0.3%
Type 2 diabetes mellitus 2.8%
Parental history of osteoporosis 0.3%
Unopposed HRT 2.2% (in the female-only subgroup)
Any antidepressant 7.7%
a Prevalence for the derivation cohort is reported here and used in the model, but similar values were obtained for the
validation cohort.
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FIGURE 69 The proportion of those aged ≥ 30 years who fall within each age category. Based on ONS data and the
age distribution in the 2012 QFracture cohort.18,159
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Data on the prevalence of oral glucocorticoid use by sex and 10-year age bands were digitally extracted
from a graph provided by van Staa et al.162 The relationship between prevalence and age appear to follow
a similar pattern for low-, medium- and high-dose users. Data were extracted for only medium-dose
(2.5–7.5 mg per day) and high-dose (≥ 7.5 mg per day) steroid users as these dosages overlapped with the
range specified in the FRAX fracture risk algorithm (≥ 5 mg per day). However, when these data were
combined with the ONS data on the current age distribution within England to estimate the average
prevalence across patients aged ≥ 30 years, this was substantially lower than the prevalence recorded in
the QFracture database (0.95% vs. 2.2%). The difference may be because we did not include low-dose
users from the van Staa et al.162 estimates or that the QFracture data do not appear to relate to a specific
dose of steroids. A more recent estimate of the prevalence based on UK GP records is provided by
Fardet et al.163 Although this did not provide a breakdown of the prevalence by age and sex, the overall
prevalence of 0.79% for 2008 reported by Fardet et al.163 is closer to that reported by van Staa et al.162
than the figure reported in the QFracture database. We therefore decided to use the combined data for
medium- and high-dose users provided by van Staa et al.’s data to characterise the age and sex
distribution of steroid use. Figure 71 shows age- and sex-specific prevalence estimates applied in the
model for steroid use.
Data on the prevalence of previous fracture were taken from a meta-analysis by Kanis et al.164 This study
was selected as it provided data on the prevalence of prior fracture, reported by sex and 10-year age
bands. The cohorts used to estimate the prevalence of prior fracture were the same cohorts used to
estimate the impact of prior fracture on future fracture risk for the FRAX algorithm.17 The prevalence of
prior fracture is difficult to quantify as it depends on whether or not all prior fractures are included
regardless of the site of fracture or the mechanism of injury. Although the definitions used varied across
the multiple cohorts that informed the estimates from Kanis et al.,164 the fact that these cohorts were then
used to derive the impact of prior fracture on future fracture risk provides some consistency between the
definition of prior fracture used for prevalence and for risk score calculation. The prevalence reported by
Kanis et al.164 for each of the 10-year age bands, which ranged from 15% at age 30 years to 48% at age
80 years in women, is much higher than that reported within the QFracture cohort (1.9% across a cohort
aged ≥ 30 years).18,164 An alternative estimate of the prevalence of prior fracture is provided by Scholes
et al.,165 who used data collected during the Health Survey for England to estimate the prevalence of
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FIGURE 70 Proportion living in an institutional residential setting by age band. Reproduced from Office for
National Statistics. Census 2011: Communal Establishment Management and Type by Sex by Age. 2011.
URL: www.nomisweb.co.uk/census/2011/dc4210ewla (accessed 28 October 2014).161 Contains public sector
information licenced under the Open Government Licence v3.0.
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previous fracture in community-dwelling people aged > 55 years. They found that the prevalence was
49% in men and 40% in women, although these data relied on the individuals’ recall and did not
distinguish between fragility fractures and those occurring in early life or associated with significant
trauma. Another source of evidence that can be used to cross-check the estimates provided by Kanis
et al.164 are studies reporting the incidence of fracture by age. Prevalence can be estimated from these
studies in an approximate manner by assuming that the prevalence of prior fracture at a particular age is
equivalent to the cumulative incidence across all previous age bands although, under this assumption, the
prevalence may be inflated by multiple fractures occurring within the same patient, if these are reported
separately in the incidence data.
Data on the incidence of fracture by age and sex and the proportion of fractures that are fall related
(standing fall, fall down stairs or fall from a low height) are provided by Court-Brown et al.166 This was a
prospective cohort study conducted in Scotland in 2010/11 that compared the rate of fractures presenting to
the Royal Infirmary of Edinburgh with population estimates from the 2001 census to estimate incidence
rates. Estimating the prevalence of fall-related fractures from these data, by assuming that it is equal to the
cumulative incidence in those aged over 35 years, provides prevalence data closer to those reported by
Kanis et al.164 than those reported in the QFracture cohort. Therefore, the data presented by Kanis et al.164
(Figure 72) were used in the model to sample the likelihood of an individual having a prior fracture.164
A second incidence study, by van Staa et al.,167 provides data on the incidence of fracture in England in a
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FIGURE 71 Prevalence of current steroid use: data from van Staa et al.162 combined for medium- and high-dose
steroid users.
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general practice (GPRD) cohort, which examined over 20 million person-years of follow-up. The proportion
of fractures that were fall related in the study by Court-Brown et al.166 was applied to the incidence data
reported by van Staa et al.167 to estimate the incidence of fall-related fractures in an attempt to exclude
fractures related to significant trauma such as road traffic accidents. Prevalence of a prior fracture after the
age of 3 years was then estimated by calculating the cumulative incidence from age 20 years, and these data
are summarised in Figure 73. The prevalence estimated in younger age groups, when using this method,
was lower compared with the data reported by Kanis et al.164 This alternative estimate of the prevalence of
prior fracture was applied in a sensitivity analysis to assess whether or not the cost-effectiveness of
bisphosphonate treatment is sensitive to the prevalence of prior fracture in the population.
Swedish estimates for the incidence of fracture at different sites across sexes and age bands were then
used to estimate the cumulative prevalence of fractures at various sites up to the start age for each age
band.148 These data were used to determine the distribution of prevalent fractures across different fracture
sites, as shown in Table 12. As the incidence data were presented for patients aged ≥ 50 years we have
assumed that the distribution of prior fractures at ages 30–55 years is equal to the distribution of incidence
TABLE 12 Distribution (%) of prevalent fractures across the four main osteoporotic fracture sites (within each sex)
Fracture site
Age band (years)
< 55 55–59 60–64 65–69 70–74 75–79 80–84 85–89
Women
Hip 6 6 8 11 15 20 27 36
Vertebral 22 22 20 23 23 25 25 22
Proximal humerus 17 17 16 14 16 15 15 13
Wrist 56 56 55 52 46 40 34 29
Men
Hip 10 10 14 18 23 29 36 44
Vertebral 48 48 41 41 35 36 35 32
Proximal humerus 16 16 12 12 11 13 12 10
Wrist 25 25 33 29 30 22 17 14
Calculated from incidence data presented by Kanis et al.148
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FIGURE 73 Proportion who have had a prior fracture by sex and age band (data applied in sensitivity analysis).
Figures presented were calculated by adjusted data from van Staa et al.,167 using additional data from
Court-Brown et al.166
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of fracture from ages 50–55 years. It can be seen that as the incidence of hip fracture rises with age, the
proportion of prior fractures that have occurred at the hip increases with each increasing age category.
Data are available from the Health Survey for England on the average BMI for different ages and sexes.168
These data, presented in Figure 74, show that BMI varies with age. Although BMI is not expected to affect
cost-effectiveness except through its influence on absolute fracture risk, it is considered to be an important
risk factor, particularly where BMD is unknown. A 2014 meta-analysis found that the relationship between
BMI and fracture risk is much weaker after adjusting for BMD.169 A significant positive correlation was
also found in this study between BMI and BMD (95% CI 0.32 to 0.33, r = 0.33; p < 0.001). Given the
significant correlation between these two variables and the fact that we are assuming that BMD is not
available when fracture risk is first assessed, we decided to model the age variation in BMI, as this may
capture some of the underlying variation in BMD with age. However, we accept this will capture only a
small proportion of the association between BMD and age. We decided to use the Health Survey for
England data168 to characterise the mean BMI for different age bands and sexes, as these data allow the
SD to be calculated. However, they do not provide any information on the shape of the BMI distribution.
We assumed that the BMI values were log-normally distributed, as we found that assuming a normal
distribution overestimated the proportion falling within the underweight category. As it is the underweight
group who are at particular risk of a fragility fracture, assuming a normal distribution would have
overestimated population fracture risk.169 As can be seen in Figure 75, assuming a log-normal distribution
still overestimated the proportion who were underweight, but by a factor of 3 rather than 5.
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Treatment strategies
The model compares the following treatment strategies:
l alendronic acid (10 mg per day or 70 mg per week)
l risedronic acid (5 mg per day or 35 mg per week)
l ibandronic acid (150 mg per month)
l i.v. ibandronic acid (3 mg every 3 months)
l zoledronic acid (5 mg/year)
l no treatment.
We have not distinguished in the model between the daily and weekly formulations of alendronic acid and
risedronic acid, as the weekly formulations for these are considered to be clinically equivalent and the
effectiveness evidence has not been analysed separately for weekly and daily doses.
We assume that all patients will receive adequate supplemental calcium and vitamin D regardless of
whether or not they are being treated with a bisphosphonate and, therefore, no cost is included within the
model for calcium and vitamin D supplements. Patients in the no-treatment arm are assumed to receive no
further treatment to reduce their fracture risk. We have not assumed any active follow-up for patients
receiving either bisphosphonates or no treatment.
We assume that the intended treatment duration is 5 years for alendronic acid, risedronic acid and
ibandronic acid (both oral and i.v.) and 3 years for zoledronic acid. However, not all patients persist
with therapy for the intended duration, as previously discussed in Chapter 3, which describes the clinical
evidence on treatment persistence. The duration of treatment in the model was therefore set to the mean
duration of persistence using data from the systematic reviews described in Chapter 3. The highest-quality
systematic review was considered to be that by Imaz et al.,128 which reported that the mean duration of
treatment persistence was 184 days (95% CI 164 to 204 days) for oral bisphosphonates (alendronic acid,
risedronic acid and ibandronic acid). Only one of the studies included in the meta-analysis of average
persistence by Imaz et al.128 examined ibandronic acid, with the rest considering alendronic acid and
risedronic acid. However, the mean duration of persistence for monthly ibandronic acid was similar to the
mean duration for weekly alendronic acid and risedronic acid (98 days for ibandronic acid vs. 116 days and
113 days for alendronic acid and risedronic acid, respectively). Therefore, we decided to use the pooled
estimate provided by Imaz et al.128 for all oral bisphosphonates.
The review by Imaz et al.128 did not provide any data on persistence in patients receiving i.v.
bisphosphonate therapy.128 However, a review by Vieira et al.132 identified a cohort study (Curtis et al.170) in
US Medicare patients that provided estimates of the mean number of infusions received for zoledronic acid
and i.v. ibandronic acid.170 It is noted that the duration of treatment with zoledronic acid estimated by
Curtis et al.170 was considered by our clinical advisors to be low compared with their own experience of
administering zoledronic acid within clinical practice. However, in the absence of an alternative estimate
these data were used to estimate the mean duration of persistence with therapy for i.v. bisphosphonates.
The full treatment effect was assumed to persist for 1 year after the last zoledronic acid infusion and
3 months after the last ibandronic acid infusion. Persistence data applied in the base-case model are
summarised in Table 13. A sensitivity analysis in which we assumed full persistence with treatment for
3 years for zoledronic acid and 5 years for all other treatments was also examined.
The fall-off period was assumed to be equal to the duration of treatment for all treatments except
zoledronic acid, for which a longer fall-off period was assumed. Clinical advice was that a 7-year fall-off
period could be assumed for 3 years of zoledronic acid treatment. We therefore assumed an approximate
fall-off period of 2.33 (= 7/3) times the treatment period for zoledronic acid.
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Estimating time to event from absolute fracture risk
Time to fracture has been estimated by fitting a parametric survival function to the estimates of absolute
risk provided by the QFracture algorithm. For the model using FRAX, the parametric form and shape
parameter fitted to the QFracture data has been used but the rate parameter of the survival function has
been adjusted to ensure that the absolute fracture risk at 10 years, predicted by the survival function,
matches that predicted by the FRAX tool. Treatment effects are incorporated by applying a HR to the rate
parameter, with further details on the incorporation of treatment efficacy provided in Incorporating the risk
of fracture at other sites and Application of hazard ratios to incorporate treatment effects both during and
beyond the treatment period.
The algorithm used by the QFracture tool to calculate the risk of fracture over varying time periods is
publicly available on the QFracture website (www.qfracture.org/). This algorithm was examined and was
found to have the following form:
Cumulative risk over t years = 1−S0(t)
exp(η), (1)
where the parameter η is the risk-modifying factor that adjusts for patient characteristics and S0 is the
underlying survival function. Different values of S0 are defined according to the time frame (t) over which
risk is to be assessed. The survival model used to estimate the risk-modifying factor η is described as a Cox
regression. In a Cox regression the values for S0 do not have to follow any particular parametric form.
However, when the S0 values were plotted, to give the fracture-free survival for patients without any
risk-modifying factors (η = 0), it was noted that they appeared to be very smooth, suggesting that it may be
possible to fit a functional form to the underlying survival function. Given that the Weibull function (which
includes the exponential function as a special case) and the Gompertz function are both compatible with
proportional hazards assumptions, we tested both of these parametric forms to see if they were suitable.
A plot of ln(–ln(S(t))) against ln(t) was produced to see whether or not the data were consistent with a
Weibull survival curve. This was done for an example patient with the following characteristics: female,
aged 50 years, BMI of 24 kg/m2 and no clinical risk factors. The same plot was then produced for a patient
with type 1 diabetes but no other clinical risk factors and the same age and BMI to examine the impact of
clinical risk factors on the shape of the plots. From Figure 76 it can be seen that the distance between the
plots is constant for these two cases, as would be expected for a proportional hazards model, but neither
plot is linear over the whole time period. The plots appear to be linear over short time periods (5 or
perhaps 10 years), but the Weibull curve does not appear to be appropriate over longer time frames.
A plot of ln(hazard) against time was generated once again for a 50-year-old female with a BMI of
24 kg/m2 and either with or without type 2 diabetes as shown in Figure 77. This was found to be linear,
suggesting that the underlying survival function was consistent with a Gompertz distribution. We have
therefore assumed that the underlying survival function follows a Gompertz distribution and used the
linear fit for the ln(hazard) function to estimate the parameters for the Gompertz distribution in patients
TABLE 13 Duration of persistence with treatment
Treatment
Mean duration of
persistence with treatment SE Source
Alendronic acid, risedronic
acid and oral ibandronic
acid
184 days (0.5 years) 10 days Meta-analysed estimate from the
Imaz et al.128 systematic review
i.v. ibandronic acid 401 days (1.1 years) 15 days Curtis et al., 2012170
Zoledronic acid 621 days (1.7 years) 6.5 days Curtis et al., 2012170
SE, standard error.
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without any risk-modifying factors (η = 0). Table 14 shows the survival parameters for the underlying
Gompertz distribution in males and females for the outcomes of hip fracture-free survival and osteoporotic
fracture-free survival with osteoporotic fracture defined as hip, wrist, vertebral or proximal humerus fracture.
Figures 78–81 show the fit of the parametric curve against the survival data specified in the QFracture
algorithm for each of these survival functions. It can be seen from the plots that the parametric curves
fit the data better in the first 10 years and that the parametric curves may underestimate long-term
fracture risk. Although this was noted as a limitation, the good fit up to 10 years means that the rates
are sufficiently accurate during the period in which drugs are assumed to affect fracture outcomes. An
underestimation of the long-term fracture risk in the period after the drug efficacy is assumed to fall to
zero is likely to affect all treatment strategies equally and, therefore, is not expected to significantly bias
the estimates of cost-effectiveness. We therefore assumed that the fitted Gompertz curve could be used to
estimate time to fracture for patients with no risk-modifying factors.
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FIGURE 76 Plot to test suitability of Weibull survival curve. Patient characteristics: female, aged 50 years, BMI of
24 kg/m2, with or without type 2 diabetes.
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FIGURE 77 Plot to test suitability of Gompertz parametric form. Patient characteristics: female, aged 50 years,
BMI of 24 kg/m2, with or without type 2 diabetes.
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TABLE 14 Parameters for fitted Gompertz functions in patients with no risk-modifying factors (η = 0)
Survival function Sex Alpha Beta R2
Osteoporotic (hip, wrist, proximal humerus or vertebral) fracture Female Exp(–6.9499) 0.0947 0.9942
Hip fracture Female Exp(–9.4486) 0.1375 0.9963
Osteoporotic (hip, wrist, proximal humerus or vertebral) fracture Male Exp(–8.0425) 0.0908 0.9882
Hip fracture Male Exp(–10.228) 0.1454 0.9902
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FIGURE 78 Gompertz fit for a female patient with no risk-modifying factors (η = 0) for the outcome of any
osteoporotic fracture (hip, wrist, proximal humerus or vertebral).
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FIGURE 79 Gompertz fit for a female patient with no risk-modifying factors (η = 0) for the outcome of hip fracture.
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QFracture does not provide individual predictions for each of the four major osteoporotic fractures (hip,
wrist, vertebral and proximal humerus). Instead, it provides an estimate of the absolute risk of fracture
across all four fracture types. In order to provide an estimate of the time to fracture for each site, we
multiplied the alpha parameter for the fitted Gompertz survival curve by the proportion of patients
experiencing an incident fracture of that type. The proportions, shown in Table 15, were estimated from
Kanis et al.148 and provide the incidence of fractures in Sweden across different fracture sites by sex and
age band.
We used these site-specific alpha values to generate samples from the Gompertz distribution for each
fracture site and plotted a survival function for time to fracture at each site. To validate this approach, of
apportioning the alpha value for major osteoporotic fracture across the four sites, we calculated the time
to first major osteoporotic fracture from these site-specific fracture survival curves and compared these to
the survival from major osteoporotic fracture predicted by the QFracture algorithm. We found that the
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FIGURE 80 Gompertz fit for a male patient with no risk-modifying factors (η = 0) for the outcome of any
osteoporotic fracture (hip, wrist, proximal humerus or vertebral).
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FIGURE 81 Gompertz fit for a male patient with no risk-modifying factors (η = 0) for the outcome of hip fracture.
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survival curves generated were comparable, suggesting that this method of calculating site-specific fracture
curves is valid, as can be seen from Figure 82.
However, as can been seen from Figure 83, when we compared the hip fracture data calculated from
major osteoporotic fracture to the hip fracture survival estimates provided directly from the QFracture
algorithm, we found that these did not match well over longer time frames (i.e. over 5 years). This can be
explained by the fact that the beta value for the hip fracture-specific Gompertz curve is higher, suggesting
a faster increase over time for hip fracture than is seen over all major osteoporotic fractures. We decided
to use the hip fracture survival predicted by apportioning the major osteoporotic fractures in the base-case
analysis, as this would provide an estimate of major osteoporotic fracture that is consistent with the
estimates from the QFracture algorithm. Furthermore, the beta value for the Gompertz function for major
osteoporotic fracture is likely, in reality, to be the average of a lower value for non-hip and a higher value
for hip, but as the non-hip value could not be calculated we felt it was better to use the beta value for
major osteoporotic fracture and apply it to all four fracture types in the base-case analysis. A sensitivity
analysis was also conducted using the hip-specific algorithm from QFracture for estimating time to hip
fracture to see whether or not this had a significant impact on the cost-effectiveness.
The following method was used to calculate time to event for each fracture type in the base-case analysis
when assuming that patients have been assessed using the QFracture algorithm.
1. calculate the proportion, p, of major osteoporotic fractures that occur at the site of interest according
to the person’s age and sex
2. calculate the risk score modifier, η, from the patient characteristics
3. select the beta for the sex-specific Gompertz survival curve
4. select HR, which incorporates any treatment effect from intervention
5. calculate alpha for the sex-specific Gompertz survival curve as follows:
alpha = alpha(for η = 0) × p × exp(η) × HR
6. sample time to fracture from Gompertz (alpha, beta)
A similar approach was not possible when estimating time to event using the estimates of absolute
fracture risk provided by the FRAX algorithm. This is because the algorithm used to calculate absolute
TABLE 15 Proportion (%) of major osteoporotic fractures occurring at each site by sex and age banda
Fracture site
Age band (years)
50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89
Women
Hip 6 6 11 15 21 28 38 53
Vertebral 22 22 19 26 23 27 25 18
Proximal humerus 17 17 15 11 19 13 14 9
Wrist 56 56 55 48 37 31 23 19
Men
Hip 10 10 18 24 31 38 49 57
Vertebral 48 48 32 40 27 39 32 28
Proximal humerus 16 16 8 11 10 16 9 7
Wrist 25 25 41 25 32 7 9 8
a Calculated from Kanis et al.148
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fracture risk within the FRAX tool is not publicly available and, therefore, it was not possible to assess
whether or not survival from fracture follows a particular parametric form. Instead, we assumed the
underlying shape of the survival curve for FRAX would be identical to that used in the QFracture algorithm.
In effect this meant assuming a Gompertz curve is followed, which has the same beta parameter as seen
in the QFracture algorithm. In doing so, we were then able to calculate the time to event for patients
assessed using the FRAX tool by calculating the multiplier, Φ, which needed to be applied to the alpha
value of the QFracture survival curve to provide the absolute risk of fracture at 10 years, predicted by
FRAX. In doing so, we assumed that there is a constant HR between the number of events predicted by
FRAX and the number predicted by QFracture across all time frames. From Equations 2–4, it can be seen
that Φ can be calculated by comparing the absolute risk of fracture estimated by the two fracture
risk tools.
Absolute risk at 10 years in FRAX:
FRAX(10) = 1− S0(10)
Φexp(η). (2)
Absolute risk at 10 years in QFracture:
QF(10) = 1− S0(10)
exp(η). (3)
From this we can derive that:
Φ = ln½1− FRAX(10)=ln½1−QF(10). (4)
One of the complicating factors with this approach is that QFracture provides an estimate of fracture risk
without the competing risk of mortality, whereas FRAX provides an estimate of absolute fracture risk when
taking into account the competing risk of mortality. Therefore, at older ages, when the risk of mortality is
higher, the FRAX algorithm will calculate lower estimates of 10-year risk than the QFracture algorithm. It
was not possible to correct for this within our model, as we did not have sufficient information regarding
the competing hazard of death used within the FRAX algorithm to adjust the FRAX estimates to exclude
the competing risk of mortality.
Incorporating the risk of fracture at other sites
Fractures at additional sites (femoral shaft, humeral shaft, pelvis, scapula, clavicle, sternum, ribs, tibia and
fibula) have been incorporated by increasing the incidence of fractures at the four main sites (hip, wrist,
spine and proximal humerus). Although several of the published cost-effectiveness analyses restricted the
fracture types to the four main sites,137,139,140 some of the studies incorporated fractures at additional
sites45,49–106,108–143 by grouping these with one of the four main fracture sites. The decision over which
fractures to group together has, in previous analyses, been justified by the expectation of similar costs and
disutilities across particular groups of fractures.171 The groupings used were consistent across the three
published cost-effectiveness analyses that incorporated additional sites.141–143
We decided to keep the groupings used in these three studies with one exception. These studies grouped
pelvic fractures with hip fractures. Pelvic fractures associated with osteoporosis were considered by our
clinical advisors not to be associated with an excess risk of mortality similar to that associated with hip
fractures and the costs were also expected to be lower. Therefore, pelvic fractures were grouped instead
with proximal humerus fractures. Therefore, the grouping of fracture sites used within our model was
as follows:
l femoral shaft grouped with hip
l clavicle, scapula, rib and sternum grouped with wrist
l tibia, fibula, pelvis and humeral shaft grouped with proximal humerus.
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Both QFracture and FRAX use a clinical definition for vertebral fractures and, therefore, the rate of vertebral
fractures predicted in our model is specific to clinical vertebral fractures. The cost and quality-of-life
implications of morphometric vertebral fractures that are not clinically apparent are likely to be much
smaller than for clinically apparent vertebral fractures. Therefore, we expect that excluding morphometric
fractures that are not clinically apparent from the model to have a small impact on the ICER. Previous
analyses by Stevenson et al.140 (reported in appendix 15 of their monograph) suggest that the exclusion of
morphometric fractures does not significantly bias the estimates of cost-effectiveness.
The multipliers applied to the rate of hip, wrist and proximal humerus fractures to incorporate the
additional fractures sites were calculated based on Swedish incidence data reported by Kanis et al.148 and
are shown in Table 16. These were applied in the model to the alpha parameter for the Gompertz
sampling of time to fracture. As the alpha parameter is the rate parameter for the Gompertz survival curve,
a multiplier > 1 increases the risk of fracture. The data from age band 50–54 years were applied to those
aged 30–50 years. The very high multiplier for wrist fractures in men is driven by a large incidence of rib
fractures compared with wrist fractures in the data reported by Kanis et al.148
Application of hazard ratios to incorporate treatment effects both during
and beyond the treatment period
As we have assumed a Gompertz underlying survival function for time to fracture, and as this is a
proportional hazards model, the HR for treatment can be applied directly to the alpha parameter as
described in Estimating time to event from absolute fracture risk. When taking a proportional hazards
approach the treatment effect, as measured by the HR, is assumed to be constant over the entire duration
of the survival curve. However, bisphosphonates are commonly given for only a few years and, therefore,
we needed the model to allow for a fall-off in treatment effect after treatment is finished. For patients
who complete the intended treatment period (5 years for all bisphosphonates except zoledronic acid) we
have assumed a linear fall-off in HR for each year from years 5 to 10 such that the HR at 10 years is 1.
For zoledronic acid, we have assumed a 3-year treatment period and a linear fall-off in treatment effect
from years 3 to 10 such that the HR is 1 at year 10. This has been done by resampling the time to fracture
at the end of the treatment period and applying a HR modified to account for the fall-off in treatment
from years 5 to 10. The HR is modified by taking the average HR for full treatment effect and zero
treatment effect. This modified HR is applied for the duration of the fall-off period. Although this linear
approximation may underestimate the treatment effect in the early years after stopping and overestimate it
TABLE 16 Multipliers applied to the rate of hip, wrist and proximal humerus fractures to include fractures at other
sites (calculated from incidence data reported by Kanis et al.148)
Fracture site
Age band (years)
50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89
Women
Hip 1.27 1.19 1.20 1.13 1.11 1.09 1.07 1.08
Proximal humerus 1.89 2.08 2.26 1.74 1.93 1.89 2.33 2.14
Wrist 1.49 1.57 1.37 1.70 1.61 2.23 2.50 3.56
Men
Hip 1.36 1.36 1.26 1.18 1.15 1.09 1.05 1.05
Proximal humerus 1.52 1.52 1.84 1.68 1.67 1.58 1.78 2.09
Wrist 5.36 5.36 6.89 4.49 4.57 12.83 6.06 15.41
Data from Kanis et al.148
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in the later years, it should provide the correct treatment effect on average over the fall-off period. Adding
more dummy events to update the HRs at more frequent intervals over the fall-off period was avoided, as
it would reduce the computational efficiency of the model.
The time to fracture is resampled at the end of the fall-off period, with a HR of 1 applied thereafter. As
the HR is assumed to increase over time in a Gompertz survival curve, the patient’s age is updated prior to
resampling the time to fracture resulting in a new alpha value in the Gompertz function. We noted that
the QFracture algorithm does not appear to be internally consistent when applied at different ages. For
example, the 1-year risk of fracture in a 55-year-old is lower than the 1-year risk of fracture predicted for
the fifth year in a patient aged 50 years. Given this internal inconsistency within the QFracture algorithm,
our method of resampling at 5 and 10 years results in a stepped linear function for the ln(hazard) even
when the HR is held constant over the whole modelled timeframe. However, this method maintains the
proportional hazards assumption within each step. This can be seen in Figure 84, where the diamonds and
squares show the stepped ln(hazard) function which results from resampling at 5 and 10 years when
applying a constant HR of 2 or 1, respectively. It can be seen that the gap between the diamonds and
squares is constant across the whole timeframe as would be expected for a proportional hazards model.
Figure 85 demonstrates the additional effect of modifying the HR at 5 and 10 years to allow for reduced
treatment effect during the fall-off period and no treatment effect beyond the fall-off period. It can be
seen that this brings the ln(hazard) function for the treated patients (with treatment associated with a HR
of 2 in this example), shown by the squares, down to match that of the no-treatment group (constant
HR = 1 across all years), shown by the diamonds, from 10 years as would be expected. It should be noted
that the squares and diamonds in Figure 85 do not match exactly, as the graphs are based on stochastic
time-to-event estimates but we would expect them to match exactly if an infinite number of samples were
used to derive the plotted points.
In those scenarios where we assume that patients do not persist with treatment for the full 5 years
(or 3 years for zoledronic acid), we have used additional dummy events at 5 and 10 years to ensure that all
patients receive an updated estimate of fracture risks at these time points.
Efficacy estimates
The HRs for fracture estimated by the systematic review and NMA described in Chapter 3 have been
applied in the model. Fracture data have been synthesised using an NMA model including all studies
defined by the inclusion/exclusion criteria (i.e. males and females, steroid users and non-steroid users,
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FIGURE 84 Plot showing how resampling at 5 and 10 years results in a stepped ln(hazard) plot, but maintains the
gap associated with the HRs.
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confirmed low BMD or BMD unknown). The resulting measure of treatment effect was a HR for the effect
of each bisphosphonate relative to placebo together with an estimate of the between-study SD.
The NMA described in Chapter 3, Methods for the network meta-analyses, has been used to generate the
joint predictive distribution of the HR for each treatment compared with no treatment in a new study; this
acknowledges heterogeneity in the effect of each treatment depending on the characteristics of patients
included in the studies. These relative treatment effects have been applied consistently across the whole
modelled population within the economic analysis.
Absolute effects of treatment predicted by the economic model (e.g. number needed to treat) vary across
the population because of some patients having a higher absolute risk of fracture based on either their
QFracture or FRAX score.
The effect of treatment on hip fracture was estimated from studies reporting hip fracture data. The effect
of treatment on vertebral fractures was estimated from studies reporting all vertebral fractures (i.e. clinical
and morphometric) because not all studies (i.e. treatments) reported outcomes for clinical vertebral
fracture. The effect of treatment on proximal humerus fractures was estimated using all non-vertebral
fractures as a proxy because too few studies reported data for fractures specifically at the proximal
humerus. Evidence on the effect of treatment on wrist fractures was available for all treatments except for
zoledronic acid. The effect of zoledronic acid was estimated from the statistical model using the predictive
distribution of a new bisphosphonate in a population of bisphosphonates.
The efficacy evidence from 2.5 mg per day of oral ibandronic acid has been applied to both 150 mg per
month of oral ibandronic acid and 3 mg per 3 months of i.v. ibandronic acid where no alternative fracture
data were available for these licensed regimens, as the monthly oral and quarterly i.v. doses were licensed
based on their non-inferiority in lumbar spine BMD outcomes when compared with the daily ibandronic
acid treatment regimen.45,47,49,172,173 Where there were fracture data available for monthly oral ibandronic
acid but none for quarterly i.v. ibandronic acid or daily oral ibandronic acid, we have assumed that the data
from the monthly oral treatment can be applied to the i.v. treatment regimen. This was considered to be
reasonable, as both the oral monthly dose and the quarterly i.v. dose were licensed based on non-inferiority
compared with the daily oral dose for lumbar spine BMD outcomes.172,173 Our own analysis of the femoral
neck BMD data for these treatments would support this assumption of similar treatment effects for oral
monthly ibandronic acid and quarterly i.v. ibandronic acid.
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FIGURE 85 Plot showing the effect of adjusting the HRs to reflect falling treatment effect during the fall-off
period (5–10 years) and after the fall-off period (> 10 years).
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Fractures occurring at sites other than one of the four main osteoporotic fracture sites have the efficacy
applied according to the site groupings previously described, that is hip fracture efficacy data are applied
to other femoral fractures; wrist fracture efficacy data are applied to scapula, clavicle, rib, sternum; and all
non-vertebral fracture efficacy data are applied to tibia and fibula, pelvis and humeral shaft.
The HR is assumed to be constant over the duration of the treatment period and then to decrease linearly
over the fall-off period, reaching no effect by the end of the fall-off period. The linear fall-off is approximated
by applying the average HR of full and zero treatment effect for the duration of the fall-off period.
The HRs applied in the base case are shown in Table 17. The median HRs estimated by the NMA were
used in the deterministic analysis, and in the PSA the convergence diagnostics and output analysis samples
from the NMA were used as these preserve the underlying joint distribution.
Adverse event estimates
The model incorporates one-off costs and QALY decrements associated with AEs experienced in the first
month of treatment. The published economic evaluations described in Chapter 4, Systematic review of
existing cost-effectiveness evidence, were examined to see how they incorporated AEs. For oral
bisphosphonates, the approach taken was based on the approach used by Stevenson et al.,140 who
incorporated AEs for upper GI symptoms in their analysis. For i.v. bisphosphonates the rates of flu-like
symptoms were taken from the RCT evidence summarised in Chapter 3 and the quality-of-life decrement
was based on an ad hoc search. The data used to incorporate AEs within the model are described in detail
below and summarised in Table 18.
TABLE 17 Hazard ratios applied in the deterministic analysis
Drug
Fracture site
Hip Vertebral Proximal humerus Wrist
Alendronic acid 0.78 0.45 0.80 0.83
Risedronic acid 0.82 0.51 0.71 0.76
Ibandronic acid (oral) 0.87 0.45 0.80 0.83
Ibandronic acid (i.v.) 0.87 0.47 0.92 0.83
Zoledronic acid 0.94 0.41 0.75 0.81
TABLE 18 Summary of AE data applied in the model
AE
Oral bisphosphonates, upper GI
symptoms
i.v. bisphosphonates, flu-like
symptoms
Incidence 3% in the first month of treatment 14% in the first month of
treatment
Utility decrement 9% (i.e. a multiplier of 0.91) 65% (i.e. a multiplier of 0.35)
Duration of utility decrement 1 month 3 days
QALY loss per patient experiencing AE 0.0075 0.0053
Resource use GP appointment and prescription for
generic ranitidine (Zantac®,
GlaxoSmithKline UK, Ltd)
None
Cost per patient experiencing an AE £45.00 (GP)+ £1.76 (drugs) = £46.76 None
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We have not explicitly modelled the relationship between AEs and treatment persistence, but it is expected
that AEs contribute to the low levels of treatment persistence described in Treatment strategies.
Adverse events associated with bisphosphonate treatment were not consistently incorporated in economic
analyses included in our review. Stevenson et al.140 did not include any AEs in the model reported in their
2005 publication, but a later Decision Support Unit (DSU) report by Stevenson and Davis174 describes
additional analyses in which AEs were included. Both Kanis et al.138 and Borgström et al.137 used the
assumptions described in the DSU report by Stevenson et al.174 within sensitivity analyses, but neither
included AEs in their base case. The remaining published analyses139,141–143,146 did not include AEs.
Stevenson et al.174 used data from prescription event monitoring studies identified in a systematic review
by Lloyd-Jones and Wilkinson116 to determine the rate of upper GI problems in patients treated with oral
bisphosphonates. In the DSU report, Stevenson et al.174 assumed 2.35% of patients required a GP
appointment and a course of H2 receptor antagonists as a result of GI AEs in the first month of therapy
and 0.35% thereafter.174 These patients were assumed to have a HRQoL decrement of 9% (utility
multiplier of 0.91 from Groeneveld et al.175) for the full month, which was described by Stevenson et al.174
as a deliberately pessimistic assumption that aimed to counterbalance the fact that no other adverse AEs,
such as nausea, had been included. Lloyd-Jones and Wilkinson116 also reported that other cohort studies
found that 30% of patients starting alendronic acid may report GI AEs. A sensitivity analysis using a higher
rate of AEs (24%) in the first month of alendronic acid treatment was considered by the Technology
Appraisal Committee when formulating recommendations for TA16021 and TA161.24
Our review of systematic reviews examining AEs did not identify any systematic reviews that examined GI
AEs that were published more recently than the review by Lloyd-Jones and Wilkinson.116 The prescription
event monitoring studies identified by Lloyd-Jones and Wilkinson116 found a greater incidence of dyspeptic
conditions in the first month of treatment with alendronic acid and risedronic acid (3%) than in later
months (1%).116 This was considered by our clinical advisors to be low compared with the rates they saw in
clinical experience, which were estimated to be around 20%.
All three oral bisphosphonates were found to have similar rates of GI symptoms when compared with
placebo in RCTs. Furthermore, prescription event monitoring data and data from two head-to-head RCTs
suggest similar rates of GI symptoms for alendronic acid and risedronic acid. The consultee submission by
Actavis176 cited a study by Ralston et al.,126 which concluded that switching patients who are stabilised
on risedronic acid to alendronic acid is associated with an increased risk of GI AEs. However, this evidence
was not considered to be directly applicable to the question of whether or not AEs are more common
when initiating treatment with alendronic acid or risedronic acid in patients without prior treatment with
bisphosphonate. Limited data were available to assess if monthly formulations result in a lower incidence
of GI symptoms than weekly formulations, but the review by Bobba et al.112 stated that increasing the
dosing interval to weekly or monthly does not appear to change the rates of GI AEs when compared with
daily dosing for any of the three oral bisphosphonates. Therefore, the rates of AEs for alendronic acid from
prescription event monitoring studies have been applied consistently to all oral bisphosphonates. Our
clinical advisors informed us that clinical experience would suggest that upper GI symptoms are most
problematic for alendronic acid, with risedronic acid being less problematic and ibandronic acid even less
so owing to less frequent dosing. However, as this evidence was anecdotal, they considered it reasonable
to assume equivalent AEs for the oral bisphosphonates.
In the model we applied the data on dyspeptic conditions from prescription event monitoring studies
described by Lloyd-Jones and Wilkinson116 and assumed that 3% of patients starting treatment with an
oral bisphosphonate experience GI symptoms requiring a GP appointment and prescription of a H2
receptor antagonist in the first month of treatment. A sensitivity analysis was also conducted examining a
rate of 30% in the first month to reflect the higher rates observed in some observational studies, as
described by Lloyd-Jones and Wilkinson.116 Clinical advice was that proton pump inhibitors are usually
prescribed instead of H2 receptor antagonists despite a caution in the British National Formulary regarding
the potential for an increased fracture risk for proton pump inhibitors.39 However, as generic lansoprazole
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(Zoton FasTab®, Pfizer) is similarly priced to generic ranitidine, we have assumed for simplicity that all
patients receive a H2 receptor antagonist. Total cost per patient experiencing a GI AE was assumed to
be £46.76 (£45 for GP appointment and £1.76 for generic ranitidine).39 We have applied the same
assumptions on disutility as Stevenson et al.,140 which we calculate to be equivalent to a QALY loss of
0.0075 per patient experiencing GI symptoms. We have applied this as a fixed QALY decrement at the
start of the model without adjustment for baseline health utility.
In our review of AEs, the incidence of flu-like symptoms was found to be significantly higher among patients
treated with zoledronic acid than among those receiving placebo. Although none of the RCTs or
observational studies reported flu-like symptoms for i.v. ibandronic acid, the SmPC for Bonronat® (Roche
Products Ltd) (branded i.v. ibandronic acid) describes influenza-like symptoms that resolve after ‘a couple of
hours/days’ as a common side effect, affecting up to 1 in 10 people. A study by van Hoek et al.177 reports the
utility for influenza-like illnesses as being 0.34 compared with a baseline (no flu-like symptoms) of 0.97
based on EQ-5D scores in a cohort of 655 patients with influenza-like illness. Based on these estimates, we
considered that a utility multiplier of 0.35 would be reasonable for flu-like symptoms. We have assumed a
disutility of 0.65 for 3 days for flu-like symptoms associated with i.v. bisphosphonates, which is equivalent to
a QALY loss of 0.005. This has been applied as a fixed QALY decrement at the start of the model without
adjustment for baseline utility. We took the rate of influenza-like symptoms to be the rate of pyrexia
reported in the HORIZON-PFT,56 as this was the largest RCT reporting data on flu-like symptoms and pyrexia
was more common than other flu-like symptoms (headache/chills). The 14% difference in pyrexia rates
between zoledronic acid and placebo was applied to patients receiving either i.v. zoledronic acid or i.v.
ibandronic acid. These were applied for only the first infusion to reflect the fact that these rates were
measured over the whole trial period (36 months) and, therefore, applying them repeatedly would
overestimate the incidence of flu-like symptoms. Furthermore, it is likely that patients who experience
significant side effects are more likely to be in the group who do not persist with treatment so repeated
episodes of significant disutility are unlikely.
Estimating time to non-fracture-related mortality
Sex-specific UK life tables were used to provide an empirical estimate of the likelihood of death for each
year after the start of the model.155 This was calculated based on the age of the patient. So for a patient
aged 30 years, the likelihood of death (denoted by dx within the life tables) between each birthday from
the age of 30 to100 years was used to estimate the empirical distribution of survival times. Similarly,
for a patient aged 90 years, the likelihood of death between each birthday from age 90 to 100 years was
used. This method assumes no survival beyond age 100 years, as this is the limit of the data provided in
the life tables. The time horizon of the model was therefore set to equal 100 years minus the starting age,
giving a variable duration modelled depending on the patient’s start age. The data used to estimate time
to non-fracture-related death were not varied in the PSA.
Mortality after hip fracture
Patients experiencing hip fracture in the model have a risk of experiencing fracture-related mortality, which is
applied as a one-off probability at the time of fracture. The risk is age and sex specific, and fracture-related
death is assumed to occur at a fixed time following fracture rather than at a sample time in the future. All of
the published cost-effectiveness analyses described in Systematic review of existing cost-effectiveness
evidence included an excess of risk of mortality attributable to hip fracture. These papers and a published
systematic review by Abrahamsen et al.178 were examined to identify suitable data to include in the model.
The systematic review by Abrahamsen et al.178 examined the relationship between hip fracture and mortality,
and found that patients with hip fracture experience a high mortality rate, which is at least double that for
age-matched population norms. Abrahamsen et al.178 also noted that while the highest excess risk appears
to be in the first 6 months following fracture, many of the studies they examined found an increased risk
that persisted for a number of years. Age and sex were both found to be important predictors of
post-fracture mortality supporting the use of age- and sex-specific estimates within our model.
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Although there is clear evidence of excess mortality following hip fracture compared with general
population norms, the extent to which underlying conditions contribute to the excess mortality associated
with hip fracture is unclear.178 Underlying health conditions, which may be more common in patients
experiencing hip fracture than in age- and sex-matched population norms, may contribute to mortality
independently of the fracture itself, confounding the relationship between fracture and mortality. Kanis
et al.179 found that 17–32% of deaths following hip fracture were causally related to fracture, whereas
Parker and Anand180 estimated that 25% of deaths were directly attributable to hip fracture, with a further
42% possibly attributable to hip fracture. A study by Tosteson et al.,181 which was able to adjust for a
number of prognostic factors including pre-fracture health status, found that excess mortality was limited
to the first 6 months after fracture.
To populate the model, data were needed on the absolute risk of mortality following hip fracture that is
directly related to the hip fracture and, therefore, potentially avoidable by treatment to prevent fractures.
Age- and sex-specific estimates were sought because these are important risk-modifying factors identified in
the systematic review by Abrahamsen et al.178 UK estimates were also considered preferable, as these are
more likely to be representative of the population likely to be affected by NICE guidance. Of the studies
included in the review by Abrahamsen et al.,178 10 reported results for UK cohorts.180,182–190 The majority of
these studies do not report data on the absolute risk stratified by age and sex. Holt et al.187 provide graphs
of survival at 120 days for different sexes and age bands. Deakin et al.183 provide age- but not sex-specific
estimates of mortality at 30 days and 1 year rates. Parker and Anand180 provide age-specific mortality rates,
but these are not reported separately for males and females. Only one study, by Roberts and Goldacre,189
provides age- and sex-specific mortality rates, and these are provided at 30, 60 and 365 days. This study
used data from the Oxford record linkage study,191 which comprises anonymised abstracts of hospital
statistics linked to death certificates. The population examined by Roberts and Goldacre189 was 32,590
people aged ≥ 65 years who were admitted to hospital as emergencies with fractured neck of femur
between 1968 and 1998. Mortality rates were compared over six time windows between 1968 and 1998
and absolute mortality rates are provided for the cohort admitted with fractures between 1984 and 1998.
The studies included in the review of published cost-effectiveness analyses were also examined to
determine the source of data used. Stevenson et al.140 used unpublished estimates from the Anglian audit
of hip fracture, which were reported for several different age bands, and adjusted these to remove those
deaths not causally related to hip fracture using the data from Parker and Anand.140,180 Ström et al.,139
Borgström et al.137 and Kanis et al.142 used data from Sweden179,192,193 rather than data from the UK.
van Staa et al.141 estimated excess mortality rates from a UK database of general practice patients
(GPRD, which is now called CPRD) and absolute rates are presented by age band, but this cohort was
restricted to postmenopausal women. A Cox proportional hazards model was used by van Staa et al.141 to
compare 1-year mortality rates for those with fracture and controls without fracture, who were matched
based on age, GP practice and calendar time. Similar methods were used in another of the included
cost-effectiveness papers, by van Staa et al.,143 which identified cases and controls from the same UK
database but examined a population treated with steroids. However, this paper did not report the absolute
mortality risks calculated. No additional studies were identified from the papers by Kanis et al.138 and
Borgström et al.146
The age- and sex-specific mortality rates reported by Roberts and Goldacre189 for 1 year were much higher
than the excess rates reported by van Staa et al.141 This is to be expected because the estimates from van
Staa et al.141 are the excess mortality rates compared with age- and sex-matched controls, whereas the
estimates reported by Roberts and Goldacre189 are raw mortality rates. As our aim was to include only the
excess mortality associated with hip fracture in our model. The rates reported by van Staa et al.141 were
incorporated in the model for women in preference over the data from Roberts and Goldacre.189 The
excess rates in men were estimated by applying the ratio of raw events observed between men and
women from Roberts and Goldacre189 to the excess rates for women from van Staa et al.141
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The excess mortality rates attributable to hip fracture that have been applied in the model are presented in
Table 19. In the PSA, these rates have been varied by estimating the numbers in each category in the
patient cohort used by van Staa et al.141 by assuming that the age distribution is similar to that of the
general population159 and using the estimated number with and without excess mortality to inform a beta
distribution for each age band. The ratio of excess mortality rates for males versus females was not varied
in the PSA.
Abrahamsen et al.178 report that approximately half of all mortality associated with hip fracture occurred
within 3 months and 70% occurred by 6 months. Given that Tosteson et al.181 reported no excess
mortality after 6 months following adjustment for a variety of factors, including pre-fracture functional
status and comorbid conditions, we decided to assume that all deaths related to hip fracture occurred at
exactly 3 months. A sensitivity analysis was conducted examining the alternative assumption that all deaths
related to hip fracture occurred at exactly 1 month post fracture. Hip fractures occurring before age
50 years were assumed not to result in any excess mortality.
A systematic review by Smith et al.157 found that the RR of death following hip fracture for those residing
at home compared with those residing in an institution prior to hip fracture was 0.57 (95% CI 0.43 to
0.72) when meta-analysed across five studies including a total of 25,497 participants. To reflect the
increased risk of mortality for those institutionalised prior to hip fracture, we applied a RR of 1.75 (1/0.57)
to the figures in Table 19 for those residing in institutional care prior to hip fracture. This may have slightly
overestimated the risk of mortality following hip fracture, as some of the patients included in the study by
van Staa et al.141 will have been institutionalised and, therefore, the risks for non-institutionalised patients
should be adjusted down. However, the study by van Staa et al.141 does not report the proportion
institutionalised by age category within their sample so this adjustment was not possible. The likely bias
introduced by not adjusting these figures is expected to be small, as the majority of patients within the
model do not reside in institutional care (see Figure 70).
Mortality after vertebral fracture
The approach used to model mortality after vertebral fracture is similar to that used to model mortality
after hip fracture. All of the papers included in the review of published cost-effectiveness analyses included
some estimate of mortality following vertebral fracture within their economic evaluation. These papers
were examined to determine the source data used.
The cost-effectiveness analysis by van Staa et al.141 used estimates of mortality following clinical vertebral
fracture which were derived by the authors themselves from a UK cohort of postmenopausal women
identified from a database of general practice patients (GPRD). The methods used in this paper to estimate
mortality after vertebral fracture were the same as those used to estimate mortality after hip fracture and
have been described above in Mortality after hip fracture. Excess mortality rates are presented in this
paper by age band, but are limited to women. As described previously in Systematic review of existing
cost-effectiveness evidence, a second paper by van Staa et al.143 used a similar method to estimate excess
TABLE 19 Excess mortality rates attributable to hip fracture
Age band (years) Data for women (%)141 Ratio of rates (male : female)189 Estimate for males (%)
50–59 2.4 1.63a 3.9
60–69 4.4 1.63a 7.2
70–79 7.5 1.75 13.1
80–89 11.4 1.58 18.1
≥ 90 13.6 1.47 20.0
a Assumed equivalent to ratio to that reported for age 65–70 years.
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mortality after fracture in a cohort of UK patients treated with steroids but mortality rates were not
reported in this second paper.
Two of the included cost-effectiveness papers137,139 reported using estimates from Oden et al.,193 but
the absolute mortality rates could not be identified from the cited paper. Kanis et al.142 cited seven
studies192,194–199 that provide data on the mortality risk after vertebral fracture. The only study to use a UK
cohort, by Jalava et al.,197 examined the impact of prevalent and incident vertebral fractures on mortality
rates in patients enrolled in a RCT of clodronic acid. Jalava et al.197 commented that the small size of this
study’s cohort limited its ability to detect a mortality effect related to incident fractures with only seven
deaths occurring in patients with incident vertebral fractures.197 Kanis et al.142 used the RR associated
with prevalent vertebral fractures from the UK study by Jalava et al.197 to determine the rate of deaths
associated with vertebral fractures in their cost-effectiveness model. Data from a Swedish study by Kanis
et al.199 were used by Kanis et al.142 to determine the percentage of deaths (28%) that were causally
related to vertebral fracture and data from a second Swedish study by Johnell et al.192 were used to justify
applying the same RR for males and females. Kanis et al.199 provide estimates of the absolute risk of
mortality stratified by sex and age bands and adjusts this to account for the proportion of deaths that are
causally related. Johnell et al.192 provide estimates of excess absolute risks by sex for ages 60 and 80 years
by comparing the mortality rate in those with fractures against age- and sex-matched general population
controls. The remaining studies cited by Kanis et al.142 did not provide estimates of absolute risk stratified
by age and sex. No additional studies were identified from the cost-effectiveness studies by Kanis et al.,138
Borgström et al.146 and Stevenson et al.140
It should be noted that not all of the studies identified agreed about the causal nature of the relationship
between vertebral fractures and mortality. Several studies found no statistically significant increase in
mortality rates for incident fractures after adjusting for potential confounding factors.197,200 Those studies
that found a significant relationship192,195,196,199 often did not adjust for potential confounding factors other
than age and sex, although Cauley et al.194 did find a significant increase after adjusting for six
comorbidities and pre-fracture health status.
Differences between findings across studies may also be related to whether or not they considered
morphometric vertebral fractures or only those coming to clinical attention, which are likely to be more
severe. The study by Kanis et al.199 considered only hospitalised vertebral fractures, which could be expected
to be more severe and associated with a higher death rate than non-hospitalised clinical vertebral fractures.
Some studies used baseline radiographs to confirm that the incident fracture was in fact new and not an
undiagnosed prevalent fracture,194,200 but many studies195,196,199 assumed that fractures that came to clinical
attention had occurred recently. Kado et al.198 considered only the impact of prevalent vertebral fractures
on mortality. The impact of incident fractures on mortality for the same cohort were considered in a later
publication by Kado et al.200 Those studies that considered morphometric fractures may also be
complicated by the potential for delay between the fracture and the time it is found on a radiograph.
Kado et al.,200 whose study relied on a single radiograph during the follow-up period to identify incident
morphometric fractures, noted that some fractures might have occurred between the last radiograph and
the end of follow-up, with those patients being allocated to the no-fracture group.
The data reported by van Staa et al.141 were used in the model, as this study used a large UK cohort,
adjusted for multiple confounding factors and reported the excess risk for incident clinically symptomatic
vertebral fractures. Although Center et al.195 reported higher standardised mortality rates for men than for
women when considering all vertebral fractures, the differences were small when considering incident
vertebral fractures alone [1.6 (95% CI 1.4 to 1.8) in women vs. 1.8 (95% CI 1.6 to 2.0) in men]. Johnell
et al.192 reported a non-significant trend for a higher RR in men than women and Kanis et al.199 noted that
the difference was not marked after taking into account sex differences in mortality within the general
population. Therefore, we used the excess rates for women from van Staa et al.141 and applied these to
both men and women within our model. The timing of excess mortality attributable to vertebral fracture
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was less well discussed in the identified studies than for similar data for hip fracture. However, a graph of
death hazard over time for both hip and vertebral fractures, presented by Kanis et al.,199 suggests that a
similar temporal pattern is seen for hip and vertebral fracture with high excess mortality in the early
months. Therefore, we assumed that all mortality related to vertebral fracture occurred at 3 months, as this
was the assumption used for hip fracture-related mortality.
The excess rates following vertebral fracture applied in the model are presented in Table 20.
In the PSA, the parameter uncertainty around these excess mortality rates has been calculated using the
same method used for excess mortality following hip fracture (see Mortality after hip fracture).
Excess mortality risk at fracture sites other than hip or vertebrae
Patients experiencing fractures at sites other than the hip or vertebrae were assumed not to experience a
fracture-related death. Having examined the published cost-effectiveness analyses to identify evidence on
the increased risk of mortality following fractures at other sites, we decided that the evidence was not
sufficient to support including this in the model.
Three of the seven papers included in our review of published cost-effectiveness analyses included an
increased mortality risk for fractures at the proximal humerus.140,142,143 Two of these studies140,142 cited the
paper by Johnell et al.,192 which found an increased risk of mortality compared with age- and sex-specific
matched general population estimates among patients with shoulder fracture, although the increase was
not statistically significant at all ages. The third paper, by van Staa et al.,143 used Cox proportional hazards
models to assess the excess mortality in the year following hip, wrist, vertebral and proximal humerus
fractures in a population treated with steroids compared with age- and sex-matched control subjects.
These 1-year excess risks were incorporated in their analysis for all four fracture sites, but no data on the
excess risks are presented in the paper. In a similar analysis, van Staa et al.141 examined the excess mortality
associated with hip, wrist, vertebral and proximal humerus fracture in a UK population of postmenopausal
women. However, they found that the excess risk of mortality was small for fracture types other than hip
or vertebral fracture and they did not include any estimates of excess mortality for wrist or proximal
humerus fractures in their analysis in postmenopausal women. A study by Cauley et al.,194 which analysed
mortality rates before and after fracture using data from a RCT, found no increased risk of mortality for
fractures at sites other than the hip or vertebrae after adjusting for six comorbidities and pre-fracture
health status. However, a more recent paper by Piirtola et al.201 found that the mortality rates following
proximal humerus fractures were significantly increased in men but not women. Given that the evidence
for an excess risk of mortality following proximal humerus fracture is not consistent across the studies we
examined, we have not included any increased mortality risk for proximal humerus fractures.
Only one of the published cost-effectiveness analyses included in our literature review incorporated an
increased risk of mortality for wrist fractures.143 This paper used estimates derived by the authors of a
general practice database for a cohort treated with steroids, but estimates of the excess mortality by
TABLE 20 Excess mortality rates following vertebral fracture
Age band (years) Excess mortality because of vertebral fracture (%)
50–59 2.3
60–69 3.5
70–79 5.2
80–89 6.7
≥ 90 6.6
Source: van Staa et al.141
DOI: 10.3310/hta20780 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 78
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Davis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
233
fracture type were not provided in the paper.143 However, two of the published analyses140,142 stated that
their assumption of no increased mortality risk following wrist fractures was consistent with published
surveys.192,194–196 We have assumed no increased risk of mortality following wrist fracture in our analysis.
Stevenson et al.140 and Kanis et al.142 grouped fractures occurring at sites other than the hip, wrist,
proximal humerus and vertebrae into one of these four fracture types. This meant that the excess mortality
of hip fracture was also attributed to femoral shaft and pelvic fracture, and the excess mortality for
proximal humerus fractures was also attributed to fractures of the humeral shaft, tibia and fibula. In our
model, we have grouped other femoral fractures, but not pelvic fractures, with hip fractures so that the
excess mortality risk associated with hip fracture is also applied to other femoral fractures. The data we
have used on excess mortality following hip fracture were taken from the paper by van Staa et al.,141 which
also grouped other femoral factures with hip fractures and, therefore, the data are being used in a manner
consistent with what they were intended for. In summary, our analysis allows for excess mortality following
fractures at the hip, femoral shaft or vertebrae but not for any other fracture site.
Risk of nursing home admission following hip fracture
Pain, reduced physical function and lack of mobility are common outcomes after hip fracture and can
lead a patient who was previously living independently to require long-term nursing care. Patients
experiencing a hip fracture who are community dwelling prior to fracture are assumed in the model to
be at risk of moving to a nursing home or residential care. The risk is applied as a one-off risk at the time
of the fracture event. The published economic analyses described in Systematic review of existing
cost-effectiveness evidence were examined to identify sources of data on this parameter and this was
supplemented by a scoping search to find additional sources.
All of the published cost-effectiveness studies included in our review appeared to include some estimate
of nursing home admission within their model. Two studies138,139 included in the review of published
cost-effectiveness analyses cited a conference poster by Zethraeus et al.,202 which gives the proportion of
patients going into long-term care in the year following hip fracture surgery in Sweden by age band. Two
of the published studies140,142 used data from the East Anglian hip audit.203 Three of the studies included in
the review of published cost-effectiveness analyses137,141,143 cited a report describing the model, which was
later published by Stevenson et al.140 as their source of data on nursing home admission following hip
fracture, suggesting that they too applied the data from the East Anglian hip audit.203
As the only UK data identified from the published cost-effectiveness analyses were data from a 1999
research report,203 more recent data were sought to inform the risk within the model of patients moving
from living in their own home to nursing home care after hip fracture. Age- and sex-specific data were
sought, as it was believed that there may be a differential risk according to the age and sex of the patient.
A scoping search identified a small number of papers addressing the issue of nursing home admission after
hip fracture, of which four contained data on risk of discharge by both age and sex.158,204–206 These papers
are summarised in Table 21.
The study by Holt et al.,204 despite covering a large sample in a UK population, was excluded on the basis
that the analysis by age included only two age groups with relatively wide bounds (50–64 years and
75–89 years) and excluded patients aged 65–74 years. This was thought inadequate to assess the
increasing risk of nursing home discharge with age.
We calculated approximate age- and sex-specific probabilities for discharge to a non-home location using
the overall probability of discharge to institutional care and ORs for age and sex reported by the remaining
three studies.158,205,206 Studies by Osnes et al.158 and Nanjayan et al.206 gave similar results, but Osnes et al.158
was thought less appropriate to the UK setting because of the potential for differences in social care
structure and cultural norms regarding institutional care between the UK and Norway. Of the two UK
studies, the study by Nanjayan et al.206 was preferred because the analysis explicitly excluded those who had
died before discharge and was based solely on patients who were living in their own home prior to the
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fracture. Both of these criteria matched the model requirements, and hence data from Nanjayan et al.206
were used in preference to those from Deakin et al.205 (Figure 86).
The overall rate of discharge to a non-home location (residential home, nursing home or hospitalisation)
was given as 20% by Nanjayan et al.206 Combining this with the known sex split of the cohort (71% female)
and the stated ORs for each age and sex group, it was possible to derive an expected risk of non-home
discharge for each age and sex group for use in the model; these are shown in Table 22. The risk of
being discharged to a non-home location increases with increasing age (OR 9.09 for patients aged between
90 and 99 years whereas OR = 1 for patients of approximately 69 years) and is higher for males than for
females (OR 1.67).
The risks of a new admission to an institutional residential setting after hip fracture, presented in Table 22,
have been applied within the model. In the PSA, these have been varied by applying a beta distribution to
the overall rate of admission to an institutional residential setting on which the rates in the individual age
and sex categories is dependent (see Appendix 8, Table 53, for details on PSA distributions).
TABLE 21 Summary of studies identified reporting risk of discharge to nursing home care after hip fracture by age
and sex
Author and
year of study
publication Location Patient group
Observation
period Method
Outcome
measure
Variables of
interest
Osnes et al.,
2004158
Norway Hip fracture patients
aged ≥ 50 years,
excluding
cancers, n = 593
living respondents
(235 died, 174
non-responses)
184–584 days Logistic
regression
Discharge to
nursing home
Age group:
l 50–74 years
l 75–79 years
l 80–84 years
l ≥ 85 years
Male/female
Holt et al.,
2008204
Scotland Hip fracture patients
aged 50–89 years,
excluding ages ≥ 90
years, or without
surgery, n= 17,357
living patients (3085
lost to follow-up)
120 days Logistic
regression
Residence at
120 days
Age group:
l 50–64 years
l 75–89 years
Male/female
Deakin et al.,
2008205
England Hip fracture patients
aged ≥ 50 years,
excluding bilateral,
periprosthetic, road
accident and
pathological
fractures, n= 3240
Not stated
(time to
discharge)
Logistic
regression
Discharge to an
alternative
location (to
normal residence)
Age group:
l 50–59 years
l 60–69 years
l 70–79 years
l 80–89 years
l ≥ 90 years
Male/female
Nanjayan et al.,
2014206
England Hip fracture patients
aged ≥ 50 years,
admitted from
home, excluding no
surgery, n= 1503
(133 died)
Not stated
(time to
discharge)
Logistic
regression
Discharge to an
alternative
location (to
home)
Age group:
l 50–59 years
l 60–69 years
l 70–79 years
l 80–89 years
l 90–99 years
l ≥ 100 years
Male/female
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Risk of nursing home admission following vertebral fracture
In the base-case analysis we have assumed that vertebral fractures do not result in new admissions to
nursing homes or residential care. The published economic evaluations identified in Systematic review of
existing cost-effectiveness evidence were examined to identify sources of data on nursing home admission
following fracture. Only one of the papers142 included in our review of published cost-effectiveness
analyses included a rate of nursing home admission following vertebral fracture. Kanis et al.142
incorporated data on the rate of nursing home admissions in Swedish patients from a paper by Borgström
et al.,207 which reported similar rates of patients living in ‘special living accommodation’ for hip and
vertebral fractures. However, Borgström et al.207 also noted in their discussion that, in their patient sample,
the proportion hospitalised was higher than expected (72% vs. expected 10%). The study by Borgström
et al.207 recruited patients at the time of fracture and no comparison was made with matched control
subjects to remove costs that may be related to comorbidities. In comparison, a study, by De Laet et al.,208
that did compare costs in fracture patients and matched control subjects found that nursing homes costs
were substantially higher for hip fracture patients than for control subjects, but were only slightly and
non-significantly higher for vertebral fracture patients. However, this analysis, conducted as part of
the Rotterdam study,209 included patients with a new morphometric fractures and may therefore
underestimate resource use in those with clinically apparent vertebral fractures. Given the lack of
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FIGURE 86 Comparison of calculateda discharge to non-home location rate by age for two UK205,206 and one Norwegian158
study. Values based on Nanjayan et al.206 F, females; M, males. a, Calculated based on ORs reported in the studies.
TABLE 22 Rate of new admission to an institutional residential setting, calculated from age- and sex-specific ORs
Variable ORa
Discharged from hospital to a non-home location, by age group (%)
Female Male
Age band (years)
50–59 0.76 4 6
60–69 1.92 7 11
70–79 1.96 12 19
80–89 4.54 21 30
90–99 9.09 33 45
Sex
Female 1.00
Male 1.67
a From Nanjayan et al.206
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consensus on the incorporation of nursing home admission rates within the published analyses and the
differing data from these two studies, we decided to omit nursing home admission following vertebral
fracture from our base-case model, but examined the impact of including a rate equivalent to that seen in
hip fracture in a sensitivity analysis.
Risk of subsequent fracture after incident fracture
A systematic review and meta-analysis by Klotzbuecher et al.149 has previously been used in several
published economic evaluations to estimate the increased risk of fracture at various sites when a patient
sustains an incident fracture within the model.139,140,142 We conducted a citation search, using the Web of
Science database, to find relevant articles published since the review by Klotzbuecher et al.,149 on the
assumption that new studies in this area would be likely to cite this published systematic review. We found
811 records of articles citing this systematic review. Given the large number of potentially relevant articles
identified, we tried to establish whether or not any more recent systematic reviews had been published.
The abstracts and titles of these articles were then searched separately using the free-text terms ‘review’,
‘meta-analysis’ and ‘synthesis’ to see if any of these articles provided an updated systematic review and
meta-analysis similar to that presented by Klotzbuecher et al.149 Two potential systematic reviews were
identified and full texts examined.210,211 The first, by Haentjens et al.,210 was specifically interested in
comparing whether or not the RR of hip fracture after a wrist or spine fracture differed by sex. Owing to
its focus on sex differences, this study had narrower inclusion criteria and excluded many of the studies
included by Klotzbuecher et al.149 and it only included one additional recent study.212
The second systematic review identified from our citation search, which was authored by Blank (on behalf
of the FRAX Position Development Conference Members),211 identified around 20 studies published since
the Klotzbuecher et al.149 review. However, these studies are discussed narratively by Blank and no
meta-analysis is provided.211 It was not considered feasible to review and meta-analyse all of these new
studies in order to update the estimates provided by Klotzbuecher et al.149
A 2011 review by Warriner et al.,213 which meta-analysed data from 25 studies published since the
Klotzbuecher et al.149 review, was identified opportunistically. The review by Warriner et al.213 does not
provide any details regarding the methods used to identify the studies. It also provides limited details on
the studies included and does not tabulate the RRs from the individual studies prior to pooling. Therefore,
it was decided that the estimates from Warriner et al.213 should be treated with caution because of the
potential for selection bias. The estimates provided by Klotzbuecher et al.149 were used in the base-case
model. These estimates were supplemented by data from Warriner et al.213 where no estimates were
provided by Klotzbuecher et al.149 Neither meta-analysis provided data on the increased risks of fracture
following proximal humerus fracture. Data on the increased risk following fracture at any site were used as
a proxy for risk following fractures at the proximal humerus. Neither meta-analysis provided data on the
risk of proximal humerus fracture after hip fracture, so the data on proximal humerus fracture following
fracture at any site from Warriner et al.213 were used. The data in Table 23 were applied in the model as
TABLE 23 Increased risk of subsequent fracture following incident fracture
Location of prior fracture
Site of subsequent fracture, HR (95% CI)
Wrist Vertebral Hip Proximal humerus
Wrist 3.3 (2.0 to 5.3)a 1.7 (1.4 to 2.1)a 1.9 (1.6 to 2.2)a 2.5 (0.6 to 10.2)b
Vertebral 1.4 (1.2 to 1.7)a 4.4 (3.6 to 5.4)a 2.3 (2.0 to 2.8)a 1.6 (0.7 to 3.0)b
Hip 3.0 (1.3 to 6.5)b 2.5 (1.8 to 3.5)a 2.3 (1.5 to 3.7)a 2.1 (0.3 to 17.3)a
Proximal humerusc 1.9 (1.3 to 2.8)a 2.0 (1.6 to 2.4)a 2.0 (1.9 to 2.2)a 2.1 (0.3 to 17.3)b
a Data from peri-/postmenopausal women from table 1 of Klotzbuecher et al.149
b Data from Warriner et al.213 applied as no data were available from Klotzbuecher et al.149
c Data from prior fracture at any site used when site-specific data not available.
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HRs within the survival curves, used to estimate time to fracture for the base-case analysis. A sensitivity
analysis has also been conducted using the estimates from Warriner et al.213 exclusively, which are shown
in Table 24.
The values from Klotzbuecher et al.149 and Warriner et al.213 are applied for the patient’s remaining lifetime
once a fracture occurs. The studies included by Klotzbuecher et al.149 in the meta-analysis had varying
durations of follow-up, but generally > 1 year, so the estimates provided by Klotzbuecher et al.149
represent the RR when averaged over all years of study follow-up. The temporal profile of increased
fracture risk after an incident fracture has been studied by van Geel et al.214 Their analysis suggests that the
RR is approximately 2 when averaged over the long term, but when assessed over different time periods is
much higher immediately after the first fracture, and tails off towards 1 over the next 20 years. We
acknowledge that our method of applying a fixed RR over the patient’s remaining lifetime probably
underestimates the increased risk in the immediate years after fracture, but it is likely to overestimate the
increased risk in the long term. The alternative would be to use additional dummy events to modify the
increased risk in the years after fracture, but this would reduce the computational efficiency of the model.
In the PSA, the HRs in Table 23 were sampled from a log-normal distribution using standard errors
calculated from the 95% CIs reported in Table 23 (see Appendix 8, Table 52, for PSA distributions).
When more than one incident fracture was sampled to occur during a patient’s lifetime, the maximum
value from Table 23 has been applied for each subsequent fracture type rather than applying several
multipliers concurrently. For example, if someone has had a prior wrist fracture and a prior vertebral
fracture then their increased risk of vertebral fracture is 4.4, which relates to their prior history of vertebral
fracture, as this is the maximum value in the vertebral column in Table 23. However, their increased risk for
proximal humerus fracture would be 2.5, which relates to their prior history of wrist fracture, as this is the
maximum value in the proximal humerus column.
Both QFracture and FRAX incorporate an increased risk for patients with a history of prior fracture and,
therefore, those with a prior fracture at the start of the model already have an increased risk applied for
prevalent fractures. This increased risk associated with fractures occurring prior to the start of the model is
removed at the time of the first incident fracture and the data from Table 24 are applied instead. This is to
prevent the risk being increased twice for the same patient characteristic using two different mechanisms
within the model.
Health-related quality of life: review of utility values following fracture
To inform the model, data were needed on the proportionate decrease in HRQoL that occurs in the year
following fracture and in subsequent years. This was then used to calculate a utility multiplier, which was
applied to the pre-fracture utility value to calculate the post-fracture utility. For example, a proportionate
decrease of 10% would translate into a utility multiplier of 0.9. If the patient’s prior fracture utility is 0.8,
then the post-fracture utility would be 0.72. Data on the absolute HRQoL after fracture can be obtained
from studies that measure HRQoL in patients who have experienced a recent fracture. However, the
TABLE 24 Increased risk of subsequent fracture following incident fracture used in sensitivity analysis
Location of prior fracture
Site of subsequent fracture, HR (95% CI)
Wrist Vertebral Hip Proximal humerus
Wrist 3.2 (1.3 to 8.1) 2.9 (1.6 to 5.3) 2.9 (2.0 to 4.1) 2.5 (0.6 to 10.2)
Vertebral 1.8 (1.1 to 3.2) 4.9 (2.4 to 9.8) 3.7 (2.3 to 5.9) 1.6 (0.7 to 3.0)
Hip 3.0 (1.3 to 6.5) 3.6 (1.9 to 6.7) 3.7 (2.5 to 5.3) 2.1 (0.3 to 17.3)
Proximal humerusa 2.6 (1.8 to 3.8) 3.0 (2.2 to 4.0) 2.4 (1.6 to 3.5) 2.1 (0.3 to 17.3)
a Data from prior fracture at any site used when site-specific data were not available.
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proportionate decrease can be obtained only if there is some estimate of pre-fracture utility. Ideally, HRQoL
would be measured prospectively in a cohort of patients at risk of fracture and these patients would be
followed up with HRQoL remeasured at regular intervals with the time of any incident fracture being
recorded so that the correlation between HRQoL and incident fracture can be obtained after adjusting for
other confounding factors. However, many studies simply recruit patients at the time of fracture and ask
them to recall their pre-fracture health state, which is subject to recall bias. Other studies may compare the
HRQoL in individuals who have fractured with matched controls or population norms, in which case the
estimates may be confounded by differences in other factors between cases and controls.
Initially, a systematic search was conducted to identify studies reporting any measure of health utility in
patients with an incident osteoporotic fracture. However, this search retrieved 3991 unique references and
it was not considered feasible to sift such a large number of papers within the timescales of the NICE
appraisal process. As the NICE methods guide144 states that the EQ-5D is the preferred measure of HRQoL
in adults, and a recent systematic review by Peasgood et al.215 had already demonstrated that EQ-5D data
exist for the four major osteoporotic fracture sites, the search was made more specific, with the aim of
identifying only those studies reporting HRQoL data measured using the EQ-5D. This more sensitive search
retrieved 132 references and was sifted for relevant papers.
Studies reporting HRQoL values measured during RCTs were excluded because of the possibility that study
interventions may affect HRQoL independently of their impact on fracture. In addition, studies that examined the
HRQoL impact of surgical interventions to treat fracture were excluded as these were focused on comparing
the impact of different surgical techniques on quality of life rather than comparing pre- and post-fracture HRQoL
under usual management. Studies reporting the quality-of-life impact of prevalent fractures were excluded on
the basis that there is no way of knowing how long ago the prevalent fracture was sustained and the model
requires information on the quality-of-life impact in the year following fracture and in subsequent years.
Sixteen studies remained207,216–230 (summarised in Table 25), of which eight provided HRQoL for
hip/fractures,216,219,220,224–227,230 eight for wrist fractures,216,217,220,221,226–228,230 10 for vertebral fractures207,216,217,
220,222,226,227,229,230 and two for shoulder fractures.217,220 Of these, two studies used non-UK utility values216,217
and two were of very specific patient cohorts,217,218 making the results of these studies less relevant to the
general population at risk of fragility fracture. Cooper et al.218 focused on women with inadequate response
to therapy and Ekström et al.219 focused on patients with subtrochanteric hip fractures only. Therefore,
HRQoL values from these studies were not considered further.
Four studies did not provide a pre-fracture or control utility value220–223 and these were excluded except
where no other values were available.
Five of the included papers contained duplicate results,207,224–227 as both papers by Tidermark et al.224,225
referred to the same study and the papers by Ström et al.226 and Borgström et al.227 referred to a
single study [known as KOFOR (the costs and effects of osteoporosis-related fractures study)]. The later
paper by Borgström et al.227 was an international extension to the KOFOR study [known as ICUROS
(the International Costs and Utilities Related to Osteoporotic fractures Study)] which gave HRQoL values by
country but not pooled values. The Swedish cohort within ICUROS appeared to have been based on a
slightly expanded version of the KOFOR sample. Of the ICUROS results, the Swedish values were thought
to be the most appropriate because they were based on the largest sample of the various country-specific
cohorts and they were expected to provide a good estimator of UK HRQoL values, as northern European
countries have been shown to have similar values.231
Values from eight papers207,224–230 reporting outcomes from five distinct studies were therefore compared.
All studies appeared to observe similar patterns in HRQoL, with an immediate, severe drop in HRQoL
associated with the acute fracture incident (where recorded), followed by a recovery to a higher HRQoL
within the first 4 months, and stabilisation or slow improvement over the course of the year to 12 months.
The exception to this was the Roux et al.230 study, which was a prospective study in which utility was
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TABLE 25 Summary of included papers reporting EQ-5D quality-of-life measures associated with osteoporotic fracture
Author and
year of study
publication Country Study design Cohort description
Sample size at baseline and % of
missing data
Valuation set
used for EQ-5D
Reasons for not considering
some studies further
Hagino et al.,
2009216
Japan Prospective cohort Patients aged ≥ 45 years with
osteoporotic hip, wrist or
spine fracture
Recruited: 122
13% dropped out, excluded because
of additional fractures or death
Japanese health
utility rating
Not used because not UK TTO
Cooper et al.,
2008218
Europe Prospective cohort
(OSSO)
PM women with osteoporosis
and inadequate response to
therapy
Recruited: 166 with incident fracture UK scoring
algorithm
Not used, study is a specific
cohort of women with
inadequate response to therapy
Ekström et al.,
2009219
Sweden Prospective cohort Patients with subtrochanteric
hip fracture treated with a
cephalomedullary nail
Recruited: 87
Missing:
4 months: 11%
12 months: 21%
24 months: 38%
UK TTO Not used, study is with patients
with subtrochanteric hip
fracture, which makes up a
small percentage of all hip
fractures
Calvo et al.,
2011217
Spain Prospective cohort PM women aged > 50 years
(acute, outpatient, non-
operative osteoporotic
fractures only)
Recruited with HRQoL: 301
Overall: 5506 (6.5% dropped out,
6.7% excluded); HRQoL, n= 301
Spanish EQ-5D Not used because not UK TTO
Zethraeus,
2002220
Sweden Prospective cohort,
pilot
Patients aged ≥ 50 years with
hip, spine, wrist or shoulder
fractures recruited at the
orthopaedic department
Recruited (response rate at 2 weeks):
Hip: 533 (18%)
Shoulder: 210 (25%)
Wrist: 334 (42%)
Spine: 172 (25%)
UK tariff No pre-fracture or control value
reported. Used only where no
other data available
A
S
S
E
S
S
M
E
N
T
O
F
C
O
S
T
-E
F
F
E
C
T
IV
E
N
E
S
S
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
2
4
0
Author and
year of study
publication Country Study design Cohort description
Sample size at baseline and % of
missing data
Valuation set
used for EQ-5D
Reasons for not considering
some studies further
Suzuki et al.,
2008222
Sweden Prospective cohort Patients aged > 40 years with
acute osteoporotic spine
fracture
Recruited: 147
27% lost to follow-up, died or
excluded
UK TTO Not used because no pre-fracture
or control value reported
Suzuki et al.,
2010223
Sweden Prospective cohort Patients aged > 40 years with
acute osteoporotic spine
fracture with or without
prevalent fracture
Recruited 56 with no prevalent
fracture
UK TTO Not used because no pre-fracture
or control value reported
Dolan et al.,
1999221
UK Prospective cohort Women with wrist fracture Recruited: 50 UK TTO Not used because no pre-fracture
or control value reported
Tidermark et al.,
2002224
Sweden Prospective cohort Patients aged ≥ 65 years with
acute hip fracture and internal
fixation
Recruited 90
33% died, excluded or lost to
follow-up by 24 months
UK TTO Considered relevant
Tidermark et al.,
2002225
Sweden Prospective cohort Patients aged ≥ 65 years with
acute hip fracture and internal
fixation
Recruited 90
28% excluded, lost to follow-up or
underwent different surgery
UK TTO Considered relevant
Ström et al.,
2008226
Sweden Prospective cohort
(KOFOR)
Patients aged ≥ 50 years with
a single osteoporotic fracture
of hip, spine or wrist
684 patients survived to the 18-month
follow-up
UK TTO Considered relevant and applied
in model
Borgström
et al., 2006207
Sweden Prospective cohort
(KOFOR)
Patients aged ≥ 50 years with
a single osteoporotic fracture
of hip, spine or wrist
Recruited 635
1% excluded
UK TTO Considered relevant
Borgström
et al., 2013227
International
(11 countries
including UK)
Prospective cohort
(ICUROS)
As in KOFOR, patients within
2 (6 in USA) weeks of fracture
2808 analysed using combined data
set with KOFOR study. Results
presented by country, UK not reported
UK TTO Considered relevant
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TABLE 25 Summary of included papers reporting EQ-5D quality-of-life measures associated with osteoporotic fracture (continued )
Author and
year of study
publication Country Study design Cohort description
Sample size at baseline and % of
missing data
Valuation set
used for EQ-5D
Reasons for not considering
some studies further
Lips et al.,
2010228
Europe (five
centres
including UK)
Prospective cohort Ambulant patients aged
45–80 years within 14 days of
wrist fracture and age-/sex-
matched controls
Recruited: 105 + 74 controls
13% dropped out
Unclear Considered relevant
Roux et al.,
2012230
International
(10 countries
including UK)
Large prospective
cohort (GLOW)
PM women with osteoporosis
followed up for spine, hip and
other fractures
Recruited: 1822 fractures from 51,491
women
Country-specific
utilities
Considered relevant
Cockerill et al.,
2004229
Europe (seven
countries
including UK)
Population-based
screening survey
case–control
follow-up (EVOS)
Men and women aged 50–79
years screened for spine
fracture
Recruited: 121 fractures with HRQoL
from 15,570 people screened
UK TTO Considered relevant
EVOS, European Vertebral Osteoporosis Study; GLOW, Global Longitudinal study of Osteoporosis in Women; ICUROS, The International Costs and Utilities Related to Osteoporotic Fractures
Study; KOFOR; the costs and effects of osteoporosis-related fractures study; OSSO; Observational Study of Severe Osteoporosis; PM, postmenopausal; TTO, time trade-off.
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measured at enrolment (pre fracture) and then after 12 months, with the post-fracture values being
12-month values for patients who experienced a fracture at any time during the previous 12 months.
As a result, values from the Roux et al.230 study showed a gradual decline over a 12-month period. The
advantage of this approach is that pre-fracture utilities were as measured and, therefore, not subject to
recall bias. Values at 12 months should also theoretically represent an average of utility loss associated with
fracture over a year, assuming all patients were surveyed at exactly 12 months. However, as a significant
amount of utility loss is experienced in the first days and weeks after fracture, the results could easily be
biased if patients who had recently experienced a fracture delayed completing the survey. As the study
was based on self-completion postal questionnaires, it was considered possible that there may be some
reporting bias in this study and, therefore, values from other studies were considered more appropriate.
One of the papers by Tidermark et al.225 did not report a HRQoL value between baseline and 4 months and,
therefore, this study did not observe the severe drop in HRQoL associated with the acute fracture incident.
A summary of the values reported by individual studies for utility after hip fracture, wrist fracture, vertebral
fracture and shoulder fracture are presented in Tables 26–29, respectively.
Values were plotted and a weighted average score was calculated for each fracture type. An example is
shown in Figure 87 for hip fracture, for which five appropriate papers were sourced,207,224–227 relating to
two studies. The weighted average score closely followed the result of the largest study (KOFOR/ICUROS)
reported in the papers by Ström et al.226 and Borgström et al.207 Similar patterns were observed for all
fracture types. The KOFOR/ICUROS study was the only study to provide pre- and post-fracture values for
hip, wrist and spine fractures. It also had the largest sample size and reported similar results to other
studies. Therefore, the decision was made to use values from the KOFOR/ICUROS study as the basis of the
TABLE 26 Utility values after hip fracture
Author and year
of study
publication
Description of
non-fracture state
Valuation of
non-fracture state,
mean (SD, n)
Description of fracture
states valued
Value of fracture
states, mean
(SD, n)
Roux et al.,
2012230
Baseline pre fracture 0.64 (0.34, 126) 0–12 months post
fracture (12-months post
recruitment)
0.60 (0.34, 126)
Ström et al.,
2008226
Pre fracture (recalled) 0.81 (0.21, 282) Post fracture, immediate 0.19 (0.21, 282)
4 months 0.64 (0.26, 282)
12 months 0.69 (0.26, 282)
8 months 0.72 (0.26, 282)
Borgström et al.,
2013227
Pre fracture (recalled) 0.80 (0.24, 355) Post fracture, immediate 0.18 (0.19, 355)
4 months 0.62 (0.24, 355)
Tidermark et al.,
2002224
Pre fracture (recalled) 0.77 (NR, 90) Post fracture at 4 months 0.66 (NR, 42)
12 months 0.62 (NR, 42)
24 months 0.59 (NR, 42)
Tidermark et al.,
2002225
Pre fracture (recalled): and
age-matched general
population
0.78 (0.21, 89) Post fracture at 1 week 0.44 (0.33, 71)
4 months 0.55 (0.37, 79)
17 months 0.51 (0.36, 69)
Borgström et al.,
2006207
Pre fracture (recalled) 0.80 (0.21, 277) Post fracture at
0–4 weeks
0.18 (0.21, 277)
4 months 0.62 (0.30 277)
12 months 0.67 (0.25, 277)
NR, not reported.
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TABLE 27 Utility values after wrist fracture
Author and year
of study
publication
Description of
non-fracture
state
Valuation of
non-fracture state,
mean (SD, n)
Description of fracture
states valued
Value of fracture
states, mean (SD, n)
Lips et al., 2010228 Age-/sex-matched
controls
0.85 (median)
(NR, 73)
Post fracture, 0–14 days
(baseline)
Median 0.59
6 weeks Median 0.66
3 months Median 0.76
6 months Median 0.78
12 months Median 0.80
Ström et al.,
2008226
Pre fracture 0.90 (0.18, 325) Post fracture, immediate 0.56 (0.28, 325)
4 months 0.83 (0.18, 325)
12 months 0.88 (0.23, 325)
18 months 0.90 (0.18, 325)
Borgström et al.,
2013227
Pre fracture
(recalled)
0.90 (0.20, 390) Post fracture, immediate 0.56 (0.25, 390)
4 months 0.83 (0.20, 390)
Borgström et al.,
2006207
Pre fracture
(recalled)
0.89 (0.17, 276) Post fracture at 0–4 weeks 0.56 (0.17, 276)
4 months 0.82 (0.17, 276)
12 months 0.86 (0.17, 276)
NR, not reported.
TABLE 28 Utility values after vertebral fracture
Author and year
of study
publication
Description of
non-fracture
state
Valuation of
non-fracture state,
mean (SD, n)
Description of fracture
states valued
Value of fracture
states, mean (SD, n)
Roux et al.,
2012230
Baseline pre
fracture
0.65 (0.02, 178) 0–12 months post fracture
(12 months post
recruitment)
0.58 (0.02, 178)
Ström et al.,
2008226
Pre fracture 0.74 (0.24, 76) Post fracture, immediate 0.18 (0.27, 76)
4 months 0.49 (0.31, 76)
12 months 0.49 (0.31, 76)
18 months 0.54 (0.31, 76)
Borgström et al.,
2013227
Pre fracture
(recalled)
0.74 (0.25, 120) Post fracture, immediate 0.20 (0.28, 120)
4 months 0.50 (0.34, 120)
Borgström et al.,
2006207
Pre fracture
(recalled)
0.73 (0.25, 81) Post fracture at 0–4 weeks 0.18 (0.25, 81)
4 months 0.47 (0.34, 81)
12 months 0.49 (0.25, 81)
Cockerill et al.,
2004229
Age-/sex-matched
controls
Incident fracture cases 0.77 (0.19, 73)
Prevalent fracture
found
0.81 (0.19, 60)
No prevalent
fracture
0.83 (0.17, 136)
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utility multipliers applied in the model. However, no study provided complete HRQoL data for shoulder
fracture, so in this case values from Zethraeus et al.220 were used, with an assumption that post-fracture
HRQoL measured at 12 months represented a return to pre-fracture HRQoL levels. No studies reported
pre-fracture (or control) and post-fracture values for fractures at sites other than the hip, wrist, spine
or shoulder.
The average utility value in the first year following fracture has been calculated by assuming an immediate
drop in HRQoL at fracture maintained for 1 month, followed by a linear improvement to 4 months and
then a further linear improvement to 12 months. The utility multiplier applied in the first year post fracture
was then calculated as the ratio of the average utility in the year post fracture to the baseline utility prior
to fracture. The utility value observed at 12 months is assumed to persist in the long term, so the multiplier
for the second and subsequent years was set to the ratio of the 12-month and pre-fracture utility value.
The data applied in the model are summarised in Table 30. The post-fracture utility values have been
varied in the PSA by sampling values from a beta distribution (see Table 51, Appendix 8, for details on
the distributions).
TABLE 29 Utility values after shoulder fracture
Author and year
of study
publication
Description of
non-fracture
state
Valuation of
non-fracture state
Description of fracture
states valued
Value of fracture
states, mean (SD, n)
Zethraeus et al.,
2002220
None NR Post fracture at 2 weeks 0.36 (0.30, 46)
6 months 0.69 (0.25, 40)
9 months 0.66 (0.26, 37)
12 months 0.65 (0.29, 30)
NR, not reported.
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FIGURE 87 Illustration of post-fracture trends in HRQoL following hip fracture taken from five papers reporting on
two different studies plus a weighted average.
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Health-related quality-of-life values for institutionalisation
The published economic analyses described in Systematic review of existing cost-effectiveness evidence
were examined to identify sources of data on HRQoL for patients living in nursing home or residential care
compared with those dwelling in the community. Additionally, a paper by Tidermark et al.225 containing
relevant data was opportunistically identified from the systematic review of papers reporting HRQoL
following fracture.
Tidermark et al.225 found that, in a prospective cohort study of 90 patients with hip fracture who were
living independently prior to their fracture, patients with an independent living status at 4 months after
fracture had significantly higher EQ-5D scores than those living in institutions (0.64 and 0.35, respectively;
p < 0.05). A similar difference in mean scores (0.56 vs. 0.35) was seen at final follow-up (> 12 months
after fracture with mean follow-up of 17 months), but this was no longer statistically significant. The lack
of statistical significance at final follow-up may be because of the small number of patients institutionalised
(seven at 4 months and eight at 17 months). We used the data from the final follow-up within our analysis
to calculate a utility multiplier for nursing home admissions following fracture of 0.625. This is higher than
the value of 0.4 used in four of the published analyses;140–143 however, this earlier value was based on
judgement by an expert panel.153 The remaining three137–139 published analyses did not describe the utility
multiplier applied for nursing home admission. The multiplier calculated from Tidermark et al.225 was used
in our model, as this was based on EQ-5D scores valued using the UK tariff, which is consistent with
the NICE reference case.144 Tidermark et al.225 did not report SDs for the mean EQ-5D values for
institutionalised patients and patients living independently. To provide an estimate of uncertainty in the
utility multiplier within the PSA, the standard error around the utility multiplier was set to give a 95% CI
that coincided with no difference between these two health states, to reflect the lack of a statistically
significant difference in the mean values at 17 months.
Age- and sex-specific utility values in the absence of clinical events
Utility in patients without fracture is dependent on age and sex and is based on EQ-5D data for the UK
general population.232 The age- and sex-dependent utility value applied to the period between two events
is taken to be the average of the utility at the start and end of that period. This ensures that patients
who do not experience any events do not stay at an artificially high level of utility, equivalent to the utility
TABLE 30 Calculation of utility multipliers from quality-of-life study results
Sample size and utility estimates
Site of subsequent fracture
Hipa Spinea Shoulderb Wrista
Number of patients 282 76 38 325
Utility index
Pre-fracture 0.81 0.74 0.65c 0.90
2 weeks post 0.19 0.18 0.36 0.56
4 months post 0.64 0.49 0.58 0.83
12 months post 0.69 0.49 0.65 0.88
Annual average 0.56 0.43 0.56 0.79
Utility multiplier (year 1) 0.69 0.57 0.86 0.88
Utility multiplier (year 2 and subsequent) 0.85 0.66 1.00 0.98
a Ström et al.226
b Zethraeus et al.220
c Assumed based on 12 months post-fracture value.
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value for their age at the start of the model. The regression used to calculate utility from age and sex is
as follows:
Utility = 0:9508566 − 0:0212126 × sex − 0:0002587 × age − 0:0000332 × age × age, (5)
where sex is 1 for males and 0 for females, and age is in years.
A multivariate normal distribution, which takes into account the correlation between the regression
coefficients, was used to sample the regression coefficients in the PSA.
Resource use and costs for bisphosphonates treatment
Drug costs for oral bisphosphonates have been taken from the The Electronic Drug Tariff,151 as it is
assumed that these are prescribed in primary care.144 zoledronic acid and i.v. ibandronic acid are assumed
to be prescribed in secondary care and costs for these have therefore been taken from the electronic
market information tool (eMIT) database, which reports the average cost paid by secondary care trusts for
generic medicines.144,152 It was noted by our clinical advisors that generic zoledronic acid has only recently
become available and, therefore, the prices reported by the eMIT database may be higher than those
currently being paid in the NHS, as the price is likely to fall after a generic preparation becomes available
and the current eMIT database uses data from the 12 months prior to June 2014. Therefore, a sensitivity
analysis was conducted using the price for the 4-mg preparation of zoledronic acid, which is for a different
indication but has been available in generic form for a longer time. This was felt to represent a realistic
lower limit for the price of the 5-mg zoledronic acid preparation.
Where there was more than one preparation available we have assumed that the lowest-cost preparation
is prescribed based on the average cost for 1 year of treatment. Therefore, for alendronic acid and
risedronic acid we assumed that weekly preparations are prescribed, as these had the lowest costs based
on the The Electronic Drug Tariff151 costs applied in the model; these are summarised in Table 31. Drug
prices are assumed to be known precisely and, therefore, have been assumed to be fixed within the PSA.
Oral therapies were assumed to incur no additional costs for administration. The costs of i.v. administration
of zoledronic acid and ibandronic acid have been based on NHS reference costs.150 ibandronic acid is given
by i.v. injection over 15–30 seconds. It is assumed that this is done during an outpatient endocrinology
consultation at a cost of £133 (NHS reference cost £302).150 zoledronic acid is given by i.v. infusion over a
longer duration and this is assumed to be done as a day case. The reference cost for a day case delivery of
a simple parenteral chemotherapy (SB12Z at £245)150 has been applied, as no alternative reference costs
were identified which would cover day case admissions for the administration of a drug by infusion. The
outpatient cost for the same HRG code (SB12Z) is £165, suggesting that it is classification of this activity as
TABLE 31 Costs based on the The Electronic Drug Tariff
Bisphosphonate
Items per pack and
dose per item Price per pack Cost per annum
Alendronic acid (oral) 4 x 70 mg £1.13a £14.73
Risedronic acid (oral) 4 x 35 mg £1.26a £16.43
Ibandronic acid (oral) 28 x 50 mg £10.56a £13.58
Ibandronic acid (i.v.) 1 x 3 mg/3 ml £19.38b £77.52
Zoledronic acid (i.v.) 1 x 5 mg/100 ml £94.67b £94.67
Zoledronic acid (i.v.) (price used in sensitivity analysis) 1 x 4 mg/5 ml £5.76b £5.76
a The Electronic Drug Tariff.151
b eMIT database.152
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a day case rather than the specific nature of chemotherapy that makes this more expensive than an
outpatient endocrinology appointment. It was therefore considered reasonable to apply the day case
reference cost for parenteral chemotherapy as a proxy for the cost of delivering zoledronic acid owing to
the longer duration of administration compared with i.v. ibandronic acid. Our clinical advisors noted that
in some cases zoledronic acid is administered as an outpatient procedure and, therefore, a sensitivity
analysis was conducted using the outpatient cost for both i.v. bisphosphonates. Reference costs for the
administration of i.v. bisphosphonates were varied in the PSA (see Table 63, Appendix 8 for details).
Resource use and costs of fracture
The published economic analyses were searched to identify published evidence on resource use
attributable to fracture. This was supplemented by ad hoc searches for UK studies published since 2006, as
this was when a DSU report detailing several different methods to estimate fracture costs was published.174
Resource use attributable to fracture was based on a UK study by Gutierrez et al.,233,234 which used a GP
database (The Health Improvement Network) to estimate resource use for those who fractured compared
with matched controls. Patients were matched on age, GP practice and comorbidity score. The study was
reported in two separate papers, with the first reporting the costs attributable to hip fracture233 and the
second reporting the costs attributable to vertebral fracture, non-hip non-vertebral fracture and also some
less detailed results for wrist and proximal humerus fracture.234 The study examined hospitalisations,
accident and emergency (A&E) visits, referrals, prescriptions and GP contacts in the year following fracture.
It did not examine any costs falling within PSS, such as nursing home admission or home help. The authors
also noted that they did not include rehabilitation costs, but they did estimate the total cost including
rehabilitation by using estimates of rehabilitation costs from other published studies.
The difference in the percentage of patients using each type of resource between those who had fractured
and matched controls was multiplied by the unit cost to get the average cost per fracture in the year
following fracture. Unit costs for hospitalisations, A&E appointments and specialist referrals were based
on NHS reference costs, while unit costs for social care and GP appointments were based on estimates
from the PSSRU. Tables 32 and 33 show the difference in resource use between patients who fractured
and their matched controls and the unit costs applied. The total first year and subsequent year costs
are summarised in Table 34. Unit costs for A&E vary by fracture type as different costs were applied
for admitted and non-admitted patients and these proportions vary by fracture type. Unit costs for
prescriptions were calculated by dividing the difference in total prescription cost by the difference in the
mean number of prescriptions using data from Gutierrez et al.234 However, this detailed information
TABLE 32 Resource use attributable to fracture
Resource use
Difference in proportion between patients with fractures and controls
Hip Vertebrae Proximal humerus Wrist
Hospitalisation 0.82 0.23 0.20 0.17
A&E 0.14 0.07 0.15 0.18
GP –0.02 0.07 0.03 0.06
Referral 0.01 0.17 0.05 0.09
Mean difference in number
Prescriptions per annum 12.34 22.35 4.61 4.61
Home help hours per weeka 1.57 2.33 0.12b 0.12
a Home help hours are based on data from Borgström et al.207 which did not compare against matched controls and is
therefore simply the mean number of hours per patient.
b Assumed equal to wrist.
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was not available for wrist and proximal humerus fractures, so data from the broader category of non-hip
non-vertebral fractures were used for wrist and proximal humerus.
In the cost-effectiveness analysis that informed TA16021 and TA161,24 it was assumed that patients who
experienced a vertebral fracture had ongoing costs in the second and subsequent years associated with the
long-term prescribing of treatments to manage the chronic symptoms associated with vertebral fractures.
The analysis by Gutierrez et al.234 does not examine costs beyond the first year; however, it can be seen
that for vertebral fracture, non-hip non-vertebral fractures and hip fractures, the costs of medications are
fairly stable in the first and second 6 months following fracture, whereas the costs for health-care contacts
such as GP appointments, referrals and A&E visits fall sharply in the second 6 months. Therefore, we
decided to apply prescription costs as an ongoing cost from the time of fracture. All other costs estimated
by Gutierrez et al.234 were applied in the first year only.
In the analysis by Stevenson et al.,140 Swedish data presented by Borgström et al.207 were used to estimate
the costs of home help. We used the same data on the average number of hours of home help following
fracture, as used by Stevenson et al.,140 but applied present-day unit costs. Home help costs are assumed
to occur in only the first year after fracture and apply only to those residing in the community and not to
institutionalised patients.
For patients living in an institutional residential setting we applied the cost of local authority-provided
residential care for older people with the unit cost (£1100 per week) taken from the PSSRU.26 The costs for
local authority-provided care were used instead of private sector or NHS residential care, as a recent report
by The King’s Fund235 states that the vast majority (78%) of residential care places are provided by local
authorities. We assumed that 36% of patients self-fund their residential care based on data presented by
the Care Quality Commission.236 The annual cost falling within the NHS and PSS budget was therefore
estimated at £36,608 per person in residential care per annum. In the PSA, both the resource-use estimates
in Table 32 and the unit costs taken from NHS reference costs were sampled from probabilistic distributions.
TABLE 33 Unit costs for resource use attributable to fracture
Unit costs for resource use
Fracture
Hip Vertebrae Proximal humerus Wrist
Hospitalisation £7487 £3846 £5320 £3662
A&E £92 £85 £85 £84
GP £45 £45 £45 £45
Referral £146 £146 £146 £146
Prescriptions £9 £15 £15 £15
Home help per hour £24 £24 £24 £24
TABLE 34 Summary of fracture costs in the year following fracture and in subsequent years
Resource use
Fracture
Hip Vertebrae Proximal humerus Wrist
Costs in year of fracture £8235 £4173 £1305 £861
Costs in subsequent years £106 £332 £70 £70
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Those taken from PSSRU were not varied in the PSA as the PSSRU does not report a measure of variance.
Further details on the distributions used in the PSA are provided in Appendix 8, Table 51.
The costs for each of the four main osteoporotic fracture sites have been applied to other sites in the same
grouping (e.g. other femoral has the same cost as hip).
Approach to sensitivity analysis
A PSA has been conducted to estimate the mean cost and QALYs gained when taking into account the
uncertainty in the parameter values used within the model. In general, parameters were estimated using
the following distributions: gamma distributions for costs; log-normal distributions for HRs; and beta
distributions for utility values and probabilities. None of the parameters used to estimate fracture risk,
in the absence of treatment, was varied in the PSA. This was to ensure that a specific set of patient
characteristics was consistently mapped to the same survival curve for fracture-free survival without any
parameter uncertainty. The following additional parameters were not varied in the PSA: drug prices;
discount rates; unit costs sourced from PSSRU; utility in the second year after proximal humerus fracture;
life expectancy after fracture associated with excess mortality; unit costs for prescriptions after fracture;
and proportion of self-funders for residential care. Full details on the distributions applied within the model
can be found in Appendix 8, Tables 51–62.
Structural sensitivity analyses were conducted to explore whether or not the results were sensitive to
different model assumptions. In the majority of cases these were conducted using the deterministic model,
which does not incorporate any parameter uncertainty, owing to the significant computational time
required to run the PSA. A summary of the structural sensitivity analyses conducted is provided in Table 35
alongside an indication of the model used.
TABLE 35 Summary of structural sensitivity analyses
Model aspect
Assumption
Model usedIn base case In sensitivity analysis
Interventions Duration of treatment based on
observational data on treatment
persistence
Full persistence for 5 years for oral
bisphosphonates and i.v. ibandronic
acid, and 3 years for i.v. zoledronic
acid
Model using mid-point
parameters
Day case costs applied for zoledronic
acid administration and costs
generic drugs costs based on eMIT
database152 for 5-mg/100-ml dose
Outpatient costs applied for
zoledronic acid administration and
costs generic drugs costs based on
eMIT database152 for 4-mg/100-ml
dose (different indication) which has
been available in a generic form for
longer
Model using PSA to
incorporate parameter
uncertainty
Baseline
characteristics
Prevalence of prior fracture
estimated from meta-analysis by
Kanis et al.164
Prevalence of prior fracture
estimated from UK incidence
data166,167
Model using mid-point
parameters
Consequences
of fracture
No admission to nursing/residential
care following vertebral fracture
Rate of admission to nursing/
residential care for vertebral fracture
equivalent to rate for hip fracture
Model using mid-point
parameters
Average post-fracture survival for
patients with fracture-related death
is 3 months
Average post-fracture survival for
patients with fracture-related death
is 1 month
Model using mid-point
parameters
Systematic review by Klotzbuecher
et al.149 is used as the preferred
source for estimates of the increased
fracture risk following an incident
fracture
Systematic review by Warriner
et al.213 is used as the preferred
source for estimates of the increased
fracture risk following an incident
fracture
Model using mid-point
parameters
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Results
Patient characteristics of the simulated cohort
Summary patient characteristics are provided in Table 36 for each risk category when using both FRAX and
QFracture to calculate the absolute fracture risk. It can be seen that the average age is higher in the
higher-risk categories and the proportion of patients with the risk factors of prior fracture, steroid use or
nursing home residency increases in the higher-risk categories. The proportion of women also appears to
increase in the higher-risk categories as would be expected given that women in general have a higher risk
of osteoporotic fracture than men.
It should be noted that, in addition to there being different risk cut-off points for the risk categories when
using either QFracture or FRAX scores to define absolute risk, the ranking of patients by risk within the
cohort will differ between the two algorithms. It is therefore possible that patients falling into a particular
risk category when using the QFracture algorithm may fall into a different risk category when using the
FRAX algorithm. Figure 88 shows the distribution of 200,000 patients eligible for risk assessment under
CG14616 across the QFracture and FRAX risk categories. It can be seen from Figure 88 that, although there
is some agreement over the categorisation of patients across the two risk scoring algorithms, there is not
perfect agreement. The correlation between the absolute risk scores was found to be 0.83 and the
correlation between the risk categories based on deciles of risk score was found to be 0.76.
TABLE 35 Summary of structural sensitivity analyses (continued )
Model aspect
Assumption
Model usedIn base case In sensitivity analysis
Estimating
fracture risk
Fractures occurring at additional
sites (femoral shaft, clavicle, scapula,
rib, sternum, tibia, fibula, pelvis and
humeral shaft) are included
Only fractures at the main fracture
sites (hip, wrist, proximal humerus
and vertebrae) are included
Model using mid-point
parameters
Hip fracture risks estimated as a
proportion of major osteoporotic
fracture (which combines hip, wrist,
proximal humerus and vertebrae)
Hip fracture risks estimated using hip
specific estimates from the QFracture
and FRAX risk scoring tools
Model using mid-point
parameters
Efficacy
assumptions
Fall-off time for zoledronic acid is
2.3 times treatment duration but
fall-off time is equal to treatment
duration for all other treatments
Fall-off time is equal to treatment
duration for all treatments including
zoledronic acid
Model using mid-point
parameters
Different HRs used for oral and i.v.
ibandronic acid for some fracture
sites. Data from monthly oral doses
used for monthly oral ibandronic
acid and data from daily oral doses
used for i.v. ibandronic acid where
both exist
Same HRs used for oral and i.v.
ibandronic acid. This is achieved by
using the data from daily oral doses
for both monthly oral and i.v. doses
where it exists
Model using PSA to
incorporate parameter
uncertainty
AEs AEs included by applying one-off
costs and QALY decrements in the
first month of treatment in 3% of
patients having oral treatment and
14% of patients having i.v.
treatment
No costs or QALY decrements
applied for AEs in either oral or
i.v. treatment
Model using PSA to
incorporate parameter
uncertainty
AE rate for oral treatment increased
to 30%
Model using PSA to
incorporate parameter
uncertainty
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Clinical outcomes predicted by the model
Clinical outcomes for 200,000 patients are presented in Table 37 for the base-case scenario in which we
have applied the mean persistence with treatment from observational data. Under these assumptions the
numbers needed to treat to prevent one fracture during the first 6 months (6 months being the duration
of persistence with oral bisphosphonates) is lowest for risedronic acid and highest for oral ibandronic acid.
Given that it is necessary to treat around 2000 patients to prevent one fracture during the period of
persistence with oral bisphosphonates treatment when using the QFracture risk score, we estimated that
we would need to simulate approximately 2 million patients to obtain stable estimates of the benefits of
treatment in each risk category. This is because we would expect around 1000 fractures to be prevented
across a cohort of 2 million patients, with around 1% falling within the lowest risk category of QFracture.
Therefore, the costs and QALY implications of treatment would be based on around 10 fractures in the
lowest risk category of QFracture when using a cohort of 2 million patients.
TABLE 36 Summary patient characteristics for each risk category defined by either FRAX or QFracture deciles
Deciles
Risk category
Mean 10-year
risk (%)
Sex, %
female
Age (years),
mean (SD)
BMI, mean
(SD)
Prior fracture
(%)
Steroid use
(%)
Nursing home
resident (%)
FRAX
First 3.1 28 53 (5) 31 (6) 6.4 0.6 0.5
Second 4.3 34 52 (11) 31 (5) 39.4 1.3 0.4
Third 5.0 25 50 (13) 29 (4) 62.3 0.5 0.4
Fourth 5.6 23 49 (14) 26 (4) 73.3 0.5 0.5
Fifth 6.2 38 54 (15) 26 (5) 66.2 0.9 0.8
Sixth 7.3 43 61 (13) 27 (5) 59.5 1.5 0.9
Seventh 8.8 48 66 (10) 28 (4) 57.6 1.6 1.0
Eighth 10.7 56 70 (8) 27 (4) 57.8 1.8 1.3
Ninth 14.9 87 73 (8) 27 (4) 48.6 3.3 2.6
Tenth 25.1 99 81 (7) 26 (4) 68.9 4.0 7.6
QFracture
First 0.5 17 41 (8) 30 (5) 86.5 0.6 0.0
Second 0.7 13 46 (9) 28 (5) 76.8 0.7 0.1
Third 1.0 17 50 (9) 28 (5) 70.2 1.0 0.3
Fourth 1.4 27 55 (9) 28 (5) 60.7 1.3 0.4
Fifth 2.0 42 59 (9) 28 (5) 50.3 1.6 0.5
Sixth 2.7 53 63 (9) 28 (5) 41.6 1.7 0.7
Seventh 3.9 65 66 (9) 28 (5) 37.4 1.8 0.7
Eighth 5.5 75 70 (8) 28 (5) 35.1 2.1 1.1
Ninth 8.4 82 75 (7) 27 (4) 37.4 2.3 2.6
Tenth 16.0 90 83 (6) 26 (4) 45.7 2.8 9.6
All NA 48 61 (15) 28 (5) 54.2 1.6 1.6
NA, not applicable.
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FIGURE 88 Distribution of patients across FRAX and QFracture risk categories. QFracture risk categories are indexed
Q1–10 and FRAX risk categories are indexed F1–10, with 1 being the lowest risk category in each case.
TABLE 37 Clinical outcomes for 200,000 patients when applying mean persistence from observational studies
Treatment
strategy
Fractures occurring in the first 6 months after starting treatment
(the mean duration of persistence with treatment for oral
bisphosphonates)
NNT to prevent one
fracture occurring
in the first 6 months
after starting
treatment
Hip fractures
(including
other femoral)
Vertebral
fractures
Proximal
humerus
fractures
(including
tibia and
fibula)
Wrist
(including
all other
additional
sites)
All fracture
sites combined
FRAX
No treatment 216 146 143 495 1000
Alendronic acid 170 72 109 400 751 803
Risedronic acid 175 80 98 360 713 697
Ibandronic acid (oral) 182 72 109 400 763 844
Ibandronic acid (i.v.) 182 75 130 400 787 939
Zoledronic acid 202 66 99 389 756 820
QFracture
No treatment 121 63 67 177 428 1770
Alendronic acid 99 19 52 145 315 1550
risedronic acid 102 24 45 128 299 1942
ibandronic acid (oral) 109 19 52 145 325 2222
ibandronic acid (i.v.) 109 19 65 145 338 1835
Zoledronic acid 115 15 48 141 319 1770
NNT, number needed to treat.
DOI: 10.3310/hta20780 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 78
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Davis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
253
It can be seen from Table 37 that the number of fractures occurring in the first 6 months is higher when
using the FRAX algorithm than when using the QFracture algorithm. This is because the absolute risk
predicted by FRAX is higher than the absolute risk predicted by QFracture in 98% of patients.
Presentation of cost-effectiveness results
The mean costs and QALYs from the PSA are presented as the base-case results. These were considered
to be preferable to estimates obtained using mid-point (mean or median) parameter inputs because we
believe that there may be a non-linear relationship between parameter values and model outcomes.
The data presented were obtained from a total patient population of 2 million across all 10 risk categories,
with one parameter sample per patient. Therefore, approximately 200,000 patients and 200,000
parameter samples informed the estimates for each risk category.
Full results tables for the base-case scenario including an incremental analysis for each risk category for
QFracture and FRAX are presented in Tables 64–73 in Appendix 9 and Tables 74–83 in Appendix 10,
respectively. Results have been summarised below by plotting the incremental net benefit (INB) compared
with a strategy of no treatment when assuming that a QALY is valued at £20,000. INB has been plotted
instead of ICERs, as these can be difficult to interpret when the QALY gain is negative, which was the case
for some treatments in some risk categories. The cost-effectiveness plane has not been presented, as a
minimum of 20 graphs would be needed to present results across all 10 risk categories for both QFracture
and FRAX. We used non-parametric regression to estimate the cost-effectiveness acceptability curves
(CEACs). This allows variation in the costs and QALYs as a result of parameter uncertainty to be separated
from variation caused by patient-level stochastic variability.
Structural sensitivity analyses have been conducted by fixing parameter values at their mid-point value.
Although it would have been preferable to rerun the PSA for each structural sensitivity analysis, this was
not possible within the time constraints. The PSA was rerun for the sensitivity analysis, which involved
changing the HRs for treatment as we considered it important in this case to capture the underlying joint
distribution for the HRs. For the sensitivity analyses on AE rates and the sensitivity analysis examining
alternative treatment costs for zoledronic acid, the outputs of the base-case PSA model were adjusted,
as these adjustments could be made without rerunning the PSA. For all other sensitivity analyses, the
model using mid-point parameter estimates was run for 2.2 million patients.
Summary of cost-effectiveness results for the base-case scenario when using QFracture
Figure 89 summarises the cost-effectiveness results across the 10 risk categories when using QFracture to
estimate absolute risk. It shows the INB, in monetary terms, when valuing a QALY at £20,000, when
compared with a strategy of no treatment. Each point shows the mean INB and the mean 10-year
absolute risk of fracture for one risk category for a particular bisphosphonate treatment. It can be seen
that the mean INB is close to zero for all three oral bisphosphonates across the first six risk categories,
which have mean absolute risks ranging from 0.5% to 2.7%; the estimates are all very close together.
Detailed results tables providing a full incremental analysis are provided in Tables 64–73 in Appendix 9.
It can be seen from these that in the third, fourth and sixth risk categories (mean absolute risks of 1.0%,
1.4% and 2.7%, respectively) at least one of the oral bisphosphonates has a positive INB, but the absolute
INB is still small and close to zero. In the fifth risk category (mean absolute risk of 2%) it is below zero for all
three oral bisphosphonates. The INB is positive for all three oral bisphosphonates from the seventh to the
tenth risk categories (mean absolute risk of 3.9% and above). A strategy of no treatment has the maximum
net benefit in the first, second and fifth risk categories (mean absolute risks of 0.5%, 0.7% and 2.0%,
respectively) and when a QALY is valued at either £20,000 or £30,000 (see Tables 64–72 in Appendix 9 for
INB at £30,000). In the other risk categories the treatment with maximum net benefit is always either
alendronic acid or risedronic acid. Oral ibandronic acid does not fall on the cost-effectiveness frontier in any
risk category when using QFracture to estimate absolute risk. The difference between oral ibandronic acid
and the other two oral bisphosphonates becomes more apparent in the higher-risk categories. This is
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because of marginally less favourable efficacy data for oral ibandronic acid, which becomes more important
as the risk increases. For the i.v. bisphosphonates the INB is negative across all 10 risk categories when
valuing a QALY at either £20,000 or £30,000 (see Tables 64–73 in Appendix 9 for INB at £30,000).
The full data from the PSA for the whole population (2 million patients with one parameter sample per
patient) were used in a non-parametric regression, which estimated the relationship between INB and absolute
fracture risk estimated by QFracture. For each of the five treatment options, the relationship between the INB
of treatment (vs. no treatment) and the absolute fracture risk was estimated using a generalised additive
model. This flexible regression approach assumes that the underlying relationship between the dependent
variable and the independent variable can be approximated by a cubic spline, a highly flexible function that
can model any smooth relationship between two variables. The regression prediction is shown in Figure 90
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FIGURE 89 Incremental net benefit (when valuing QALY at £20,000) compared with no treatment against the
10-year fracture risk from QFracture.
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FIGURE 90 Regression for INB (when valuing QALY at £20,000) compared with no treatment against the 10-year
fracture risk from QFracture.
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with a close-up provided in Figure 91 of the lower-risk range. The results here differ from those presented in
Figure 89 because the non-parametric regression method is able to average over the stochastic uncertainty
associated with the individual-level patients while simultaneously estimating the relationship between INB and
absolute risk. It can be seen that the INB of alendronic acid and risedronic acid increases with increasing risk.
A strategy of no treatment is predicted to have the greatest net benefit for the lowest-risk patients. Table 38
summarises the thresholds over which each treatment has a positive INB compared with no treatment (when
valuing a QALY at £20,000) and the range over which each treatment has the maximum INB based on the
non-parametric regression. Alendronic acid is predicted to have the maximum net benefit from 1.5% and
risedronic acid is predicted to have the maximum net benefit from 7.2% upwards. Oral and i.v. ibandronic
acid have differing relationships with absolute risk, which may reflect the fact that different efficacy data were
applied. However, the results for i.v. ibandronic acid should be treated with caution as no fracture data were
available for this treatment and data from other ibandronic acid regimens were applied. It should also be
noted that the regression may predict INB less well in higher-risk patients, as only 10% of the population had
a risk score of > 11%. It is also important to consider the uncertainty around the INB estimates by considering
the CEACs.
TABLE 38 QFracture absolute risk thresholds obtained from regression of INB compared with no treatment over
absolute risk (when valuing a QALY at £20,000)
Treatment
Range over which INB is positive
compared with no treatment
Range over which INB is greater
than for all other treatments
No treatment NA < 1.5%
Alendronic acid > 1.5% > 1.5 and < 7.2%
Risedronic acid > 2.3% > 7.2%
Ibandronic acid (oral) > 4.2 and < 13.1% Never
Ibandronic acid (i.v.) > 75.5% Never
Zoledronic acid Never Never
NA, not applicable.
0
– 10
0
10
20
30
40
50
5
4.2 7.2 13.1 2.3 1.5 
IN
B
 v
s.
 n
o
 t
re
a
tm
e
n
t 
(£
)
10
QFracture score (%)
No treatment
Alendronic acid
Risedronic acid
Ibandronic acid (oral)
15
FIGURE 91 Close-up of regression for INB (when valuing QALY at £20,000) compared with no treatment against
the 10-year fracture risk from QFracture.
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Figures 92–101 present the CEACs for each of the risk categories when using QFracture to determine
absolute risk. It can be seen that in the first and second risk categories (mean absolute risk of 0.5% and
0.7%, respectively), the no-treatment strategy has a much higher probability of being optimal, when
valuing a QALY at £20,000 than any of the other strategies. However, in the third risk category (mean
absolute risk of 1.0%), no treatment has the third highest probability of being most cost-effective with
both risedronic acid and oral ibandronic acid having a greater probability when valuing a QALY at either
£20,000 or £30,000. Although all three oral bisphosphonates have a positive INB compared with no
treatment, in the seventh risk category (mean absolute risk of 3.9%) when valuing a QALY at £20,000,
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FIGURE 92 Cost-effectiveness acceptability curve for QFracture risk category 1 (mean absolute risk of 0.5%).
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FIGURE 93 Cost-effectiveness acceptability curve for QFracture risk category 2 (mean absolute risk of 0.7%).
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no treatment has a higher probability of being cost-effective than either risedronic acid or oral ibandronic
acid, suggesting that there is still considerable uncertainty regarding the relative cost-effectiveness of
oral bisphosphonates.
The i.v. bisphosphonates have a low probability of being optimal when valuing a QALY at £20,000, even
in the highest-risk categories, although by the 10th risk category (mean absolute risk of 16.0%) they have
a similar probability of being cost-effective as no treatment.
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FIGURE 94 Cost-effectiveness acceptability curve for QFracture risk category 3 (mean absolute risk of 1.0%).
0
0.0
0.2
0.4
0.6
0.8
1.0
50 100 150 200
Threshold willingness to pay (£000)
P
ro
b
a
b
il
it
y
 s
tr
a
te
g
y
 i
s 
co
st
-e
ff
e
ct
iv
e
No treatment
Alendronic acid
Risedronic acid
Ibandronic acid (oral)
Ibandronic acid (i.v.)
Zoledronic acid
FIGURE 95 Cost-effectiveness acceptability curve for QFracture risk category 4 (mean absolute risk of 1.4%).
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Summary of cost-effectiveness results for the base-case scenario when using FRAX
Figure 102 summarises the cost-effectiveness results across the 10 risk categories for FRAX. It shows the
INB for each bisphosphonate treatment when compared with no treatment plotted against the 10-year
absolute risk of fracture. Each point shows the mean INB and the mean 10-year absolute risk of fracture
for one risk category when valuing a QALY at £20,000. It can be seen that the INB compared with no
treatment does not have a simple relationship with absolute risk when using FRAX to define absolute risk.
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FIGURE 96 Cost-effectiveness acceptability curve for QFracture risk category 5 (mean absolute risk of 2.0%).
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FIGURE 97 Cost-effectiveness acceptability curve for QFracture risk category 6 (mean absolute risk of 2.7%).
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At first, the INB rises, but it later falls before rising again. This may reflect the differing patient
characteristics across the risk categories. However, it can be seen that the mean INB compared with no
treatment is above zero for all oral bisphosphonates across all 10 risk categories. The detailed results
tables provided in Appendix 9 show that none of the bisphosphonates is consistently more cost-effective
than the others, with all three having the highest INB (when valuing a QALY at £20,000) in at least
one risk category and all three being dominated by another oral bisphosphonate in at least one
risk category.
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FIGURE 98 Cost-effectiveness acceptability curve for QFracture risk category 7 (mean absolute risk of 3.9%).
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FIGURE 99 Cost-effectiveness acceptability curve for QFracture risk category 8 (mean absolute risk of 5.5%).
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The mean INB for the two i.v. bisphosphonates is below zero across all 10 risk categories. This remains the
case even when valuing a QALY at £30,000 (see Tables 74–83 in Appendix 10). Furthermore, i.v. ibandronic
acid is always extendedly dominated by the other treatment strategies across all 10 risk categories for FRAX.
The full data from the PSA for the whole population (2 million patients with one parameter sample per
patient) were used in a non-parametric regression, which estimated the relationship between INB and
absolute fracture risk estimated by FRAX. For each of the five treatment options, the relationship between
the INB of treatment (vs. no treatment) and the absolute fracture risk was estimated using a generalised
additive model. This flexible regression approach assumes that the underlying relationship between the
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FIGURE 100 Cost-effectiveness acceptability curve for QFracture risk category 9 (mean absolute risk of 8.4%).
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FIGURE 101 Cost-effectiveness acceptability curve for QFracture risk category 10 (mean absolute risk of 16.0%).
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dependent variable and the independent variable can be approximated by a cubic spline, a highly flexible
function that can model any smooth relationship between two variables. The regression prediction is
shown in Figure 103, with a close-up shown in Figure 104 for the lower risk range. The results here
differ from those presented in Figure 102 because non-parametric regression is able to average over
the stochastic uncertainty associated with the individual-level patients while simultaneously estimating the
relationship between INB and absolute risk. It can be seen that the INB of alendronic acid and risedronic
acid increases with increasing risk. For all three oral bisphosphonates, the INB is positive compared with no
treatment across the full range of absolute risk observed in the modelled population. Table 39 summarises
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FIGURE 102 Incremental net benefit (when valuing QALY at £20,000) compared with no treatment against the
10-year fracture risk from FRAX.
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FIGURE 103 Regression for INB (when valuing QALY at £20,000) compared with no treatment against the 10-year
fracture risk from FRAX.
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the thresholds over which the INB of each treatment is positive compared with no treatment (when valuing
a QALY at £20,000) and the range over which the INB of each treatment is maximum based on the
non-parametric regression. Oral ibandronic acid is predicted to have the maximum INB up to an absolute
risk level of 8.6%. Alendronic acid is predicted to have the maximum net benefit from 8.6%% to
38.5% and risedronic acid is predicted to have the maximum net benefit from 38.5% upwards. The
INB compared with no treatment is negative for both the i.v. bisphosphonates across the full range
of absolute risk observed in the modelled population when using FRAX to estimate absolute risk.
By comparing Figure 90 with Figure 103 it can be seen that the relationship between INB and absolute
risk for the i.v. bisphosphonates appears to differ when using FRAX and QFracture for patients with an
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FIGURE 104 Close-up of regression for INB (when valuing QALY at £20,000) compared with no treatment against
the 10-year fracture risk from FRAX.
TABLE 39 FRAX absolute risk thresholds obtained from regression of INB compared with no treatment over
absolute risk (when valuing a QALY at £20,000)
Treatment
Range over which INB is positive
compared with no treatment
Range over which INB is greater
than for all other treatments
No treatment NA Never
Alendronic acid Whole range observed in modelled population > 8.6 and < 38.5%
Risedronic acid Whole range observed in modelled population > 38.5%
Ibandronic acid (oral) Whole range observed in modelled population < 8.6%
Ibandronic acid (i.v.) Never Never
Zoledronic acid (i.v.) Never Never
NA, not applicable.
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absolute risk of > 20%. However, this may not reflect a true difference, as the estimates of > 11%
for QFracture and > 18% for FRAX are informed by only one-tenth of the modelled population and,
therefore, it is also important to consider the uncertainty in these estimates of mean INB by considering
the CEACs.
Figure 105–114 show the CEACs for the 10 FRAX risk categories. It can be seen that the strategy of no
treatment has a low probability of being most cost-effective when valuing a QALY at £20,000, across all
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FIGURE 105 Cost-effectiveness acceptability curve for FRAX risk category 1 (mean absolute risk of 3.1%).
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FIGURE 106 Cost-effectiveness acceptability curve for FRAX risk category 2 (mean absolute risk of 4.3%).
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10 risk categories. The i.v. bisphosphonates always have a lower probability of being optimal compared
with no treatment or the oral bisphosphonates until risk category 8 (mean absolute risk of 10.7%) when
i.v. zoledronic acid has a higher probability of being cost-effective than no treatment. In FRAX risk category
10 (mean absolute risk of 25.1%), i.v. zoledronic acid has the highest probability of being cost-effective,
when valuing a QALY at £20,000 and i.v. ibandronic acid has a higher probability than oral ibandronic
acid. However, it should be noted that the mean INB for both the i.v. bisphosphonates is negative in this
risk category when valuing a QALY at £20,000.
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FIGURE 107 Cost-effectiveness acceptability curve for FRAX risk category 3 (mean absolute risk of 5.0%).
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FIGURE 108 Cost-effectiveness acceptability curve for FRAX risk category 4 (mean absolute risk of 5.6%).
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Summary of cost-effectiveness results for the base-case scenario when
using FRAX
Figure 115 summarises the results from the model using mid-point parameter inputs. It shows the INB for
each bisphosphonate treatment when compared with no treatment plotted against the 10-year absolute
risk of fracture. The ‘F’ and ‘Q’ labels after the drug name indicate where the FRAX and QFracture
algorithms have predicted the risk, respectively. The INB at the various risk levels appear to fall on a slightly
higher curve when using FRAX than when using QFracture, with the difference being more pronounced for
the i.v. bisphosphonates. This behaviour was also observed when examining the PSA results for QFracture
and FRAX on the same plot, but the difference was slightly less pronounced (data not presented).
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FIGURE 109 Cost-effectiveness acceptability curve for FRAX risk category 5 (mean absolute risk of 6.2%).
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FIGURE 110 Cost-effectiveness acceptability curve for FRAX risk category 6 (mean absolute risk of 7.3%).
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Structural sensitivity analyses
A sensitivity analysis was conducted in which we assumed that all patients would persist with treatment
for the intended treatment duration (5 years for oral bisphosphonates and i.v. ibandronic acid and 3 years
for zoledronic acid). In Figure 116, it can be seen that the INB is positive for oral bisphosphonates in all but
the lowest risk category when using QFracture and in all risk categories when using FRAX. This is to be
expected because the absolute benefits of treatment are greater when assuming that patients persist with
treatment for longer. Therefore, as treatment continues the net benefit of treatment outweighs the
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FIGURE 111 Cost-effectiveness acceptability curve for FRAX risk category 7 (mean absolute risk of 8.8%).
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FIGURE 112 Cost-effectiveness acceptability curve for FRAX risk category 8 (mean absolute risk of 10.7%.)
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upfront costs and disutilities associated with AEs in the first month after initiating treatment. The ICER
for i.v. ibandronic acid compared with no treatment falls below £30,000 per QALY in the eighth risk
category for FRAX (mean absolute risk of 10.7%) and below £20,000 per QALY in the 10th risk category
of FRAX (mean absolute risk of 25.1%). For QFracture, the ICER compared with no treatment for i.v.
ibandronic acid remains above £30,000 per QALY across all risk categories. For zoledronic acid,
the ICER compared with no treatment does not fall below £30,000 in any risk category for either FRAX
or QFracture.
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FIGURE 114 Cost-effectiveness acceptability curve for FRAX risk category 10 (mean absolute risk of 25.1%).
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FIGURE 113 Cost-effectiveness acceptability curve for FRAX risk category 9 (mean absolute risk of 14.9%).
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A sensitivity analysis was conducted in which the rate of admission to a nursing home following hip fracture
was applied to both hip and vertebral fractures. The results for this analysis are presented in Figure 117.
The results are broadly similar to the base-case results, suggesting that our decision not to include nursing
home admission following vertebral fracture within the analysis is unlikely to have significantly biased the
cost-effectiveness results.
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FIGURE 115 Incremental net benefit for the base-case scenario when using mid-point parameter estimates.
F, predicted by FRAX; Q, predicted by QFracture.
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FIGURE 116 Incremental net benefit for the sensitivity analysis assuming full persistence with treatment for 3 years
for zoledronic acid and 5 years for all other bisphosphonate treatments. F, predicted by FRAX; Q, predicted
by QFracture.
DOI: 10.3310/hta20780 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 78
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Davis et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
269
A sensitivity analysis was conducted in which we removed any fractures occurring at sites other than the
four main osteoporotic fracture sites (hip, wrist, proximal humerus and vertebrae). The INBs compared with
no treatment for both QFracture and FRAX are summarised in Figure 118. It can be seen that the results
when using the QFracture algorithm are similar to the base case, but the results when using the FRAX
algorithm have a lower INB and are more closely aligned with those for QFracture when considering risk
categories with a similar mean absolute risk. The results from this structural sensitivity analysis suggests
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FIGURE 117 Incremental net benefit for sensitivity analysis applying nursing home admission rates following hip
fracture to vertebral fractures in addition to hip fractures. F, predicted by FRAX; Q, predicted by QFracture.
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FIGURE 118 Incremental net benefit for the sensitivity analysis excluding fractures occurring at sites other than the
hip, wrist, proximal humerus and vertebrae. F, predicted by FRAX; Q, predicted by QFracture.
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that the method used to uplift the fracture risk to incorporate fractures at additional sites may have caused
the INBs of bisphosphonate treatment to be overestimated in the base-case analysis based on FRAX.
A sensitivity analysis was conducted in which the survival curves for hip fracture were based on the
hip-specific absolute risk estimates from QFracture rather than a proportion of the absolute risk for
the four main osteoporotic fracture sites. The results, shown in Figure 119, are broadly similar to the
base case although the INB estimates for the FRAX risk categories are generally lower and fall closer to
those for the QFracture categories with comparable absolute fracture risk. The INBs for all three oral
bisphosphonates are negative in the first FRAX risk category (mean absolute risk of 3.1%) and the INB
for risedronic acid is negative in the second FRAX risk category (mean absolute risk of 4.3%). The results
of this structural sensitivity analysis suggests that the base-case scenario may have overestimated the
cost-effectiveness of treatment for the FRAX risk categories because of the method used to calculate
survival curves for FRAX from the data available for QFracture. The cost-effectiveness results for
bisphosphonates treatment compared with no treatment may therefore be favourable to treatment when
using the FRAX risk scores.
In the analysis, assuming full persistence with treatment, the duration of treatment for zoledronic acid was
3 years but the fall-off period was set to 7 years, while for the other bisphosphonates the treatment
duration was 5 years and the fall-off period was 5 years. Although the assumption ensured that treatment
effects fell to zero at 10 years for all drugs, when assuming full persistence, this assumption might have be
favourable to zoledronic acid. In the base-case scenario in which mean persistence from observational
studies was applied, the treatment duration and fall-off period for zoledronic acid were set to 1.7 years
and 4 years (7/3 x 1.7), respectively. A sensitivity analysis was conducted in which the fall-off period for
zoledronic acid was set equal to the treatment duration (1.7 years for both). The results are summarised in
Figure 120. It can be seen that for lower-risk categories for QFracture the INB estimates for zoledronic acid
do not vary smoothly suggesting that they have failed to reach a stable estimate probably owing to the
limited number of fractures prevented when assuming only 1.7 years of treatment and 1.7 years of fall-off
time. However, the INB for zoledronic acid versus no treatment remains below zero for all risk categories
for both QFracture and FRAX, as was observed in the base-case scenario.
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FIGURE 119 Incremental net benefit for scenario using hip-specific estimates of absolute fracture risk. F, predicted
by FRAX; Q, predicted by QFracture.
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A sensitivity analysis was conducted to examine whether or not uncertainty regarding the average survival
in patients who die following a hip fracture was an important determinant of cost-effectiveness. For this
analysis the average duration of survival after hip fractures associated with excess mortality was reduced
from 3 months to 1 month. The results, which are summarised in Figure 121, are very close to those seen
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FIGURE 120 Incremental net benefit for scenario in which fall-off time was set equal to treatment duration for
zoledronic acid. F, predicted by FRAX; Q, predicted by QFracture.
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FIGURE 121 Incremental net benefit when assuming that excess mortality associated with hip fractures occurs
1 month after the hip fracture. F, predicted by FRAX; Q, predicted by QFracture.
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in the base-case scenario and, therefore, it can be concluded that the exact duration of survival following a
hip fracture associated with excess mortality is not an important determinant of cost-effectiveness.
A sensitivity analysis was conducted using the more recent data on the increased risk of fracture following
an incident fracture from the systematic review by Warriner et al.213 The results, summarised in Figure 122,
show marginally higher INBs for treatment compared with no treatment, which is expected because several
of the HRs for increased fracture risk following an incident fracture were greater in the paper by Warriner
et al.213 than the figures presented in the paper by Klotzbuecher et al.149 which were used in the base-case
scenario. However, the results do not appear to be particularly sensitive to the choice of data source for
these model parameters.
A sensitivity analysis was conducted in which the prevalence of a prior fracture at baseline was estimated
from UK fracture incidence data rather than using estimates of the prevalence of a prior fracture from a
meta-analysis of the cohort studies which informed the FRAX algorithm. It can be seen from Figure 123
that the results are very similar to the base-case results and, therefore, the model is not particularly
sensitive to the prevalence of a prior fracture at baseline. This may be because a history of prior fracture
has only a marginal impact on the individual’s utility and health resource use and the increased risk
attributed to prior fracture would simply move patients between risk categories rather than making it more
or less cost-effective to treat within a particular risk category.
In the base-case analysis, data from the 150 mg per month of oral ibandronic acid regimen were applied
in the model for the monthly oral dose for all four fracture sites. However, no fracture data were available
for the i.v. ibandronic acid regimen. As this regimen was licensed based on a non-inferiority trial
comparing it to the previously licensed 2.5 mg per day oral regimen, data from the 2.5-mg oral dose were
applied to the i.v. regimen where these were available. Where these were not available, data from the
150 mg per month oral regimen were applied instead. However, this meant that different data were
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FIGURE 122 Incremental net benefit for sensitivity analysis using Warriner et al.213 instead of Klotzbuecher et al.149
as the preferred source for the HR of subsequent fracture following incidence fracture. F, predicted by FRAX;
Q, predicted by QFracture.
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applied for the oral and i.v. regimen for some fracture sites (vertebral and proximal humerus). A sensitivity
analysis was conducted in which the same efficacy data were applied to both the monthly oral and the
quarterly i.v. ibandronic acid regimens. For vertebral and proximal humerus fractures data from the 2.5 mg
per day oral ibandronic acid regimen were applied to both as both were licensed based on non-inferiority
trials comparing them to the daily 2.5-mg oral dose (no longer licensed). Data for hip and wrist were
unchanged as the only data available were for the 150-mg dose and these data were applied to both
regimens in the base case. The efficacy data applied in the base-case and the sensitivity analysis are
summarised in Table 40.
– 600
– 500
– 400
– 300
– 200
– 100
0
100
200
0 5 10 15 20 25 30
IN
B
 v
s.
 n
o
 t
re
a
tm
e
n
t 
(£
)
10-year risk of fracture (%)
Alendronic acid F
Risedronic acid F
Ibandronic acid (oral) F
Ibandronic acid (i.v.) F
Zoledronic acid F
Alendronic acid Q
Risedronic acid Q
Ibandronic acid (oral) Q
Ibandronic acid (i.v.) Q
Zoledronic acid Q
FIGURE 123 Incremental net benefit for sensitivity analysis using UK incidence data to estimate the prevalence of
prior fracture. F, predicted by FRAX; Q, predicted by QFracture.
TABLE 40 Hazard ratios applied in the base-case and sensitivity analysis for ibandronic acid treatment regimens
Fracture site Monthly oral ibandronic acid, HR (95% CI) Quarterly i.v. ibandronic acid, HR (95% CI)
Base case
Hip 0.87 (0.27 to 2.92) from monthly dosing 0.87 (0.27 to 2.92) from monthly dosing
Vertebrae 0.45 (0.21 to 0.96) from monthly dosing 0.47 (0.25 to 0.86) from daily dosing
Proximal humerus 0.80 (0.49 to 1.43) from monthly dosing 0.92 (0.59 to 1.43) from daily dosing
Wrist 0.83 (0.31 to 2.39) from monthly dosing 0.83 (0.31 to 2.39) from monthly dosing
Sensitivity analysis
Hip 0.87 (0.27 to 2.92) from monthly dosing 0.87 (0.27 to 2.92) from monthly dosing
Vertebrae 0.47 (0.25 to 0.86) from daily dosing 0.47 (0.25 to 0.86) from daily dosing
Proximal humerus 0.92 (0.59 to 1.43) from daily dosing 0.92 (0.59 to 1.43) from daily dosing
Wrist 0.83 (0.31 to 2.39) from monthly dosing 0.83 (0.31 to 2.39) from monthly dosing
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The results for this sensitivity are summarised in Figure 124 for the QFracture risk categories and in Figure 125
for the FRAX risk categories. The estimates presented here are the mean outputs from the PSA, which
incorporated the joint distribution of the HRs from the NMA. The results are very similar to the base-case
analysis, suggesting that the model is not particularly sensitive to the choice of data source for the ibandronic
acid HRs. This was to be expected given that the NMA did not find any strong evidence of a difference in
efficacy between the monthly and daily dosing ibandronic acid regimens. It remains possible that there is a
difference between fracture outcome for the monthly oral and quarterly i.v. regimens, but this could not be
assessed within the NMA because no fracture outcomes were available for the quarterly i.v. regimen.
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FIGURE 125 Incremental net benefit for sensitivity analysis using the same efficacy data for oral and i.v. ibandronic
acid treatments for FRAX risk categories.
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FIGURE 124 Incremental net benefit for sensitivity analysis using the same efficacy data for oral and i.v. ibandronic
acid treatments for QFracture risk categories.
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Scenario sensitivity analyses were also conducted on the costs and QALY decrements attributable to AEs.
As AEs were not included as an uncertain parameter in the PSA, it was possible to adjust the PSA outputs
for different assumptions regarding AEs. Figures 126 and 127 summarise the results when assuming no
costs or QALY decrements attributable to AEs for the QFracture and FRAX risk categories, respectively. It can
be seen that in this scenario the oral bisphosphonates are more cost-effective, with only risedronic acid
having a negative INB compared with no treatment in the first QFracture risk decile (mean absolute risk of
0.5%), when valuing a QALY at £20,000. In all other risk categories the oral bisphosphonates have a
positive INB, except for the fifth risk category (mean absolute risk of 2.0%), in which only alendronic acid
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FIGURE 126 Incremental net benefit for sensitivity analysis assuming no costs or QALY decrements for adverse side
effects for QFracture risk categories.
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FIGURE 127 Incremental net benefit for sensitivity analysis assuming no costs or QALY decrements for adverse side
effects for FRAX risk categories.
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has a positive INB. However, the results for the i.v. bisphosphonates are similar, with negative INBs
compared with no treatment across all 10 risk categories for QFracture.
The results across the FRAX risk categories when assuming no costs of QALY decrements attributable to
AEs were similar to the base-case scenario, with positive INBs for the oral bisphosphonates and negative
INBs for the i.v. bisphosphonates when valuing a QALY at either £20,000 or £30,000.
In addition, a scenario analysis was conducted in which the rate of adverse side effects for oral
bisphosphonates was increased from 3% to 30%. In this scenario none of the oral bisphosphonates had a
positive INB compared with no treatment across any of the QFracture risk categories when valuing a QALY
at £20,000, as shown in Figure 128. The INBs remained negative for all treatments when valuing a QALY
at £30,000 (data not presented).
The results for the FRAX risk categories when assuming an AE rate of 30% for oral bisphosphonates in the
first month of treatment are shown in Figure 129. It can be seen that the INB is negative for the three oral
bisphosphonates for the first eight risk categories (mean absolute risk of 10.7% and below), but is positive
for alendronic acid in the ninth FRAX risk category (mean absolute risk of 14.9%) and for all three oral
bisphosphonates in the 10th FRAX risk category (mean absolute risk of 25.1%).
Our clinical advisors were concerned that the price of zoledronic acid, which was taken from the eMIT
database,152 may not be reflective of real-world prices because zoledronic acid has only recently become
available in a generic format for this indication. Therefore, we conducted a sensitivity analysis using
the price from eMIT for the 4-mg dose of generic zoledronic acid, which is licensed for the prevention of
skeletal-related events in patients with advanced malignancies involving the bone. The average price on
eMIT for the most commonly prescribed preparation of zoledronic acid for this alternative indication was
£5.76. It was also noted by clinicians that zoledronic acid may be administered in some cases as an
outpatient procedure rather than as a day case. Therefore, we also applied these lower administration
costs in addition to the lower drug acquisition cost. This was done using the average outputs from the PSA
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FIGURE 128 Incremental net benefit for sensitivity analysis assuming a 30% AE rate for oral bisphosphonates in the
first month of treatment for QFracture risk categories.
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and by assuming 1.67 doses of zoledronic acid are administered on average, with the mean number of
doses estimated based on 500,000 PSA samples.
The results, when assuming these lower costs for zoledronic acid treatment, are summarised in Figure 130
for both QFracture and FRAX. It can be seen that, although the INB compared with no treatment has
increased for zoledronic acid under these more favourable cost assumptions, the INB is still negative across
all 10 risk categories for both QFracture and FRAX.
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FIGURE 129 Incremental net benefit for sensitivity analysis assuming a 30% AE rate for oral bisphosphonates in the
first month of treatment for FRAX risk categories.
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FIGURE 130 Incremental net benefit for zoledronic acid when assuming a lower acquisition price and outpatient
rather than day case administration costs. F, predicted by FRAX; Q, predicted by QFracture.
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Discussion
In summary, when valuing a QALY at £20,000, a strategy of no treatment is predicted to have the greatest
net benefit for patients with a QFracture score of < 1.5%. Alendronic acid is predicted to have the
maximum net benefit from 1.5% to 7.2% and risedronic acid is predicted to have the maximum net
benefit for a score of ≥ 7.2%. However, the absolute costs and QALY gains are small in patients with low
absolute risk and there is considerable uncertainty regarding whether or not no treatment is the optimal
strategy until the QFracture score is approximately 5.5% (the mean absolute risk for the eighth risk
category for QFracture).
The mean INBs for oral bisphosphonate treatment compared with no treatment were positive across all
FRAX risk categories. However, in the base-case scenario the INBs of bisphosphonate treatments compared
with no treatment were generally higher for FRAX than QFracture for risk categories with similar absolute
fracture risk. We would expect from the way the model is structured that the threshold for cost-effective
treatment would be broadly similar across the two risk scores. The results of two structural sensitivity
analyses suggest that the base-case analysis may have overestimated the INB of bisphosphonate treatment
compared with no treatment. Given this possible bias in the estimates generated by the model using the
FRAX risk score, and our belief that the results should be broadly similar across the two risk scores, it
would be reasonable to assume that the absolute risk threshold estimated in the QFracture model could be
applied to patients whose score had been calculated using either QFracture or FRAX.
Intravenous bisphosphonates had much higher ICERs than no treatment. In the highest-risk categories the
ICERs for i.v. ibandronic acid and zoledronic acid compared with oral bisphosphonates were > £50,000 per
QALY, even though the base-case analysis assumed longer durations of persistence with i.v. bisphosphonates
than with oral bisphosphonates. Although the mean INB compared with no treatment for i.v. ibandronic acid
did become positive at very high levels of absolute risk when using QFracture, the results when using FRAX
went in the opposite direction. This may be because of the small number of patients and parameter samples
informing the estimates at high levels of absolute risk, which makes these estimates more uncertain.
The results appeared to be broadly similar when we conducted the following structural sensitivity analyses:
applying the risk of nursing home admission following hip fracture to vertebral fractures; shorter duration
of survival for hip fractures associated with excess mortality; alternative data source for increased risk of
fracture following incident fracture; alternative data source for prevalence of prior fracture at baseline;
using the same efficacy estimates for oral and i.v. ibandronic acid; reducing the acquisition and
administration costs for zoledronic acid; and reducing the fall-off period for zoledronic acid. The results
were broadly similar for QFracture but slightly less favourable for FRAX for the sensitivity analysis in which
fractures at additional sites were removed from the model and for the sensitivity analysis using hip specific
absolute risks to estimate time to hip fracture. The results were more favourable to treatment when
assuming full persistence with treatment or when assuming no AEs. The sensitivity analysis examining
an AE rate of 30% in the month following initiation of oral bisphosphonate therapy showed that the
cost-effectiveness of oral bisphosphonate is very sensitive to the rate of AEs experienced.
The model’s estimates of cost-effectiveness are generalisable to patients eligible for risk assessment under
CG146,16 as this is the population we have simulated. However, there are some groups with secondary
osteoporosis who may be considered eligible for risk assessment under CG14616 who have not been
explicitly simulated within our model. Patients at increased risk of fracture after receiving hormone
treatments for breast and prostate cancer have not been explicitly simulated, although patients with the
more general risk factor of ‘any cancer’ have been included in the simulated cohort. Patients at increased
risk of fracture following untreated premature menopause have not been simulated but the prevalence
of HRT usage in female patients has been taken into account within the simulated cohort. We might
expect the cost-effectiveness in these groups to be similar to groups with other secondary causes of
osteoporosis that have been explicitly modelled, such as steroid-induced osteoporosis, provided the groups
who have not been explicitly modelled have an increased risk of fracture and similar life expectancy to
other causes of secondary osteoporosis that have been modelled.
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We have applied all-cause mortality data from the UK general population to the whole modelled cohort.
This may overestimate the cost-effectiveness of treating patients who have higher mortality risks because
of the presence of comorbidities and, therefore, the cost-effectiveness estimates may be less generalisable
to groups with lower-than-average life expectancy.
One of the strengths of the patient-level simulation approach we have used is that we have been able to
simulate how the distribution of patient characteristics, such as age, varies between different risk scores
and how this influences the cost-effectiveness of treatment. However, the patient-level simulation
approach used required a large number of patients to be simulated because of the scarcity of events in
lower-risk populations. This made it difficult to accurately measure the incremental costs and QALYs
associated with treatment in the lowest-risk categories when the treatment durations were reduced to
reflect real-world persistence with treatment. However, we were able to use non-parametric regression to
estimate the relationship between INB and absolute risk across the whole modelled cohort when averaging
over both parameter uncertainty and the stochastic uncertainty associated with patient-level simulations.
This made it possible to estimate the absolute risk at which the INB crosses zero for each treatment to a
more accurate level than could be achieved by simply examining the INBs for each risk category.
Fracture risk prediction within the model is based on the risk predicted over time from the QFracture
algorithm, but when validating the model we identified some internal inconsistencies within QFracture,
which have implications for our model. The underlying survival function applied in QFracture for patients
without any risk factors incorporates a hazard that increases over time. This makes sense, as the hazard for
fracture is likely to increase as the patient ages. However, the 1-year risk of fracture predicted for a patient
5 years after their 50th birthday is higher than the 1-year risk of fracture predicted in the following year
for a 55-year-old. We have assumed that the data points from the earlier years of the QFracture algorithm
are likely to be more reliable than points from later years, when there may have been fewer patients with
follow-up in the cohort used to derive the QFracture algorithm. Hippisley-Cox and Coupland18 report
that the 2012 QFracture algorithm was based on approximately 23.6 million patient-years of follow-up in
approximately 3.1 million patients, suggesting that the mean duration of follow-up was around 7.6 years.
We would therefore expect the model predictions to be more robust when used to estimate fracture risk
over 5 years than over 10 years. Therefore, we have resampled the patient’s fracture risk every time an
event occurs and at 5 and 10 years after baseline in all patients. In doing so we have ensured that we have
repeatedly sampled from the early part of the survival curve, which should be less uncertain as it is based
on more patients from the QFracture database. This does, however, result in some model behaviour that
goes against clinical expectations in that the hazard for an individual patient may be lower in the sixth year
of the model than in the fourth year despite the increase in the patient’s age. Unfortunately, there is no
way to correct this internal inconsistency while using QFracture as the basis for risk prediction within the
model. Introducing more frequent events to update risk at annual intervals would minimise the impact of
this internal inconsistency but it would significantly reduce the computational efficiency of the model and
would not remove the inconsistency altogether. However, this issue is not expected to bias the estimates
of cost-effectiveness as it has an equal impact across all treatment strategies.
Several assumptions had to be made to incorporate the FRAX algorithm within the model. First, the FRAX
calculator does not provide estimates of the fracture risk for different time periods. Therefore, we assumed
that the shape of the survival curve for fracture-free survival would be similar in FRAX and QFracture and
applied a simple ratio to the rate parameter of the QFracture survival curve to generate time-to-event
estimates for the FRAX model. The ratio was calculated to ensure that the time-to-event estimates for the
FRAX model generated a survival curve with the 10-year risk predicted by the FRAX model. Second, the
FRAX algorithm provides the estimate of fracture risk after taking into account the competing risk of
mortality, whereas the QFracture algorithm does not incorporate any competing mortality risk. Therefore,
we may have underestimated the fracture risk in the FRAX model by applying our own competing
mortality hazard on top of that incorporated by FRAX.
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The estimates of INB versus absolute fracture risk appear to fall on a slightly higher curve for all treatments
when using FRAX than when using QFracture. This difference in the INBs estimated for QFracture and
FRAX risk categories with similar levels of absolute fracture risk could have occurred, in part, because of
the different risk scores selecting patients with different characteristics into certain risk categories. For
example, in the sixth QFracture risk category, which has a mean risk of 2.7%, the proportion of patients
with a prior fracture was 41.6%, whereas in the first FRAX risk category, which has a mean risk of 3.1%,
the proportion with a prior fracture was 6.4%. As those with a prior fracture have a lower starting utility,
it is more cost-effective to prevent future fractures in those without a history of prior fracture. This may
explain why the sixth QFracture risk category had lower estimates of INB for bisphosphonate treatment
than the first FRAX risk category, despite having similar fracture risks. Furthermore, the structural sensitivity
analyses conducted on hip fracture risk and the uplift for fractures at additional sites suggest that the
INB of treatment with bisphosphonates compared with a strategy of no treatment may have been
overestimated in the base case because of the method used to calculate the survival curve for FRAX from
the survival curve for QFracture. We suspect this is because we have assumed that the proportion of major
osteoporotic fractures that occur at the hip is the same across both risk tools, but in fact the proportion is
lower for FRAX than QFracture in 64% of the modelled population. This suggests that the number of hip
fractures may have been overestimated in the model based on FRAX in the base-case analysis.
Our population was sampled taking into account the correlation between age and sex, and the risk factors
of prior fracture, steroid use and nursing home residency. The relationship between age, sex and BMI was
also incorporated. However, there are likely to be other correlations within the general population that
we have not captured. This may mean that the mix of patient characteristics within each decile may not
perfectly reflect the mix within each risk category for the population eligible for risk assessment. However,
we have tried to capture the correlations between those factors likely to affect risk independently of the
absolute risk of fracture, as these have the most potential to bias the estimates of cost-effectiveness.
The model does not allow for patients to move from community living to an institutional residential setting
at any time other than following a fracture, which may overestimate the impact of fractures that result in
residential care in patients who would have eventually moved into residential care for other reasons.
However, the model does allow for patients to live in residential care or to have experienced a prior
fracture before being treated with bisphosphonates. This avoids treatment benefits being overestimated in
these groups.
The decision to group fractures occurring at additional sites (scapula, clavicle, sternum, rib, pelvis, humeral
shaft and femoral shaft) with one of the four main osteoporotic sites (hip, wrist, proximal humerus,
vertebral) may have over- or underestimated the impact of fractures at these additional sites if these
fractures have different costs and QALY implications from the ones they have been grouped with.
However, evidence on the resource-use and HRQoL impactions of fractures was focused on the four main
fracture sites associated with osteoporosis, making it difficult to identify site-specific evidence on the
consequences of fracture for fractures occurring at other sites.
One of the key limitations of our analysis is that we have assumed that all of the bisphosphonate
treatment strategies are viable options for all patients within the population. This allowed us to run the
model once for the whole population eligible for risk assessment and to determine a single absolute risk
threshold for cost-effective intervention with each bisphosphonate. Applying a strict interpretation of the
licensed indications for each bisphosphonate would have required running the analysis multiple times for
different groups who have different treatment options, which was not feasible. Although incremental
analyses are usually conducted over a set of potentially interchangeable treatments, in reality it is often the
case that some of the cohort of patients who are eligible for one treatment would be contraindicated for
another and allowances are made for this when interpreting the cost-effectiveness results. For example,
it is possible to rank the treatments in order of decreasing net benefit and treat with the next most
cost-effective treatment when the optimal treatment is contraindicated.
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Another limitation of our analysis is that we have assumed equal treatment effectiveness across all patients
eligible for risk assessment under CG146.16 There was no evidence of differential treatment effects with
respect to sex and age. However, there was some heterogeneity in treatment effects between studies,
suggesting that differential treatment effects according to study characteristics and the effect of treatment
on femoral neck BMD depended on the baseline response.
The cost-effectiveness results for i.v. ibandronic acid should be treated with some caution as the fracture
data used were taken from studies which used a daily dose of oral ibandronic acid. This was considered
reasonable as i.v. ibandronic acid was licensed based on its non-inferiority in lumbar spine BMD outcomes
when compared with the daily ibandronic acid treatment regimen. Any uncertainty regarding whether or
not equivalent lumbar spine BMD outcomes do in fact translate into an equivalent reduction in fractures
has not been captured within our assessment of model uncertainty.
Our estimates of the costs attributable to fracture do not include the costs of rehabilitation and may
therefore underestimate the total cost. They do, however, include costs for home help and residential care
which fall within the NHS and PSS perspective recommended in the methods guide.144
The way in which the DES has been implemented only allows for one acute utility multiplier to be applied
at any one time. This may mean that the utility decrement in the year following a severe fracture may be
underestimated if another less severe fracture occurs within a year. This may have marginally biased the
cost-effectiveness analysis against treatment with bisphosphonates by underestimating the benefits of
treatments that prevent hip and vertebral fractures, which have the greatest utility impact in the year
following fracture in populations with a high risk of fractures at other sites. However, two events occurring
in the same year is expected to be a rare outcome, particularly in lower-risk patients, so any bias is
expected to be small.
The model is sensitive to the assumptions regarding AEs, particularly in the low-risk populations, in which
the mean absolute cost savings and QALY gains are small. We have included AEs for oral bisphosphonates
using the rates observed in prescription event monitoring studies. However, no significant difference in
upper GI AEs was found in the placebo-controlled RCTs for oral bisphosphonates. It is unclear whether or
not this is because the RCT population are not representative of the real-world population, which may be
more likely to experience AEs, or if the apparent increased risk in real-world cohorts is confounded by
other factors which are controlled for within a RCT.
Our analysis has used the FRAX calculator for patients with unknown BMD, as CG14616 recommends that
patients should receive a BMD scan only if they are close to the treatment threshold and, therefore, the
majority of patients are expected to receive treatment without a BMD scan. FRAX also provides an
estimate of fracture risk in patients with known BMD. It is possible that the threshold for cost-effective
treatment when using the version of the FRAX calculator developed for patients with known BMD may be
slightly different if BMD is correlated with patient characteristics that affect risk independently of BMD.
However, to properly ascertain whether or not the treatment thresholds would be different, we would
need information on the relationships between BMD and a range of other risk factors such as age, sex,
prior fracture and steroid use. Including BMD within the model without information on these relationships
would simply shuffle patients with similar characteristics between the different risk groups. Although
information is available on the relationship between BMD and some of these risk factors, such as age and
BMI,237 adding additional but incomplete information on the relationship between the various risk factors
and BMD may introduce an unintended bias in the estimates of cost-effectiveness. Given that both the
QFracture and FRAX algorithm have been developed for use without BMD, the correlations between
the risk factors included in these risk sores and BMD is already incorporated within the calculation of
fracture risk. Therefore, we decided not to run the model using the FRAX algorithm for patients with
known BMD.
ASSESSMENT OF COST-EFFECTIVENESS
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Although the mean INBs for treatment with oral bisphosphonates are positive at low levels of absolute risk,
it is important to note that the absolute costs and benefits are small and the no-treatment strategy has a
reasonable probability of being optimal until the QFracture score is above approximately 5.5% (the mean
absolute risk for the eighth risk category for QFracture). It is therefore possible that patients and clinicians
may not consider treatment worthwhile in the lowest-risk patients even though it may be cost-effective.
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Chapter 5 Assessment of factors relevant to the
NHS and other parties
C linical guideline 146
16 provides recommendations for risk assessment for fragility fracture, including the
use of DXA scans, and, therefore, we have not considered the services required to assess fragility
fracture risk prior to offering treatment with bisphosphonates. We do not anticipate that any additional
services would be required to offer oral bisphosphonate treatment to the population eligible for risk
assessment within CG146 as these treatments are prescribed in primary care. Widespread use of
zoledronic acid or i.v. ibandronic acid across the population eligible for risk assessment would be likely to
result in the requirement for additional capacity in existing services to administer these treatments in
secondary care.
We have conducted a simple budget impact analysis to estimate the potential impact on the NHS of
changes to current prescribing patterns under certain assumptions. For the purposes of assessing the
budget impact we have assumed that bisphosphonate treatment with weekly alendronic acid is offered to
all patients who have a QFracture score of > 1.5%, but that uptake is gradual, with only one-fifth of the
patients eligible for treatment starting treatment each year over the next 5 years. Alendronic acid has been
chosen as it is neither the cheapest nor the most expensive oral bisphosphonate. The generic weekly
alendronic acid preparation has been assumed to be prescribed in all patients as it is both the lowest cost
and currently the most commonly prescribed treatment (see Table 1). A QFracture score of 1.5% has been
chosen as the threshold for offering treatment as this was the lowest absolute risk at which the INB for
any bisphosphonate compared with no treatment was positive when valuing a QALY at £20,000. The
economic model simulates a population aged ≥ 30 years and selects from this population the cohort
eligible for risk assessment. Therefore, it also provides an estimate of the proportion of the general
population aged > 30 years who would be eligible for risk assessment. The model estimates that for every
100,000 patients who are eligible for risk assessment there are another 63,763 who are not eligible for
risk assessment and, therefore, 61% of the general population are eligible. Combining this with
information on the number of people aged > 30 years in England from the ONS (33.7 million)159 allows the
calculation of the number of people eligible for risk assessment (20.6 million). From the characteristics of
200,000 simulated patients we have estimated that 61% of those eligible for risk assessment have a
QFracture score of > 1.5%. We have assumed that the treatment duration is 6 months, as this was the
treatment duration applied in the cost-effectiveness model for oral bisphosphonates based on
observational data on the average persistence with treatment. Using these assumptions, the total
undiscounted cost of treating the current prevalent population is estimated to be £95M over 5 years.
Data from the prescription cost analysis suggest that there are currently 8.3 million prescriptions per
annum for oral bisphosphonate treatment in primary care, at an estimated cost of £10M per annum.38
For this cost estimate we applied the cost for generic preparations for each dose to make the figures
comparable with those above, where generic prescribing was assumed. Over 5 years the undiscounted cost
for oral bisphosphonate treatment at the current level of prescribing is estimated to be £50M.38
Therefore, we estimate that if all patients with a QFracture score of > 1.5% were prescribed oral
bisphosphonates, this could double the current cost of bisphosphonate prescribing over the next 5 years.
These estimates are provided to give an indication of the maximum cost of additional prescribing with
costs likely to be lower if uptake is less than 100%. Costs would also be expected to fall once the
prevalent population eligible for treatment have been treated as the numbers becoming eligible for
treatment each year will be smaller than the current population who are eligible. Furthermore, some of
those whom we have included in the eligible population will already have received bisphosphonate
treatment, which would further reduce the numbers likely to initiate treatment in the next 5 years.
Therefore, our estimates provide an upper ceiling on the expected costs.
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Chapter 6 Discussion
Statement of principal findings
Principal findings: clinical effectiveness
A total of 46 RCTs were identified that provided data for the clinical effectiveness systematic review.
Alendronic acid was compared with placebo in 17 RCTs. A daily dose of 2.5 mg of oral ibandronic acid
(dose no longer licensed) was compared with placebo in three RCTs and with i.v. administration in one
RCT. Daily administration of 2.5 mg of oral ibandronic acid was compared with 150 mg per month of oral
ibandronic acid administration in one RCT. Risedronic acid was compared with placebo in 12 RCTs and
zoledronic acid was compared with placebo in four RCTs. One RCT compared alendronic acid with 150 mg
per month of oral ibandronic acid, five RCTs compared alendronic acid with risedronic acid, one RCT
compared zoledronic acid with alendronic acid and one RCT compared zoledronic acid with risedronic acid.
The maximum trial duration was 48 months.
The risk of bias associated with the included RCTs was assessed using the Cochrane risk-of-bias
instrument. An attrition bias of 10% across treatment groups was evident for 29 (63%) of the included
RCTs. Five trials were reported as either open label or single blind and were considered at high risk of
performance bias. Blinded outcome assessment was reported by only 13 (28%) trials.
The outcome measures prespecified in the final NICE scope23 were addressed by the included trial evidence
to varying degrees. Femoral neck BMD was the most widely reported outcome and fracture was the
second most widely reported outcome. AEs were reported by the majority of included trials. Across the
included trials there was limited reporting on outcomes of compliance (adherence and persistence),
hospitalisation and service use, and quality of life.
A total of 27 RCTs provided suitable fracture data for inclusion in the fracture NMA: nine compared
alendronic acid with placebo; two compared 150 mg per month of oral ibandronic acid with placebo; one
compared 2.5 mg per day of oral ibandronic acid with placebo; nine compared risedronic acid with
placebo; three compared zoledronic acid with placebo; one compared alendronic acid with risedronic acid;
one compared 150 mg per month of oral ibandronic acid with alendronic acid; and one compared
zoledronic acid with risedronic acid.
A total of 35 RCTs provided suitable femoral neck BMD data for inclusion in the BMD NMA: 12 compared
alendronic acid with placebo; one compared 2.5 mg per day of oral ibandronic acid with placebo; one
compared 150 mg per month of oral ibandronic acid with placebo; one compared 2.5 mg per day of oral
ibandronic acid with 3 mg every 3 months of i.v. ibandronic acid; one compared 2.5 mg per day of oral
ibandronic acid with 150 mg per month of oral ibandronic acid; 10 compared risedronic acid with placebo;
four compared zoledronic acid with placebo; three compared alendronic acid with risedronic acid; one
compared alendronic acid with 150 mg per month of oral ibandronic acid; and one compared zoledronic
acid with risedronic acid.
Bone mineral density may be considered a surrogate for fracture outcomes. Analysis of the femoral neck
BMD data was of interest in order to confirm the direction of treatment effects. As more studies presented
data on femoral neck BMD than any of the individual fracture outcome types, the network analysis also
provides more information for assessing treatment effect modifiers.
All treatments were associated with beneficial effects on fractures and femoral neck BMD relative to
placebo. HRs for fractures varied from 0.41 to 0.92 depending on treatment and fracture site. For vertebral
fractures and percentage change in femoral neck BMD the treatment effects were also statistically
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significant at a conventional 5% level for all treatments. Pairwise comparisons between treatments
indicated that no active treatment was statistically significantly more effective than any other active
treatment for fracture outcomes. For vertebral fractures and percentage change in femoral neck BMD,
the greatest effect was for zoledronic acid, although in general the ranking of treatments varied for the
different outcomes, with the treatments providing broadly similar effects. There was no evidence to
suggest different treatment effects according to age or sex.
Assessment of vertebral fractures was based on both clinical and morphometric fractures. Ideally, the effect
of assessment method would be assessed through metaregression; however, data for clinical fractures
were limited. An analysis of the studies reporting clinical fractures did not provide any evidence to suggest
differential treatment effects according to assessment method, although the evidence was limited.
The main analyses were based on a class-effects model such that the bisphosphonates are assumed to be
related but not identical. The treatment effects estimated using the class-effects model were broadly similar
qualitatively (i.e. direction of effect) and quantitatively (i.e. magnitude of effect) to those estimated using the
standard random-effects model but with the treatments effects in the class-effects model shrunk towards
the overall bisphosphonate treatment effect. The qualitative effects of treatment (i.e. direction of effect)
were the same for the majority of outcome types and treatments from the class effects and standard
random-effects models with the exception of zoledronic acid (hip fractures), 150 mg per month of oral
ibandronic acid (hip and wrist fractures) and 2.5 mg per day of oral ibandronic acid (non-vertebral fractures).
Although the point estimates changed from being relative increases in effect in the standard random-effects
model to relative decreases in effect in the class-effects model, there was considerable uncertainty about the
true effects as reflected in the CrIs.
Non-vertebral fractures are used as proxy for fractures of the proximal humerus, as this outcome is not
commonly reported. Two studies presented results for proximal humerus fractures, both considering the
effects of risedronic acid against placebo.70,85 A random-effects meta-analysis of these two studies provided
a HR of 0.45 (95% CrI 0.13 to 1.41), which was greater than that estimated for non-vertebral fractures
but with considerably more uncertainty.
There were no statistically significant differences between treatments in the incidence of upper GI events
associated with any oral bisphosphonate (alendronic acid, risedronic acid or ibandronic acid) compared
with placebo when data were pooled across RCTs for each bisphosphonate. However, evidence from one
RCT indicated a significantly higher risk of upper GI events in men receiving risedronic acid than in those
receiving placebo. Where reported across the RCTs, treatments were prescribed in accordance with the
SmPC for oral bisphosphonates to minimise gastric irritation. There was no evidence of significant
differences between treatments in mortality across the RCT evidence when data were pooled by
bisphosphonate. However, evidence from one RCT indicated that the proportion of men and women dying
following hip fracture was significantly higher among those receiving placebo than among those receiving
zoledronic acid. There was also no evidence of significant differences between treatments in participants
withdrawing because of AEs across the RCT evidence when data were pooled by bisphosphonate.
However, evidence from one RCT indicated that the proportion of men withdrawing because of AEs was
significantly higher in the alendronic acid group than in the placebo group.
In agreement with the SmPC, there was evidence of influenza-like symptoms associated with zoledronic
acid. There was no statistically significant difference in the incidence of atrial fibrillation associated with
zoledronic acid compared with placebo (one RCT) or risedronic acid (one RCT). There was no statistically
significant difference in the incidence of bone pain associated with zoledronic acid compared with placebo
(one RCT) or alendronic acid (one RCT). There was evidence that the risk of eye inflammation in the first
3 days following drug administration was significantly higher for zoledronic acid than for placebo (one RCT).
Single RCT evidence indicated no statistically significant difference between zoledronic acid and placebo
in the incidence of stroke over 36 months. No RCT evaluating zoledronic acid reported any case of
spontaneous osteonecrosis of the jaw in any treatment group during the trial period.
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Adverse events of hypocalcaemia and atypical femoral fracture were not reported outcomes by any RCT of
any bisphosphonate.
A summary of evidence from systematic reviews that include observational data indicates that the rates of
GI toxicity associated with alendronic acid, risedronic acid and oral ibandronic acid are similar to that
observed in placebo-treated participants. However, prescription event monitoring study data suggest a
high level of reporting of a number of conditions in the first month of therapy with alendronic acid or
risedronic acid, particularly those affecting the upper GI tract. Retrospective cohort data also suggest that
switching patients who are stabilised on risedronic acid to alendronic acid is associated with an increased
risk of GI AEs. Zoledronic acid may be compromised by renal toxicity, and myalgias and arthralgias are
evident in the acute phase following i.v. administration. Intravenous bisphosphonates, especially zoledronic
acid, are more likely to predispose patients to osteonecrosis of the jaw; however, in addition to
bisphosphonate use, there appears to be several other factors involved in the development of
osteonecrosis of the jaw (e.g. dental trauma). There is an increased risk of atypical fracture among
bisphosphonate users; however, events are rare and long-term bisphosphonate therapy might not be a
prerequisite for development of atypical fractures. Moreover, the use of glucocorticoids and proton pump
inhibitors is a potentially important risk factor for atypical fracture. Bisphosphonates are associated with
serious atrial fibrillation, but heterogeneity of the existing evidence and a paucity of information on some
agents preclude any definitive conclusions with respect to risk. The review evidence for the use of
bisphosphonates and oesophogeal cancer is equivocal.
Evidence for persistence and adherence reported by RCTs was very limited. Where reported, high levels
of compliance, reported as a pill count, were evident over the trial duration. A summary of evidence
from systematic reviews including observational data indicates that, although patients using weekly
bisphosphonate medication follow their prescribed regimens better than those using daily therapy, overall
compliance and persistence rates are suboptimal for postmenopausal women receiving bisphosphonate
therapy for the treatment of osteoporosis. Furthermore, one-third to one-half of patients, including men
being treated with bisphosphonates for osteoporosis, do not take their medication as directed.
With the exception of the RCTs evaluating bisphosphonates in steroid users, the majority of trials included in
the clinical effectiveness systematic review typically excluded patients with underlying conditions or receiving
medications that affect bone metabolism. Furthermore, patients with history of, or receiving medication for,
upper GI tract disorders were also excluded by the majority of included trials. Therefore, the effects of
alendronic acid, ibandronic acid, risedronic acid and zoledronic acid are unknown in these populations.
Principal findings: cost-effectiveness
The de novo economic model estimates that a strategy of no treatment is predicted to have the greatest
net benefit for patients with an absolute risk of < 1.5% when using QFracture to estimate absolute risk
and valuing a QALY at £20,000. Alendronic acid is predicted to have the maximum INB from 1.5% to
7.2% and risedronic acid is predicted to have the maximum INB from 7.2% upwards. However, the
absolute costs and QALY gains are small in patients with low absolute risk, and the PSA suggested that
there is considerable uncertainty regarding whether or not no treatment is the optimal strategy until the
QFracture score is approximately 5.5% (the mean absolute risk for the eighth risk category for QFracture).
The mean INBs for oral bisphosphonate treatment (alendronic acid, risedronic acid or ibandronic acid)
compared with no treatment were positive across all FRAX risk categories. An exact threshold for the
absolute risk at which the INB became positive was therefore not available, but the minimum FRAX score
in the modelled population was 1.2% and the lowest risk category had a mean absolute risk of 3.1%.
Oral ibandronic acid is predicted to have the highest INB compared with no treatment up to 8.6%, with
alendronic acid having the highest INB from 8.6% to 38.5% and risedronic acid having the maximum INB
> 38.5%. The PSA suggested that there was a low probability of the no-treatment strategy being optimal
across all FRAX risk categories when valuing a QALY at £20,000. However, the PSA also demonstrated
that there is considerable uncertainty regarding the optimal bisphosphonate treatment with all of the oral
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bisphosphonates having reasonably similar probabilities of having maximum INB across most of the FRAX
risk categories.
Intravenous bisphosphonates (ibandronic acid and zoledronic acid) were predicted to have lower INBs than
oral bisphosphonates across all levels of absolute risk when estimated using either QFracture or FRAX.
In the highest-risk categories the ICERs for i.v. ibandronic acid and zoledronic acid compared with oral
bisphosphonates were consistently > £50,000 per QALY even though the base-case analysis assumed
longer durations of persistence for i.v. bisphosphonates than oral bisphosphonates. Although the mean
INB compared with no treatment for i.v. ibandronic acid did become positive at very high levels of absolute
risk when using QFracture, the results when using FRAX went in the opposite direction. This may be
because of the small number of patients and parameter samples informing the estimates at high levels of
absolute risk which makes these estimates more uncertain.
The results appeared to be broadly similar across the majority of the structural sensitivity analyses which
examined the application of alternative data or assumptions. The results were more favourable to
treatment when assuming full persistence with treatment for the intended treatment duration (3 years for
zoledronic acid and 5 years for all other bisphosphonates) or when assuming no AEs. The sensitivity
analysis examining an AE rate of 30% in the month following initiation of oral bisphosphonate therapy
showed that the cost-effectiveness of oral bisphosphonates is very sensitive to the rate of AEs experienced.
The INBs compared with no treatment fell below zero (when valuing a QALY at £20,000) for all 10
QFracture risk categories and for all but the highest FRAX risk category when assuming an AE rate of 30%
in the first month of oral bisphosphonate treatment.
The structural sensitivity analyses, which varied the way in which the fracture risk was estimated, showed
results that were broadly similar for QFracture but slightly less favourable for FRAX, which brought the
cost-effectiveness estimates from the QFracture and FRAX model closer together for patients with similar
mean absolute risk. We would expect from the way the model is structured that the threshold for
cost-effective treatment would be broadly similar across the two risk scores but in the base-case scenario
the INBs of bisphosphonates compared with no treatment were higher for FRAX than QFracture for risk
categories with similar absolute fracture risk. The fact that the results are similar in these particular
structural sensitivity analyses suggests that the base-case analysis may have overestimated the proportion
of fractures occurring at the hip for the FRAX model. We suspect this is because we have assumed that the
proportion of major osteoporotic fractures which occur at the hip is the same across both risk tools but, in
fact, the proportion is lower for FRAX than QFracture in 64% of the modelled population.
Some of the difference in the INBs estimated for QFracture and FRAX risk categories with similar levels of
absolute fracture risk may also have occurred because of the different risk scores selecting patients with
different characteristics who have different consequences of fracture into risk categories with a similar
absolute fracture risk.
Strengths and limitations of the assessment
The clinical effectiveness systematic review was based on rigorous methods, with comprehensive searches
for evidence, a good level of consistency between reviewers in study selection and double-checking of
data extraction. A formal assessment of methodological quality of included trial was undertaken. Attrition
of ≥ 10% across treatment groups was evident for 63% of the included RCTs.
Fracture data were reported for 27 (59%) of the 46 included RCTs and femoral neck BMD data were
reported for 35 (76%). However, for fracture data there was variability across the included trials in the
skeletal fracture site evaluated, the most frequently evaluated being vertebral fracture. In addition, femoral
neck BMD was summarised in study reports as the percentage change from baseline, which is a relative
measure of treatment effect and tends to have poor statistical properties. Ideally, for a continuous
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outcome measure assessed at baseline and post treatment, we would work with the post-treatment
response adjusted for baseline in an analysis of covariance.
Network meta-analyses were used to synthesise the evidence to permit a coherent comparison of the
efficacy of interventions in terms of fracture and femoral neck BMD. An assumption of the model is that
the studies are exchangeable in the sense that we would be prepared to treat any patient in the
population with all of the treatments. However, not all treatments are licensed in all patient populations,
which means that the studies are not exchangeable, although the analysis follows the scope defined
by NICE.23
Adverse event data were widely reported and also supplemented by review evidence of observational data.
However, evidence for compliance and concordance was limited in the RCT evidence base and, where
reported, was reported as being assessed mainly through pill counts. Evidence for compliance and
treatment persistence was limited to review evidence of observational data.
In summary, fracture, BMD and AE data were widely reported. However, these data were limited as there
was variability across the included trials in the skeletal fracture site evaluated with a limited number of
trials reporting data for the hip. Summary statistics for BMD were not provided by all trials and were
extracted from graphical representations. Furthermore, the majority of RCTs were placebo-controlled trials
with a limited number of head-to-head comparison trials.
Although the search strategy for this assessment report was comprehensive, the possibility of a publication
bias cannot be discounted. A formal assessment of publication bias was not undertaken.
The majority of included trials typically excluded patients with underlying conditions or receiving
medications that affect bone metabolism. Furthermore, patients with a history of or who were currently
receiving medication for upper GI tract disorders were also excluded by the majority of included trials;
therefore, the effects of alendronic acid, ibandronic acid, risedronic acid and zoledronic acid are unknown
in these populations.
None of the consultee submissions included a de novo economic evaluation and none of the published
economic evaluations compared all five bisphosphonate treatment regimens specified within the scope of
this appraisal in a fully incremental analysis as required by the NICE reference case.
The patient-level simulation approach used in the Assessment Group’s model allowed the distribution of
patient characteristics to differ across the risk categories providing estimates of cost-effectiveness that have
taken into account the differing consequences of fracture in patients with different characteristics.
However, the DES modelling approach provides a stochastic estimate of the costs and QALYs gained.
We therefore needed to simulate a large number of patients to obtain stable estimates of the cost and
benefits of treatment. This was particularly true in the lower-risks groups in the base-case scenario where
we reduced the treatment duration to reflect evidence from observational studies on the duration of
persistence with bisphosphonate treatment. In order to obtain stable estimates of the costs and QALYs at
differing levels of absolute risk, we had to group the patients into broad risk categories. A full incremental
analysis has been conducted for each risk category and CEACs have also been provided allowing the
uncertainty in the cost-effectiveness to be assessed at different levels of absolute risk. We have also used a
non-parametric regression to estimate the relationship between INB and absolute risk across the whole
population eligible for risk assessment in CG146.16 From this we have identified treatment thresholds for
each treatment for both QFracture and FRAX.
The model generally adheres to the NICE reference case and fully addresses the decision problem set out
in the final NICE scope. In particular, the modelling approach used allows intervention thresholds to be
linked to absolute risk measured using the two risk assessment tools recommended in CG146 as specified
in the scope.23 However, in order to provide a single intervention threshold for each treatment that could
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be applied across the whole population, we had to assume that all of the bisphosphonate treatment
strategies were viable treatment options across all patients eligible for risk assessment within CG146.
This would not be true if the licensed indications for each intervention were to be strictly applied.
The de novo economic model is underpinned by a NMA across all drug options which provides a coherent
synthesis of the evidence within a single model. Where appropriate and possible, systematic search
methods have been used to identify evidence to inform the model’s parameters (efficacy evidence and
HRQoL). However, it was not feasible to conduct a full systematic review to identify evidence to inform all
model parameters and, therefore, published cost-effectiveness models and published systematic reviews
were used to identify appropriate sources of evidence for some model parameters. It is possible that if we
had searched systematically we may have found other more appropriate data sources for some model
parameters but it is not possible to say whether or not this would have changed the model results.
The main limitations of the economic analysis relate to the assumptions required to populate the model
given the data available. In particular, several assumptions were necessary to generate estimates of time to
fracture for each fracture type from the estimates of absolute risk provided by the QFracture and
FRAX tools.
Uncertainties
Although differential effects were found when comparing the bisphosphonates with placebo, and the
effects of the bisphosphonates were generally similar, there was uncertainty about the true treatment
effects and some evidence of heterogeneity in treatment effects between studies.
It is uncertain whether or not the cost-effectiveness of bisphosphonate treatment at a particular level of
absolute fracture risk would be similar for patients who have been assessed using the FRAX algorithm for
patients with known BMD.
Other relevant factors
Although the mean INBs for treatment with oral bisphosphonates are positive at low levels of absolute risk,
it is important to note that the absolute costs and benefits are small and the no-treatment strategy has a
reasonable probability of being optimal until the QFracture score is above approximately 5.5% (the mean
absolute risk for the eighth risk category for QFracture). Therefore, it is possible that patients and clinicians
may not consider treatment worthwhile in the lowest-risk patients even though it may be cost-effective.
DISCUSSION
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Chapter 7 Conclusions
A ll treatments were associated with beneficial effects relative to placebo with HRs for fracture varyingfrom 0.41 to 0.92 depending on treatment and fracture site. For vertebral fractures and percentage
change in BMD, the treatment effects were also statistically significant for all treatments. For non-vertebral
fractures, the treatment effects were statistically significant at a conventional 5% level for risedronic acid,
alendronic acid and zoledronic acid. For the outcomes of hip fracture and wrist fracture, all treatments
were associated with beneficial treatment effects relative to placebo, although the treatment effects were
not statistically significant at a conventional 5% level. Pairwise comparisons between treatments indicated
that no active treatment was significantly more effective than other active treatments for fracture
outcomes. For vertebral fractures and percentage change in BMD, the greatest effect was for zoledronic
acid, although, in general, the ranking of treatments varied for the different outcomes, with the
treatments providing broadly similar effects.
For the majority of AEs reported in RCTs no significant difference was found between active treatment and
placebo, suggesting that bisphosphonates are generally well tolerated in patients enrolled within clinical
trials. Prescription event monitoring study data suggest a high level of reporting of a number of conditions
in the first month of therapy with alendronic acid or risedronic acid, particularly those affecting the upper
GI tract, suggesting that oral bisphosphonates may be less well tolerated in clinical practice. A significant
difference in the incidence of influenza-like symptoms was identified from the RCTs for zoledronic acid
compared with placebo, although clinical advice was that these symptoms are generally limited to the first
dose and usually last only a few days.
Continuance and concordance data were limited for the RCT evidence evaluated. Supplementary review
evidence of observational data indicates that, although patients using weekly bisphosphonate medication
follow their prescribed regimens better than those using daily therapy, overall compliance and persistence
rates are suboptimal for postmenopausal women.
The de novo economic model estimates that when using QFracture to estimate absolute risk, a strategy of
no treatment is predicted to have the greatest net benefit, when valuing a QALY at £20,000, in the
lowest-risk patients (QFracture absolute risk < 1.5%), with oral bisphosphonates (alendronic acid,
risedronic acid, ibandronic acid) having the greatest INB at higher levels of absolute risk. However, the
absolute costs and QALY gains are small in patients with low absolute risk and the PSA suggested that
there is considerable uncertainty regarding whether or not no treatment is the optimal strategy until the
QFracture score is approximately 5.5% (the mean absolute risk for the eighth risk category for QFracture).
Therefore, it is possible that patients and clinicians may not consider treatment worthwhile in the
lowest-risk patients even though it may be cost-effective.
The mean INBs compared with no treatment (when valuing a QALY at £20,000) were positive for all oral
bisphosphonate treatments across all FRAX risk categories. However, in the base-case scenario the INBs
of bisphosphonate treatments compared with no treatment were generally higher for FRAX than for
QFracture for risk categories with similar absolute fracture risk. We would expect from the way the model
is structured that the threshold for cost-effective treatment would be broadly similar across the two risk
scores. The results of two structural sensitivity analyses suggest that the base-case analysis may have
overestimated the INBs of treatment in the model based on FRAX because of the assumption that the
proportion of major osteoporotic fractures that occur at the hip is the same for FRAX and QFracture. Given
this possible bias in the estimates generated by the model using the FRAX absolute risk estimates, and our
belief that the results should be broadly similar across the two risk scores, it would be reasonable to
assume that the absolute risk thresholds estimated in the QFracture model could be applied to patients
whose score had been calculated using either QFracture or FRAX.
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The de novo economic model suggests that the cost-effectiveness of i.v. bisphosphonates (ibandronic acid
and zoledronic acid) is less favourable than for oral bisphosphonates with a negative INB (when valuing a
QALY at £20,000) than no treatment estimated for both i.v. bisphosphonates across all 10 risk categories
for both FRAX and QFracture.
Implications for service provision
The prescribing of oral bisphosphonates in patients who have already received risk assessment under
CG146 is not anticipated to have any major implications for service provision as these can be prescribed in
primary care. If i.v. bisphosphonates were to be widely prescribed across the population eligible for risk
assessment under CG146, it is likely that additional capacity would be required in existing services to
administer these treatments in secondary care.
Suggested research priorities
Given that the cost-effectiveness results are sensitive to the assumptions regarding the rate of AEs for oral
bisphosphonates, further research to quantify both the incidence of AEs and the impact of those AEs on
HRQoL and treatment persistence would allow patients and clinicians to make better-informed decisions
regarding the balance of costs, benefits and AEs. Although further RCTs evaluating efficacy and tolerability
of bisphosphonates as well as assessing HRQoL and persistence could be recommended, data on the
relationships between AEs and HRQoL alongside persistence could also be evaluated through observational
study design.
We identified only a limited number of RCTs in men. There was evidence from single RCTs in men which
showed a significant increase in upper GI AEs and withdrawals because of AEs than those receiving
placebo. Further research to assess efficacy and tolerability of bisphosphonate treatment in men may
be beneficial.
The existing economic model could be extended to include non-bisphosphonate treatments, as these are
potential alternatives to bisphosphonate therapy in some patients. Non-bisphosphonates were not included
as comparators in the economic model, as the scope for this NICE MTA stated that non-bisphosphonates
licensed for the prevention of fragility fractures in women and men would be considered in a separate
MTA. The economic model could also be extended to consider the cost-effectiveness of second-line
treatments in patients who experience fractures while being treated with a bisphosphonate.
Given that an individual’s risk usually increases with age, and bisphosphonate treatment is not usually
continued indefinitely, it is currently unclear whether or not treatment should be given as soon as an
individual’s increased fracture risk is identified or whether treatment should be delayed so that the patient
has the full benefit of treatment during the period that they are at greatest risk. The economic model
could also be adapted to assess the optimal timing of bisphosphonate therapy in patients whose life
expectancy exceeds the anticipated duration of treatment effect.
The economic analysis presented here focused on examining how cost-effectiveness varies with absolute
fracture risk. This was done in order to meet the requirement laid out in the scope to link absolute fracture
risk with intervention thresholds, based on cost-effectiveness. However, further work could be done to
explore how cost-effectiveness varies across the cohort of patients at risk of fragility fracture and whether
or not any factors other than absolute fracture risk could be used to select patients who can be treated
cost-effectively.
CONCLUSIONS
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Appendix 1 Literature search strategies
Search strategy in MEDLINE for the clinical effectiveness review
Date of search: 26 September 2014.
Date range: 2008 to 26 September 2014.
Search strategy
1. exp osteoporosis/
2. osteoporo$.tw.
3. bone diseases, metabolic/
4. exp Bone Density/
5. (bone adj3 densit$).tw.
6. exp fractures, bone/
7. fractures, cartilage/
8. fracture$.ti,ab.
9. (bone$ adj2 fragil$).tw.
10. bone mineral densit$.tw.
11. bone loss.tw.
12. bmd.tw.
13. or/1-12
14. (alendron$ or fosomax or fosavance).mp.
15. 121268-17-5.rn.
16. (ibandron$ or boniva or bondronat or bonviva or adronil).mp.
17. 114084-78-5.rn.
18. (risedron$ or actonel or atelvia or benet).mp.
19. 105462-24-6.rn.
20. (zoledron$ or zometa or zomera or aclasta or reclast).mp.
21. 118072-93-8.rn.
22. or/14-21
23. 13 and 22
24. Randomized controlled trials as Topic/
25. Randomized controlled trial/
26. Random allocation/
27. randomized controlled trial.pt.
28. Double blind method/
29. Single blind method/
30. Clinical trial/
31. exp Clinical Trials as Topic/
32. controlled clinical trial.pt.
33. clinical trial$.pt.
34. multicenter study.pt.
35. or/24-34
36. (clinic$ adj25 trial$).ti,ab.
37. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$ or mask$)).tw.
38. Placebos/
39. Placebo$.tw.
40. (allocated adj2 random).tw.
41. or/36-40
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42. 35 or 41
43. Case report.tw.
44. Letter/
45. Historical article/
46. 43 or 44 or 45
47. exp Animals/
48. Humans/
49. 47 not (47 and 48)
50. 46 or 49
51. 42 not 50
52. 23 and 51
53. limit 52 to yr=“2008 –Current”
54. meta-analysis as topic/
55. (meta analy$ or metaanaly$).tw.
56. Meta-Analysis/
57. (systematic adj (review$1 or overview$1)).tw.
58. “Review Literature as Topic”/
59. or/54-58
60. (cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or cinhal or science
citation index or bids or cancerlit).ab.
61. ((reference adj list$) or bibliograph$ or hand-search$ or (relevant adj journals) or (manual adj
search$)).ab.
62. ((selection adj criteria) or (data adj extraction)).ab.
63. “review”/
64. 62 and 63
65. comment/ or editorial/ or letter/
66. Animals/
67. Humans/
68. 66 not (66 and 67)
69. 65 or 68
70. 59 or 60 or 61 or 64
71. 70 not 69
72. 23 and 71
73. limit 72 to yr=“2008 –Current”
Clinical Trials.gov: US National Institutes of Health
(http://clinicaltrials.gov/)
Date of search: 30 September 2014.
Date range: 1 January 2008 to 30 September 2014.
Sixty-seven studies found for alendronate – received on or after 1 January 2008.
Two studies found for alendronic – received on or after 1 January 2008.
No studies found for fosomax – received on or after 1 January 2008.
Three studies found for fosavance – received on or after 1 January 2008.
Twenty-three studies found for ibandronate – received on or after 1 January 2008.
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Twenty studies found for ibandronic – received on or after 1 January 2008.
Twenty-four studies found for boniva – received on or after 1 January 2008.
Twenty-three studies found for bondronat – received on or after 1 January 2008.
Twenty-four studies found for bonviva – received on or after 1 January 2008.
No studies found for adronil – received on or after 1 January 2008.
Forty-five studies found for risedronate – received on or after 1 January 2008.
Thirty-seven studies found for risedronic – received on or after 1 January 2008.
Forty-five studies found for actonel – received on or after 1 January 2008.
Forty-five studies found for atelvia – received on or after 1 January 2008.
Thirteen studies found for benet – received on or after 1 January 2008.
One hundred and ten studies found for zoledronate – received on or after 1 January 2008.
One hundred and seven studies found for zoledronic – received on or after 1 January 2008.
One hundred and ten studies found for zometa – received on or after 1 January 2008.
One study found for zomera – received on or after 1 January 2008.
One hundred and ten studies found for aclasta – received on or after 1 January 2008.
One hundred and ten studies found for reclast – received on or after 1 January 2008.
International Clinical Trials Registry Platform: World Health
Organization (http://apps.who.int/trialsearch/AdvSearch.aspx)
Search strategy
Date of search: 30 September 2014.
Date range: 1 January 2008 to 30 September 2014.
Fifty-eight records for 25 trials found for alendronate or alendronic or fosomax or fosavance received on or
after 1 January 2008.
Six records for five trials found for ibandronate or ibandronic received on or after 1 January 2008.
Four records for two trials found for boniva or bondronat or bonviva or adronil received on or after
1 January 2008.
Sixty-three records for 35 trials found for risedronate or risedronic or actonel or atelvia or benet received
on or after 1 January 2008.
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One hundred and eighteen records for 81 trials found for zoledronate or zoledronic or zometa or zomera
or aclasta or reclast received on or after 1 January 2008.
Supplementary search strategy for adverse events
1. (alendron$ or fosomax or fosavance).mp.
2. 121268-17-5.rn.
3. (ibandron$ or boniva or bondronat or bonviva or adronil).mp.
4. 114084-78-5.rn.
5. (risedron$ or actonel or atelvia or benet).mp.
6. 105462-24-6.rn.
7. (zoledron$ or zometa or zomera or aclasta or reclast).mp.
8. 118072-93-8.rn.
9. or/1-8
10. (ae or to or po or co).fs.
11. (safe or safety).ti,ab.
12. side effect$.ti,ab.
13. ((adverse or undesirable or harms$ or serious or toxic) adj3 (effect$ or reaction$ or event$ or outcome
$)).ti,ab.
14. (toxicity or complication$ or noxious or tolerability).ti,ab.
15. or/10-14
16. 9 and 15
17. MEDLINE.tw.
18. systematic review.tw.
19. meta analysis.pt.
20. or/17-19
21. 16 and 20
Supplementary search strategy for compliance and
concordance search
1. (alendron$ or fosomax or fosavance).mp.
2. 121268-17-5.rn.
3. (ibandron$ or boniva or bondronat or bonviva or adronil).mp.
4. 114084-78-5.rn.
5. (risedron$ or actonel or atelvia or benet).mp.
6. 105462-24-6.rn.
7. (zoledron$ or zometa or zomera or aclasta or reclast).mp.
8. 118072-93-8.rn.
9. or/1-8
10. exp Patient Compliance/
11. (complian$ or comply or adhere$ or capacitance or persistan$ or concordan$).ti,ab.
12. (noncomplian$ or nonadhere$ or nonpersistan$ or nonconcordan$).ti,ab.
13. or/10-12
14. 9 and 13
15. MEDLINE.tw.
16. systematic review.tw.
17. meta analysis.pt.
18. or/15-17
19. 14 and 18
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Search strategy in MEDLINE for the cost-effectiveness review
1. exp osteoporosis/
2. osteoporo$.tw.
3. bone diseases, metabolic/
4. exp Bone Density/
5. (bone adj3 densit$).tw.
6. exp fractures, bone/
7. fractures, cartilage/
8. fracture$.ti,ab.
9. (bone$ adj2 fragil$).tw.
10. bone mineral densit$.tw.
11. bone loss.tw.
12. bmd.tw.
13. or/1-12
14. (alendron$ or fosomax or fosavance).mp.
15. 121268-17-5.rn.
16. (ibandron$ or boniva or bondronat or bonviva or adronil).mp.
17. 114084-78-5.rn.
18. (risedron$ or actonel or atelvia or benet).mp.
19. 105462-24-6.rn.
20. (zoledron$ or zometa or zomera or aclasta or reclast).mp.
21. 118072-93-8.rn.
22. or/14-21
23. 13 and 22
24. exp “Costs and Cost Analysis”/
25. Economics/
26. exp Economics, Hospital/
27. exp Economics, Medical/
28. Economics, Nursing/
29. exp models, economic/
30. Economics, Pharmaceutical/
31. exp “Fees and Charges”/
32. exp Budgets/
33. budget$.tw.
34. ec.fs.
35. cost$.ti.
36. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
37. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
38. (price$ or pricing$).tw.
39. (financial or finance or finances or financed).tw.
40. (fee or fees).tw.
41. (value adj2 (money or monetary)).tw.
42. quality-adjusted life years/
43. (qaly or qalys).af.
44. (quality adjusted life year or quality adjusted life years).af.
45. or/24-44
46. 23 and 45
47. limit 46 to yr=“2006 –Current”
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Search strategy in MEDLINE for quality of life
The strategy was adapted from appendix 4 in Stevenson et al.140
Search strategy
1. exp osteoporosis/
2. bone diseases, metabolic/
3. osteoporo$.tw.
4. or/1-3
5. (bone adj6 densit$).tw.
6. bone density/
7. bmd.ti,ab.
8. (bone or bones).mp.
9. exp densitometry/
10. tomography, x-ray computed/
11. densit$.tw.
12. 10 and 11
13. 9 or 12
14. 8 and 13
15. 5 or 6 or 7 or 14
16. exp fractures, bone/
17. fractures, cartilage/
18. fracture$.ti,ab.
19. or/16-18
20. 15 or 19
21. 4 and 20
22. (euroqol or euro qol or eq5d or eq 5d).mp.
23. 21 and 22
24. limit 23 to yr=“2006 –Current”
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Appendix 2 Table of excluded studies: clinical
effectiveness review
TABLE 41 Studies excluded from the clinical effectiveness review and reasons for exclusion
Citation Reason for exclusion
Adachi J, Lyles K, Colon-Emeric C, Boonen S, Pieper C, Mautalen C, et al.
Zoledronic acid improves health-related quality of life in patients with hip
fracture: results of HORIZON-RFT. J Bone Miner Res 2010;25:S125
Parallel publication, no additional information
Adachi JD, Lyles KW, Colon-Emeric CS, Boonen S, Pieper CF, Mautalen C,
et al. Zoledronic acid improves health-related quality of life in patients
with hip fracture: results of HORIZON-RFT. Osteoporos Int 2010;21:S151
Parallel publication, no additional information
Adachi JD, Lyles KW, Boonen S, Colon-Emeric C, Hyldstrup L, Nordsletten L,
et al. Subtrochanteric fractures: results from the HORIZON-recurrent
fracture trial. Osteoporos Int 2010;21:S23
Parallel publication, no additional information
Adachi J, Bucci-Rechtweg C, Su G, Eriksen E, Magaziner J, Lyles K, et al.
Zoledronic acid improves health-related quality of life in patients with hip
fracture: results of HORIZON-RFT. Osteoporos Int 2011;22:S140–2
Parallel publication, no additional information
Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P,
et al. Efficacy and safety of ibandronate given by intravenous injection
once every 3 months. Bone 2004;34:881–9
Not treatment of interest, not currently
licensed dose
Bauer D, Schwartz A, Palermo L, Cauley J, Ensrud K, Hochberg M, et al.
Utility of serial BMD for fracture prediction after discontinuation of
prolonged alendronate therapy: the FLEX trial. J Bone Miner Res
2010;25:S30–1
Parallel publication, no additional information
Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, et al.
Fracture prediction after discontinuation of 4 to 5 years of alendronate
therapy: the FLEX study. JAMA Interm Med 2014;174:1126–34
Parallel publication, no additional information
Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC,
et al. Fracture risk reduction with alendronate in women with
osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab
2000;85:4118–24
Parallel publication, no additional information
Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al.
The effects of parathyroid hormone and alendronate alone or in combination
in postmenopausal osteoporosis. N Engl J Med 2003;349:1207–15
Not comparator of interest
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al.
One year of alendronate after one year of parathyroid hormone (1–84) for
osteoporosis. N Engl J Med 2005;353:555–65
Not comparator of interest
Black DM, Schwartz VA, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al.
Effects of continuing or stopping alendronate after 5 years of treatment:
the Fracture Intervention Trial Long-term Extension (FLEX): a randomized
trial. JAMA 2014;296:2927–38
Extension study, participants not in original
randomised groups
Black DM, Eastell R, Cosman F, Man Z, Bucci-Rechtweg C, Mesenbrink P.
Effect of once-yearly zoledronic acid 5 mg on ‘Super Six’ non-vertebral
fractures. Bone 2009;44:S429
Parallel publication, no additional information
Black DM, Seeman E, Bucci-Rechtweg C, Eastell R, Boonen S,
Mesenbrink P. Zoledronic acid reduces the increased risk conferred by
further fractures. Int Med J 2010;40:27
Parallel publication, no additional information
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F,
et al. The effect of 3 versus 6 years of zoledronic acid treatment of
osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture
Trial (PFT). J Bone Miner Res 2012;27:243–54. [Erratum published in
J Bone Miner Res 2012;27:2612]
Extension study, participants not in original
randomised groups
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TABLE 41 Studies excluded from the clinical effectiveness review and reasons for exclusion (continued )
Citation Reason for exclusion
Black DM, Eastell R, Cosman F, McLellan A, Man Z, Bucci-Rechtweg C,
et al. Effect of once-yearly zoledronic acid 5 mg on ‘super six’
non-vertebral fractures. Osteoporos Int 2009;20:S281
Parallel publication, no additional information
Black DM, Eastell R, Cosman F, Man Z, Bucci-Rechtweg C, Mesenbrink P.
Effect of once-yearly zoledronic acid 5 mg on a sub-set of six
non-vertebral fractures. J Clin Densitomet 2010;13:132
Parallel publication, no additional information
Black D, Reid I, Cauley J, Boonen S, Cosman F, Leung PC, et al. The effect
of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a
randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone
Miner Res 2010;25:S22–3
Parallel publication, no additional information
Black D, Reid I, Eastell R, Buccirechtweg C, Su G, Hue TF, et al. Reduction
in the risk of clinical fractures after a single dose of zoledronic acid 5 mg.
Osteoporos Int 2011;22:S105–6
Parallel publication, no additional information
Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, et al.
Dose–response relationships for alendronate treatment in osteoporotic
elderly women. J Clin Endocrinol Metab 1997;82:265–74
Not treatment of interest, not currently
licensed dose
Boonen S, Magaziner J, Orwig D, Lyles K, Nordsletten L, Adachi J, et al.
BMD after hip fractures: response to annual i.v. zoledronic acid 5 mg.
Bone 2009;44:S446
Parallel publication, no additional information
Boonen S, Orwoll E, Magaziner J, Colon-Emeric C, Adachi J,
Bucci-Rechtweg C, et al. Effect of once-yearly zoledronic acid in men
after recent hip fracture: results from HORIZON recurrent fracture trial.
J Bone Miner Res 2010;25:S471
Parallel publication, no additional information
Boonen S, Black DM, Colón‐Emeric CS, Eastell R, Magaziner JS, Eriksen EF,
et al. Efficacy and safety of a once‐yearly intravenous zoledronic acid 5 mg
for fracture prevention in elderly postmenopausal women with
osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292–9
Parallel publication, no additional information
Boonen S, Black DM, Colon-Emeric CS, Eastell R, Magaziner JS, Eriksen EF,
et al. Efficacy and safety of a once-yearly intravenous zoledronic acid
5 mg for fracture prevention in elderly postmenopausal women with
osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292–9
Parallel publication, no additional information
Boonen S, Kaufmann J-M, Orwoll E, Magaziner J, Colon-Emeric C,
Adachi R, et al. Effect of once-yearly zoledronic acid in men after recent
hip fracture: results from HORIZON recurrent fracture trial. Osteoporos Int
2011;22:S180
Parallel publication, no additional information
Boonen S, Su G, Incera E, Orwoll E, Kaufman J-M, Reginster J-Y, et al.
Antifracture efficacy and safety of once-yearly zoledronic acid 5 mg in
men with osteoporosis: a prospective, randomized, controlled trial.
Osteoporos Int 2011;22:S112
Parallel publication, no additional information
Boonen S, Reginster J-Y, Kaufman J-M, Lippuner K, Zanchetta J,
Langdahl B, et al. Efficacy of once-yearly zoledronic acid 5 mg in men with
osteoporosis with different levels of serum total testosterone. Osteoporos
Int 2012;23:S79–80
Parallel publication, no additional information
Boonen S, Eastell R, Su G, Mesenbrink P, Cosman F, Cauley JA, et al. Time
to onset of antifracture efficacy and year-by-year persistence of effect
of zoledronic acid in women with osteoporosis. J Bone Miner Res
2012;27:1487–93
Parallel publication, no additional information
Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES, et al.
Evidence for safety and efficacy of risedronate in men with osteoporosis
over 4 years of treatment: results from the 2-year, open-label, extension
study of a 2-year, randomized, double-blind, placebo-controlled study.
Bone 2012;51:383–8
Parallel publication, no additional information
Colon-Emeric C, Mesenbrink P, Lyles K, Pieper C, Boonen S, Delmas P,
et al. Potential mediators of the reduction in mortality with zoledronic acid
after hip fracture. J Bone Miner Res 2010;25:91–7
Parallel publication, no additional information
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TABLE 41 Studies excluded from the clinical effectiveness review and reasons for exclusion (continued )
Citation Reason for exclusion
Cosman F, Cauley J, Eastell R, Boonen S, Palermo L, Reid I, et al. Who is at
highest risk for new vertebral fractures after 3 years of annual zoledronic
acid and who should remain on treatment? Annual Meeting of the
American Society for Bone and Mineral Research (ASBMR), San Diego,
CA, 16–20 September 2011
Parallel publication, no additional information
Delmas PD, Recker RR, Chesnut CH III, Skag A, Stakkestad JA, Emkey R,
et al. Daily and intermittent oral ibandronate normalize bone turnover and
provide significant reduction in vertebral fracture risk: results from the
BONE study. Osteoporos Int 2004;15:792–8
Parallel publication, no additional information
Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, Nagant de
Deuxchaisnes C, Geusens P, et al. Oral alendronate induces progressive
increases in bone mass of the spine, hip, and total body over 3 years in
postmenopausal women with osteoporosis. Bone 1996;18:141–50
No outcomes of interest
Durchschlag E, Paschalis EP, Zoehrer R, Roschger P, Fratzl P, Recker R,
et al. Bone material properties in trabecular bone from human iliac crest
biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res
2006;21:1581–90
No outcomes of interest
Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, et al.
Effect of once-yearly zoledronic acid five milligrams on fracture risk and
change in femoral neck bone mineral density. J Clin Endocrinol Metab
2009;94:3215–25
No outcomes of interest
Eastell R, Cosman F, Cauley JA, Boonen S, Palermo L, Reid IR, et al. After
3 years of annual zoledronic acid, who should remain on treatment?
Results from the HORIZON-PFT extension study. Osteoporos Int
2012;23:S240–1
Parallel publication, no additional information
Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, et al.
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and
once-weekly oral alendronate (70 mg): additional results from the Monthly
Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION)
study. Clin Therap 2009;31:751–61
Parallel publication, no additional information
Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE.
Oral ibandronate significantly reduces the risk of vertebral fractures of greater
severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
Bone 2005;37:651–4
Not treatment of interest, not currently
licensed dose
Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE.
Oral ibandronate significantly reduces the risk of vertebral fractures of greater
severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
Bone 2005;37:651–4
Parallel publication, no additional information
Genant HK, Bucci-Rechtweg C, Bauer DC, Mesenbrink PG, Palermo L,
Nusgarten L, et al. Does zoledronic acid increase risk of atypical femoral
shaft fractures? Results from the HORIZON-PFT. Osteoporos Int
2010;21:S161–2
Parallel publication, no additional information
Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR, et al. The
antiresorptive effects of a single dose of zoledronate persist for two years:
a randomized, placebo-controlled trial in osteopenic postmenopausal
women. J Clin Endocrinol Metab 2009;94:538–44
Population outside scope of appraisal, not
licensed indication
Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR, et al. Low-dose
zoledronate in osteopenic postmenopausal women: a randomized
controlled trial. J Clin Endocrinol Metab 2012;97:286–92
Population outside scope of appraisal, not
licensed indication
Grey A, Bolland M, Mihov B, Wong S, Horne A, Gamble G, et al. Duration
of antiresorptive effects of low-dose zoledronate in osteopenic
postmenopausal women: a randomized, placebo-controlled trial.
J Bone Miner Res 2014;29:166–72
Population outside scope of appraisal, not
licensed indication
Guo-ping L, Bin K, Hui Z. Effect of alendronate on bone mineral density of
middle-aged and elderly patients with osteoporosis. Chin J Clin Rehabil
2005;39:186–7
Not comparator of interest
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TABLE 41 Studies excluded from the clinical effectiveness review and reasons for exclusion (continued )
Citation Reason for exclusion
Hakala M, Kroger H, Valleala H, Hienonen-Kempas T, Lehtonen-Veromaa M,
Heikkinen J, et al. Once-monthly oral ibandronate provides significant
improvement in bone mineral density in postmenopausal women treated
with glucocorticoids for inflammatory rheumatic diseases: a 12-month,
randomized, double-blind, placebo-controlled trial. Scand J Rheumatol
2012;41:260–6
Population outside scope of appraisal, not
licensed indication
Haworth CS, Sharples L, Hughes V, Elkin SL, Hodson M, Conway S, et al.
Two-year multicenter, randomised, doubleblind, placebo-controlled trial
assessing the effect of weekly risedronate on bone mineral density in
adults with CF. Pediatr Pulmonol 2010;45:423
Population outside scope of appraisal, not
licensed indication
Haworth CS, Sharples L, Hughes V, Elkin SL, Hodson ME, Conway SP,
et al. Multicentre trial of weekly risedronate on bone density in adults with
cystic fibrosis. J Cystic Fibros 2011;10:470–6
Population outside scope of appraisal, not
licensed indication
Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P,
et al. Effect of alendronate on the age-specific incidence of symptomatic
osteoporotic fractures. J Bone Miner Res 2005;20:971–6
Parallel publication, no additional information
Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P, et al.
Prevention of bone loss with alendronate in postmenopausal women
under 60 years of age. N Engl J Med 1998;338:485–92
Not treatment of interest, not currently
licensed dose
Hwang JS, Chin LS, Chen JF, Yang TS, Chen PQ, Tsai KS et al. The effects
of intravenous zoledronic acid in Chinese women with postmenopausal
osteoporosis. J Bone Miner Metab 2011;29:328–33
Parallel publication, no additional information
Hwang JS, Liou MJ, Ho C, Lin JD, Huang YY, Wang CJ, et al. The effects
of weekly alendronate therapy in Taiwanese males with osteoporosis.
J Bone Miner Metab 2010;28:328–33
Population outside scope of appraisal, not
licensed indication
Kasayama S, Fujita M, Goya K, Yamamoto H, Fujita K, Morimoto Y, et al.
Effects of alendronate on bone mineral density and bone metabolic
markers in postmenopausal asthmatic women treated with inhaled
corticosteroids. Metabolism 2005;54:85–90
Not treatment of interest, not currently
licensed dose
Klotz L, McNeil I, Kebabdjian M, Zhang L, Chin J. A phase III, double-blind,
randomized, parallel group, placebo-controlled study of oral aledronate,
70 mg once-a-week, for the prevention of androgen deprivation bone
loss in non-metastatic prostate cancer. A Canadian urology research
consortium study. J Urol 2011;185(Suppl. 1):e359
Parallel publication, no additional information
Langenegger IQ, Opazo MF, Garcia AMZ. Therapeutic equivalence and
adherence to treatment with ibandronate 150 mg and alendronate 70 mg
in postmenopausal women of concepcion city, Chile. Actualizaciones
Osteol 2011;7:175–83
Population outside scope of appraisal, not
licensed indication
Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, et al.
Addition of alendronate to ongoing hormone replacement therapy in the
treatment of osteoporosis: a randomized, controlled clinical trial.
J Clin Endocrinol Metab 1999;84:3076–81
Not treatment of interest – combination
therapy with HRT
Lindsay R, Cosman F, Lobo RA, Walsh BW, Harris ST, Reagan JE, et al.
Addition of alendronate to ongoing hormone replacement therapy in the
treatment of osteoporosis: a randomized, controlled clinical trial.
J Clin Endocrinol Metab 1999;84:3076–81
Not treatment of interest, not currently
licensed dose
Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, et al.
Clinical significance of risedronate for osteoporosis in the initial
treatment of male patients with Graves' disease. J Bone Miner Metab
2006;24;105–13
Not treatment of interest, not currently
licensed dose
McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS,
et al. Alendronate prevents postmenopausal bone loss in women without
osteoporosis: a double-blind, randomized, controlled trial. Ann Intern Med
1998;128:253–61
Not comparator of interest
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TABLE 41 Studies excluded from the clinical effectiveness review and reasons for exclusion (continued )
Citation Reason for exclusion
McClung MR, Wasnich RD, Hosking DJ, Christiansen C, Ravn P, Wu M,
et al. Prevention of postmenopausal bone loss: six-year results from the
early postmenopausal intervention cohort study. J Clin Endocrinol Metab
2004;89:4879–85
Not treatment of interest, not currently
licensed dose
McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE,
et al. Oral daily ibandronate prevents bone loss in early postmenopausal
women without osteoporosis. J Bone Miner Res 2004;19:11–18
No outcomes of interest
McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M,
et al. Opposite bone remodeling effects of teriparatide and alendronate in
increasing bone mass. Arch Intern Med 2005;165:1762–8
Not treatment of interest, not currently
licensed dose
Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD,
Chines AA. Seven years of treatment with risedronate in women with
postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462–8
Extension study, participants not in original
randomised groups
Miller PD, Schnitzer T, Emkey R, Orwoll E, Rosen C, Ettinger M, et al.
Weekly oral alendronic acid in male osteoporosis. Clin Drug Invest
2004;25:333–41
Population outside scope of appraisal, not
licensed indication
Mok CC, Tong KH, To CH, Siu YP, Ma KM. Risedronate for prevention of
bone mineral density loss in patients receiving high-dose glucocorticoids:
a randomized double-blind placebo-controlled trial. Osteoporos Int
2008;19:357–64
Population outside scope of appraisal, not
licensed indication
Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC. Risedronate
increases bone mass in an early postmenopausal population: two years
of treatment plus one year of follow-up. J Clin Endocrinol Metab
1998;83:396–402
Population outside scope of appraisal, not
licensed indication
Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, et al.
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month
intravenous ibandronate versus 2.5 mg/day oral risedronate in patients
with primary osteoporosis. Calcif Tissue Int 2013;93:137–46
Not treatment of interest, not currently
licensed dose
Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, et al.
Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg
versus a once-weekly 70-mg oral alendronate in the treatment of male
osteoporosis: a randomized, multicenter, double-blind, active-controlled
study. J Bone Miner Res 2010;25:2239–50
Population outside scope of appraisal, not
licensed indication
Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G,
et al. Efficacy and safety of monthly ibandronate in men with low bone
density. Bone 2010;46:970–6
Population outside scope of appraisal, not
licensed indication
Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al.
Alendronate and estrogen-progestin in the long-term prevention of bone
loss: four-year results from the early postmenopausal intervention cohort
study: a randomized, controlled trial. Ann Intern Med 1999;131:942
Not treatment of interest, not currently
licensed dose
Reid I, Boonen S, Black DM, Colon-Emeric C, Eastell R, Magaziner J, et al.
Once-yearly treatment with zoledronic acid continues to be effective in old
age. Bone 2009;44:S94
Parallel publication, no additional information
Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, et al.
Reduction in the risk of clinical fractures after a single dose of zoledronic
acid 5 milligrams. J Clin Endocrinol Metab 2013;98:557–63
Parallel publication, no additional information
Rossini M, Gatti D, Zamberlan N, Braga V, Dorizzi R, Adami S. Long-term
effects of a treatment course with oral alendronate of postmenopausal
osteoporosis. J Bone Miner Res 1994;9:1833–7
Not treatment of interest, not currently
licensed dose
Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, et al.
Post hoc analysis of a single IV infusion of zoledronic acid versus daily
oral risedronate on lumbar spine bone mineral density in different
subgroups with glucocorticoid-induced osteoporosis. Osteoporos Int
2012;23:1083–90
No outcomes of interest
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TABLE 41 Studies excluded from the clinical effectiveness review and reasons for exclusion (continued )
Citation Reason for exclusion
Sambrook PN, Rodriguez JP, Wasnich RD, Luckey MM, Kaur A, Meng L,
et al. Alendronate in the prevention of osteoporosis: 7-year follow-up.
Osteoporos Int 2004;15:483–8
Not comparator of interest
Sambrook PN, Silverman SL, Cauley JA, Recknor C, Olson M, Su G, et al.
Health-related quality of life and treatment of postmenopausal
osteoporosis: results from the HORIZON-PFT. Bone 2011;48;1298–304
Parallel publication, no additional information
Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L,
et al. Efficacy of continued alendronate for fractures in women with and
without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res
2010;25:976–82
Parallel publication, no additional information
Seeman E. The antifracture efficacy of alendronate. Int J Clin Pract Suppl
1999;101:40–5
Parallel publication, no additional information
Seeman E, Black D, Bucci-Rechtweg C, Eastell R, Boonen S, Mesenbrink P.
Zoledronic acid substantially reduces the risk of morphometric vertebral
and clinical fractures. Arthritis Rheum 2009;60:892
Parallel publication, no additional information
Siris ES, Simon JA, Barton IP, McClung MR, Grauer A, Siris ES, et al.
Effects of risedronate on fracture risk in postmenopausal women with
osteopenia. Osteoporos Int 2008;19:681–6
Parallel publication, no additional information
Stakkestad JA, Benevolenskaya LI, Stepan JJ, Skag A, Nordby A, Oefjord E
et al. Intravenous ibandronate injections given every three months: a new
treatment option to prevent bone loss in postmenopausal women. Ann
Rheum Dis 2003;62:969–75
Not treatment of interest, not currently
licensed dose
Tee SI, Yosipovitch G, Chan YC, Chua SH, Koh ET, Chan YH, et al.
Prevention of glucocorticoid-induced osteoporosis in immunobullous
diseases with alendronate: a randomized, double-blind, placebo-controlled
study. Arch Dermatol 2012;148:307–14
Population outside scope of appraisal, not
licensed indication
Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR,
et al. Three monthly intravenous injections of ibandronate in the
treatment of postmenopausal osteoporosis. Am J Med 1997;103:298–307
Not treatment of interest, not currently
licensed dose
Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M,
et al. Therapeutic effects of alendronate 35 mg once weekly and 5mg
once daily in Japanese patients with osteoporosis: a double-blind,
randomized study. J Bone Miner Metab 2005;23:382–8
Not treatment of interest, not currently
licensed dose
Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM,
et al. Changes in bone density and turnover after alendronate or estrogen
withdrawal. Menopause 2004;11:622–30
Not treatment of interest, not currently
licensed dose
Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA,
et al. Zoledronic acid for prevention of bone loss in patients receiving
primary therapy for lymphomas: a prospective, randomized controlled
phase III trial. Clin Lymphoma Myeloma Leuk 2013;13:99–105
Not treatment of interest, not currently
licensed dose
Yildirim K, Gureser G, Karatay S, Melikoglu MA, Ugur M, Erdal A, et al.
Comparison of the effects of alendronate, risedronate and calcitonin
treatment in postmenopausal osteoporosis. J Back Musculoskel Rehabil
2005;18:85–9
No outcomes of interest
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Appendix 3 Network meta-analyses
supplementary information
Additional details on the statistical models used for the
network meta-analyses
Statistical model for the network meta-analysis of fracture outcomes
The RCTs presented data in terms of the number of individuals experiencing at least one fracture. For each
fracture type, rik is defined as the number of events out of the total number of participants, nik, where the
participants are receiving treatment tik in arm k of trial i. The data generation process is assumed to follow
a binomial likelihood such that:
r ik ∼ bin(pik, nik), (6)
where pi,k represents the probability of an event in arm k of trial i (i = 1 . . . ns, k = 1 . . . na) after follow-up
time fi. For all RCTs, the number of arms included in the analysis is 2 (i.e. na = 2) and the number of RCTs,
ns, varies according to fracture type.
To account for different trial durations, an underlying Poisson process is assumed for each trial arm, so that
Tik (the time until a fracture occurs in arm k of study i) follows an exponential distribution, Tik ∼ exp(λik),
where λik is the event rate in arm k of study i, assumed constant over time. The probability that there are
no events at time fi is given by the survivor function, P(Tik > fi) = exp(–λikfi). For each study, i, the probability
of an event in arm k after follow-up time fi can be written as:
pik = 1− P(T ik > f i) = 1− exp(−λikf i), (7)
which is dependent on follow-up time. The probabilities of fracture are non-linear functions of event rates
and so were modelled using the complementary log–log link function:
cloglog(pik) = log(f i) + µi + δi, 1k Ik≠1. (8)
Here, the µi are trial-specific baselines, representing the log-hazards of fracture in the baseline treatment,
which is assumed to be arm k = 1 for all trials. Note that for some trials, the baseline may be an active
treatment rather than placebo. The trial-specific treatment effects, δi,1k, are log-HRs of fracture for the
treatment in arm k, relative to the baseline treatment.
As described below, two different modelling strategies were considered for the treatment effects:
(1) standard, independent random (treatment)-effects model; and (2) exchangeable treatment-effects
model (i.e. effects model where the treatment effects are assumed to arise from a common distribution
according to the class of drug). The main results are presented in Chapter 3, Results from the network
meta-analyses and are based on the class-effects model for reasons discussed below, while the results for
the standard independent random-effects model are provided in Results for the standard random-effects
model for comparison.
Standard, independent random-effects model
The trial-specific treatment effects, δi,1k, were assumed to arise from a common population distribution
with mean treatment effect relative to the reference treatment, which was defined as placebo for this
analysis, such that:
δi, 1k∼N(dti1tik, τ
2), (9)
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where dti1tik represents the mean effect of the treatment in arm k of study i(tik) compared with the
treatment in arm 1 of study i(ti1) and τ2 represents the between-study variance in treatment effects
(heterogeneity), which is assumed to be the same for all treatments.
The model was completed by specifying prior distributions for the parameters. Where there were sufficient
sample data, conventional reference prior distributions were used:
trial‐specific baseline, µl ∼ N(0, 100
2), (10)
treatment effects relative to reference treatment, d1k ∼ N(0, 100
2), (11)
between‐study SD of treatment effects, τ∼ U(0, 2). (12)
For both hip and wrist fracture outcomes, there were relatively few RCTs to allow Bayesian updating
(i.e. estimation of parameters from the sample data alone) of the reference prior distribution for the
between-study SD. When prior distributions do not represent reasonable prior beliefs then, in the absence
of sufficient sample data, posterior distributions will not represent reasonable posterior beliefs. Therefore,
rather than using a reference prior distribution, a weakly informative prior distribution was used for the
between-study SD such that τ ∼ HN(0,0.322).
Only one RCT74 assessed the effect of ibandronic acid (monthly oral dose), relative to placebo, on hip
fractures. There were no fractures in the control arm and the model was unable to converge for this
parameter. A weakly informative prior distribution was used for the baseline of this study (details provided
in Appendix 3), whereas reference prior distributions were used for the baselines of the remaining RCTs.
Class-effects model
Not all RCTs contributing wrist fracture data provide evidence about all bisphosphonates; in particular,
there was no evidence about zoledronic acid. To allow an assessment of the uncertainty associated with
zoledronic acid for inclusion in the economic model, a class-effects model was fitted from which the
predictive distribution of a new intervention in the same class can be generated. This modelling approach
also has the benefit of addressing data scarcity in the hip network without the need to use of a weakly
informative prior for the baseline of Lester et al.74 (as was required when fitting a standard, independent
random-effects model).
A class-effects model was also fitted for all fracture types. Under a class-effects model, the trial-specific
treatment effects are again assumed to be normally distributed as in Equation 8, but the mean effects of
each treatment are assumed to be exchangeable and assumed to arise from a normal distribution with
mean, D, and with variance τ2D:
dti1tik ∼ N(D, τ
2
D). (13)
The model was completed by specifying prior distributions for the parameters.
Mean bisphosphonate effect, D∼N(0, 1002), (14)
Between‐treament SD, τD ∼U(0, 2). (15)
For hip and wrist outcomes where information for some treatments was either weak or absent, a weakly
informative prior was used for the between-treatment SD such that: σ2D∼HN(0, 0:32
2).
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Predicting effects in new randomised controlled trials
To account for heterogeneity in the effect of treatments between RCTs, results are also presented for the
predictive distributions of the effect of treatment in a new (randomly chosen) study.
From Equation 9, it follows that the study-specific population log-HR, δi,j, for study i, evaluating
bisphosphonate j in reference to the control treatment can be written as:
δi, j = d1 j + εi j, (16)
where εij ∼ N(0,τ2). The predictive distribution for the effect of a particular bisphosphonate in a new study,
δi,j, from the same class following, in a new study is:
δnew, j∼N(d1 j, τ
2). (17)
The class-effects model also allows generation of the predictive distribution of a new, randomly chosen
treatment from the same class. From Equation 13, it follows that the population log-HR for each treatment
can be written as:
d1 j = D + ξ j, (18)
where ξ j∼N(0, τ
2
D). Therefore, combining Equations 16 and 18, the study-specific population log-HR, δij, for
study i evaluating bisphosphonate j is:
δi j = D + ζ j + εi j. (19)
For a new, randomly chosen, bisphosphonate, the expectation is E[δij] = E[D + ζj + ϵij] = D, with variance:
V ½δi j = V ½D + ζ j + εi j = τ
2
+ τ2D. (20)
Therefore, the predictive distribution for the effect of a new, randomly chosen study from the same
class is:
δnew∼N(D, τ
2
D + τ
2), (21)
which accounts for both between-study, τ2, and between-treatment within class, τ2D, heterogeneity for any
(including a new) treatment.
It is the predictive distribution of a new treatment within the class and the predictive distribution of a new
study for a new treatment within the class that we used to characterise the uncertainty about the effect of
zoledronic acid for hip fractures.
Statistical model for the network meta-analysis of femoral neck bone
mineral density
Data for femoral neck BMD outcomes were presented in two different formats: as the percentage change
in femoral neck BMD for each treatment group or as the mean difference in the percentage change
between treatment groups. Two different data generation (i.e. likelihood) models are therefore required.
Percentage change in femoral neck bone mineral density
The majority of RCTs presented data as the percentage change in femoral neck BMD, yik, and associated
standard errors, seik, for arm k of trial i with study duration fi years. The data generation process is
assumed to follow a normal likelihood such that:
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y ik∼N(θik, se
2
ik), (22)
where the population variance of the mean, se2ik, is assume to be known and equal to the sample
estimate. The parameters of interest, θik, are modelled using the identity link function and, to account
for differing trial lengths, study duration was included as a trial-level covariate. The link function is
given by:
θik = µi + (δi, 1k + (β1tik−β1ti1)f i)lk≠1, (23)
where β11 = 0 and β1k (k = 2, . . na) are the treatment-specific interactions, describing the relationship
between the effect of treatment on percentage change in femoral neck BMD and duration of study.
The trial baselines, µi, represent the percentage change in femoral neck BMD from baseline in the
reference arm. The treatment effects, δi,1k, represent the difference between the percentage change in
the treatment group and the reference group. Assumptions about the relationship between the interaction
terms are described further in the meta-regression section.
Difference between treatments in mean change in femoral neck bone
mineral density
Some RCTs provided data in terms of the mean difference in percentage change in femoral neck BMD
between two treatments, defined as:
MDi, 1k = y ik−y i1, (24)
together with the associated standard errors of the mean difference, νi,1k, rather than the percentage
change in femoral neck BMD for individual treatments. The difference between treatments in the mean
change are also assumed to be normally distributed such that:
MDi, 1k∼N(θ′ik, ν
2
i1k), (25)
where the population standard error of the difference, ν2i1k, is assumed to be known and equal to the
sample estimate. From the mean differences, no trial-specific effects of the baseline treatment can be
estimated. The linear predictor is then given by
θ′ik(δi, 1k + (β1tik−β1ti1)f i)lk≠1. (26)
The study-specific treatment effects, δi,1k, have the same interpretation as those from the Equation 23 and
thus can be combined to estimate the mean effects for each treatment, regardless of the way the data
were reported.
A class-effects model was assumed such that the treatment effects of the individual bisphosphonates were
assumed to be exchangeable and to arise from a normal distribution with mean, D, with variance τ2D:
dti1tik∼N(D, τ
2
D). (27)
The model was completed by specifying prior distributions for the parameters, using conventional
reference prior distributions:
l trial-specific baseline, µi ∼ N(0,1002)
l treatment effects relative to reference treatment, d1k ∼ N(0,1002)
l between-study SD of treatment effects, τ ∼ U(0,100)
l mean of related treatment effects, D ∼ N(0,1002)
l between-treatment SD, τD ∼ U(0,100).
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Meta-regression
Where appropriate, heterogeneity in treatment effects was explored by considering potential treatment
effect modifiers. Meta-regression was used to test for interactions between the treatment effects and
trial-level covariates, as described in Dias et al.238
An interaction term, β, is introduced on the treatment effect by replacing:
δi, 1k = δi, 1k + (β1tik − β1ti1)(x i − x), (28)
where xi is the trial-level covariate for trial i and may represent a subgroup, continuous covariate, or
baseline risk (as described in more detail in Metaregression on baseline risk/response), and β11 = 0.
The regression is centred at the mean value of the covariate across the RCTs so that the interpretation of
the treatment effect is as the effect at the average value of the covariate.
Different assumptions can be made about the relationship between the interaction terms for each
treatment. For the main analysis, we assume a common interaction for each treatment relative to
treatment 1, such that:
β1, tik = b, (29)
for k = 2, … , na. We also considered a model in which the interaction terms for each treatment were
considered to be related but not identical (i.e. exchangeable) such that:
β1, tik ∼ N(b, τ
2
B). (30)
Metaregression on baseline risk/response
Baseline risk/response can be used as a proxy for differences in patient characteristics across trials that,
may be modifiers of treatment effect, and so introduce a potential source of heterogeneity in the NMA.
Adjustment for baseline risk/response was assessed using the method of Achana et al.239
Dependence on baseline risk is introduced through an interaction term, so that:
δi, 1k = dti1tik + βti1tik(µiP − µP) + εi, ti1tik, (31)
where ϵi,ti1tik ∼ N(0,τ2). The updated study-specific treatment effects, δi, 1k, are now adjusted using the
‘true’ but unobserved baseline risk/response in the placebo arm of trial I, µip. The coefficient βti1tik
represents the change in the treatment effect (e.g. log-HR or difference between treatments in mean
change) per unit change in the baseline risk/response. The baseline risk/response is centred on µP, the
observed mean (e.g. log-HR or difference between treatments in mean change), in the placebo group,
and β11 = 0.
For RCTs with an active treatment control, (ti1 ≠ P), there is no direct estimate of the placebo baseline
risk/response. Under the consistency of evidence arising from the exchangeability assumption,
the substitution dti1tik = dPtik – dPti1 can be made, allowing Equation 31 to be expressed as:
δi, 1k = (dPtik − dPti1) + (βPtik − βPti1)(µiP − µP). (32)
Although a placebo treatment may not be included in all RCTs, the assumption of exchangeability means
that the treatment arms can be assumed missing at random without loss to efficacy, and the baseline
risk/response in RCTs without a placebo arm can be estimated, borrowing strength from other RCTs.239
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As previously described (see Chapter 3, Methods for the network meta-analyses), some RCTs report data
on the mean differences in percentage change between two treatments. Under the model described in
Equations 25 and 21 study-specific effects of the baseline treatment cannot be estimated. These RCTs still
contribute to the model through estimation of the treatment effects, but do not directly contribute to
estimation of the slope in the meta-regression.
Statistical model for the meta-analysis of placebo baselines
To provide a suitable prior distribution for the study-specific baseline of Lester et al.,74 a random-effects
meta-analysis was performed on the placebo arms of all other studies. Again, the data generation process
is assumed to follow a binomial likelihood, that is:
r ip ∼ bin(pip, nip), (33)
where pip represents the probability of an event in the placebo arm of trial i (i = . . . np). For the hip fracture
network, the number of studies with placebo baseline, np, is 8. The probabilities of fracture are modelled
using the complementary log–log link function:
cloglog(pip) = log(f i) + µi. (34)
A random-effects model is assumed, such that the trial-specific baselines are drawn from a normal
distribution with common mean and variance:
µi ∼ N(m, τ
2
m). (35)
To complete the model, common reference priors were assumed for the mean and variance, µi ∼ N(0,1002),
and τ2m∼U(0, 2). The predictive distribution of a new baseline is given by
µnew ∼ N(m, τ
2
m). (36)
Assessing inconsistency between direct and indirect evidence
Inconsistency between direct and indirect evidence arises because of an imbalance in treatment effect
modifiers across treatments comparing different pairs of treatments. Consistency of evidence was assessed
using the node-splitting method of Dias et al.,240 which separates evidence on a particular comparison into
direct and indirect evidence.
In the case of fracture data, inconsistency was assessed for vertebral fractures only. For non-vertebral fractures,
no indirect evidence was available. For hip and wrist fractures, an assessment of inconsistency was not
performed because the direct evidence about treatment effect in the active comparator study is provided
by one small study82 with no events in each baseline arm, thereby providing imprecise evidence of treatment
effect.
All analyses were conducted in the freely available software package WinBUGS (MRC Biostatistics Unit,
Cambridge, UK)241 and R (The R Foundation for Statistical Computing, Vienna, Austria), using the
R2–WinBUGS interface package.242 Convergence to the target posterior distributions was assessed using
the Gelman–Rubin statistic, as modified by Brooks and Gelman,243 for two chains with different initial
values. For all outcomes, a burn-in of 50,000 iterations of the Markov chain was used, with a further
20,000 iterations retained to estimate parameters. The NMA exhibited moderate correlation between
successive iterations of the Markov chain, so were thinned by retaining every 10th sample.
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Model fit was assessed using the total residual deviance, which provides an absolute measure of
goodness of fit.244 The total residual deviance can be compared with the number of independent data
points to check whether or not the model provides a reasonable representation of the data. The DIC
provides a relative measure of goodness of fit that penalises complexity and can be used to compare
different models for the same likelihood and data.245 Lower values of DIC are favourable, suggesting a
more parsimonious model.
Data used to populate the network meta-analysis
A summary of the data used in the NMA is provided in Tables 42–46.
TABLE 42 Summary of the trials included in the NMA of vertebral fractures
Author and year of study
publication (trial acronym)
Study
duration
(years)
Assessment
method
Treatmentsa Events
Number of
participants
Arm
1
Arm
2
Arm
1
Arm
2
Arm
1
Arm
2
Cohen et al., 199963 1 0 1 2 5 2 35 34
Fogelman et al., 200066 2 0 1 2 17 8 125 112
Harris et al., 199970 (VERT-NA) 3 0 1 2 93 61 678 696
Reginster et al., 200085 (VERT-MN) 3 0 1 2 89 53 346 344
Hooper et al., 200572 2 0 1 2 10 10 125 129
Reid et al., 200086 1 0 1 2 9 3 60 60
Boonen et al., 200958 2 0 1 2 0 1 80 191
Ringe et al., 200689 1 1 1 2 20 8 158 158
Liberman et al., 199576 3 0 1 3 22 5 355 175
Orwoll et al., 200083 2 0 1 3 7 1 94 146
Black et al., 199655 (FIT I) 3 0 1 3 192 83 965 981
Cummings et al., 199864 (FIT II) 4 0 1 3 78 43 2077 2057
Dursun et al., 200165 1 0 1 3 14 12 35 38
Carfora et al., 199860 2.5 0 1 3 4 1 34 34
Boonen et al., 201259 2 0 1 4 28 9 574 533
Black et al., 200756 (HORIZON-PFT) 3 1 1 4 84 19 3861 3875
Lyles et al., 200777 (HORIZON-RFT) 3 1 1 4 39 21 1062 1065
Chesnut et al., 200445 (BONE) 3 0 1 6 93 46 975 977
Muscoso et al., 200482 1 NA 2 3 0 2 100 1000
Reid et al., 200988 1 NA 2 4 3 5 381 378
Miller et al., 200881 1 1 3 5 5 5 859 874
NA, not available.
a Treatments are coded as 1 = placebo; 2= risedronic acid; 3= alendronic acid; 4= zoledronic acid; 5= ibandronic acid
150 mg monthly oral; and 6= ibandronic acid 2.5 mg daily oral. Assessment method coded as 0=morphometric;
and 1= clinical.
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TABLE 43 Summary of the trials included in the NMA of non-vertebral fractures
Author and year of study publication
(trial acronym)
Study duration
(years)
Treatmentsa Events
Number of
participants
Arm 1 Arm 2 Arm 1 Arm 2 Arm 1 Arm 2
Fogelman et al., 200066 3 1 2 13 7 125 112
Harris, 199970 (VERT-NA) 3 1 2 52 33 815 812
Reginster et al., 200085 (VERT-MN) 2 1 2 51 36 406 406
Hooper et al., 200572 1 1 2 6 5 125 129
Ringe et al., 200689 4 1 2 17 10 158 158
Black et al., 199655 (FIT I) 3 1 3 148 122 1005 1022
Cummings et al., 199864 (FIT II) 4 1 3 294 261 2077 2057
Orwoll et al., 200083 2 1 3 5 6 94 146
Pols et al., 199984 (FOSIT) 1 1 3 37 19 958 950
Bone et al., 200057 2 1 3 4 5 50 92
Black et al., 200756 (HORIZON-PFT) 0.92 1 4 388 292 3861 3875
Lyles et al., 200777 (HORIZON-RFT) 3 1 4 107 79 1062 1065
Chesnut et al., 200445 (BONE) 3 1 6 80 89 975 977
Miller et al., 200881 (MOTION) 1 3 5 12 14 859 874
a Treatments are coded as 1= placebo; 2= risedronic acid; 3= alendronic acid; 4= zoledronic acid; 5= ibandronic acid
150mg monthly oral; and 6= ibandronic acid 2.5 mg daily oral.
TABLE 44 Summary of the trials included in the NMA of hip fractures
Author and year of study publication
(trial acronym)
Study duration
(years)
Treatmentsa Events
Number of
participants
Arm 1 Arm 2 Arm 1 Arm 2 Arm 1 Arm 2
McClung et al., 200178 3 1 2 46 32 1821 1812
Harris et al., 199970 (VERT-NA) 3 1 2 15 12 815 812
Reginster et al., 200085 (VERT-MN) 3 1 2 11 9 406 406
Black et al., 199655 (FIT I) 3 1 3 22 11 1005 1022
Cummings et al., 199864 (FIT II) 4 1 3 24 19 2218 2214
Greenspan et al., 200267 2 1 3 4 2 164 163
Black et al., 200756 (HORIZON-PFT) 3 1 4 88 52 3861 3875
Lyles et al., 200777 (HORIZON-RFT) 3 1 4 33 79 1062 1065
Lester et al., 200874 (ARIBON) 2 1 5 0 1 19 21
Muscoso et al., 200482 1 2 3 0 1 100 1000
a Treatments are coded as 1= placebo; 2= risedronic acid; 3= alendronic acid; 4= zoledronic acid; and 5 = ibandronic
acid 150 mg monthly.
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TABLE 45 Summary of the trials included in the NMA of wrist fractures
Author and year of study publication
(trial acronym)
Study duration
(years)
Treatmentsa Events
Number of
participants
Arm 1 Arm 2 Arm 1 Arm 2 Arm 1 Arm 2
Harris et al., 199970 (VERT-NA) 3 1 2 22 14 815 812
Reginster et al., 200085 (VERT-MN) 3 1 2 21 15 406 406
Black et al., 199655 (FIT I) 3 1 3 41 22 1005 1022
Cummings et al., 199864 (FIT II) 4 1 3 70 83 2218 2214
McClung et al., 200980 1 1 4 0 1 83 77
Lester et al., 200874 (ARIBON) 2 1 4 1 1 19 21
Muscoso et al., 200482 1 2 3 0 1 100 1000
a Treatments are coded as 1 = placebo; 2= risedronic acid; 3= alendronic acid; and 4= ibandronic acid 150 mg monthly.
TABLE 46 Summary of the trials included in the NMA of femoral neck BMD
Author and year of
study publication
(trial acronym)
Study
duration
(years)
Treatmentsa
% change in
BMD
Standard
error %
change in
BMD
Number of
participants Mean difference
Arm
1
Arm
2
Arm
1
Arm
2
Arm
1
Arm
2
Arm
1
Arm
2
% change
in BMD
Standard
error
Adami et al., 199553 2 1 2 –2.58 1.19 0.89 0.88 62 61 NA NA
Bone et al., 200057 2 1 2 –0.6 2.9 0.60 0.50 46 87 NA NA
Dursun et al., 200165 1 1 2 2.33 3.75 0.73 1.00 35 38 NA NA
Pols et al., 199984
(FOSIT)
1 1 2 –0.2 2.3 0.15 0.15 884 863 NA NA
Greenspan et al.,
200368
3 1 2 –0.65 4.2 0.53 0.59 93 93 NA NA
Orwoll et al., 200083 2 1 2 –0.1 2.5 0.50 0.40 81 128 NA NA
Saag et al., 199891 0.92 1 2 –1.2 1 0.40 0.40 142 145 NA NA
Klotz et al., 201373 1 1 2 –2.06 1.65 0.78 1.12 53 45 NA NA
Fogelman et al.,
200066
2 1 3 –1 1.3 0.32 0.44 180 175 NA NA
Harris 1999 et al.70
(VERT-NA)
3 1 3 –1.2 1.6 0.45 0.60 417 457 NA NA
Leung et al., 200575 1 1 3 1.1 1.8 0.90 0.70 34 31 NA NA
Cohen et al., 199963 1 1 3 –2.94 –1.04 0.84 0.94 36 34 NA NA
Reid et al., 200086 1 1 3 –0.29 1.63 0.50 0.62 43 52 NA NA
Boonen et al., 200958 2 1 3 0.73 1.71 0.34 0.25 93 191 NA NA
Choo et al., 201162 2 1 3 –5.56 –2.55 2.92 2.89 52 52 NA NA
Taxel et al., 201095 1 1 3 –2 0 0.61 0.61 20 20 NA NA
continued
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TABLE 46 Summary of the trials included in the NMA of femoral neck BMD (continued )
Author and year of
study publication
(trial acronym)
Study
duration
(years)
Treatmentsa
% change in
BMD
Standard
error %
change in
BMD
Number of
participants Mean difference
Arm
1
Arm
2
Arm
1
Arm
2
Arm
1
Arm
2
Arm
1
Arm
2
% change
in BMD
Standard
error
McClung et al.,
200979
2 1 4 –1.35 1.64 0.29 0.31 202 181 NA NA
Boonen et al., 201259 2 1 4 0.1 3.4 0.58 0.60 63 56 NA NA
McClung et al.,
200980
1 1 5 –0.73 1.09 0.46 0.33 83 77 NA NA
Sarioglu et al.,
200692
1 2 3 3.7 2.6 0.96 0.60 25 25 NA NA
Miller et al., 200881
(MOTION)
1 2 5 2.3 2.1 0.07 0.06 822 836 NA NA
Reid et al., 200988
(HORIZON)
1 3 4 0.39 1.4 0.25 0.26 374 373 NA NA
Miller et al., 200547
(MOBILE)
1 5 6 2.22 1.71 0.21 0.21 320 318 NA NA
Delmas et al., 200649
(DIVA)
1 6 7 1.6 2.3 0.21 0.20 381 368 NA NA
Black et al., 199655
(FIT I)
3 1 2 –0.31 3.54 0.18 0.17 1005 1022 4.10 0.25
Cummings et al.,
199864 (FIT II)
4 1 2 –0.8 3.6 0.16 0.16 2218 2214 4.60 0.23
Greenspan et al.,
200267
2 1 2 –0.36 2.84 0.06 0.35 164 163 3.40 0.50
Liberman et al.,
199576
3 1 2 –1.28 4.65 0.30 0.47 397 196 5.90 0.50
Hooper et al., 200572 2 1 3 –2.43 2.29 0.33 0.20 125 125 3.30 0.27
Reginster et al.,
200085 (VERT-MN)
3 1 3 –0.97 2.09 0.37 0.38 407 407 3.10 0.70
Lyles et al., 200777
(HORIZON-RFT)
3 1 4 NA NA NA NA 1062 1065 2.90 1.31
Black et al., 200756
(HORIZON-PFT)
3 1 4 –0.04 5.06 0.16 0.15 3083 3067 5.06 0.15
Chesnut et al.,
200445 (BONE)
3 1 6 NA NA NA NA 975 977 2.20 0.86
Rosen et al., 200590
(FACT)
1 2 3 1.6 0.9 0.21 0.21 454 438 –0.70 0.28
Reid et al., 200687
(FACTS)
1 2 3 2.25 1.67 0.18 0.18 424 430 –0.56 0.27
NA, not available; SE, standard error.
a Treatments are coded as 1= placebo; 2= alendronic acid; 3= risedronic acid; 4= zoledronic acid; 5= ibandronic acid
150mg monthly; 6= ibandronic acid oral 2.5 mg daily; and 7= ibandronic acid 3 mg i.v. every 3 months.
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Results for the standard random-effects model
Vertebral fractures: random-effects model
The model fitted the data well, with the total residual deviance of 42.17 being close to the total number
of data points, 42, included in the analysis. The DIC was 72.50, suggesting a mild decline in model fit
compared with the class-effects model (DIC 69.28). The between-study SD was estimated to be 0.20
(95% CrI 0.02 to 0.57), implying mild heterogeneity in treatment effects between studies.
Versus placebo
Risedronic acid 0.54 (0.38 to 0.72)
0.54 (0.27 to 1.00)
0.45 (0.31 to 0.63)
0.45 (0.22 to 0.87)
0.36 (0.23 to 0.56)
0.35 (0.18 to 0.76)
0.44 (0.10 to 1.86)
0.44 (0.09 to 2.05)
0.48 (0.25 to 0.92)
0.48 (0.20 to 1.15)
Versus risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Alendronic acid 0.83 (0.53 to 1.38)
0.82 (0.33 to 2.19)
0.66 (0.40 to 1.17)
0.65 (0.27 to 1.85)
0.82 (0.18 to 3.60)
0.81 (0.15 to 4.29)
0.88 (0.44 to 1.90)
0.88 (0.31 to 2.79)
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus alendronic acid
Zoledronic acid 0.79 (0.47 to 1.45)
0.79 (0.31 to 2.23)
0.98 (0.23 to 3.98)
0.98 (0.20 to 4.91)
1.07 (0.51 to 2.24)
1.06 (0.36 to 3.36)
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus zoledronic acid
Ibandronic acid 150 mg/month 1.22 (0.26 to 5.44)
1.23 (0.22 to 6.41)
1.35 (0.59 to 2.83)
1.34 (0.42 to 4.05)
Versus ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day 1.09 (0.23 to 5.42)
1.09 (0.19 to 6.62)
Ibandronic acid 2.5 mg/day
– 0.25 0.31 0.88 1.44 2.00
Treatment comparison HR (95% Crl)
FIGURE 131 Vertebral fractures: random-effects model. Note that the mean effect estimates are plotted in black
and the predictive effects in a new study are plotted in green beneath. Points to the right of the line favour the
reference treatment (shown in green text).
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Non-vertebral fractures: random-effects model
The model fitted the data well, with the total residual deviance of 22.78 being close to the total number
of data points, 28, included in the analysis. The DIC was 43.47, suggesting a mild decline in model fit
compared with the class-effects model (DIC 42.32). The between-study SD was estimated to be 0.08
(95% CrI 0.00 to 0.35), implying mild heterogeneity in treatment effects between studies.
Versus placebo
Risedronic acid
Versus risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Alendronic acid
Zoledronic acid
Zoledronic acid
Ibandronic acid 2.5 mg/day
Ibandronic acid 150 mg/month
Versus alendronic acid
Ibandronic acid 2.5 mg/day
Ibandronic acid 150 mg/month
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Ibandronic acid 2.5 mg/day
Versus zoledronic acid
Versus ibandronic acid 150 mg/month
– 0.25 0.31 0.88 2.001.44
Treatment comparison HR (95% Crl)
0.65 (0.47 to 0.88)
0.65 (0.42 to 0.98)
0.81 (0.62 to 0.97)
0.81 (0.52 to 1.12)
0.74 (0.57 to 0.94)
0.74 (0.49 to 1.09)
0.94 (0.39 to 2.19)
0.94 (0.37 to 2.27)
1.12 (0.73 to 1.69)
1.12 (0.67 to 1.85)
1.24 (0.83 to 1.77)
1.24 (0.69 to 2.10)
1.13 (0.77 to 1.69)
1.13 (0.64 to 2.04)
1.45 (0.57 to 3.55)
1.45 (0.52 to 3.83)
1.72 (1.02 to 2.93)
1.72 (0.89 to 3.41)
0.91 (0.68 to 1.33)
0.91 (0.55 to 1.65)
1.17 (0.50 to 2.69)
1.17 (0.46 to 2.95)
1.39 (0.89 to 2.29)
1.39 (0.76 to 2.72)
1.27 (0.50 to 3.11)
1.28 (0.46 to 3.37)
1.52 (0.94 to 2.45)
1.52 (0.80 to 2.86)
1.20 (0.45 to 3.14)
1.20 (0.43 to 3.43)
FIGURE 132 Non-vertebral fractures: random-effects model. Note that the mean effect estimates are plotted in
black and the predictive effects in a new study are plotted in green beneath. Points to the right of the line favour
the reference treatment (shown in green text).
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Hip fractures: random-effects model
There were insufficient studies with which to estimate the between-study SD from the sample data alone
and there were no events in the baseline treatment in the Lester et al.74 study, which meant that the
Markov chain did not converge. In this case, a weakly informative prior distribution was used for the
between-study SD such that τi ∼ HN(0,0.322) and weakly informative prior distribution for the study-specific
baseline of the Lester et al.74 study such that µi ∼ N(–3.56,0.592); this was generated by performing a
random-effects meta-analysis of the baselines from the other studies.
The model fitted the data well, with the total residual deviance of 17.73 being close to the total number
of data points, 18, included in the analysis. The DIC was 33.61, suggesting little difference in model fit
compared with the class-effects model (DIC 33.82). The between-study SD was estimated to be 0.44
(95% CrI 0.23 to 0.76), implying moderate heterogeneity between studies.
Versus placebo
Risedronic acid
Versus risedronic acid
Alendronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Alendronic acid
Zoledronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Versus alendronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 150 mg/month
0.74 (0.37 to 1.47)
0.74 (0.23 to 2.42)
0.61 (0.29 to 1.28)
0.62 (0.18 to 2.05)
1.17 (0.57 to 2.46)
1.17 (0.36 to 3.97)
2.56 (0.08 to 25.42)
2.49 (0.07 to 30.89)
0.82 (0.30 to 2.25)
0.83 (0.15 to 4.57)
1.58 (0.59 to 4.37)
1.58 (0.30 to 8.59)
3.41 (0.10 to 36.83)
3.33 (0.08 to 52.64)
1.91 (0.68 to 5.59)
1.90 (0.35 to 10.67)
4.13 (0.12 to 46.71)
3.98 (0.10 to 66.23)
2.15 (0.06 to 24.09)
2.09 (0.05 to 34.48)
Versus zoledronic acid
– 0.25 1.06 2.38 5.003.69
Treatment comparison HR (95% Crl)
FIGURE 133 Hip fractures: random-effects model. Note that the mean effect estimates are plotted in black and the
predictive effects in a new study are plotted in green beneath. Points to the right of the line favour the reference
treatment (shown in green text).
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Wrist fractures: random-effects model
There were insufficient studies with which to estimate the between-study SD from the sample data alone.
In this case, a weakly informative prior distribution was used for the between-study SD such that
τ ∼ HN(0,0.322).
The model fitted the data well, with the total residual deviance, 13.88, being close to the total number of
data points included in the analysis, 12. The DIC was 24.70, suggesting a mild decline in model fit
compared with the class-effects model (DIC 23.23). The between-study SD was estimated to be 0.30
(95% CrI 0.03 to 0.71), implying mild to moderate heterogeneity between studies.
Versus placebo
Risedronic acid
Versus risedronic acid
Alendronic acid
Ibandronic acid 150 mg/month
Alendronic acid
Ibandronic acid 150 mg/month
Versus alendronic acid
Ibandronic acid 150 mg/month
0.66 (0.33 to 1.31)
0.66 (0.23 to 1.81)
0.87 (0.46 to 1.51)
0.87 (0.31 to 2.18)
2.32 (0.17 to 64.67)
2.34 (0.16 to 68.31)
1.31 (0.52 to 3.15) 
1.31 (0.32 to 5.27)
3.54 (0.24 to 109.10)
3.56 (0.20 to 124.30)
2.75 (0.19 to 78.66)
2.78 (0.16 to 93.45)
– 0.25 1.06 2.8 5.003.69
Treatment comparison HR (95% Crl)
FIGURE 134 Wrist fractures: random-effects model. Note that the mean effect estimates are plotted in black and
the predictive effects in a new study are plotted in green beneath. Points to the right of the line favour the
reference treatment (shown in green text).
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Femoral neck bone mineral density, random-effects model
The model fitted the data well, with the total residual deviance of 55.30 being close to the total number
of data points included in the analysis, 59. The DIC was 99.34, suggesting a mild decline in model fit
compared with the class-effects model (DIC 96.5). The between-study SD was estimated to be 0.55
(95% CrI 0.31 to 0.88), implying moderate heterogeneity between studies.
– 3.00 – 1.00 1.00 5.003.00
Treatment comparison TE (95% Crl)
Versus placebo
Risedronic acid
Zoledronic acid
Alendronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Ibandronic acid 3 mg/3 months
Versus alendronic acid
Risedronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Ibandronic acid 3 mg/3 months
Versus risedronic acid
Zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Ibandronic acid 3 mg/3 months
Versus zoledronic acid
Ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Ibandronic acid 3 mg/3 months
Versus ibandronic acid 150 mg/month
Ibandronic acid 2.5 mg/day
Versus ibandronic acid 2.5 mg/day
Ibandronic acid 3 mg/3 months
3.13 (2.70 to 3.57)
3.13 (1.91 to 4.41)
2.30 (1.81 to 2.76)
2.30 (1.04 to 3.55)
3.37 (2.61 to 4.06)
3.38 (1.97 to 4.70)
2.66 (1.75 to 3.55)
2.67 (1.19 to 4.12)
1.90 (0.62 to 3.15)
1.90 (0.12 to 3.57)
2.59 (0.75 to 4.35)
2.60 (0.39 to 4.70)
– 0.83 (– 1.40 to – 0.30)
– 0.84 (– 2.62 to 0.86)
0.25 (– 0.61 to 1.02)
0.25 (– 1.66 to 2.02)
– 0.46 (– 1.38 to 0.40)
– 0.47 (– 2.38 to 1.35)
– 1.23 (– 2.54 to 0.00)
– 1.22 (– 3.38 to 0.77)
– 0.53 (– 2.41 to 1.24)
– 0.53 (– 3.08 to 1.89)
1.08 (0.26 to 1.83)
1.08 (– 0.77 to 2.86)
0.36 (– 0.63 to 1.36)
0.37 (– 1.57 to 2.27)
– 0.40 (– 1.73 to 0.94)
– 0.39 (– 2.56 to 1.71)
0.30 (– 1.59 to 2.13)
0.29 (– 2.20 to 2.76)
– 0.71 (– 1.82 to 0.46)
– 0.72 (– 2.71 to 1.29)
– 1.47 (– 2.90 to – 0.05)
– 1.46 (– 3.67 to 0.70)
– 0.78 (– 2.72 to 1.14)
– 0.78 (– 3.27 to 1.75)
– 0.76 (– 1.90 to 0.32)
– 0.76 (– 2.76 to 1.22)
– 0.07 (– 1.83 to 1.62)
– 0.06 (– 2.50 to 2.32)
0.70 (– 0.60 to 1.99)
0.69 (– 1.39 to 2.76)
Ibandronic acid 3 mg/3 months
FIGURE 135 Femoral neck BMD: random-effects model – treatment effects (TE) and 95% Crls. Note that the mean
effect estimates are plotted in black and the predictive effects in a new study are plotted in green beneath. TEs to
the right of the reference line favour the comparator treatment.
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Clinical vertebral fractures: random-effects model
There were insufficient studies with which to estimate the between-study SD from the sample data alone.
In this case, a weakly informative prior distribution was used for the between-study SD such that
τ ∼ HN(0,0.322).
The model fitted the data well, with the total residual deviance, 6.56, being close to the total number of
data points included in the analysis, 6. The between-study SD was estimated to be 0.32 (95% CrI 0.03 to
0.78), which implies mild to moderate heterogeneity between studies.
Treatment comparison HR (95% Crl)
Versus placebo
Versus risedronic acid
Risedronic acid 0.37 (0.11 to 1.14)
0.37 (0.07 to 1.86)
Zoledronic acid 0.33 (0.17 to 0.67)
0.33 (0.09 to 1.30)
Zoledronic acid 0.89 (0.24 to 3.49)
0.89 (0.16 to 5.28)
– 0.25 0.31 0.88 1.44 2.00
FIGURE 136 Clinical vertebral fractures: random-effects model. Note that the mean effect estimates are plotted in
black and the predictive effects in a new study are plotted in green beneath. Points to the right of the line favour
the reference treatment (shown in green text).
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Appendix 4 Adverse events reported across
included randomised controlled trials
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TABLE 47 Summary of AEs data extracted from included RCTs (continued )
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Appendix 5 Summary of review findings of
adverse events associated with bisphosphonates
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 48 Summary of AEs associated with bisphosphonates extracted from published systematic reviews (continued )
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Appendix 6 Summary of review findings of
compliance and concordance with bisphosphonates
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TABLE 49 Summary of data on compliance and concordance with bisphosphonates extracted from published systematic reviews
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TABLE 49 Summary of data on compliance and concordance with bisphosphonates extracted from published systematic reviews (continued )
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TABLE 49 Summary of data on compliance and concordance with bisphosphonates extracted from published systematic reviews (continued )
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Appendix 7 Table of excluded studies:
cost-effectiveness review
TABLE 50 Studies excluded from the cost-effectiveness review and reasons for exclusion
Citation Reason for exclusion
Jansen J, Gaugris S, Bergman G, Sen SS. P339. Cost-effectiveness of Fasavance® in the
treatment and prevention of osteoporosis in the United Kingdom. Osteoporos Int
2006;17(Suppl. 1):S96
Conference abstract
Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost-effectiveness of
therapy with teriparatide and alendronate in women with severe osteoporosis. Arch Int Med
2006;166:1209–17
Excluded interventions
Boonen S. Impact of treatment efficacy and dosing frequency on cost-effectiveness of
bisphosphonate treatment for osteoporosis: A perspective. Curr Med Res Opin
2009;25:2335–41
Systematic review
Botteman MF, Meijboom M, Foley I, Stephens JM, Chen YM, Kaura S. Cost-effectiveness of
zoledronic acid in the prevention of skeletal-related events in patients with bone metastases
secondary to advanced renal cell carcinoma: application to France, Germany, and the United
Kingdom. Eur J Health Econ 2011;12:575–88
Patients with renal cell
carcinoma
Brandao CMR, Machado GPM, Acurcio FA. Pharmacoeconomic analysis of treatment
strategies for osteoporosis in postmenopausal women: a systematic review. Rev Bras
Reumatol 2012;52:924–37
Systematic review
Cowell W, Koay A, Hunjan M. Economic analysis: ibandronate (Bonviva®) IV injection for the
treatment of postmenopausal osteoporosis (PMO) in the UK. Value Health 2006;9:A380
Conference abstract
Dell R, Greene D. Is osteoporosis disease management cost effective? Curr Osteoporos Rep
2010;8:49–55
USA location
Fardellone P, Cortet B, Thomas T, Legrand E, Bresse X, Bisot-Locard S, et al.
Cost-effectiveness simulation modeling of the compliance of 5 mg zoledronic acid once a
year versus current treatments in post-menopausal osteoporosis. Value Health 2007;10:A395
Conference abstract
Farquhar D, Pasquale M. Cost-effectiveness of risedronate versus ibandronate at one year:
the case of the United Kingdom. J Bone Miner Res 2008;23:S212
Conference abstract
Grima D, Borisov N. Cost-effectiveness of risedronate vs. generic alendronate: 1-year analysis
among women 50–64 years old. J Bone Miner Res 2008;23:S212
Conference abstract
Halperin M. The ethics of generics: medical and economic advantages of a generic
alendronate in treating osteoporosis patients. Osteoporos Int 2006;17:S263
Conference abstract
Hiligsmann M, Ethgen O, Bruyere O, Reginster J-Y. An economic evaluation of quantitative
ultrasonometry as pre-screening test for the identification of patients with osteoporosis.
Dis Manag Health Outcomes 2008;16:429–438
Cost-effectiveness of a
pretreatment scanning
strategy
Hiligsmann M, Bruyere O, Ethgen O, Reginster J. Cost-effectiveness of bone densitometry
screening combined with alendronate therapy for those who have osteoporosis.
Value Health 2007;10:A236
Conference abstract
Hiligsmann M, Kanis JA, Compston J, Cooper C, Flamion B, Bergmann P, et al.
Health technology assessment in osteoporosis. Calcif Tissue Int 2013;93:1–14
Systematic review
Jansen J, Gaugris S, Bergman G, Sen S. Cost-effectiveness of Fosavance® in the treatment
and prevention of osteoporosis in the United Kingdom. Osteoporos Int 2006;17:S96
Conference abstract
Jansen JP, Gaugris S, Bergman G, Sen SS, Jansen JP, Gaugris S, et al. Cost-effectiveness of a
fixed dose combination of alendronate and cholecalciferol in the treatment and prevention
of osteoporosis in the United Kingdom and the Netherlands. Curr Med Res Opin
2008;24:671–84
Excluded interventions
continued
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TABLE 50 Studies excluded from the cost-effectiveness review and reasons for exclusion (continued )
Citation Reason for exclusion
Johnell O. Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and
prevention of fractures. PharmacoEconomics 2006;21:305–14
Swedish location
Kanis J, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R. Partial adherence:
a new perspective on health economic assessment in osteoporosis. Osteoporos Int
2011;22:2565–73
Systematic review
Kanis JA, McCloskey EV, Jonsson B, Cooper A, Ström O, Borgström F. An evaluation of the
NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal
women. Arch Osteoporos 2010;5:19–48
Excluded interventions
Kanis JA, McCloskey EV, Johansson H, Ström O, Borgström F, Oden A, et al. Case finding for
the management of osteoporosis with FRAX–assessment and intervention thresholds
for the UK. Osteoporos Int 2008;19:1395–408. [Erratum published in Osteoporos Int
2009;20:499–502]
Very limited discussion of
modelling
Kanis JA, Adams J, Borgström F, Cooper C, Jonsson B, Preedy D, et al. Modelling
cost-effectiveness in osteoporosis. Bone 2008;43:215–16
Response to a letter
published previously in the
same journal
Logman F, Heeg B, Botteman M, Marfatia A, van Hout B. Cost-effectiveness of zoledronic
acid in the prevention of fractures in postmenopausal women with early breast cancer
receiving aromatase inhibitor: application to the United Kingdom. EJC Suppl 2007;5:156
Conference abstract
Logman F, Heeg B, Botteman M, Kaura S, van Hout B. Economic evaluation of zoledronic
acid for the prevention of osteoporotic fractures in post-menopausal women with early
breast cancer receiving aromatase inhibitors in the United Kingdom. Cancer Res
2009;69:S574
Conference poster
Logman J, Heeg B, Botteman M, Kaura S, van Hout B. Economic evaluation of zoledronic
acid for the prevention of osteoporotic fractures in post-menopausal women with early-stage
breast cancer receiving aromatase inhibitors in the United Kingdom. EJC Suppl 2008;6:69–70
Conference abstract
Logman JF, Heeg BM, Botteman MF, Kaura S, van Hout BA, Logman JFS, et al. Economic
evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal
women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann Oncol
2010;21:1529–36
Excluded intervention
Lynch N, Earnshaw S, Graham C, Middelhoven H. Cost-effectiveness of ibandronate injection
IV in the treatment of UK women with postmenopausal osteoporosis who are intolerant to
oral bisphosphonates. Osteoporos Int 2007;18:S11–12
Conference abstract
Lynch N, Earnshaw S, Beard S, Cowell W. Ibandronate is cost-effective in the treatment
of postmenopausal osteoporosis: a comparision of bisphosphonates. Osteoporos Int
2006;17:S11
Conference abstract
Lynch N, Earnshaw S, Graham C, Patroe V, Boisdron J, Middelhoven H. Ibandronate IV
injection is cost-effective in the treatment of UK women with postmenopausal osteoporosis
who are intolerant to oral bisphosphonates. Ann Rheum Dis 2007;66:529
Conference abstract
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, et al. Fracture
liaison services for the evaluation and management of patients with osteoporotic fracture:
a cost-effectiveness evaluation based on data collected over 8 years of service provision.
Osteoporos Int 2011;22:2083–98
Cost-effectiveness
assessment of methods of
treatment delivery with
same pharmaceuticals use
in both arms
Olson M, Brereton N, Huels J, Roberts D, Akerhurst R. Comparison of the cost-effectiveness
of zoledronic acid 5 mg for the management of post-menopausal osteoporosis in the UK
setting. Value Health 2007;10:A395–6
Conference abstract
Rizzoli R, Akesson K, Bouxsein M, Kanis J, Napoli N, Papapoulos S, et al. Subtrochanteric
fractures after long-term treatment with bisphosphonates: a European Society on Clinical
and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis
Foundation Working Group Report. Osteoporos Int 2011;22:373–90
Systematic review
Rosenzweig A, Mishra R. Evaluation and management of osteoporosis and fragility fractures
in the elderly. Aging Health 2009;5:833–50
Review of osteoporosis,
prevention and treatment,
no economic aspect
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TABLE 50 Studies excluded from the cost-effectiveness review and reasons for exclusion (continued )
Citation Reason for exclusion
Simbula S, Burchini G, Santarlasci B, Trippoli S, Messori A. Cost-effectiveness analysis of
therapeutic or preventive interventions <not enough value for money>. G Itali Farmacia Clin
2008;22:86–105
Full-text paper not in the
English language
Stevenson MD, Oakley JE, Lloyd JM, Brennan A, Compston JE, McCloskey EV, et al.
The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate
treatment is the better duration for women with a prior fracture. Med Dec Making
2009;29:678–89
Establishing optimum
duration of treatment
Stevenson MD, Jones ML, Stevenson MD, Jones ML. The cost effectiveness of a randomized
controlled trial to establish the relative efficacy of vitamin K1 compared with alendronate.
Med Dec Making 2011;31:43–52
Excluded interventions
Sunyecz J, Silberman C, Poston S, Earnshaw S. Cost-effectiveness of ibandronate therapy for
women with postmenopausal osteoporosis with respect to nonvertebral fracture efficacy.
J Bone Miner Res 2008;23:S213
Conference abstract
Warde N. Prostate cancer: is fracture prevention therapy cost-effective in patients with
prostate cancer treated with ADT? Nature Rev Urol 2010;7:363
In-brief article
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Appendix 8 Parameter distributions used in the
probabilistic sensitivity analysis
TABLE 51 Distributions assigned to the parameters used in the model
Parameter description Distribution Mean
Standard
error Parameter 1 Parameter 2 Source(s)
Patients hospitalised
Following vertebral fracture Beta 0.40 NA α = 587 β = 884 Gutierrez et al.234
Following wrist or forearm
fracture
Beta 0.29 NA α = 2081 β = 4989 Gutierrez et al.234
Following humerus fracture Beta 0.35 NA α = 894 β = 1651 Gutierrez et al.234
Following hip fracture Fixed 1.00 NA NA NA Gutierrez et al.233
A&E visits
Following vertebral fracture Beta 0.11 NA α = 171 β = 1300 Gutierrez et al.234
Following wrist or forearm
fracture
Beta 0.21 NA α = 1489 β = 5581 Gutierrez et al.234
Following humerus fracture Beta 0.18 NA α = 469 β = 2076 Gutierrez et al.234
Following hip fracture Beta 0.18 NA α = 442 β = 1985 Gutierrez et al.233
GP visits
Following vertebral fracture Beta 0.97 NA α = 1425 β = 46 Gutierrez et al.234
Following wrist or forearm
fracture
Beta 0.95 NA α = 6689 β = 381 Gutierrez et al.234
Following humerus fracture Beta 0.94 NA α = 2385 β = 160 Gutierrez et al.234
Following hip fracture Beta 0.88 NA α = 2141 β = 286 Gutierrez et al.233
Referral visits
Following vertebral fracture Beta 0.50 NA α = 730 β = 741 Gutierrez et al.234
Following wrist or forearm
fracture
Beta 0.37 NA α = 2623 β = 4447 Gutierrez et al.234
Following humerus fracture Beta 0.34 NA α = 875 β = 1670 Gutierrez et al.234
Following hip fracture Beta 0.33 NA α = 805 β = 1622 Gutierrez et al.233
Patient deaths
Following vertebral fracture Beta 0.09 NA α = 131 β = 1340 Gutierrez et al.234
Following wrist or forearm
fracture
Beta 0.04 NA α = 271 β = 6799 Gutierrez et al.234
Following humerus fracture Beta 0.07 NA α = 197 β = 2348 Gutierrez et al.234
Following hip fracture Beta 0.08 NA α = 197 β = 2230 Gutierrez et al.233
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TABLE 51 Distributions assigned to the parameters used in the model (continued )
Parameter description Distribution Mean
Standard
error Parameter 1 Parameter 2 Source(s)
Patients hospitalised
Matched controls for
vertebral fracture
Beta 0.17 NA α= 245 β = 1226 Gutierrez et al.234
Matched controls for wrist
or forearm fracture
Beta 0.13 NA α= 895 β = 6175 Gutierrez et al.234
Matched controls for
humerus fracture
Beta 0.15 NA α= 383 β = 2162 Gutierrez et al.234
Matched controls for hip
fracture
Beta 0.18 NA α= 432 β = 1995 Gutierrez et al.233
A&E visits
Matched controls for
vertebral fracture
Beta 0.04 NA α= 64 β = 1407 Gutierrez et al.234
Matched controls for wrist
or forearm fracture
Beta 0.03 NA α= 208 β = 6862 Gutierrez et al.234
Matched controls for
humerus fracture
Beta 0.03 NA α= 82 β = 2463 Gutierrez et al.234
Matched controls for hip
fracture
Beta 0.04 NA α= 95 β = 2332 Gutierrez et al.233
GP visits
Matched controls for
vertebral fracture
Beta 0.90 NA α= 1319 β = 152 Gutierrez et al.234
Matched controls for wrist
or forearm fracture
Beta 0.89 NA α= 6268 β = 802 Gutierrez et al.234
Matched controls for
humerus fracture
Beta 0.91 NA α= 2305 β = 240 Gutierrez et al.234
Matched controls for hip
fracture
Beta 0.91 NA α= 2200 β = 227 Gutierrez et al.233
Referral visits
Matched controls for
vertebral fracture
Beta 0.32 NA α= 475 β = 996 Gutierrez et al.234
Matched controls for wrist
or forearm fracture
Beta 0.28 NA α= 1988 β = 5082 Gutierrez et al.234
Matched controls for
humerus fracture
Beta 0.29 NA α= 749 β = 1796 Gutierrez et al.234
Matched controls for hip
fracture
Beta 0.32 NA α= 775 β = 1652 Gutierrez et al.233
Difference in medications prescribed between patients with a previous fracture and those without
Following vertebral fracture Normal 22.35 2.16 µ= 2.35 σ = 2.16 Gutierrez et al.234
Following wrist or forearm
fracture
Normal 4.61 0.61 µ= 4.61 σ = 0.61 Gutierrez et al.234
Following humerus fracture Normal 4.61 0.61 µ= 4.61 σ = 0.61 Gutierrez et al.234
Following hip fracture Normal 12.34 1.72 µ= 2.34 σ = 1.72 Gutierrez et al.233
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TABLE 51 Distributions assigned to the parameters used in the model (continued )
Parameter description Distribution Mean
Standard
error Parameter 1 Parameter 2 Source(s)
Utility multipliers in year of fracture
Hip fracture Beta 0.69 0.016 α = 575.84 β = 258.71 Ström et al.226
Vertebral fracture Beta 0.57 0.035 α = 113.48 β = 85.61 Ström et al.226
Humerus fracture Beta 0.86 0.085 α = 13.47 β = 2.19 Ström et al.226
Wrist or forearm fracture Beta 0.88 0.015 α = 412.13 β = 56.20 Zethraeus et al.220
Utility multiplier in subsequent years
Hip fracture Beta 0.85 0.016 α = 422.49 β = 74.56 Ström et al.226
Vertebral fracture Beta 0.66 0.035 α = 120.24 β = 61.94 Strom et al.226
Humerus fracture Fixed 1.00 NA NA NA Zethraeus et al. 220
Wrist or forearm fracture Beta 0.98 0.015 α = 84.39 β = 1.72 Ström et al.226
Patient admitted to nursing
home
Beta 0.63 0.191 α = 3.38 β = 2.03 Tidermark et al.225
Life expectancy for patient
suffering a fatal hip
fracture
Fixed 0.25 NA NA NA Assumption
RR of mortality following
hip fracture for patients
admitted to a nursing
home
Log-normal 0.57 0.074 µ = –0.56212 σ= 0.13150 Smith et al.157
Duration of treatment (years)
Alendronic acid/risedronic
acid/ibandronic acid (oral)
Normal 0.504 0.028 µ = 0.504 σ= 0.028 Imaz et al.128
ibandronic acid (i.v.
preparation)
Normal 1.100 0.041 µ = 1.100 σ= 0.041 Curtis et al. 2012170
Zoledronic acid Normal 1.700 0.018 µ = 1.700 σ= 0.018 Curtis et al. 2012170
Annual cost of treatment
Alendronic acid Fixed £14.73 NA NA NA Drug tariff151
Risedronic acid Fixed £16.43 NA NA NA Drug tariff151
ibandronic acid (oral
preparation)
Fixed £13.58 NA NA NA Drug tariff151
ibandronic acid (i.v.
preparation)
Fixed £221.52 NA NA NA eMIT152
Zoledronic acid Fixed £339.67 NA NA NA eMIT152
Patient admitted to nursing
home
Fixed £36,608.00 NA NA NA Care Quality
Commission236 and
Curtis26
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TABLE 51 Distributions assigned to the parameters used in the model (continued )
Parameter description Distribution Mean
Standard
error Parameter 1 Parameter 2 Source(s)
Hours of home help per week in first 4 months after fracture
Hip fracture Normal 1.87 0.30 µ= 1.87 σ = 0.30 Borgström et al.207
Vertebral fracture Normal 1.88 0.50 µ= 1.88 σ = 0.50 Borgström et al.207
Humerus/wrist or forearm
fracture
Normal 0.21 0.10 µ= 0.21 σ = 0.10 Borgström et al.207
Hours of home help per week in months 8–12 following fracture
Hip fracture Normal 1.42 0.21 µ= 1.42 σ = 0.21 Borgström et al.207
Vertebral fracture Normal 2.56 0.61 µ= 2.56 σ = 0.61 Borgström et al.207
Humerus/wrist or forearm
fracture
Normal 0.07 0.04 µ= 0.07 σ = 0.04 Borgström et al.207
NA, not available.
TABLE 52 Distributions used in the PSA for the increased risk of fracture following incident fracture
Description Distribution Mid-point
Standard
error Parameter 1 Parameter 2 Source
HR for future hip fracture given
Prior hip fracture Log-normal 2.3 0.561 µ= 0.832909 σ = 0.230323 Klotzbuecher et al.149
Prior vertebral fracture Log-normal 2.3 0.204 µ= 0.832909 σ = 0.085835 Klotzbuecher et al.149
Prior humerus fracture Log-normal 2.0 0.077 µ= 0.693147 σ = 0.037399 Klotzbuecher et al.149
Prior wrist/forearm
fracture
Log-normal 1.9 0.153 µ= 0.641854 σ = 0.081238 Klotzbuecher et al.149
HR for future vertebral fracture given
Prior hip fracture Log-normal 2.5 0.434 µ= 0.916291 σ = 0.169637 Klotzbuecher et al.149
Prior vertebral fracture Log-normal 4.4 0.459 µ= 1.481605 σ = 0.103435 Klotzbuecher et al.149
Prior humerus fracture Log-normal 2.0 0.204 µ= 0.693147 σ = 0.103435 Klotzbuecher et al.149
Prior wrist/forearm
fracture
Log-normal 1.7 0.179 µ= 0.530628 σ = 0.103435 Klotzbuecher et al.149
HR for future humerus fracture given
Prior hip fracture Log-normal 2.1 4.337 µ= 0.741937 σ = 1.034357 Warriner et al.213
Prior vertebral fracture Log-normal 1.6 0.587 µ= 0.470004 σ = 0.371247 Warriner et al.213
Prior humerus fracture Log-normal 2.1 4.337 µ= 0.741937 σ = 1.034357 Klotzbuecher et al.149
Prior wrist/forearm
fracture
Log-normal 2.5 2.449 µ= 0.916291 σ = 0.722759 Warriner et al.213
HR for future wrist/forearm fracture given
Prior hip fracture Log-normal 3.0 1.327 µ= 1.098612 σ = 0.410571 Warriner et al.213
Prior vertebral fracture Log-normal 1.4 0.128 µ= 0.336472 σ = 0.088854 Klotzbuecher et al.149
Prior humerus fracture Log-normal 1.9 0.383 µ= 0.641854 σ = 0.195728 Klotzbuecher et al.149
Prior wrist/forearm
fracture
Log-normal 3.3 0.383 µ= 1.193922 σ = 0.142759 Klotzbuecher et al.149
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TABLE 53 Distributions used in the PSA for the probability of mortality following hip fracture
Description Distribution Mean Standard error Parameter 1 Parameter 2 Source
Female patients, age (years)
30–39 Fixed 0.000 NA NA NA van Staa et al.141
40–49 Fixed 0.000 NA NA NA van Staa et al.141
50–59 Beta 0.024 NA α = 21.649 β = 880.386 van Staa et al.141
60–69 Beta 0.044 NA α = 109.383 β = 2376.587 van Staa et al.141
70–79 Beta 0.075 NA α = 301.095 β = 3713.504 van Staa et al.141
80–89 Beta 0.114 NA α = 433.698 β = 3370.667 van Staa et al.141
90–99 Beta 0.136 NA α = 139.921 β = 888.912 van Staa et al.143
Male patients, age (years)
30–39 NA 0.000 NA NA NA –
40–49 NA 0.000 NA NA NA –
50–59 NA 0.037 NA NA NA –
60–69 NA 0.072 NA NA NA –
70–79 NA 0.134 NA NA NA –
80–89 NA 0.181 NA NA NA –
90–99 NA 0.200 NA NA NA –
NA, not available.
Note
For male patients the values sampled for female patients are multiplies by a sex–mortality ratio taken from Roberts
and Goldacre.189
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TABLE 54 Distributions used in the PSA for the probability of nursing home admission following fracture
Description Distribution Mean Standard error Parameter 1 Parameter 2 Source
Overall rate of new
admission to nursing
home across all ages
and sex
Beta 20% NA α = 274 β= 1370 Najayan et al.206
Female patients
Age 30–39 years Not sampled 0.000 NA NA NA Najayan et al.206
Age 40–49 years 0.000 NA NA NA Najayan et al.206
Age 50–59 years 0.035 NA NA NA Najayan et al.206
Age 60–69 years 0.064 NA NA NA Najayan et al.206
Age 70–79 years 0.113 NA NA NA Najayan et al.206
Age 80–89 years 0.192 NA NA NA Najayan et al.206
Age 90–99 years 0.307 NA NA NA Najayan et al.206
Male patients
Age 30–39 years Not sampled 0.000 NA NA NA Najayan et al.206
Age 40–49 years 0.000 NA NA NA Najayan et al.206
Age 50–59 years 0.057 NA NA NA Najayan et al.206
Age 60–69 years 0.102 NA NA NA Najayan et al.206
Age 70–79 years 0.175 NA NA NA Najayan et al.206
Age 80–89 years 0.284 NA NA NA Najayan et al.206
Age 90–99 years 0.425 NA NA NA Najayan et al.206
NA, not available.
TABLE 55 Distributions used in the PSA for the probability of mortality following vertebral fracture
Description Distribution Mean Standard error Parameter 1 Parameter 2 Source
All patients
Age 30–39 years Fixed 0.000 NA NA NA van Staa et al.141
Age 40–49 years Fixed 0.000 NA NA NA van Staa et al.141
Age 50–59 years Beta 0.023 NA α= 85.581 β= 3635.314 van Staa et al.141
Age 60–69 years Beta 0.035 NA α= 247.105 β= 6813.048 van Staa et al.141
Age 70–79 years Beta 0.052 NA α= 378.597 β= 6902.117 van Staa et al.141
Age 80–89 years Beta 0.067 NA α= 285.369 β= 3973.865 van Staa et al.141
Age 90–99 years Beta 0.066 NA α= 53.757 β= 760.736 van Staa et al.141
NA, not available.
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TABLE 57 Distributions used in the PSA for referrals in the year after fracture
Service code, currency code
and description
Number of
patients
treated
Mean unit
cost (£) SD (£) Distribution Parameter 1 Parameter 2
WF01B, 302 non-consultant-
led outpatient appointments,
first attendance, not admitted,
face to face, endocrinology
109,162 186.54 66 Gamma κ = 955.04 θ = 0.20
WF01 A, 302 non-consultant-
led outpatient appointments,
follow-up attendance, not
admitted, face to face,
endocrinology
353,215 133.00 47 Gamma κ = 989.53 θ = 0.13
Source was 2013/14 NHS reference costs.150
TABLE 56 Distributions used in the PSA for A&E treatment in the year after fracture
Service code, currency code
and description
Number of
patients
treated
Mean unit
cost (£) SD (£) Distribution Parameter 1 Parameter 2
T02 A, VB07Z emergency
medicine, category 2
investigation with category 2
treatment patient admitted
34,920 94 £28 Gamma κ = 382,885.49 θ = 0.0002
T02NA, VB07Z emergency
medicine, category 2
investigation with category 2
treatment patient not admitted
24,835 82 £39 Gamma κ = 109,477.62 θ = 0.0007
Source was 2013/14 NHS reference costs.150
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TABLE 58 Distributions used in the PSA for hospitalisation for humerus fracture in the year after fracture
Currency code and description
Number of
patients
treated
Mean unit
cost (£) SD (£) Distribution Parameter 1 Parameter 2
Non-elective inpatient procedures, long stay
HA61B major shoulder or upper
arm procedures for trauma,
with cc
951 7194 1931 Gamma κ = 1943.78 θ = 3.7
HA61C major shoulder or upper
arm procedures for trauma,
without cc
1880 4305 1270 Gamma κ = 1618.63 θ = 2.66
HA62Z intermediate shoulder or
upper arm procedures for trauma
249 3654 1613 Gamma κ = 549.10 θ = 6.65
HA63Z minor shoulder or upper
arm procedures for trauma
611 2520 944 Gamma κ = 947.75 θ = 2.66
HA69Z minimal shoulder or
upper arm procedures for trauma
1 323 NA Fixed NA NA
Non-elective inpatient procedures, long stay, excess bed-day
HA61B major shoulder or upper
arm procedures for trauma,
with cc
1,622 276.43 110 Gamma κ = 421.63 θ = 0.66
HA61C major shoulder or upper
arm procedures for trauma,
without cc
3010 312.62 89 Gamma κ = 1607.77 θ = 0.19
HA62Z intermediate shoulder or
upper arm procedures for trauma
1158 294.37 114 Gamma κ = 380.05 θ = 0.77
HA63Z minor shoulder or upper
arm procedures for trauma
2155 244.89 86 Gamma κ = 800.88 θ = 0.31
cc, complications and comorbidities; NA, not available.
Source was 2013/14 NHS reference costs.150
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TABLE 59 Distributions used in the PSA for hospitalisation for wrist fracture in the year after fracture
Currency code and
description
Number of
patients
treated
Mean unit
cost (£) SD (£) Distribution Parameter 1 Parameter 2
Non-elective inpatient procedures, long stay
HA71B major elbow or lower arm
procedures for trauma, with cc
1356 3835 1196 Gamma κ= 186.41 θ = 7.27
HA71C major elbow or lower
arm procedures for trauma,
without cc
7494 2913 888 Gamma κ= 10,408.22 θ = 0.72
HA72Z intermediate elbow or
lower arm procedures for
trauma
845 2585 1026 Gamma κ= 87.52 θ = 9.66
HA73B minor elbow or lower
arm procedures for trauma,
18 years and under
869 1637 492 Gamma κ= 369.14 θ = 2.19
HA73C minor elbow or lower
arm procedures for trauma,
19 years and over
963 1481 704 Gamma κ= 254.31 θ = 3.79
HA79Z minimal elbow or lower
arm procedures for trauma
1 371 NA Fixed NA NA
Non-elective inpatient procedures, long stay, excess bed-day
HA71B major elbow or lower
arm procedures for trauma,
with cc
2475 291 £88 Gamma κ= 993.96 θ = 0.29
HA71C major elbow or lower
arm procedures for trauma,
without cc
3716 314 £120 Gamma κ= 974.53 θ = 0.32
HA72Z intermediate elbow or
lower arm procedures for
trauma
975 256 £101 Gamma κ= 531.39 θ = 0.48
HA73B minor elbow or lower
arm procedures for trauma,
18 years and under
110 379 £144 Gamma κ= 152.54 θ = 2.48
HA73C minor elbow or lower
arm procedures for trauma,
19 years and over
2703 265 £93 Gamma κ= 943.70 θ = 0.28
cc, complications and comorbidities; NA, not available.
Source was 2013/14 NHS reference costs.150
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TABLE 60 Distributions used in the PSA for hospitalisation for hip fracture (procedure costs) in the year
after fracture
Currency code and description
Number of
patients
treated
Mean unit
cost (£) SD (£) Distribution Parameter 1 Parameter 2
Non-elective inpatient procedures, long stay
HA11 A major hip procedures for
trauma, category 2, with major cc
713 13,408 4678 Gamma κ = 1117.05 θ = 12.00
HA11B major hip procedures for
trauma, category 2, with
intermediate cc
319 8791 3503 Gamma κ = 680.27 θ = 12.92
HA11C major hip procedures for
trauma, category 2, without cc
773 7337 1847 Gamma κ = 2051.83 θ = 3.58
HA12B major hip procedures for
trauma, category 1, with cc
19,080 8210 1786 Gamma κ = 3064.35 θ = 2.68
HA12C major hip procedures for
trauma, category 1, without cc
9890 6417 1159 Gamma κ = 4507.56 θ = 1.42
HA13A intermediate hip
procedures for trauma, with
major cc
10,212 8237 1997 Gamma κ = 2415.09 θ = 3.41
HA13B intermediate hip
procedures for trauma, with
intermediate cc
5355 6570 1726 Gamma κ = 2057.28 θ = 3.19
HA13C intermediate hip
procedures for trauma, without cc
9673 5551 1129 Gamma κ = 3528.05 θ = 1.57
HA14A minor hip procedures for
trauma, with major cc
249 7312 3737 Gamma κ = 398.07 θ = 18.37
HA14B minor hip procedures for
trauma, with intermediate cc
216 4905 2020 Gamma κ = 595.70 θ = 8.23
HA14C minor hip procedures for
trauma, without cc
645 3939 1064 Gamma κ = 1904.04 θ = 2.07
HA19Z minimal hip procedures
for trauma
1 7790 NA Fixed NA NA
cc, complications and comorbidities; NA, not available.
Source was 2013/14 NHS reference costs.150
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TABLE 61 Distributions used in the PSA for hospitalisation for hip fracture (excess bed-day costs) in the year
after fracture
Currency code
Number of
patients
treated
Mean unit
cost (£) SD (£) Distribution Parameter 1 Parameter 2
Non-elective inpatient procedures, long stay, excess bed-day
HA11 A major hip procedures for
trauma, category 2, with major cc
1404 312 84 Gamma κ = 410.74 θ = 0.76
HA11B major hip procedures for
trauma, category 2, with
intermediate cc
307 299 115 Gamma κ = 177.30 θ = 1.69
HA11C major hip procedures for
trauma, category 2, without cc
394 311 89 Gamma κ = 296.08 θ = 1.05
HA12B major hip procedures for
trauma, category 1, with cc
16,310 282 88 Gamma κ = 1376.53 θ = 0.20
HA12C major hip procedures for
trauma, category 1, without cc
4463 267 98 Gamma κ = 886.70 θ = 0.30
HA13A intermediate hip
procedures for trauma, with
major cc
8630 290 88 Gamma κ = 1176.62 θ = 0.25
HA13B intermediate hip
procedures for trauma, with
intermediate cc
2502 292 95 Gamma κ = 746.43 θ = 0.39
HA13C intermediate hip
procedures for trauma, without cc
3674 262 69 Gamma κ = 1715.15 θ = 0.15
HA14A minor hip procedures for
trauma, with major cc
466 256 120 Gamma κ = 86.67 θ = 2.95
HA14B minor hip procedures for
trauma, with intermediate cc
198 339 226 Gamma κ = 45.04 θ = 7.53
HA14C minor hip procedures for
trauma, without cc
962 317 159 Gamma κ = 232.60 θ = 1.37
cc, complications and comorbidities.
Source was 2013/14 NHS reference costs.150
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TABLE 62 Distributions used in the PSA for vertebral fracture hospitalisations in the year after fracture
Currency code
Number of
patients
treated
Mean unit
cost (£) SD (£) Distribution Parameter 1 Parameter 2
Non-elective inpatient procedures, long stay
HC20D vertebral column injury
without procedure, with a
cc score of ≥ 6
1609 5479 2858 Gamma κ = 543.85 θ = 10.07
HC20E vertebral column injury
without procedure, with a
cc score of 3–5
2459 3732 1648 Gamma κ = 758.57 θ = 4.92
HC20F vertebral column injury
without procedure, with a
cc score of 1–2
2611 2971 1136 Gamma κ = 1031.87 θ = 2.88
HC20G vertebral column injury
without procedure, with a
cc score of 0
1904 2265 646 Gamma κ = 1806.58 θ = 1.25
Non-elective inpatient procedures, long stay, excess bed-day
HC20D vertebral column injury
without procedure, with a
cc score of ≥ 6
2317 328.19 128 Gamma κ = 347.54 θ = 0.94
HC20E vertebral column injury
without procedure, with a
cc score of 3–5
3772 260.82 125 Gamma κ = 393.07 θ = 0.66
HC20F vertebral column injury
without procedure, with a
cc score of 1–2
2363 266.99 76 Gamma κ = 1171.35 θ = 0.23
HC20G vertebral column injury
without procedure, with a
cc score of 0
2047 282.03 117 Gamma κ = 599.23 θ = 0.47
cc, complications and comorbidities.
Source was 2013/14 NHS reference costs.150
TABLE 63 Distributions used in the PSA for administration of i.v. bisphosphonates
Currency code
Number of
patients
treated
Mean unit
cost (£) SD (£) Distribution Parameter 1 Parameter 2
WF01 A, 302, non-admitted
face-to-face attendance,
follow-up, endocrinology
353,215 133 114.37 Gamma κ = 989.48 θ = 0.13
DCRDN, SB12Z, deliver simple
parenteral chemotherapy at first
attendance, day case and
regular day/night
222,981 245 46.70 Gamma κ = 583.60 θ = 0.42
Source was 2013/14 NHS reference costs.150
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Appendix 9 Base-case results from the
probabilistic sensitivity analysis for QFracture
TABLE 64 Base-case results from 200,000 PSA samples for QFracture risk category 1
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
No treatment 827.18 15.88153 0.00 0.00000 NA 316,803 475,619 NA
Ibandronic
acid (oral)
834.63 15.88164 7.45 0.00011 67,340 316,798 475,615 67,340
Alendronic
acid
835.01 15.88164 7.83 0.00011 68,204 316,798 475,614 91,325
Risedronic
acid
835.96 15.88157 8.78 0.00004 219,757 316,795 475,611 Dominated
Ibandronic
acid (i.v.)
1053.14 15.88123 225.96 –0.00030 –757,885 316,571 475,384 Dominated
Zoledronic
acid
1385.41 15.88196 558.24 0.00043 1,301,875 316,254 475,073 1,752,783
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 65 Base-case results from 200,000 PSA samples for QFracture risk category 2
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
No treatment 1532.33 14.74097 0.00 0.00000 NA 293,287 440,697 NA
Ibandronic
acid (oral)
1539.62 14.74105 7.29 0.00008 96,451 293,281 440,692 Extendedly
dominated
Alendronic
acid
1540.17 14.74108 7.84 0.00010 76,943 293,281 440,692 Extendedly
dominated
Risedronic
acid
1540.77 14.74110 8.44 0.00013 65,692 293,281 440,692 65,692
Ibandronic
acid (i.v.)
1757.78 14.74075 225.45 –0.00023 –997,490 293,057 440,465 Dominated
Zoledronic
acid
2088.19 14.74166 555.86 0.00068 813,849 292,745 440,162 987,243
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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TABLE 66 Base-case results from 200,000 PSA samples for QFracture risk category 3
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
No treatment 2971.75 13.55783 0.00 0.00000 NA 268,185 403,763 NA
Risedronic
acid
2977.17 13.55813 5.42 0.00030 17,906 268,185 403,767 17,906
Alendronic
acid
2979.29 13.55813 7.54 0.00030 24,867 268,183 403,765 Extendedly
dominated
Ibandronic
acid (oral)
2979.64 13.55808 7.89 0.00025 31,440 268,182 403,763 Dominated
Ibandronic
acid (i.v.)
3196.69 13.55889 224.94 0.00106 213,067 267,981 403,570 291,495
Zoledronic
acid
3520.69 13.55932 548.94 0.00150 367,160 267,666 403,259 737,415
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 67 Base-case results from 200,000 PSA samples for QFracture risk category 4
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
No treatment 3881.90 12.32917 0.00 0.00000 NA 242,702 365,993 NA
Alendronic
acid
3886.67 12.32946 4.77 0.00028 16,820 242,702 365,997 16,820
Ibandronic
acid (oral)
3888.83 12.32930 6.93 0.00012 55,519 242,697 365,990 Dominated
Risedronic
acid
3889.93 12.32945 8.02 0.00027 29,255 242,699 365,994 Dominated
Ibandronic
acid (i.v.)
4106.75 12.32927 224.84 0.00009 2,444,347 242,479 365,771 Dominated
Zoledronic
acid
4436.61 12.33057 554.71 0.00140 397,032 242,175 365,481 493,762
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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TABLE 68 Base-case results from 200,000 PSA samples for QFracture risk category 5
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
Net
benefit at
£30,000
per QALY
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
No treatment 4052.25 11.42224 0.00 0.00000 NA 224,393 338,615 NA
Alendronic
acid
4059.38 11.42235 7.13 0.00010 68,244 224,388 338,611 68,244
Ibandronic
acid (oral)
4060.12 11.42216 7.86 –0.00008 –98,972 224,383 338,605 Dominated
Risedronic
acid
4065.83 11.42228 13.58 0.00003 415,596 224,380 338,602 Dominated
Ibandronic
acid (i.v.)
4276.53 11.42247 224.28 0.00022 997,367 224,173 338,398 Extendedly
dominated
Zoledronic
acid
4604.88 11.42422 552.63 0.00198 279,227 223,880 338,122 290,988
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 69 Base-case results from 200,000 PSA samples for QFracture risk category 6
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
No treatment 4371.39 10.40268 0.00 0.00000 NA 203,682 307,709 NA
Alendronic
acid
4374.47 10.40301 3.08 0.00032 9468 203,686 307,716 9468
Risedronic
acid
4378.91 10.40296 7.52 0.00028 27,166 203,680 307,710 Dominated
Ibandronic
acid (oral)
4379.07 10.40298 7.67 0.00029 26,208 203,680 307,710 Dominated
Ibandronic
acid (i.v.)
4603.74 10.40323 232.35 0.00055 421,634 203,461 307,493 Extendedly
dominated
Zoledronic
acid
4916.96 10.40474 545.57 0.00206 265,440 203,178 307,225 313,498
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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TABLE 70 Base-case results from 200,000 PSA samples for QFracture risk category 7
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Risedronic
acid
4584.47 9.38541 –0.57 0.00047 –1213 183,124 276,978 NA
Alendronic
acid
4584.52 9.38539 –0.52 0.00045 –1152 183,123 276,977 Dominated
No treatment 4585.04 9.38494 0.00 0.00000 NA 183,114 276,963 Dominated
Ibandronic
acid (oral)
4590.32 9.38526 5.28 0.00032 16,705 183,115 276,967 Dominated
Ibandronic
acid (i.v.)
4806.39 9.38577 221.35 0.00083 267,841 182,909 276,767 Extendedly
dominated
Zoledronic
acid
5136.10 9.38814 551.06 0.00320 172,324 182,627 276,508 202,041
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 71 Base-case results from 200,000 PSA samples for QFracture risk category 8
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted)
ICER vs. no
treatment
Net
benefit at
£20,000
per QALY
Net
benefit at
£30,000
per QALY
Incremental
analysisa (£)Cost (£) QALYs Cost QALYs
Risedronic
acid
5603.84 8.33619 –4.24 0.00067 –6287 161,120 244,482 NA
Alendronic
acid
5607.53 8.33657 –0.55 0.00106 –515 161,124 244,490 9563
No treatment 5608.08 8.33551 0.00 0.00000 NA 161,102 244,457 Dominated
Ibandronic
acid (oral)
5616.53 8.33618 8.45 0.00066 12,715 161,107 244,469 Dominated
Ibandronic
acid (i.v.)
5837.84 8.33648 229.77 0.00097 237,905 160,892 244,256 Dominated
Zoledronic
acid
6157.62 8.33899 549.54 0.00348 157,893 160,622 244,012 227,376
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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TABLE 72 Base-case results from 200,000 PSA samples for QFracture risk category 9
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted)
ICER vs. no
treatment
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Alendronic
acid
8678.06 6.51525 –10.66 0.00114 –9322 121,627 186,780 NA
Risedronic
acid
8680.76 6.51549 –7.97 0.00138 n5791 121,629 186,784 11,621
Ibandronic
acid (oral)
8688.18 6.51507 –0.54 0.00096 –563 121,613 186,764 Dominated
No treatment 8688.72 6.51411 0.00 0.00000 NA 121,594 186,735 Dominated
Ibandronic
acid (i.v.)
8902.45 6.51557 213.72 0.00146 146,407 121,409 186,565 Extendedly
dominated
Zoledronic
acid
9221.00 6.51944 532.28 0.00533 99,907 121,168 186,362 136,695
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 73 Base-case results from 200,000 PSA samples for QFracture risk category 10
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Risedronic
acid
19,576.95 4.01080 –17.24 0.00118 –14,610 60,639 100,747 NA
Alendronic
acid
19,587.52 4.01086 –6.67 0.00124 –5,392 60,630 100,738 188,505
No treatment 19,594.19 4.00962 0.00 0.00000 NA 60,598 100,695 Dominated
Ibandronic
acid (oral)
19,624.63 4.01018 30.44 0.00055 54,995 60,579 100,681 Dominated
Ibandronic
acid (i.v.)
19,840.81 4.01059 246.62 0.00096 255,998 60,371 100,477 Dominated
Zoledronic
acid
20,137.69 4.01250 543.50 0.00288 189,028 60,112 100,237 335,702
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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Appendix 10 Base-case results from the
probabilistic sensitivity analysis for FRAX
TABLE 74 Base-case results from 200,000 PSA samples for FRAX risk category 1
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
No treatment 5838.92 13.56127 0.00 0.00000 NA 265,387 400,999 NA
Alendronic
acid
5841.54 13.56248 2.62 0.00121 2175 265,408 401,033 2175
Risedronic
acid
5842.90 13.56252 3.98 0.00125 3197 265,408 401,033 34,124
Ibandronic
acid (oral)
5844.50 13.56216 5.57 0.00089 6268 265,399 401,020 Dominated
Ibandronic
acid (i.v.)
6060.14 13.56305 221.22 0.00177 124,931 265,201 400,831 Extendedly
dominated
Zoledronic
acid
6394.34 13.56640 555.41 0.00512 108,395 264,934 400,598 141,073
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 75 Base-case results from 200,000 PSA samples for FRAX risk category 2
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Risedronic
acid
5863.60 13.24259 –10.18 0.00140 –7272 258,988 391,414 NA
Ibandronic
acid (oral)
5873.38 13.24252 –0.40 0.00133 –300 258,977 391,402 Dominated
No treatment 5873.78 13.24119 0.00 0.00000 NA 258,950 391,362 Dominated
Alendronic
acid
5875.18 13.24287 1.40 0.00168 835 258,982 391,411 41,144
Ibandronic
acid (i.v.)
6089.91 13.24364 216.14 0.00245 88,127 258,783 391,219 Extendedly
dominated
Zoledronic
acid
6401.88 13.24829 528.10 0.00710 74,347 258,564 391,047 97,132
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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TABLE 76 Base-case results from 200,000 PSA samples for FRAX risk category 3
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Risedronic
acid
6324.67 13.33625 –6.81 0.00176 –3879 260,400 393,763 NA
Ibandronic
acid (oral)
6330.04 13.33636 –1.44 0.00186 –775 260,397 393,761 Extendedly
dominated
No treatment 6331.48 13.33450 0.00 0.00000 NA 260,358 393,703 Dominated
Alendronic
acid
6333.01 13.33660 1.53 0.00211 727 260,399 393,765 23,752
Ibandronic
acid (i.v.)
6549.59 13.33764 218.11 0.00314 69,413 260,203 393,580 Extendedly
dominated
Zoledronic
acid
6854.23 13.34360 522.75 0.00910 57,436 260,018 393,454 74,509
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 77 Base-case results from 200,000 PSA samples for FRAX risk category 4
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Alendronic
acid
6940.02 13.57697 –3.78 0.00214 –1768 264,599 400,369 NA
Ibandronic
acid (oral)
6940.34 13.57684 –3.47 0.00201 –1726 264,597 400,365 Dominated
No treatment 6943.81 13.57483 0.00 0.00000 NA 264,553 400,301 Dominated
Risedronic
acid
6945.84 13.57692 2.04 0.00208 978 264,593 400,362 Dominated
Ibandronic
acid (i.v.)
7157.83 13.57920 214.02 0.00437 49,021 264,426 400,218 Extendedly
dominated
Zoledronic
acid
7474.18 13.58617 530.37 0.01134 46,776 264,249 400,111 58,061
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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TABLE 78 Base-case results from 200,000 PSA samples for FRAX risk category 5
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Ibandronic
acid (oral)
7466.53 12.32601 –9.83 0.00183 –5379 239,054 362,314 NA
Risedronic
acid
7471.92 12.32603 –4.44 0.00184 –2406 239,049 362,309 329,090
No treatment 7476.36 12.32418 0.00 0.00000 NA 239,007 362,249 Dominated
Alendronic
acid
7478.51 12.32595 2.14 0.00177 1213 239,041 362,300 Dominated
Ibandronic
acid (i.v.)
7671.16 12.32710 194.80 0.00292 66,739 238,871 362,142 Extendedly
dominated
Zoledronic
acid
8001.50 12.33301 525.14 0.00882 59,513 238,659 361,989 75,873
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 79 Base-case results from 200,000 PSA samples for FRAX risk category 6
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost QALYs Cost QALYs
No treatment 7616.23 10.59846 0.00 0.00000 NA 204,353 310,338 NA
Alendronic
acid
7618.25 10.60009 2.02 0.00163 1242 204,384 310,384 1242
Risedronic
acid
7619.22 10.59995 3.00 0.00149 2008 204,380 310,379 Dominated
Ibandronic
acid (oral)
7620.80 10.59974 4.57 0.00128 3574 204,374 310,371 Dominated
Ibandronic
acid (i.v.)
7833.82 10.60192 217.59 0.00346 62921 204,205 310,224 Extendedly
dominated
Zoledronic
acid
8138.66 10.60773 522.44 0.00927 56,383 204,016 310,093 68,144
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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TABLE 80 Base-case results from 200,000 PSA samples for FRAX risk category 7
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost QALYs Cost QALYs
Alendronic
acid
7162.84 9.10272 –5.67 0.00150 –3766 174,892 265,919 NA
Risedronic
acid
7164.94 9.10275 –3.57 0.00154 –2321 174,890 265,918 64,125
No treatment 7168.51 9.10121 0.00 0.00000 NA 174,856 265,868 Dominated
Ibandronic
acid (oral)
7177.99 9.10236 9.48 0.00114 8295 174,869 265,893 Dominated
Ibandronic
acid (i.v.)
7392.35 9.10398 223.84 0.00276 80,986 174,687 265,727 Extendedly
dominated
Zoledronic
acid
7702.81 9.10946 534.31 0.00825 64,770 174,486 265,581 80,140
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 81 Base-case results from 200,000 PSA samples for FRAX risk category 8
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
No treatment 7830.38 7.91916 0.00 0.00000 NA 150,553 229,744 NA
Risedronic
acid
7833.78 7.92086 3.40 0.00170 1996 150,583 229,792 1996
Ibandronic
acid (oral)
7836.05 7.92098 5.67 0.00182 3112 150,584 229,793 19,441
Alendronic
acid
7839.16 7.92096 8.78 0.00181 4864 150,580 229,790 Dominated
Ibandronic
acid (i.v.)
8049.13 7.92224 218.75 0.00308 70,929 150,396 229,618 Extendedly
dominated
Zoledronic
acid
8378.29 7.92722 547.91 0.00807 67,934 150,166 229,438 86,829
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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TABLE 82 Base-case results from 200,000 PSA samples for FRAX risk category 9
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Alendronic
acid
11,167.83 6.90026 –7.38 0.00232 –3175 126,837 195,840 NA
No treatment 11,175.20 6.89794 0.00 0.00000 NA 126,784 195,763 Dominated
Risedronic
acid
11,176.94 6.90016 1.74 0.00223 782 126,826 195,828 Dominated
Ibandronic
acid (oral)
11,195.85 6.89967 20.65 0.00174 11,891 126,798 195,794 Dominated
Ibandronic
acid (i.v.)
11,430.76 6.90139 255.55 0.00345 73,995 126,597 195,611 Extendedly
dominated
Zoledronic
acid
11,734.98 6.90722 559.78 0.00929 60,287 126,409 195,482 81,469
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
TABLE 83 Base-case results from 200,000 PSA samples for FRAX risk category 10
Treatment
strategy
Mean outcomes
(discounted)
Incremental
outcomes vs. no
treatment
(discounted) ICER vs. no
treatment
(£)
Net
benefit at
£20,000
per QALY
(£)
Net
benefit at
£30,000
per QALY
(£)
Incremental
analysisa (£)Cost (£) QALYs Cost (£) QALYs
Risedronic
acid
18,699.06 4.56088 –27.62 0.00220 –12,566 72,519 118,127 NA
Alendronic
acid
18,704.64 4.56166 –22.04 0.00297 –7411 72,529 118,145 7194
Ibandronic
acid (oral)
18,724.98 4.56022 –1.70 0.00154 –1104 72,479 118,082 Dominated
No treatment 18,726.68 4.55868 0.00 0.00000 NA 72,447 118,034 Dominated
Ibandronic
acid (i.v.)
18,943.03 4.56193 216.35 0.00325 66,600 72,296 117,915 Extendedly
dominated
Zoledronic
acid
19,257.85 4.56644 531.17 0.00775 68,498 72,071 117,735 115,714
NA, not applicable.
a ICER vs. next least costly non-dominated strategy.
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